



# Effective Health Care Program

---

Comparative Effectiveness Review  
Number 67

## **Nitrous Oxide for the Management of Labor Pain**



Agency for Healthcare Research and Quality  
Advancing Excellence in Health Care • [www.ahrq.gov](http://www.ahrq.gov)

# *Comparative Effectiveness Review*

---

Number 67

## **Nitrous Oxide for the Management of Labor Pain**

### **Prepared for:**

Agency for Healthcare Research and Quality  
U.S. Department of Health and Human Services  
540 Gaither Road  
Rockville, MD 20850  
[www.ahrq.gov](http://www.ahrq.gov)

**Contract No. 290-2007-10065-I**

### **Prepared by:**

Vanderbilt Evidence-based Practice Center  
Institute for Medicine and Public Health  
Nashville, TN

### **Investigators:**

Frances E. Likis, Dr.P.H., N.P., C.N.M.  
Jeffrey C. Andrews, M.D.  
Michelle R. Collins, Ph.D., M.S.N., C.N.M., R.N.C.  
Rashonda M. Lewis, J.D., M.H.A.  
Jeffrey J. Seroogy, B.S.  
Sarah A. Starr, M.D.  
Rachel R. Walden, M.L.I.S.  
Melissa L. McPheeters, Ph.D., M.P.H.

This report is based on research conducted by the Vanderbilt Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2007-10065-I). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients.

This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.

This document is in the public domain and may be used and reprinted without permission except those copyrighted materials that are clearly noted in the document. Further reproduction of those copyrighted materials is prohibited without the specific permission of copyright holders.

Persons using assistive technology may not be able to fully access information in this report. For assistance contact [EffectiveHealthCare@ahrq.hhs.gov](mailto:EffectiveHealthCare@ahrq.hhs.gov).

None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report.

**Suggested citation:** Likis FE, Andrews JA, Collins MR, Lewis, RM, Seroogy JJ, Starr SA, Walden RR, McPheeters ML. Nitrous Oxide for the Management of Labor Pain. Comparative Effectiveness Review No. 67. (Prepared by the Vanderbilt Evidence-based Practice Center under Contract No. 290-2007-10065-I.) AHRQ Publication No. 12-EHC071-EF. Rockville, MD: Agency for Healthcare Research and Quality; August 2012.  
[www.effectivehealthcare.ahrq.gov/reports/final.cfm](http://www.effectivehealthcare.ahrq.gov/reports/final.cfm).

## Preface

The Agency for Healthcare Research and Quality (AHRQ) conducts the Effective Health Care Program as part of its mission to organize knowledge and make it available to inform decisions about health care. As part of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Congress directed AHRQ to conduct and support research on the comparative outcomes, clinical effectiveness, and appropriateness of pharmaceuticals, devices, and health care services to meet the needs of Medicare, Medicaid, and the Children's Health Insurance Program (CHIP).

AHRQ has an established network of Evidence-based Practice Centers (EPCs) that produce Evidence Reports/Technology Assessments to assist public- and private-sector organizations in their efforts to improve the quality of health care. The EPCs now lend their expertise to the Effective Health Care Program by conducting comparative effectiveness reviews (CERs) of medications, devices, and other relevant interventions, including strategies for how these items and services can best be organized, managed, and delivered.

Systematic reviews are the building blocks underlying evidence-based practice; they focus attention on the strength and limits of evidence from research studies about the effectiveness and safety of a clinical intervention. In the context of developing recommendations for practice, systematic reviews are useful because they define the strengths and limits of the evidence, clarifying whether assertions about the value of the intervention are based on strong evidence from clinical studies. For more information about systematic reviews, see

[www.effectivehealthcare.ahrq.gov/reference/purpose.cfm](http://www.effectivehealthcare.ahrq.gov/reference/purpose.cfm).

AHRQ expects that CERs will be helpful to health plans, providers, purchasers, government programs, and the health care system as a whole. In addition, AHRQ is committed to presenting information in different formats so that consumers who make decisions about their own and their family's health can benefit from the evidence.

Transparency and stakeholder input from are essential to the Effective Health Care Program. Please visit the Web site ([www.effectivehealthcare.ahrq.gov](http://www.effectivehealthcare.ahrq.gov)) to see draft research questions and reports or to join an email list to learn about new program products and opportunities for input. Comparative Effectiveness Reviews will be updated regularly.

We welcome comments on this CER. They may be sent by mail to the Task Order Officer named below at: Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850, or by email to [epc@ahrq.hhs.gov](mailto:epc@ahrq.hhs.gov).

Carolyn M. Clancy, M.D.  
Director  
Agency for Healthcare Research and Quality

Jean Slutsky, P.A., M.S.P.H.  
Director, Center for Outcomes and Evidence  
Agency for Healthcare Research and Quality

Stephanie Chang M.D., M.P.H.  
Director, EPC Program  
Center for Outcomes and Evidence  
Agency for Healthcare Research and Quality

Shilpa H. Amin, M.D., M.Bsc, F.A.A.F.P.  
Task Order Officer  
Center for Outcomes and Evidence  
Agency for Healthcare Research and Quality

## Acknowledgments

We are indebted to a tireless and exceptional group of colleagues who made this report possible. Each step of a systematic review draws on the skills and attention of an entire team.

Ms. Kerry Jordan served as project coordinator shepherding innumerable planning, implementation, and writing tasks to completion. She guided and contributed to production of the plethora of forms, spreadsheets, and tables that are required to produce reliable evidence tables and summary data. Her attentiveness to the needs of the investigator team and to pacing the work was especially valued.

Ms. Tracy Shields is a key member of the library science staff and her detailed approach to abstract and full text review, evidence table construction, and quality scoring was invaluable.

Ms. Kathy Lee was always willing to contribute time and effort when having extra assistance with tasks like printing and distributing articles and preparing meeting materials were a priority. We appreciate her generosity in helping while simultaneously assisting on several other major reports.

## Key Informants

Judith Bishop, C.N.M., M.P.H.  
Professor, Obstetrics, Gynecology, and  
Reproductive Sciences  
University of California, San Francisco  
San Francisco, CA

William Camann, M.D.  
Director of Obstetric Anesthesia  
Brigham and Women's Hospital, Harvard  
Medical School  
Boston, MA

Sharon Holley, D.N.P., C.N.M.  
Instructor of Nursing  
Vanderbilt University Nursing School  
Nashville, TN

Holly Powell Kennedy, C.N.M., Ph.D.,  
F.A.C.N.M., F.A.A.N.  
Helen Varney Professor of Midwifery  
Yale University School of Nursing  
President, American College of Nurse-  
Midwives  
New Haven, CT

Ellice Lieberman, M.D., Dr.P.H.  
Professor, Department of Society, Human  
Development, and Health, Department of  
Epidemiology  
Brigham and Women's Hospital, Harvard  
Medical School  
Boston, MA

Nancy K. Lowe, C.N.M., Ph.D.,  
F.A.C.N.M., F.A.A.N.  
Chair for Division of Women, Children, and  
Family Health  
University of Colorado Denver College of  
Nursing  
Denver, CO

Judith Rooks, C.N.M., M.P.H., F.A.C.N.M.  
Courtesy Instructor, College of Public  
Health  
University of South Florida  
Tampa, FL

Carol Sakala, Ph.D., M.S.P.H.  
Director of Programs  
Childbirth Connection  
New York, NY

## Technical Expert Panel

Judith Bishop, C.N.M., M.P.H.  
Professor, Obstetrics, Gynecology, and  
Reproductive Sciences  
University of California, San Francisco  
San Francisco, CA

William Camann, M.D.  
Director of Obstetric Anesthesia  
Brigham and Women's Hospital, Harvard  
Medical School  
Boston, MA

Jo Davies, M.B.B.S., F.R.C.A.  
Associate Professor, Anesthesiology and  
Pain Medicine  
University of Washington  
Seattle, WA

Sharon Holley, D.N.P., C.N.M.  
Instructor of Nursing  
Vanderbilt University Nursing School  
Nashville, TN

Lucky Jain, M.D.  
Professor of Pediatrics, Executive Vice  
Chairman for Department of Pediatrics  
Emory University School of Medicine  
Atlanta, GA

Holly Powell Kennedy, C.N.M., Ph.D.,  
F.A.C.N.M., F.A.A.N.  
Helen Varney Professor of Midwifery  
Yale University School of Nursing  
President, American College of Nurse-  
Midwives  
New Haven, CT

Ellice Lieberman, M.D., Dr.P.H.  
Professor, Department of Society, Human  
Development, and Health, Department of  
Epidemiology  
Brigham and Women's Hospital, Harvard  
Medical School  
Boston, MA

Judith Rooks, C.N.M., M.P.H., F.A.C.N.M.  
Courtesy Instructor, College of Public  
Health  
University of South Florida  
Tampa, FL

Carol Sakala, Ph.D., M.S.P.H.  
Director of Programs  
Childbirth Connection  
New York, NY

## Peer Reviewers

William Camann, M.D.  
Director of Obstetric Anesthesia  
Brigham and Women's Hospital, Harvard  
Medical School  
Boston, MA

Jo Davies, M.B.B.S., F.R.C.A.  
Associate Professor, Anesthesiology and  
Pain Medicine  
University of Washington  
Seattle, WA

Jesse M. Ehrenfeld, M.D., M.P.H.  
Director of the Center for Evidence Based  
Anesthesia  
Vanderbilt University Medical Center  
Nashville, TN

Ellice Lieberman, M.D., Dr.P.H.  
Professor, Department of Society, Human  
Development, and Health, Department of  
Epidemiology  
Brigham and Women's Hospital, Harvard  
Medical School  
Boston, MA

Peter Norman, M.D., F.R.C.P.C.  
Professor, Anesthesiology & Perioperative  
Medicine  
The University of Texas  
Houston, TX

Judith Rooks, C.N.M., M.P.H., F.A.C.N.M.  
Courtesy Instructor, College of Public  
Health  
University of South Florida  
Tampa, FL

Mark Rosen, M.D.  
Director of Obstetric Anesthesia  
University of California San Francisco  
San Francisco, CA

Carol Sakala, Ph.D., M.S.P.H.  
Director of Programs  
Childbirth Connection  
New York, NY

Allison Shorten, Ph.D., R.N., R.M.,  
F.A.C.M.  
Associate Professor  
Yale School of Nursing  
New Haven, CT

# Nitrous Oxide for the Management of Labor Pain

## Structured Abstract

**Objectives.** The Vanderbilt Evidence-based Practice Center systematically reviewed evidence addressing the use of nitrous oxide for the management of labor pain.

**Data Sources.** We searched the MEDLINE®, Embase, and Cumulative Index to Nursing and Allied Health Literature (CINAHL) databases for articles published in English.

**Review Methods.** We excluded studies that did not address a Key Question, were not original research, or had fewer than 20 participants. We identified a total of 58 publications, representing 59 distinct study populations: 2 of good quality, 11 fair, and 46 poor.

**Results.** Inhalation of nitrous oxide provided less effective pain relief than epidural analgesia, but the quality of studies was predominately poor. The heterogeneous outcomes used to assess women's satisfaction with their birth experience and labor pain management made synthesis of studies difficult. The strength of evidence was insufficient to determine the effect of nitrous oxide on route of birth. Most maternal harms reported in the literature were unpleasant side effects that affect tolerability (e.g., nausea, vomiting, dizziness, and drowsiness). Apgar scores in newborns whose mothers used nitrous oxide were similar to those of newborns whose mothers used other labor pain management methods or no analgesia. Evidence about occupational harms and exposure was limited.

**Conclusions.** The literature addressing nitrous oxide for the management of labor pain has few studies of good or fair quality. Synthesis of effectiveness and satisfaction studies is challenging because of heterogeneous interventions, comparators, and outcome measures. Research assessing nitrous oxide is needed across all of the Key Questions addressed: effectiveness, women's satisfaction, route of birth, harms, and health system factors affecting use.



# Contents

<b>Executive Summary .....</b>	<b>ES-1</b>
<b>Introduction.....</b>	<b>1</b>
Background .....	1
Nitrous Oxide as a Labor Pain Management Option.....	1
Scope of This Report.....	5
Key Questions .....	5
Organization of This Evidence Report.....	5
Uses of This Report.....	6
<b>Methods.....</b>	<b>7</b>
Technical Expert Panel .....	7
Analytic Framework for Nitrous Oxide for Labor Pain Management.....	7
Literature Review Methods.....	10
Literature Search and Retrieval Process .....	10
Literature Synthesis.....	13
Development of Evidence Tables and Data Abstraction Process .....	13
Rating Quality of Individual Studies .....	13
Grading Strength of Evidence.....	14
Applicability.....	15
<b>Results .....</b>	<b>16</b>
KQ1: Effectiveness of Nitrous Oxide for Labor Pain Management .....	22
Key Points .....	22
Overview of the Literature .....	23
Detailed Synthesis.....	23
KQ2: Effect of Nitrous Oxide on Women’s Satisfaction.....	27
Key Points .....	27
Overview of the Literature .....	27
KQ3: Effect of Nitrous Oxide on the Route of Birth .....	29
Key Points .....	29
Detailed Synthesis.....	30
KQ4: Adverse Effects of Nitrous Oxide for Labor Pain Management .....	32
Key Points .....	31
Overview of the Literature .....	31
Detailed Synthesis.....	32
KQ5: Effects of Provider and Health System Factors.....	44
Grey Literature Search Results.....	44
<b>Discussion.....</b>	<b>45</b>
State of the Literature .....	45
Strength of Evidence .....	45
Principal Findings and Considerations .....	46
KQ1: Effectiveness of Nitrous Oxide for Labor Pain Management.....	46
KQ2: Effect of Nitrous Oxide on Women’s Satisfaction .....	46
KQ3: Effect of Nitrous Oxide on the Route of Birth.....	46
KQ4: Adverse Effects of Nitrous Oxide for Labor Pain Management.....	46
KQ5: Effects of Provider and Health System Factors .....	47

Applicability.....	47
Future Research.....	48
State of the Science .....	48
Conclusions .....	49
<b>References and Included Studies</b> .....	50
<b>Acronyms/Abbreviations/Symbols</b> .....	54

## Tables

Table A. Labor Pain Management Methods Used in Studies Included in This Review.....	ES-3
Table B. Strength of Evidence for Nitrous Oxide for the Management of Labor Pain .....	ES-13
Table 1. Labor Pain Management Methods Used in Studies Included in This Review .....	3
Table 2. Inclusion and Exclusion Criteria.....	11
Table 3. Summary of Nitrous Oxide Interventions, RCTs .....	18
Table 4. Summary of Nitrous Oxide Interventions, Nonrandomized Trials and Cohort Studies .....	20
Table 5. Summary of Nitrous Oxide Interventions, Other Study Designs .....	21
Table 6. Effectiveness of Inhalational Anesthetic Gases .....	24
Table 7. Route of Birth in Women Using Nitrous Oxide .....	30
Table 8. Maternal Adverse Effects Associated With Nitrous Oxide Use During Labor, Side Effects .....	34
Table 9. Fetal Adverse Effects, Cord Blood Gases.....	39
Table 10. Neonatal Adverse Effects, Mean and Median Apgar Scores.....	40
Table 11. Neonatal Adverse Effects, Range of Apgar Scores .....	41
Table 12. Strength of Evidence for Nitrous Oxide for the Management of Labor Pain .....	45

## Figures

Figure A. Stages of Labor .....	ES-1
Figure B. Analytic Framework for Nitrous Oxide for the Management of Labor Pain .....	ES-7
Figure C. Disposition of Articles Identified by the Search Strategy .....	ES-10
Figure 1. Stages of Labor .....	2
Figure 2. Analytic Framework for Nitrous Oxide for the Management of Labor Pain .....	9
Figure 3. Disposition of Articles Identified by the Search Strategy .....	17

## Appendixes

Appendix A. Exact Search Strings and Results
Appendix B. Sample Data Abstraction Forms
Appendix C. Evidence Tables
Appendix D. Applicability and Quality Tables
Appendix E. Excluded Studies
Appendix F. Regulatory Considerations of Nitrous Oxide

# Executive Summary


## Background

More than 4 million births occur in the United States each year; in 2008, there were 4,247,694 births.<sup>1</sup> The most commonly used labor pain management method in the United States is epidural analgesia (hereafter epidural).<sup>2</sup> Use of inhaled nitrous oxide is a common option for labor pain management in several countries outside the United States, including the United Kingdom, Finland, Sweden, Canada, Australia, and New Zealand. Only five centers in the United States are known to currently provide nitrous oxide as an option for labor pain management: the Birth Center at the University of California San Francisco Medical Center; the University of Washington Hospital in Seattle; St. Joseph Regional Medical Center in Lewiston, ID; Okanogan Douglas Hospital in Brewster, WA; and Vanderbilt University Medical Center in Nashville, TN (which began offering nitrous oxide in June 2011 after this review was under way). A significant barrier to use in the United States is limited availability of equipment to blend and deliver a mixture of nitrous oxide and oxygen for self-administration by laboring women.

Nitrous oxide, sometimes called “laughing gas” because it can produce euphoria, is an inhalational anesthetic and analgesic gas. Nitrous oxide has been used in dental care since the mid-1800s<sup>3</sup> and is commonly used for this indication today. Use of nitrous oxide during labor began in the late 1800s, and equipment for self-administration was introduced by Minnitt in England in 1934.<sup>4</sup>

The mechanism of action of nitrous oxide is thought to be an increased release of endorphin, dopamine, and other natural pain relievers in the brain, which modulate pain stimuli via descending spinal cord nerve pathways. Nitrous oxide does not completely relieve the pain of labor but creates “diminished pain, or a continued awareness of pain without feeling bothered by it.”<sup>5</sup> Nitrous oxide also has an antianxiety effect, which may be helpful if laboring women are restless and doubt their ability to cope, emotions that are not uncommon, especially during transition (see Figure A for an overview of the stages of labor).

**Figure A. Stages of labor**



The most common concentration of nitrous oxide administration for labor pain management in the biomedical literature and in current clinical practice is 50 percent nitrous oxide in oxygen, which can be mixed from two separate gas sources with a blender device (e.g., Nitronox<sup>®</sup>) or premixed in a single cylinder (e.g., Entonox<sup>®</sup>). Nitrous oxide is usually self-administered via a

facemask or mouthpiece on an intermittent basis, beginning about 30 to 60 seconds before each contraction.<sup>6</sup>

A variety of pain management methods were described in studies in this review (Table A). Epidural analgesia is the most commonly used method in the United States and may block pain entirely. Although epidurals are more effective for pain relief than other pain management methods, epidurals are associated with increased risk of assisted (vacuum or forceps) vaginal birth, use of oxytocin, maternal hypotension, motor blockade, urinary retention, maternal fever, and cesarean for maternal distress.<sup>7</sup> Women who have epidurals must have additional monitoring and may need confinement to bed, which limits mobility and options for positioning, and placement of a Foley catheter.

Although nitrous oxide would not be expected to be as effective for analgesia as an epidural because of the differences in their mechanism of action, nitrous oxide has other benefits, including its lower cost and less invasive nature. Nitrous oxide has a rapid onset and end of action. Thus women who do not like nitrous oxide or find it inadequate for pain management can easily discontinue its use and switch to another method, unlike epidurals and systemic opioids, which diminish gradually over a much longer period. Mobility and options for positioning are not limited and nitrous oxide does not require additional monitoring and potential anesthesia-related interventions (e.g., bladder catheterization). Women self-administer nitrous oxide, which allows them to control the amount they need.<sup>8</sup> Nitrous oxide may not be an ideal method for women who want maximum pain relief, but it could be preferable to other pharmacologic pain management methods for women who want increased mobility with less intervention and monitoring. Nitrous oxide might also be useful when a woman wants to delay use of epidural anesthesia until later in labor, when epidural anesthesia is not immediately available (e.g., in hospitals that do not have in-house anesthesia staff and must call in an anesthesia provider), when a woman arrives at the hospital too far along in labor to allow for an epidural to be placed and take effect, and when a woman finds epidural analgesia ineffective or inadequate.

One concern with nitrous oxide use is the potential for the gas to escape into the room and potentially affect health care workers as well as other individuals present with laboring women. For this reason, multiple organizations are responsible for regulating the use of nitrous oxide, and factors other than clinical outcomes are important to decisionmaking about its use (Appendix F). Room ventilation systems and scavenging systems that remove waste gases are used to reduce exposure to caregivers and others present for labor. Equipment capable of scavenging provides constant negative pressure so that the woman's exhalations, which contain nitrous oxide, are captured and removed from the room and facility.<sup>6</sup>

Finding the appropriate measure of effectiveness on which to assess nitrous oxide with other pain management methods is challenging. Nitrous oxide is not intended to provide the extent of pain relief expected with epidural. Therefore, rather than a direct comparison of effectiveness, the more important questions are whether women are satisfied with the use of nitrous oxide for labor pain management and if it is safe for the woman and her fetus/newborn.

**Table A. Labor pain management methods used in studies included in this review**

Method	Description	Timing and Frequency of Administration
Nitrous oxide	Anesthetic and analgesic gas usually inhaled intermittently via a facemask or mouthpiece, can be given continuously via nasal cannula Reduces the perception of pain, alters consciousness, decreases anxiety	Can be used for first- and second-stage labor pain Self-administered between and/or during contractions May be continued into third stage if procedures, such as perineal repair or manual removal of the placenta, are needed
Other inhalational anesthetic gases (desflurane, sevoflurane, isoflurane, enflurane, methoxyflurane, trichloroethylene, cyclopropane)	Anesthetic gas usually inhaled intermittently via a facemask or mouthpiece, can be given continuously via nasal cannula Reduces the perception of pain, alters consciousness	None is used currently used for management of labor pain in the United States Desflurane, sevoflurane, and isoflurane are used for other types of anesthesia in the United States
Epidural	Injection of medications (usually a combination of local anesthetic and opioid) into the epidural space around the spinal cord Blocks pain in lower half of body May partially or fully block voluntary motor control in lower half of body	Initiated during first stage of labor with infusion usually continuing into second stage May be continued into third stage if procedures, such as perineal repair or manual removal of the placenta, are needed
Opioids (for example, pethidine/meperidine)	Medication given intravenously or by intramuscular injection Provides some relief of labor pain and causes sedation, which can also alter perception of pain Opioids commonly used in labor include meperidine/pethidine, morphine, fentanyl, remifentanyl, butorphanol, and nalbuphine	Used during the first stage of labor Administered at regular intervals as needed for pain (usually every 1 to 4 hours depending on specific medication)
Paracervical block	Injection of local anesthetic at lateral cervix Provides some relief from the pain of cervical dilation	Rarely used in the United States because it causes fetal bradycardia (slow heart rate) Used during the first stage of labor Can be repeated
Pudendal block	Injection of local anesthetic in the vaginal wall near the pudendal nerves, bilaterally Relieves pain in the lower vagina, perineum, and external genitalia that occur when the woman is pushing	Used during the second stage of labor Administered once

**Table A. Labor pain management methods used in studies included in this review (continued)**

Method	Description	Timing and Frequency of Administration
Transcutaneous electrical nerve stimulation (TENS)	Low-voltage electrical impulses are sent from a handheld device controlled by the woman to electrodes placed on the skin of the lower back	Used during the first stage of labor Used as needed
Sterile water injections	Injection of sterile water intradermally (just below the skin) in four locations on the lower back	Used during the first stage of labor, most commonly for low back pain Can be repeated
Hydrotherapy	Immersion of the laboring woman in water	Can be used during the first and second stages of labor Used as needed
Psychoprophylaxis	Use of breathing and relaxation techniques taught during pregnancy	Can be used during the first and second stages of labor Used as needed

## Scope of this Report

Most women in the United States use some type of medication for labor pain management. However, the option of using nitrous oxide to relieve labor pain is limited by its lack of availability. Use of nitrous oxide during labor is common in other countries, increasing interest in this method in the United States, in part because it is less expensive and invasive than widely used regional anesthesia. This review attempts to assess the effectiveness of nitrous oxide in managing labor pain and to identify potential factors that may influence its availability and use within the United States. Our Key Questions have been structured with this goal in mind. The primary questions include the comparative effectiveness of nitrous oxide for the management of labor pain, the influence of nitrous oxide on women's satisfaction with their birth experience, the health system factors influencing its use within the United States, and any adverse effects associated with this intervention. With the rate of cesarean birth continuing to rise—32.3 percent of all U.S. births reported in 2008<sup>1</sup>—it is also important to address whether the use of nitrous oxide during labor influences the route of birth in women initially intending a vaginal birth.

## Objectives

### Population

We focused this review on pregnant women in first and second stages of labor, other attendees and health care providers present during labor, and the fetus/neonate.

### Intervention(s)

We examined the use of nitrous oxide for the management of labor pain.

### Comparators

We compared nitrous oxide with the following pain management methods: no analgesic/anesthetic intervention, other inhalational anesthetic gases, epidural, opioids, paracervical block, pudendal block, transcutaneous electrical nerve stimulation (TENS), sterile water injections, hydrotherapy, and psychoprophylaxis (see Table A).

## Outcomes

Our primary outcomes included pain management, satisfaction with pain management, satisfaction with birth experience, effect of nitrous oxide on the route of birth, adverse effects associated with the use of nitrous oxide for the management of labor pain, and health system factors associated with the use of nitrous oxide for the management of labor pain.

## Timing

Intermediate outcomes include associated labor outcomes, while long-term outcomes include associated birth outcomes. We did not place a restriction of the duration of followup.

## Setting

We considered all birth settings, including hospital, birth center, and home.

## Key Questions

1. What is the effectiveness of nitrous oxide when compared with other methods for the management of labor pain among women intending a vaginal birth?
2. What is the comparative effectiveness of nitrous oxide on women's satisfaction with their birth experience and pain management?
3. What is the comparative effectiveness of nitrous oxide on the route of birth?
4. What is the nature and frequency of adverse effects associated with the use of nitrous oxide for the management of labor pain, including but not limited to:
  - Maternal adverse effects, such as nausea and vomiting, dreams, dizziness, unconsciousness, and postpartum complications.
  - Fetal/neonatal adverse effects, such as low Apgar scores and abnormal fetal cord blood gases.
  - Childhood adverse effects, such as drug dependency and developmental complications.
  - Adverse effects on health care providers and other individuals present for labor.
5. What are the health system factors influencing the use of nitrous oxide for the management of labor pain, including but not limited to provider preferences, availability, setting, and resource utilization?


## Analytic Framework

We developed the analytic framework (Figure B) based on clinical expertise and refined it with input from our key informants and Technical Expert Panel (TEP) members. The figure represents the population of interest, women intending a vaginal birth, and the factors and decision points that influence the use of nitrous oxide for the management of labor pain. The initial preference for pain management methods, which is often determined prior to the onset of labor, can be shaped by past birth experience, cultural or familial influence, and knowledge of various pain management options. Women acquire knowledge about pain management options from a variety of sources including health care providers, childbirth educators, patient education books and other materials, popular media, friends, and family. Once labor begins, health system factors such as availability, setting, and provider preference may affect the utilization of the desired pain management methods (Key Question [KQ] 5). The first two decision points reflect the initial preference for and actual implementation of pain management methods. A third

decision point occurs after the onset of labor but prior to birth, at which point the woman in labor may opt to modify the pain management method. We sought to examine how the administration of nitrous oxide at various mixes, routes, and intervals affects outcomes that occur during labor, after birth, and in the long term (KQs 1–3). Adverse effects of treatment are examined in KQ4. Portions of the framework that are unexplored in the scientific literature are highlighted in the discussion of future research needs.



**Figure B. Analytic framework for nitrous oxide for the management of labor pain**



## **Methods**

### **Input From Stakeholders**

The topic was nominated in a public process. With key informant input, we drafted initial KQs, which were reviewed by the Agency for Healthcare Research and Quality (AHRQ) and posted to a public Web site for public comment. Using public input, we drafted final KQs, which were reviewed by AHRQ. We convened a technical expert panel to provide input during the project on issues such as setting inclusion/exclusion criteria and refining the analytic framework

### **Literature Search**

Our search included the MEDLINE<sup>®</sup>, Embase, and Cumulative Index to Nursing and Allied Health Literature (CINAHL) databases. Reviews conducted by the Cochrane Collaboration are indexed in the MEDLINE database and were also included in the search. We also hand-searched references of included articles to identify additional studies. Controlled vocabulary terms served as the foundation of our search, complemented by additional keyword phrases to represent the myriad ways in which nitrous oxide is referred to in the clinical literature. We also employed indexing terms within each database to exclude ineligible publication types and articles in languages other than English.

### **Inclusion and Exclusion Criteria**

We excluded studies that:

- Were not original research
- Did not include 20 or more pregnant women in labor
- Did not address adverse effects or occupational exposure during labor
- Did not report information pertinent to any KQ
- Were not published in English

### **Article Selection Process**

We examined abstracts of articles to determine whether studies met our criteria. Two reviewers separately evaluated the abstracts for inclusion or exclusion. If one reviewer concluded the article could be eligible for the review based on the abstract, we retained it. Full publications were then dually reviewed for final inclusion, with disagreements resolved via adjudication by an independent third reviewer. Reasons and process for exclusions are described in the full report.

### **Data Extraction**

All team members shared the task of entering information into evidence tables. After initial data extraction, another member checked table entries for accuracy, completeness, and consistency. Abstractors reconciled inconsistencies.

### **Quality Assessment**

The quality of individual studies was assessed using existing, widely accepted tools for each type of study. For randomized controlled trials (RCTs), the Cochrane Risk of Bias tool was

employed. Fundamental domains include: adequate sequence generation, allocation concealment, blinding, incomplete outcome data addressed, and free of selective reporting bias. For nonrandomized and observational studies, the Newcastle-Ottawa Quality Assessment Scale was utilized. The scale assesses three broad perspectives: (1) the selection of the study groups; (2) the comparability of the groups; and (3) the ascertainment of either the exposure or outcome of interest for case-control or cohort studies, respectively. Both tools are presented in the full report. Additionally, the thresholds for converting the Cochrane Risk of Bias tool and Newcastle-Ottawa Quality Assessment Scale results to the AHRQ standard of “good,” “fair,” and “poor” quality designations are presented in the full report.

## Evidence Synthesis

Text that summarizes the research evidence is organized by KQ. Within each KQ, evidence is organized by aspects of the question, such as the compared intervention and outcomes. In the full report, we include evidence tables for individual studies and summary tables of common outcomes and provide extended analysis.

## Grading Strength of Evidence

We evaluated the overall strength of the evidence for the primary outcomes. We graded available evidence for each key outcome for each of the following domains:

- Risk of bias (low, medium, or high)
- Consistency of findings (inconsistency not present, inconsistency present, or unknown or not applicable)
- Directness (direct comparison of influence on outcomes in RCT, or indirect information from observational research)
- Precision (precise or imprecise based on outcomes rates, size of the individual studies and the total number of women in the studies for the category of intervention)

We combined the grades of each domain to develop the strength of evidence for each key outcome. Possible grades for each domain were: low, moderate, or high risk of bias; consistent or inconsistent; direct or indirect; and precise or imprecise. We considered additional domains, including publication bias and large effect size, on a per-KQ basis.

We graded the body of literature for effectiveness of nitrous oxide, women’s satisfaction with their birth experience and pain management, effect of nitrous oxide on route of birth, and adverse effects associated with nitrous oxide. The possible grades were:

**High:** High confidence that the evidence reflects the true effect. Further research is unlikely to change estimates.

**Moderate:** Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of effect and may change the estimate.

**Low:** Low confidence that the evidence reflects the true effect. Further research is likely to change confidence in the estimate of effect and is also likely to change the estimate.

**Insufficient:** Evidence is either unavailable or does not permit a conclusion.


When no studies were available for an outcome or comparison of interest, we assessed the evidence as insufficient. Two reviewers independently graded the body of evidence; disagreements were resolved through discussion or a third reviewer adjudication.

# Results

## Literature Search Yield

We identified 1,428 nonduplicate titles or abstracts. Fifty-eight publications were included in the review (Figure C), representing 59 distinct study populations: 13 RCTs, 7 crossover RCTs, 4 nonrandomized clinical trials, 14 prospective cohorts, 1 retrospective cohort, 3 case series, 4 case-control studies, 11 cross-sectional studies, and 2 trend studies. The most common reasons for exclusion were irrelevance to the topic and ineligible study size. Twenty-one articles pertain to KQ1, 9 articles to KQ2, 6 articles to KQ3, 49 articles to KQ4, and 0 articles to KQ5.

**Figure C. Disposition of articles identified by the search strategy**



KQ = Key Question

\*The number of articles addressing Key Questions and those excluded exceed the total number of articles in each category because some articles fit multiple exclusion categories or addressed more than one Key Question.

## **KQ1. Effectiveness of Nitrous Oxide for Labor Pain Management**

Twenty-one studies addressed the effect of nitrous oxide on pain or pain relief.<sup>9-29</sup> Four studies were of fair quality,<sup>19, 22-23, 25</sup> and 17 were of poor quality.<sup>9-18, 20-21, 24, 26-29</sup> There was considerable variation in the concentration of nitrous oxide and frequency (continuous vs. intermittent) administered, additional pain management methods used, and methods and persons (i.e., women, obstetricians, midwives, and anesthesia providers) assessing pain and pain relief. The substantial variation in timing of assessment may have affected the reported outcomes because women's opinions about pain relief change with time lapsed after birth.<sup>10-11, 14</sup>

The majority of the effectiveness studies (12 of 21) had as comparators other inhalational anesthetic gases that are not used to manage labor pain in the United States. Only one study compared nitrous oxide with placebo and found no significant difference in pain scores. As expected, epidurals provide more effective pain relief than nitrous oxide. The evidence is insufficient to determine the effectiveness of nitrous oxide for the management of labor pain compared with other, nonepidural labor pain management methods because the studies are predominately of poor quality, use heterogeneous outcome measures, and have inconsistent findings.

## **KQ2. Effect of Nitrous Oxide on Women's Satisfaction**

Nine studies addressed women's satisfaction with their birth experience or pain management.<sup>16-17, 20-21, 24, 27, 30-32</sup> One study was of good quality,<sup>31</sup> one of fair quality,<sup>32</sup> and seven of poor quality.<sup>16-17, 20-21, 24, 27, 30</sup> Measures of satisfaction were not uniform, making it difficult to synthesize studies. The strength of the evidence is low for equivalence or superiority of nitrous oxide compared with other pain management methods for women's satisfaction with their birth experience and pain management.

## **KQ3. Effect of Nitrous Oxide on the Route of Birth**

Six studies compared the route of birth in women who used nitrous oxide with that in women who used other pain management methods.<sup>10, 14, 17, 24, 27, 31</sup> Two of these included only women who had vaginal births,<sup>10, 17</sup> and five were of poor quality.<sup>10, 14, 17, 24, 27</sup> The evidence is insufficient to determine the effect of nitrous oxide on the route of birth because the studies are predominately of poor quality and have inconsistent findings.

## **KQ4. Adverse Effects of Nitrous Oxide for Labor Pain Management**

Forty-nine studies addressed the maternal, fetal, neonatal, and occupational harms related to nitrous oxide use during labor.<sup>9-14, 17-21, 24, 26, 29, 31, 33-65</sup> Two were of good quality,<sup>31, 54</sup> 7 of fair quality,<sup>19, 33, 45, 47, 57, 59, 66</sup> and 40 of poor quality.<sup>9-14, 17-18, 20-21, 24, 26, 29, 34-44, 46, 48-53, 55-56, 58, 60-65</sup> Although these 49 studies report data from more than 27,000 women, only 6 were conducted in the United States (n = 2,445 women).

One-third (16 of 49) of studies reporting harms were conducted prior to 1980, when nitrous oxide was often used in combination with sedatives, tranquilizers, and other inhaled anesthetics in labor, a practice that has largely been abandoned. Studies reporting harms associated with sedative analgesic regimens may not translate effectively to contemporary labor analgesia practice. For example, in older studies, amnesia in labor was considered to be a positive outcome.

Most maternal harms reported in the literature were unpleasant side effects that affect tolerability (e.g., nausea, vomiting, dizziness, and drowsiness). Some maternal harms (e.g., nausea and oxygen desaturation) are common in all laboring women regardless of the type of analgesia used. Study sizes were inadequate to assess for unusual or rare harms that might be more serious.

Nitrous oxide is transmitted via the placenta and is rapidly eliminated by the neonate following birth once breathing begins. Apgar scores in newborns whose mothers used nitrous oxide did not differ significantly from those of newborns whose mothers used other labor pain management methods or no analgesia. Followup of newborns was short, most frequently lasting only to birth or discharge of the neonate from the hospital.

Few data are available to draw conclusions regarding potential occupational harms as a result of exposure to nitrous oxide. Evidence about occupational levels of nitrous oxide is limited, and some studies were conducted prior to the use of room ventilation systems or scavenging systems. The implementation of these systems in clinical practice has reduced occupational exposure, which should mitigate potential risks.

## **KQ5. Effects of Provider and Health System Factors**

No studies addressed KQ5.

## **Discussion**

### **Summary Strength of Evidence and Findings**

Overall, the strength of evidence to answer the KQs was insufficient for effectiveness for the management of labor pain (KQ1), route of birth (KQ3), and health system factors (KQ5); low for satisfaction with birth experience and pain management (KQ2); and moderate for harms (KQ4) (Table B). Deficiencies in the strength of evidence most often related to a preponderance of study designs with high risk of bias; inconsistent findings across studies and inconsistencies among outcomes that would be expected to show corresponding benefit; use of intermediate outcomes; and small studies with poor precision.

**Table B. Strength of evidence for nitrous oxide for the management of labor pain**

Total Studies (Total Participants)	Domains Pertaining to Strength of Evidence				Strength of Evidence
	Risk of Bias	Consistency	Directness	Precision	
<b><i>Effectiveness of Nitrous Oxide vs. Other, Nonepidural Labor Pain Management Methods for the Management of Labor Pain (KQ1)</i></b>					
<b>25 (15,991)</b>	High	Inconsistent	Indirect	Imprecise	Insufficient; includes 6 RCTs; 5 studies of fair quality and 20 studies of poor quality total
<b><i>Equivalence or Superiority of Nitrous Oxide vs. Other Labor Pain Management Methods for Women's Satisfaction With Their Birth Experience (KQ2)</i></b>					
<b>2 (1,303)</b>	High	Consistent	Direct	Imprecise	Low; includes no RCTs; 1 study of fair quality and 1 study of poor quality total
<b><i>Equivalence or Superiority of Nitrous Oxide vs. Other Labor Pain Management Methods for Women's Satisfaction With Their Pain Management (KQ2)</i></b>					
<b>8 (2,825)</b>	High	Consistent	Direct	Imprecise	Low; includes 2 RCTs; 1 study of good quality and 7 studies of poor quality total
<b><i>Effect of Nitrous Oxide for the Management of Labor Pain on Route of Birth (KQ3)</i></b>					
<b>6 (33,031)</b>	High	Inconsistent	Direct	Imprecise	Insufficient; includes 2 RCTs; 1 study of good quality and 5 studies of poor quality total
<b><i>Adverse Effects Associated With Nitrous Oxide for the Management of Labor Pain are Primarily Unpleasant Side Effects That Affect Tolerability (KQ4)</i></b>					
<b>48 (27,530)</b>	High	Consistent	Direct	Imprecise	Moderate; includes 18 RCTs; 2 studies of good quality, 6 studies of fair quality, and 40 studies of poor quality total

KQ = Key Question, RCT = randomized controlled trial

Note: Domains pertaining to SOE are taken from the AHRQ methods guide and are explained in the Methods section.

## Applicability

Applicability describes the extent to which study populations and characteristics in the literature reviewed apply to the larger population. In this report, the study populations were healthy women in labor who should be similar to the target population. Most studies used a 50/50 mix of nitrous and oxygen, often premixed in the form of Entonox<sup>®</sup>. The 50/50 mix is available, although Entonox is not used in the United States and has not been reviewed by the U.S. Food and Drug Administration. In addition, mechanical equipment for administration of nitrous oxide in labor and delivery has very limited availability in the United States at the time of this writing. The comparators include standard pain management methods, such as epidural, narcotics, and nonpharmacologic methods such as TENS. However, some comparators are not commonly used and/or available for laboring women, such as other inhalational anesthetic gases.

For KQ1, the most frequent outcome was an assessment of pain, generally during labor but sometimes in the immediate postpartum period and/or weeks to months after birth. Those assessing outcomes included participants, obstetricians, midwives, and anesthesia providers. These studies are unable to demonstrate whether nitrous provided adequate pain relief for women who knowingly accept less effective pain relief in exchange for increased mobility, less intervention and monitoring, and avoidance of potential complications associated with epidurals. Generally speaking, therefore, pain relief is likely to be an inadequate measure of effectiveness

for nitrous oxide in the absence of other outcomes such as women's satisfaction. Satisfaction with pain management and the birth experience were assessed in KQ2. Satisfaction is a more relevant measure of effectiveness than assessment of pain because nitrous oxide is not intended to provide complete pain relief. The outcomes for KQ3 were vaginal birth, assisted vaginal birth, and cesarean. For KQ4, the most frequent outcomes were assessments of nausea, vomiting, dizziness, drowsiness, hypoxia, oxygen saturation, Apgar scores, and cord blood gases.

Only 6 of 58 studies were conducted in the United States. The options for labor pain management in the United States are somewhat dissimilar to those in other countries because nitrous oxide for laboring women is widely available outside of the United States, whereas in this country its availability is extremely limited. All of the studies were conducted in hospitals; thus, the effectiveness, women's satisfaction, route of birth, and harms associated with nitrous oxide in birth centers and the home setting have not been reported.

## Conclusions

The literature addressing nitrous oxide for the management of labor pain has few studies of good or fair quality. Synthesis of effectiveness and satisfaction studies was challenging because of heterogeneous interventions, comparators, and outcome measures. Satisfaction may be a more relevant measure of effectiveness than assessment of pain because nitrous oxide is not intended to provide complete pain relief. The strength of evidence for the effect of nitrous oxide on route of birth was insufficient. Most maternal harms reported in the literature were unpleasant side effects that affect tolerability (e.g., nausea, vomiting, dizziness, and drowsiness), and Apgar scores did not differ significantly across labor pain management methods. Data for occupational harms were limited. Research assessing nitrous oxide is needed across all of the KQs examined: effectiveness, women's satisfaction, route of birth, harms, and health system factors affecting use.

## References

1. Martin JA, Hamilton BE, Sutton PD, et al. Births: Final Data for 2008. National Vital Statistics Reports. Released December 8, 2010;59(1):1-72.
2. Osterman MJ and Martin JA. Epidural and spinal anesthesia use during labor: 27-state reporting area, 2008. Natl Vital Stat Rep. 2011 Apr 6;59(5):1-13, 16.
3. Smith WD. A history of nitrous oxide and oxygen anaesthesia. I. Br J Anaesth. 1965;37(10):790-798.
4. Rosen MA. Nitrous oxide for relief of labor pain: A systematic review. Am J Obstet Gynecol. 2002;186(5 SUPPL):S110-S126.
5. Camann W, Alexander K. Easy labor: Every woman's guide to choosing less pain and more joy during childbirth. New York: Ballantine Books; 2007.
6. Rooks JP. Safety and risks of nitrous oxide labor analgesia: A review. J Midwifery Women's Health. 2011;56(6):557-565.
7. Anim-Somuah M, Smyth RM, and Jones L. Epidural versus non-epidural or no analgesia in labour. Cochrane Database Syst Rev. 2011;12:CD000331.
8. From the American College of Nurse-Midwives. Nitrous oxide for labor analgesia. J Midwifery Womens Health. 2010 May-Jun;55(3):292-6.
9. McGuinness C and Rosen M. Enflurane as an analgesic in labour. Anaesthesia. 1984 Jan;39(1):24-6.
10. Jones PL, Rosen M, Mushin WW, et al. Methoxyflurane and nitrous oxide as obstetric analgesics. I. A comparison by continuous administration. Br Med J. 1969 Aug 2;3(5665):255-9.



11. Jones PL, Rosen M, Mushin WW, et al. Methoxyflurane and nitrous oxide as obstetric analgesics. II. A comparison by self-administered intermittent inhalation. *Br Med J*. 1969 Aug 2;3(5665):259-62.
12. Yeo ST, Holdcroft A, Yentis SM, et al. Analgesia with sevoflurane during labour: ii. Sevoflurane compared with Entonox for labour analgesia. *Br J Anaesth*. 2007 Jan;98(1):110-5.
13. McLeod DD, Ramayya GP and Tunstall ME. Self-administered isoflurane in labour. A comparative study with Entonox. *Anaesthesia*. 1985 May;40(5):424-6.
14. Rosen M, Mushin WW, Jones PL, et al. Field trial of methoxyflurane, nitrous oxide, and trichloroethylene as obstetric analgesics. *Br Med J*. 1969 Aug 2;3(5665):263-7.
15. Morgan B, Bulpitt CJ, Clifton P, et al. Effectiveness of pain relief in labour: survey of 1000 mothers. *Br Med J (Clin Res Ed)*. 1982 Sep 11;285(6343):689-90.
16. Holdcroft A and Morgan M. An assessment of the analgesic effect in labour of pethidine and 50 per cent nitrous oxide in oxygen (Entonox). *J Obstet Gynaecol Br Commonw*. 1974 Aug;81(8):603-7.
17. Abboud TK, Swart F, Zhu J, et al. Desflurane analgesia for vaginal delivery. *Acta Anaesthesiol Scand*. 1995 Feb;39(2):259-61.
18. Smith BE and Moya F. Inhalational analgesia with methoxyflurane for vaginal delivery. *South Med J*. 1968 Apr;61(4):386-90.
19. Clark RB, Cooper JO, Brown WE, et al. An evaluation of methoxyflurane analgesia and anesthesia for obstetrics. *South Med J*. 1968 Jul;61(7):687-91.
20. Abboud TK, Shnider SM, Wright RG, et al. Enflurane analgesia in obstetrics. *Anesth Analg*. 1981 Mar;60(3):133-7.
21. Abboud TK, Gangolly J, Mosaad P, et al. Isoflurane in obstetrics. *Anesth Analg*. 1989 Mar;68(3):388-91.
22. Waldenstrom U, Bergman V, and Vasell G. The complexity of labor pain: Experiences of 278 women. *J Psychosom Obstet Gynaecol*. 1996;17(4):215-228.
23. Waldenstrom U and Irestedt L. Obstetric pain relief and its association with remembrance of labor pain at two months and one year after birth. *J Psychosom Obstet Gynaecol*. 2006 Sep;27(3):147-56.
24. Ranta P, Jouppila P, Spalding M, et al. Parturients' assessment of water blocks, pethidine, nitrous oxide, paracervical and epidural blocks in labour. *IntJ Obstet Anesth*. 1994;3(4):193-198.
25. Ranta P, Spalding M, Kangas-Saarela T, et al. Maternal expectations and experiences of labour pain - options of 1091 Finnish parturients. *Acta Anaesth Scand*. 1995;39(1):60-66.
26. Carstoniu J, Levytam S, Norman P, et al. Nitrous oxide in early labor. Safety and analgesic efficacy assessed by a double-blind, placebo-controlled study. *Anesthesiology*. 1994 Jan;80(1):30-5.
27. Harrison RF, Shore M, Woods T, et al. A comparative study of transcutaneous electrical nerve stimulation (TENS), Entonox, pethidine + promazine and lumbar epidural for pain relief in labor. *Acta Obstet Gynecol Scand*. 1987;66(1):9-14.
28. Chia YT, Arulkumaran S, Chua S, et al. Effectiveness of transcutaneous electric nerve stimulator for pain relief in labour. *Asia Oceania J Obstet Gynaecol*. 1990 Jun;16(2):145-51.
29. Bergsjö P and Lindbaek E. Comparison between nitrous oxide and methoxyflurane for obstetrical analgesia. *Acta Obstet Gynecol Scand*. 1971;50(3):285-90.
30. Henry A and Nand SL. Intrapartum pain management at the Royal Hospital for Women. *Aust N Z J Obstet Gynaecol*. 2004 Aug;44(4):307-13.
31. Leong EW, Sivanesaratnam V, Oh LL, et al. Epidural analgesia in primigravidae in spontaneous labour at term: a prospective study. *J Obstet Gynaecol Res*. 2000 Aug;26(4):271-5.
32. Waldenstrom U. Experience of labor and birth in 1111 women. *J Psychosom Res*. 1999 Nov;47(5):471-82.
33. Henderson KA, Matthews IP, Adishes A, et al. Occupational exposure of midwives to nitrous oxide on delivery suites. *Occup Environ Med*. 2003 Dec;60(12):958-61.

34. Ross JA, Tunstall ME, Campbell DM, et al. The use of 0.25% isoflurane premixed in 50% nitrous oxide and oxygen for pain relief in labour. *Anaesthesia*. 1999 Dec;54(12):1166-72.
35. Arfeen Z, Armstrong PJ and Whitfield A. The effects of Entonox and epidural analgesia on arterial oxygen saturation of women in labour. *Anaesthesia*. 1994 Jan;49(1):32-4.
36. Landon MJ, Creagh-Barry P, McArthur S, et al. Influence of vitamin B12 status on the inactivation of methionine synthase by nitrous oxide. *Br J Anaesth*. 1992 Jul;69(1):81-6.
37. Reed PN, Colquhoun AD, and Hanning CD. Maternal oxygenation during normal labour. *Br J Anaesth*. 1989 Mar;62(3):316-8.
38. Arthurs GJ and Rosen M. Self-administered intermittent nitrous oxide analgesia for labour. Enhancement of effect with continuous nasal inhalation of 50 per cent nitrous oxide (Entonox). *Anaesthesia*. 1979 Apr;34(4):301-9.
39. Rosen M, Latto P, and Asscher AW. Kidney function after methoxyflurane analgesia during labour. *Br Med J*. 1972 Jan 8;1(5792):81-3.
40. Phillips TJ and Macdonald RR. Comparative effect of pethidine, trichloroethylene, and Entonox on fetal and neonatal acid-base and PO<sub>2</sub>. *Br Med J*. 1971 Sep 4;3(5774):558-60.
41. Clinical trials of different concentrations of oxygen and nitrous oxide for obstetric analgesia. Report to the Medical Research Council of the Committee on Nitrous Oxide and Oxygen Analgesia in Midwifery. *Br Med J*. 1970 Mar 21;1(5698):709-13.
42. Stirk P, Staines J, and Brown DW. Maternal diamorphine administration during labour: the effect on neonate admissions to NNU. *J Neonatal Nurs*. 2002;8(2):56-7.
43. Constantine G, Luesley DM, O'Connor A, et al. The use of Entonox in conjunction with a rebreathing humidifier. *J Obstet Gynaecol*. 1989;10(1):23-25.
44. Murphy JF, Dauncey M, and Rees GAD. Obstetric analgesia, anaesthesia and the Apgar score. *Anaesthesia*. 1984;39(8):760-763.
45. Arora S, Tunstall M, and Ross J. Self-administered mixture of Entonox and isoflurane in labour. *Int J Obstet Anesth*. 1992 Sep;1(4):199-202.
46. McAneny T and Doughty A. Self-administered nitrous-oxide/oxygen analgesia in obstetrics. *Anaesthesia*. 1963 1963;18(4):488-497.
47. Mills GH, Singh D, Longan M, et al. Nitrous oxide exposure on the labour ward. *Int J Obstet Anesth*. 1996 Jul;5(3):160-4.
48. Bodin L, Axelsson G and Ahlberg G, Jr. The association of shift work and nitrous oxide exposure in pregnancy with birth weight and gestational age. *Epidemiology*. 1999 Jul;10(4):429-36.
49. Ahlberg G, Jr., Axelsson G and Bodin L. Shift work, nitrous oxide exposure and subfertility among Swedish midwives. *Int J Epidemiol*. 1996 Aug;25(4):783-90.
50. Axelsson G, Ahlberg G, Jr. and Bodin L. Shift work, nitrous oxide exposure, and spontaneous abortion among Swedish midwives. *Occup Environ Med*. 1996 Jun;53(6):374-8.
51. Einarsson S, Stenqvist O, Bengtsson A, et al. Gas kinetics during nitrous oxide analgesia for labour. *Anaesthesia*. 1996 May;51(5):449-52.
52. Nyberg K, Allebeck P, Eklund G, et al. Socio-economic versus obstetric risk factors for drug addiction in offspring. *Br J Addict*. 1992 Dec;87(12):1669-76.
53. Westling F, Milsom I, Zetterstrom H, et al. Effects of nitrous oxide/oxygen inhalation on the maternal circulation during vaginal delivery. *Acta Anaesthesiol Scand*. 1992 Feb;36(2):175-81.
54. Zack M, Adami HO and Ericson A. Maternal and perinatal risk factors for childhood leukemia. *Cancer Res*. 1991 Jul 15;51(14):3696-701.
55. Jacobson B, Nyberg K, Gronbladh L, et al. Opiate addiction in adult offspring through possible imprinting after obstetric treatment. *Br Med J*. 1990 Nov 10;301(6760):1067-70.
56. Jacobson B, Nyberg K, Eklund G, et al. Obstetric pain medication and eventual adult amphetamine addiction in offspring. *Acta Obstet Gynecol Scand*. 1988;67(8):677-82.

57. Westberg H, Egelrud L, Ohlson CG, et al. Exposure to nitrous oxide in delivery suites at six Swedish hospitals. *Int Arch Occup Environ Health*. 2008;81(7):829-836.
58. Marx GF, Joshi CW, and Orkin LR. Placental transmission of nitrous oxide. *Anesthesiology*. 1970 May;32(5):429-32.
59. Paech MJ. The King Edward Memorial Hospital 1,000 mother survey of methods of pain relief in labour. *Anaesth Intensive Care*. 1991 Aug;19(3):393-9.
60. Zelcer J, Owers H, and Paull JD. A controlled oximetric evaluation of inhalational, opioid and epidural analgesia in labour. *Anaesth Intensive Care*. 1989 Nov;17(4):418-21.
61. Deckardt R, Fembacher PM, Schneider KT, et al. Maternal arterial oxygen saturation during labor and delivery: pain-dependent alterations and effects on the newborn. *Obstet Gynecol*. 1987 Jul;70(1):21-5.
62. Talebi H, Nourozi A, Jamilian M, et al. Entonox for labor pain: a randomized placebo controlled trial. *Pak J Biol Sci*. 2009 Sep 1;12(17):1217-21.
63. Harrison RF and Cullen R. A comparative study of the behaviour of the neonate following various forms of maternal intrapartum analgesia and anaesthesia. *Ir J Med Sci*. 1986;155(1):12-18.
64. Beppu K. Transmission of the anesthetic agents through the placenta in painless delivery and their effects on newborn infants. *Keio J Med*. 1968 Jun;17(2):81-107.
65. Soyannwo OA. Self-administered Entonox (50% nitrous oxide in oxygen) in labour: report of the experience in Ibadan. *Afr J Med Med Sci*. 1985 Mar-Jun;14(1-2):95-8.
66. Newton C, Fitz-Henry J, and Bogod D. The occupational exposure of midwives to nitrous oxide - a comparison between two labour suites. *Int J Obstet Anesth*. 1999 Jan;8(1):7-10.

# Introduction

## Background

More than 4 million births occur in the United States each year; in 2008, there were 4,247,694 births.<sup>1</sup> A 2002 review of labor pain management in United States hospitals—stratified by number of yearly births and size of hospital—found that, among women who gave birth in 1997, 21 to 50 percent received epidural analgesia (hereafter epidural), 5 to 11 percent received combined spinal-epidural analgesia, 40 to 56 percent received parenteral analgesia, and 2 to 13 percent received paracervical or spinal analgesia. Ten to 17 percent of women did not receive any form of analgesia.<sup>2</sup> The 2006 Listening to Mothers II survey found that 86 percent of 1,573 responding women reported using one or more types of medication for pain relief during labor; 76 percent used epidural or spinal analgesia/anesthesia, 22 percent received narcotics, 3 percent received general anesthesia, and 3 percent used nitrous oxide.<sup>3</sup> Although limited by reliance on women's self-report, this survey provides data on the relative use of each method in the United States.<sup>3</sup> Given that so few facilities offer nitrous oxide, a survey intended to provide national estimates of medication use may not provide accurate numbers.

Use of inhaled nitrous oxide is a common option for labor pain management in several countries outside the United States. A 2002 systematic review on the topic, the most recent source available, cites evidence that nitrous oxide is used in the United Kingdom by approximately 50 to 75 percent of women and in Finland by approximately 60 percent of women.<sup>4</sup> In one study, 65 percent of women in Sweden received nitrous oxide for labor pain in 1991,<sup>5</sup> and a 1995 survey of hospitals in Ontario, Canada, found that nitrous oxide was available for labor pain analgesia in 75 percent of responding hospitals.<sup>6</sup> Nitrous oxide is also commonly used for labor analgesia in Australia and New Zealand.<sup>4</sup> Five centers in the United States are known to currently provide nitrous oxide as an option for labor pain management: the Birth Center at the University of California San Francisco (UCSF) Medical Center; the University of Washington Hospital in Seattle; St. Joseph Regional Medical Center in Lewiston, ID; Okanogan Douglas Hospital in Brewster, WA; and Vanderbilt University Medical Center in Nashville, TN (which began offering nitrous oxide in June 2011 after this review was under way). The UCSF practices have been described in the literature, including contraindications, preparation of the patient, and the documentation and competency requirements for midwives.<sup>7</sup> The UCSF model uses a mixture of 50 percent nitrous oxide and 50 percent oxygen that is self-administered by the patient after initial instruction on use and potential side effects. No related publications or descriptions of the option used at the University of Washington Hospital, St. Joseph Regional Medical Center, Okanogan Douglas Hospital, or Vanderbilt University could be located in the literature. A significant barrier to use in the United States is limited availability of equipment to blend and deliver a mixture of nitrous oxide and oxygen for self-administration by laboring women.


## Nitrous Oxide as a Labor Pain Management Option

Nitrous oxide, sometimes called “laughing gas” because it can produce euphoria, is an inhalational anesthetic and analgesic gas. Nitrous oxide has been used in dental care since the mid-1800s<sup>8</sup> and is commonly used for this indication today. Use of nitrous oxide during labor

began in the late 1800s, and equipment for self-administration was introduced by Minnitt in England in 1934.<sup>4</sup>

The mechanism of action of nitrous oxide is thought to be an increased release of endorphin, dopamine, and other natural pain relievers in the brain, which modulate pain stimuli by way of descending spinal cord nerve pathways.<sup>9-10</sup> Nitrous oxide does not completely relieve the pain of labor but instead creates “diminished pain, or a continued awareness of pain without feeling bothered by it.”<sup>11</sup> Nitrous oxide also has an anti-anxiety effect, which may be helpful if laboring women are restless and doubt their ability to cope, emotions that are not uncommon especially during transition (the end of the first stage of labor, see Figure 1 for an overview of the stages of labor).

**Figure 1. Stages of labor**



Nitrous oxide in a 50/50 mix, which can be mixed with a blender device (e.g., Nitronox<sup>®</sup>) or premixed (e.g., Entonox<sup>®</sup>), is the most common concentration of nitrous oxide administered for labor pain management, although some literature addresses varying concentrations of nitrous oxide in oxygen.<sup>12-13</sup> Nitrous oxide is usually self-administered via a facemask or mouthpiece on an intermittent basis, beginning about 30 to 60 seconds before each contraction.<sup>14</sup> Some literature addresses continuous vs. self-administered/intermittent administration.<sup>15-16</sup>

A variety of pain management methods are available for the pain women experience during the different stages of labor. See Table 1 for the labor pain management methods found in studies in this review. Epidural analgesia is the most commonly used method in the United States<sup>17</sup> and may block pain entirely. Although epidurals are more effective for pain relief than other pain management methods, epidurals are associated with increased risk of assisted (vacuum or forceps) vaginal birth, use of oxytocin, maternal hypotension, motor blockade, urinary retention, maternal fever, and cesarean for fetal distress.<sup>18</sup> In addition, the second stage of labor can be longer in women who have epidurals than in women who receive other pain management methods.<sup>19</sup> Women who have epidurals must have additional monitoring and may need confinement to bed, which limits mobility and options for positioning, and placement of a Foley catheter. Epidural placement is an invasive procedure that can have uncommon but clinically significant complications such as spinal headache.<sup>20</sup> Catastrophic complications, such as epidural hematoma and epidural abscess, are very rare but do occur.<sup>20</sup>

Although nitrous oxide would not be expected to be as effective for analgesia as an epidural because of the differences in their mechanism of action, nitrous oxide has other benefits including that it is inexpensive and noninvasive. Nitrous oxide has a rapid onset and end of action. Thus women who do not like nitrous oxide or find it inadequate for pain management can easily discontinue its use and switch to another method, unlike epidurals and systemic opioids

that diminish gradually over a much longer time period. Mobility and options for positioning are not limited nor does nitrous oxide require additional monitoring and potential anesthesia-related interventions (e.g., bladder catheterization). Women self-administer nitrous oxide, which allows them to control the amount they need.<sup>21</sup> Nitrous oxide may not be an ideal method for women who want maximum pain relief, but it could be preferable to other pharmacologic pain management methods for women who want increased mobility with less intervention and monitoring. Nitrous oxide might also be useful when a woman wants to delay use of epidural analgesia until later in labor, when epidural anesthesia is not immediately available (e.g., in hospitals that do not have in-house anesthesia staff and must call in an anesthesia provider), when a woman arrives at the hospital too far along in labor to allow for an epidural to be placed and take effect, and when a woman finds epidural analgesia ineffective or inadequate.

One concern with nitrous oxide use is the potential for the gas to escape into the room and potentially affect health care workers as well as other individuals present with laboring women. For this reason, there are multiple organizations responsible for regulation of the use of nitrous oxide and factors other than clinical outcomes are important to decisionmaking about its use (see Appendix F for a description of regulatory considerations). Room ventilation systems and scavenging systems that remove waste gases are used to reduce exposure to caregivers and others present for labor. Equipment capable of scavenging provides constant negative pressure so that the woman's exhalations, which contain nitrous oxide, are captured and removed from the room and facility.<sup>14</sup>

Identifying the appropriate outcome measure by which to assess nitrous oxide is challenging. Nitrous oxide is not intended to provide the extent of pain relief expected with epidural. Rather than a head to head comparison of effectiveness, the benefits of nitrous oxide rest on women's satisfaction and safety of the approach for the woman and her fetus/newborn.

**Table 1. Labor pain management methods used in studies included in this review**

Method	Description	Timing and Frequency of Administration
Nitrous oxide	Anesthetic and analgesic gas usually inhaled intermittently via a facemask or mouthpiece, can be given continuously via nasal cannula Reduces the perception of pain, alters consciousness, decreases anxiety	Can be used for first- and second-stage labor pain Self-administered between and/or during contractions May be continued into third stage if procedures, such as perineal repair or manual removal of the placenta, are needed
Other inhalational anesthetic gases (desflurane, sevoflurane, isoflurane, enflurane, methoxyflurane, trichloroethylene, cyclopropane)	Anesthetic gas usually inhaled intermittently via a facemask or mouthpiece, can be given continuously via nasal cannula Reduces the perception of pain, alters consciousness	None are used for management of labor pain in the United States Desflurane, sevoflurane, and isoflurane are used for other types of anesthesia in the United States

**Table 1. Labor pain management methods used in studies included in this review (continued)**

Method	Description	Timing and Frequency of Administration
Epidural	Injection of medications (usually a combination of local anesthetic and opioid) into the epidural space around the spinal cord Blocks pain in lower half of body May partially or fully block voluntary motor control in lower half of body	Initiated during first stage of labor with infusion usually continuing into second stage May be continued into third stage if procedures, such as perineal repair or manual removal of the placenta, are needed
Opioids (for example, pethidine/meperidine)	Medication given intravenously or by intramuscular injection Provides some relief of labor pain and causes sedation, which can also alter perception of pain Opioids commonly used in labor include meperidine/pethidine, morphine, fentanyl, remifentanyl, butorphanol, and nalbuphine	Used during the first stage of labor Administered at regular intervals as needed for pain (usually every 1 to 4 hours depending on specific medication)
Paracervical block	Injection of local anesthetic at lateral cervix Provides some relief from the pain of cervical dilation	Rarely used in the United States because it causes fetal bradycardia (slow heart rate) Used during the first stage of labor Can be repeated
Pudendal block	Injection of local anesthetic in the vaginal wall near the pudendal nerves, bilaterally Relieves pain in the lower vagina, perineum, and external genitalia that occur when the woman is pushing	Used during the second stage of labor Administered once
Transcutaneous electrical nerve stimulation (TENS)	Low-voltage electrical impulses are sent from a handheld device controlled by the woman to electrodes placed on the skin of the lower back	Used during the first stage of labor Used as needed
Sterile water injections	Injection of sterile water intradermally (just below the skin) in four locations on the lower back	Used during the first stage of labor, most commonly for low back pain Can be repeated
Hydrotherapy	Immersion of the laboring woman in water	Can be used during the first and second stages of labor Used as needed
Psychoprophylaxis	Use of breathing and relaxation techniques taught during pregnancy	Can be used during the first and second stages of labor Used as needed

## Scope of This Report

Most women in the United States use some type of medication for labor pain management. However, the option of using nitrous oxide to relieve labor pain is limited by its lack of availability. With such prevalent use of nitrous oxide during labor in other countries, increasing interest in this method in the United States, and potential advantages of this pain management method, such as being less expensive and invasive than widely used regional anesthesia, this review attempts to assess the effectiveness of nitrous oxide in managing labor pain and to identify potential factors that may influence its availability and use within the United States. Our Key Questions have been structured with this goal in mind. The primary outcomes for consideration, as identified by our technical expert panel, include the comparative effectiveness of nitrous oxide for the management of labor pain, the influence of nitrous oxide on women's satisfaction with their birth experience, the health system factors influencing its use within the United States, and any adverse effects associated with this intervention. With the rate of cesarean birth continuing to rise—32.3 percent of all U.S. births reported in 2008<sup>1</sup>—it is also important to address whether the use of nitrous oxide during labor influences the route of birth in women initially intending a vaginal birth.

## Key Questions

We have synthesized evidence in the published literature to address these Key Questions:

1. What is the effectiveness of nitrous oxide when compared with other methods for the management of labor pain among women intending a vaginal birth?
2. What is the comparative effectiveness of nitrous oxide on women's satisfaction with their birth experience and pain management?
3. What is the comparative effectiveness of nitrous oxide on the route of birth?
4. What is the nature and frequency of adverse effects associated with the use of nitrous oxide for the management of labor pain, including but not limited to:
  - Maternal adverse effects, such as nausea and vomiting, dreams, dizziness, unconsciousness, and postpartum complications.
  - Fetal/neonatal adverse effects, such as low Apgar scores and abnormal fetal cord blood gases.
  - Childhood adverse effects, such as drug dependency and developmental complications.
  - Adverse effects on health care providers and other individuals present for labor.
5. What are the health system factors influencing the use of nitrous oxide for the management of labor pain, including but not limited to provider preferences, availability, setting, and resource utilization?

## Organization of This Evidence Report

The following chapter describes our methods, including our search strategy, inclusion and exclusion criteria, approach to review of abstracts and full publications, and methods for extraction of data into evidence tables, and compiling evidence. We also describe our approach to grading the quality of the literature and to describing the strength of the literature.

In the Results chapter, we review the evidence identified by Key Question. We report the number and type of studies identified and we differentiate between total numbers of publications and unique studies to bring into focus the number of duplicate publications in this literature in



which multiple publications are derived from the same study population. In the final chapter of the report we discuss the results and enlarge on the methodologic considerations relevant to each Key Question. We also outline the current state of the literature and challenges for future research on the use of nitrous oxide for the management of labor pains.

## **Uses of This Report**

We anticipate this report will be of value to all health care providers who take care of women of childbearing age, including members of the American Congress of Obstetricians and Gynecologists; the Association of Women's Health, Obstetric and Neonatal Nurses; the American College of Nurse-Midwives; the American Association of Birth Centers; the American Society of Anesthesiologists; the Society for Obstetric Anesthesia and Perinatology; the American Association of Nurse Anesthetists; the American Academy of Family Physicians; and other clinical professional organizations. In addition, this review will be of use to the National Institutes of Health, Centers for Disease Control and Prevention, Centers for Medicare and Medicaid Services, and the Health Resources and Services Administration – all of which have offices or bureaus devoted to women's health issues. This report can bring providers up to date about the current state of evidence, and it provides an assessment of the quality of studies that aim to determine the outcomes of the use of nitrous oxide for the management of labor pain. It will be of interest to individual women and the general public because millions of women per year give birth in the United States, and the recurring need for women and their health care providers to decide among numerous options for labor pain management. This report will also be useful to facilities considering providing nitrous oxide for labor pain management. We also anticipate it will be of use to private sector organizations concerned with women's health, such as Childbirth Connection, the National Women's Health Network, and Our Bodies Ourselves.

Researchers can obtain a concise analysis of the current state of knowledge in this field. They will be poised to pursue further investigations that are needed to advance research methods, understand risk factors, develop options for labor pain management, and optimize the effectiveness and safety of clinical care for women in labor.

## Methods

In this chapter, we document the procedures that the Vanderbilt Evidence-based Practice Center used to produce a systematic review on the use of nitrous oxide for the management of labor pain. We first describe the assistance provided by the technical expert panel (TEP) throughout the topic refinement and review process. We then present the Key Questions and analytic framework. We also discuss our strategy for identifying articles relevant to our five Key Questions, our inclusion and exclusion criteria, and the process we used to abstract pertinent information from the eligible articles and generate our evidence tables. In addition, we discuss our method for grading the quality of individual articles and for rating the strength of the evidence. Finally, we describe the applicability of this report.

### Technical Expert Panel

We identified technical experts on the topic of the use of nitrous oxide for the management of labor pain in the fields of obstetrics and gynecology, anesthesiology, midwifery, nursing, pediatric care, primary care, and patient advocacy to provide assistance during the project. The TEP was expected to contribute to broader goals of the Agency for Healthcare Research and Quality (AHRQ), including (1) creating and maintaining science partnerships as well as public-private partnerships and (2) meeting the needs of an array of potential customers and users of its products. Thus, the TEP was both an additional resource and a sounding board during the project. The TEP included nine members serving as technical or clinical experts. To ensure robust scientifically relevant work, we called on the TEP to provide reactions to work in progress and advice on substantive issues or possibly overlooked areas of research. TEP members participated in conference calls and discussion through email to:

- Refine the analytic framework and Key Questions during topic refinement
- Discuss the preliminary assessment of the literature, including inclusion/exclusion criteria
- Provide input on the information and domains included in evidence tables
- Develop a hierarchy of participant characteristics and outcomes to systematically assess
- Advise about the clinical availability and use of nitrous oxide for the management of labor pain in the United States

Because of their extensive knowledge of the literature, including numerous articles authored by TEP members themselves, and their active involvement in professional societies and trial networks, and as practitioners in the field, we also asked TEP members to participate in the external peer review of the draft report.


### Analytic Framework for Nitrous Oxide for Labor Pain Management

The analytic framework in Figure 2 summarizes the conceptual model used to guide this systematic review by focusing the Key Questions on the critical health care related pathways and decision points. Our analytic framework emphasizes that care takes place at the interface of the health care system and the individual. The pathway through care is indicated in the boxes along the center line where the person and care meet. Each Key Question is indicated within the framework at the relevant point of influence in care. Each of the domains listed among individual and system factors, such as patient factors, use of cointerventions, provider factors and health

system factors, has been shown to influence care trajectories and outcomes. Making these domains explicit as they influence the care pathway provides the framework in which the review team and technical expert panel conducted this review. To the degree that individuals or care settings vary in context-specific points of influence, this framework may or may not be applicable.

Overall, the figure represents the population of interest, women intending a vaginal birth, and the factors and decision points that influence the use of nitrous oxide for the management of labor pain. The initial preference for pain management methods, which is often determined prior to the onset of labor, can be shaped by past birth experience, cultural or familial influence, and knowledge of various pain management options. Women acquire knowledge about pain management options from a variety of sources including health care providers, childbirth educators, patient education books and other materials, popular media, friends, and family. Once labor begins, health system factors such as availability, setting, and provider preference may affect the utilization of the desired pain management methods (Key Question 5). The first two decision points reflect the initial preference for and actual implementation of pain management methods. A third decision point occurs after the onset of labor but prior to birth, at which point the woman in labor may opt to modify the pain management method. We sought to examine how the administration of nitrous oxide at various mixes, routes, and intervals affects outcomes that occur during labor, after birth, and in the long term (Key Questions 1–3). Adverse effects of treatment are examined in Key Question 4. Portions of the framework that are unexplored in the scientific literature are highlighted in the discussion of future research needs.

**Figure 2. Analytic framework for nitrous oxide for the management of labor pain**



# **Literature Review Methods**

## **Literature Search and Retrieval Process**

### **Databases**

Our search included MEDLINE®, Embase, and Cumulative Index to Nursing and Allied Health Literature (CINAHL). Reviews conducted by the Cochrane Collaboration are indexed in the MEDLINE database and were also included in the search. We also hand-searched references of included articles to identify additional studies. We employed indexing terms within each database to exclude ineligible publication types and articles in languages other than English.

### **Search Terms**

Controlled vocabulary terms served as the foundation of our search in each database, complemented by additional keyword phrases to represent the myriad ways in which nitrous oxide is referred to in the clinical literature. We limited the MEDLINE search strategy to exclude studies not relevant to human populations and non-English-language papers. We also used the search strategy to perform an initial exclusion of publications that lay beyond the scope of the review (letters, comments, case reports, reviews, news, editorials, historical articles, and meta-analyses), focusing on retaining items comprising primary data (prospective and retrospective studies).

We searched CINAHL and Embase to supplement the MEDLINE results with additional nursing and drug-focused results. Similarly, we used a combination of controlled vocabulary and keywords, limited to primary data, English-language reports, and human subjects. Our review process also allowed identification of additional articles which should be retained for hand searching of references. Appendix A outlines our search terms and results. Our searches were executed between July 2010 and July 2011 and were not limited by date.

### **Grey Literature**

Grey literature was searched with a focus on background and regulatory material. Sources included websites and databases of the U.S. Food and Drug Administration (FDA), the Joint Commission, the Occupational Safety and Health Administration (OSHA), and the National Institute for Occupational Safety and Health (NIOSH); thesis/dissertation databases (ProQuest Dissertations and Theses A&I, Networked Digital Library of Theses & Dissertations, Index to Theses); New York Academy of Medicine's Grey Literature Report; PAIS International; Hazardous Substances Data Bank; legal resources (LexisNexis Academic, HeinOnline); meeting/abstract databases (BIOSIS Previews, BioMed Central meeting abstracts); OpenDOAR open access repository; general web searching (Google, GoogleScholar, Scirus); and files posted to an email group focused on the use of nitrous oxide in labor (N2Oduringlabor Yahoo! Group).

### **Inclusion and Exclusion Criteria**

Our inclusion and exclusion criteria and population, intervention, comparators, outcomes, timing, and setting (PICOTS) were developed in consultation with the TEP, to capture the literature most tightly related to the Key Questions. The PICOTS and criteria are summarized in Table 2.

**Table 2. Inclusion and exclusion criteria**

Category	Criteria
Study population	Pregnant women in first and second stages of labor (up to birth), other attendees and health care providers, and the fetus/neonate
Intervention	Nitrous oxide inhalation
Comparators	<ul style="list-style-type: none"> <li>No analgesic/anesthetic intervention, analgesia/anesthesia, other inhalational agents, and pharmacologic and nonpharmacologic pain management methods <ul style="list-style-type: none"> <li>Pharmacologic pain management methods include, but are not limited to, epidural analgesia, paracervical block, pudendal block, and parenteral opioids</li> <li>Nonpharmacologic pain management methods include, but are not limited to, acupuncture, aromatherapy, continuous labor support, heat and cold, hydrotherapy, hypnosis, movement and positioning, music and audioanalgesia, patterned breathing and relaxation, sterile water injections, touch and massage, and transcutaneous electrical nerve stimulation (TENS)</li> </ul> </li> </ul>
Outcomes	<ul style="list-style-type: none"> <li>Primary outcomes: <ul style="list-style-type: none"> <li>Pain reduction</li> <li>Satisfaction with pain management</li> <li>Satisfaction with birth experience</li> <li>Long-term maternal, child, and occupational health outcomes</li> </ul> </li> <li>Other outcomes: <ul style="list-style-type: none"> <li>Labor and intermediate outcomes <ul style="list-style-type: none"> <li>Pain</li> <li>Coping</li> <li>Labor progress</li> <li>Satisfaction with pain management.</li> <li>Satisfaction with birth experience</li> <li>Availability and timeliness</li> <li>Cointerventions associated with the use of nitrous oxide or other pain management methods</li> </ul> </li> <li>Birth and long-term outcomes <ul style="list-style-type: none"> <li>Maternal outcomes, including but not limited to route of birth and postpartum course</li> <li>Child outcomes, including but not limited to Apgar scores, fetal cord blood gases, and neurobehavioral outcomes</li> <li>Health care provider outcomes (occupational health) from exposure</li> <li>Maternal satisfaction with pain management</li> <li>Maternal satisfaction with birth experience</li> </ul> </li> <li>Adverse effects, including but not limited to: <ul style="list-style-type: none"> <li>Maternal adverse effects, such as nausea and vomiting, dreams, dizziness, and unconsciousness</li> <li>Fetal/neonatal adverse effects, such as drug dependency</li> <li>Childhood adverse effects, such as drug dependency and developmental complications.</li> <li>Individuals present for labor adverse effects.</li> <li>Health care provider adverse effects (occupational health)</li> </ul> </li> </ul> </li> </ul>

**Table 2. Inclusion and exclusion criteria (continued)**

Category	Criteria
Timing	<ul style="list-style-type: none"> <li>Intermediate outcomes will include associated labor outcomes</li> <li>Long-term outcomes will include associated birth outcomes</li> <li>There will be no restriction on duration of follow-up</li> </ul>
Setting	<ul style="list-style-type: none"> <li>All birth settings will be considered, including hospital, birth center, and home</li> </ul>
Publication date	No limit
Publication languages	English only
Admissible evidence (study design and other criteria)	<u>Admissible designs</u> <ul style="list-style-type: none"> <li>Study size <math>\geq 20</math> pregnant women using nitrous oxide during labor and reporting outcomes</li> <li>Addresses harms or occupational exposures</li> </ul> <u>Other criteria</u> <ul style="list-style-type: none"> <li>Original research studies that provide sufficient detail regarding methods and results to enable use and adjustment of the data and results</li> <li>Studies with mixed patient populations must include <math>\geq 20</math> pregnant women in labor or provide extractable information addressing harms or occupational outcomes</li> <li>Studies must include at least one outcome measure of an outcome listed in the PICOTS</li> <li>Relevant outcomes must be extractable from data presented in the papers</li> </ul>

The study population includes pregnant women in labor, birth attendees or health care providers who may be exposed to nitrous oxide during labor, and the fetus/neonate. We did not restrict by parity or risk status. The initial study size was set at greater than or equal to 20 women using any intervention for labor pain management, provided that nitrous oxide was included in the study (i.e. studies with multiple arms that include nitrous oxide as an intervention for labor pain management would be included if the total N was greater than or equal to 20). However, once we completed the data abstraction, we determined that a meta-analysis would not be feasible given the heterogeneity among included studies in several key areas, most notably nitrous oxide mix, outcome assessment methods, and comparators. The study size inclusion criterion was then amended to specify that included studies must report outcomes on greater than or equal 20 women using nitrous oxide for labor pain management. Studies with fewer than 20 women reporting outcomes related to nitrous oxide use are too small to provide meaningful results in the absence of a meta-analysis. We excluded four studies based on the amended study size criterion.

We did not have translation services available to us to review non-English papers, and our TEP agreed that the vast majority of the relevant literature would be published in English. Furthermore, this review is intended to inform U.S. health care, and most research in the population of pregnant women in the United States is published in English language journals. Empirical evidence on the potential for bias created by excluding non-English studies also suggests little effect.<sup>22</sup>

## Article Selection Process

Once we identified articles through the electronic database searches, review articles, and bibliographies, we examined abstracts of articles to determine whether studies met our criteria. Two reviewers separately evaluated the abstracts for inclusion or exclusion, using an Abstract

Review Form (Appendix B). If one reviewer concluded that the article could be eligible for the review based on the abstract, we retained it. Following abstract review, two reviewers independently assessed the full text of each included study using a standardized form (Appendix B) that included questions stemming from our inclusion/exclusion criteria. Disagreements between reviewers were resolved by a third-party adjudicator. The group of abstract and full text reviewers included three physicians (two obstetrician-gynecologists and an anesthesiologist), two certified nurse-midwives, two health services researchers, and two library scientists. Excluded studies, and the reasons for exclusion, are presented in Appendix E.

## **Literature Synthesis**

### **Development of Evidence Tables and Data Abstraction Process**

The staff members and clinical experts who conducted this review jointly developed the evidence tables. We designed the tables to provide sufficient information to enable readers to understand the studies and to determine their quality; we gave particular emphasis to essential information related to our Key Questions. We based the format of our evidence tables on successful designs used for prior systematic reviews.

The team was trained to abstract by abstracting several articles into evidence tables and then reconvening as a group to discuss the utility of the table design. We repeated this process through several iterations until we decided that the tables included the appropriate categories for gathering the information contained in the articles. All team members shared the task of initially entering information into the evidence tables. Another member of the team also reviewed the articles and edited all initial table entries for accuracy, completeness, and consistency. The two abstractors reconciled disagreements concerning the information reported in the evidence tables, the most common of which were study design and study setting. The full research team met regularly during the article abstraction period and discussed global issues related to the data abstraction process. In addition to outcomes related to intervention effectiveness, we abstracted all data available on harms. Harms encompass the full range of specific negative effects, including the narrower definition of adverse events.

The final evidence tables are presented in their entirety in Appendix C. Studies are presented in the evidence tables alphabetically by the last name of the first author. When possible, studies resulting from the same study population were grouped into a single evidence table. A list of abbreviations and acronyms used in the tables appears at the beginning of that appendix.

### **Rating Quality of Individual Studies**

To assess the quality of individual studies, the team considered both novel and existing rating tools. Two existing, widely accepted tools were selected to account for the variety of potentially included study types (e.g. randomized controlled trials [RCTs] and cohorts); specifically the Cochrane Risk of Bias tool<sup>23</sup> and the Newcastle-Ottawa Quality Assessment Scale.<sup>24</sup> The Cochrane Risk of Bias tool is designed for the assessment of studies with experimental designs and randomized participants. As such, we employed the Cochrane Risk of Bias tool to assess the quality of RCTs. Fundamental domains include sequence generation, allocation concealment, blinding, completeness of outcome data, and selective reporting bias. The Newcastle-Ottawa Quality Assessment Scale was used to assess the quality of nonrandomized studies (e.g. cohort and case-control studies). This scale assesses three broad perspectives: the selection of study



groups, the comparability of study groups, and the ascertainment of either the exposure or outcome of interest for case-control or cohort studies, respectively. Both tools are presented in Appendix D.

Quality assessment of each study was conducted using the Distiller Systematic Review online reference manager (Evidence Partners Incorporated, Ottawa, Ontario). Web-based assessment forms were created using the tools provided in Appendix D as templates. Investigators did not rely on the study design as described by authors of individual papers; rather, the methods section of each paper was reviewed to determine which rating tool to employ. Four investigators independently assessed the quality of individual studies, with the Senior Scientist reviewing and resolving any discrepancies. Thresholds for converting the Cochrane Risk of Bias tool and Newcastle-Ottawa Quality Assessment Scale results to the AHRQ standard of “good,” “fair,” and “poor” quality designations are described in Appendix D.

## Grading Strength of Evidence

We evaluated the overall strength of the evidence for the primary outcomes. We used the approach to strength of evidence described in the EPCs’ Methods Guide for Effectiveness and Comparative Effectiveness Reviews.<sup>25</sup> We graded available evidence for each key outcome for each of the following domains:

- Risk of bias (low, medium, or high)
- Consistency of findings (inconsistency not present, inconsistency present, or unknown or not applicable)
- Directness (direct comparison of influence on outcomes in RCT, or indirect information from observational research)
- Precision (precise or imprecise based on outcomes rates, size of the individual studies and the total number of women in the studies for the category of intervention)

We combined the grades of each domain to develop the strength of evidence for each key outcome. Possible grades for each domain were: low, moderate, or high risk of bias; consistent or inconsistent; direct or indirect; and precise or imprecise. We considered additional domains, including publication bias and large effect size, on a per-Key Question basis.

We graded the body of literature for effectiveness of nitrous oxide for the management of labor pain, women’s satisfaction with their birth experience and pain management, effect of nitrous oxide on route of birth, and adverse effects associated with nitrous oxide. We present those ratings as part of the discussion in the final chapter of the report. The possible grades were:

**High:** High confidence that the evidence reflects the true effect. Further research is unlikely to change estimates.

**Moderate:** Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of effect and may change the estimate.

**Low:** Low confidence that the evidence reflects the true effect. Further research is likely to change confidence in the estimate of effect and is also likely to change the estimate.

**Insufficient:** Evidence is either unavailable or does not permit a conclusion.

When no studies were available for an outcome or comparison of interest, we assessed the evidence as insufficient. Two reviewers independently graded the body of evidence; disagreements were resolved through discussion or a third reviewer adjudication.

## **Applicability**


For decision makers to use this report to inform clinical care, they need information clarifying the degree to which findings of the included research might be expected to apply in the types of populations and settings in which intrapartum care is provided in the United States. Our assessment of applicability implemented the PICOTS framework, as described in AHRQ's Methods Guide for Effectiveness and Comparative Effectiveness Reviews.<sup>25</sup> Applicability tables depicting the similarity or lack of comparability of populations, interventions, comparison groups, outcomes, and settings represented in the available literature for each Key Question are presented in Appendix D.

Additionally, we used input from team and TEP members to identify study characteristics to be included in evidence tables and routinely abstracted. These characteristics were critical in highlighting limitations of current research, and in turn assessing applicability. We discuss applicability further in the Discussion chapter of the report.

## Results

We identified 1,428 nonduplicate titles or abstracts, with 574 proceeding to full text review (Figure 3). Fifty-eight publications were included in the review, representing 59 distinct study populations: 13 randomized controlled trials (RCTs), seven crossover RCTs, four nonrandomized clinical trials, 14 prospective cohorts, one retrospective cohort, three case series, four case-control studies, 11 cross-sectional studies, and two trend studies. The most common reasons for exclusion were irrelevance to the topic and ineligible study size. Twenty-one articles pertain to Key Question (KQ) 1, nine articles to KQ2, six articles to KQ3, 49 articles to KQ4, and zero articles to KQ5. Tables 3, 4 and 5 provide summaries of the nitrous oxide interventions represented in this review. Studies are grouped by study type and displayed in reverse chronological order. Seven studies of occupational exposure to nitrous oxide,<sup>26-32</sup> three studies of addiction in offspring following nitrous oxide use during labor,<sup>33-35</sup> and one study of leukemia in offspring following nitrous oxide use during labor<sup>36</sup> are not included in the tables but are described in detail in the results of KQ4.

**Figure 3. Disposition of articles identified by the search strategy**



KQ = Key Question

\*The number of articles addressing Key Questions and those excluded exceed the total number of articles in each category because some articles fit multiple exclusion categories or addressed more than one Key Question.

**Table 3. Summary of nitrous oxide interventions, RCTs**

<b>Study Country Total N Study Type, Quality</b>	<b>Nitrous Oxide Mix and Administration Method</b>	<b>Comparator(s)</b>
Talebi et al., <sup>37</sup> 2009 Iran N = 523 RCT, poor	50%;self-administered via facemask	50% oxygen
Yeo et al., <sup>38</sup> 2007 U.K. N = 32 Crossover RCT, poor	Entonox (50%); self-administered	0.8% sevoflurane
Einarsson et al., <sup>39</sup> 1996 Sweden N = 24 RCT, poor	50%, 70%; administered via mouthpiece	The alternate nitrous oxide mixes were compared (50% vs. 70%)*
Abboud et al., <sup>40</sup> 1995 U.S. N = 80 RCT, poor	30 - 60%; administered by an anesthesiologist	1 – 4.5% desflurane
Carstoniu et al., <sup>41</sup> 1994 Canada N = 26 Crossover RCT, poor	50%; self-administered	Compressed air
Arora et al., <sup>42</sup> 1992 U.K. N = 41 RCT, fair	Entonox (50%); administration method not reported	Entonox and isoflurane
Westling et al., <sup>43</sup> 1992 Sweden N = 24 Crossover RCT, poor	40% and 70% (intermittent), 40% (continuous); administered via facemask	Intermittent oxygen, alternate nitrous oxide mixes, intermittent vs. continuous
Chia et al., <sup>44</sup> 1990 Singapore N = 121 RCT, poor	Entonox (50%); administration method not reported	TENS
Abboud et al., <sup>45</sup> 1989 U.S. N = 60 RCT, poor	30 - 60%	0.7% isoflurane
Constantine et al., <sup>46</sup> 1989 U.K. N = 149 RCT, poor	Entonox (50%); administered via facemask, mouthpiece, or humidifier	The alternate administration methods were compared*
McLeod et al., <sup>47</sup> 1985 U.K. N = 32 Crossover RCT, poor	Entonox (50%); administered via facemask	0.75% isoflurane
McGuinness and Rosen, <sup>48</sup> 1984 U.K. N = 20 Crossover RCT, poor	Entonox (50%); administered by an anesthesiologist via mouthpiece	1% enflurane

**Table 3. Summary of nitrous oxide interventions, RCTs (continued)**

<b>Study Country Total N Study Type, Quality</b>	<b>Nitrous Oxide Mix and Administration Method</b>	<b>Comparator(s)</b>
Abboud et al., <sup>49</sup> 1981 U.S. N = 105 RCT, poor	30 - 60%; administered by an anesthesiologist	0.25 – 1.25% enflurane
Rosen et al., <sup>50</sup> 1972 U.K. N = 250 RCT and prospective cohort, poor	Entonox (50%); administration method not reported	0.35% methoxyflurane
Bergsjø and Lindbaek, <sup>51</sup> 1971 Norway N = 63 Crossover RCT, poor	50%; administered via facemask	0.5 – 0.8% methoxyflurane
Phillips and Macdonald, <sup>52</sup> 1971 U.K. N = 152 RCT, poor	Entonox (50%); administration method not reported	Trichloroethylene and pethidine, pethidine only
NA, <sup>12</sup> 1970 U.K. N = 778 RCT, fair	50%, 70%; administration method not reported	The alternate nitrous oxide mixes were compared (50% vs. 70%)*
Jones et al., <sup>53</sup> 1969 U.K. N = 50 RCT, poor	50%; administration method not reported	0.35% methoxyflurane
Jones et al., <sup>54</sup> 1969 U.K. N = 50 RCT, poor	0 - 80%; administration method not reported	60% methoxyflurane

TENS = transcutaneous electrical nerve stimulation

\*Studies that assessed nitrous oxide and no other pain management methods were only included in the harms KQ.

**Table 4. Summary of nitrous oxide interventions, nonrandomized trials and cohort studies**

<b>Study Country Total N Study Type, Quality</b>	<b>Nitrous Oxide Mix and Administration Method</b>	<b>Comparator(s)</b>
Stirk et al., <sup>55</sup> 2002 U.K. N = 115 Prospective cohort, poor	Entonox (50%); administration method not reported	Diamorphine
Leong et al., <sup>56</sup> 2000 Malaysia N = 118 Prospective cohort, good	Entonox (50%); administration method not reported	Epidural and bupivacaine and/or fentanyl
Arfeen et al., <sup>57</sup> 1994 U.K. N = 40 Prospective cohort, poor	Entonox (50%); administration method not reported	Epidural and bupivacaine
Ranta et al., <sup>58</sup> 1994 Finland N = 1,091 Prospective cohort, poor	50%; administered by an anesthesiologist	Epidural, water block, pethidine, multiple analgesics, no analgesia
Landon et al., <sup>59</sup> 1992 U.K. N = 58 Prospective cohort, poor	Entonox (50%); administration method not reported	No nitrous oxide
Zelcer et al., <sup>60</sup> 1989 Australia N = 75 Prospective cohort, poor	% not reported, administration method not reported	Epidural, pethidine
Deckardt et al., <sup>61</sup> 1987 Germany N = 55 Prospective cohort, poor	50%; administration method not reported	Lumbar peridural anesthesia, no analgesic drugs
Harrison et al., <sup>62</sup> 1987 Ireland N = 170 Prospective cohort, poor	Entonox (50%); self-administered	Epidural, TENS, pethidine and promazine
Harrison and Cullen <sup>63</sup> 1986 Ireland N = 110 Prospective cohort, poor	Entonox (50%); self-administered	Epidural, pethidine and promazine, TENS, TENS placebo, general anesthesia
Soyannwo, <sup>64</sup> 1985 Nigeria N = 150 Prospective cohort, poor	Entonox (50%); self-administered	Entonox and pethidine or pethilorphan
Murphy et al., <sup>65</sup> 1984 U.K. N = 8,392 Retrospective cohort, poor	Entonox (50%); administration method not reported	Epidural, pethidine

**Table 4. Summary of nitrous oxide interventions, nonrandomized trials and cohort studies (continued)**

Study Country Total N Study Type, Quality	Nitrous Oxide Mix and Administration Method	Comparator(s)
Arthurs et al., <sup>16</sup> 1979 U.K. N = 49 Prospective cohort, poor	Entonox (50%); self-administered intermittently via facemask, or continuously via nasal cannula	Facemask and nasal cannula vs. facemask only*
Rosen et al., <sup>66</sup> 1969 U.K. N = 1,522 Nonrandomized trial, poor	Entonox (50%); administration method not reported	0.35%, 0.5% trichloroethylene; 0.35% methoxyflurane
Beppu, <sup>67</sup> 1968 Japan N = 667 Prospective cohort, poor	50 – 80%; administration method not reported	Trichloroethylene, halothane
Smith et al., <sup>68</sup> 1968 U.S. N = 2,066 Nonrandomized trial, poor	25 – 50%; administration method not reported	0.2 – 0.5% methoxyflurane, 1 – 5% cyclopropane, pudendal, spinal
Clark et al., <sup>69</sup> 1967 U.S. N = 94 Nonrandomized trial, fair	50% oxygen with nitrous oxide and methoxyflurane <sup>†</sup> ; administered via inhaler	Methoxyflurane
McAneny and Doughty, <sup>13</sup> 1963 U.K. N = 501 Nonrandomized trial, poor	50%, 60%, 70%, 75%, 80%; self- administered	Alternate nitrous oxide mixes*

TENS = transcutaneous electrical nerve stimulation

\*Studies that assessed nitrous oxide and no other pain management methods were only included in the harms KQ.

†Nitrous oxide concentration not reported.

**Table 5. Summary of nitrous oxide interventions, other study designs**

Study Country Total N Study Type, Quality	Nitrous Oxide Mix and Administration Method	Other Pain Management Method(s) Assessed
Waldenstrom and Irestedt, <sup>70</sup> 2006 Sweden N = 2,482 Trend, fair	% not reported; administration method not reported	Epidural block , pethidine, paracervical bock, pudendal block
Henry and Nand, <sup>71</sup> 2004 Australia N = 496 Cross-sectional, poor	% not reported; administration method not reported <sup>†</sup>	Pethidine, epidural, local anesthesia, nonpharmacological methods
Peach, <sup>72</sup> 1999 Australia N = 1,000 Cross-sectional, fair	% not reported; administration method not reported <sup>†</sup>	Epidural, pethidine, nonpharmacological (alone and in combination)
Ross et al., <sup>73</sup> 1999 U.K. N = 221 Case series, poor	Entonox (50%) with isoflurane; administration method not reported	None



**Table 5. Summary of nitrous oxide interventions, other study designs (continued)**

<b>Study Country Total N Study Type, Quality</b>	<b>Nitrous Oxide Mix and Administration Method</b>	<b>Other Pain Management Method(s) Assessed</b>
Waldenstrom, <sup>74</sup> 1999 Sweden N = 1,148 Cross-sectional, fair	Entonox (50%); administration method not reported	Epidural, pethidine
Waldenstrom et al., <sup>75</sup> 1996 Sweden N = 385 Cross-sectional, fair	Entonox (50%); administration method not reported	Epidural, local anesthesia, acupuncture, bath, breathing techniques
Ranta et al., <sup>76</sup> 1995 Finland N = 1,091 Cross-sectional, fair	50%; administered via facemask	Epidural, pethidine, paracervical block, bupivacaine
Reed et al., <sup>77</sup> 1988 U.K. N = 41 Case series, poor	Entonox (50%); administration method not reported	Pethidine
Morgan et al., <sup>78</sup> 1982 U.K. N = 1,000 Cross-sectional, poor	Entonox (50%); self-administered	Epidural, pethidine, pudendal block
Holdcroft and Morgan, <sup>79</sup> 1974 U.K. N = 705 Cross-sectional, poor	Entonox (50%); administration method not reported	Entonox and pethidine, pethidine only
Marx et al., <sup>80</sup> 1970 U.S. N = 40 Case series, poor	50 – 70%; administered via facemask	None

\*Survey of the prevalence of pain management methods; concentrations of nitrous oxide not reported

## **KQ1: Effectiveness of Nitrous Oxide for Labor Pain Management**

### **Key Points**

- The heterogeneous outcomes used to assess pain make synthesis of studies challenging.
- Epidural anesthesia provides more effective pain relief than nitrous oxide, but the quality of the studies is predominately poor.
- The strength of the evidence for the effectiveness of nitrous oxide to manage labor pain compared with other, nonepidural pain management methods is insufficient because the studies are predominately of poor quality, use heterogeneous outcome measures, and have inconsistent findings.
- The strength of the evidence for the effectiveness of nitrous oxide to manage labor pain compared with epidurals was not assessed because the two interventions have different goals with the purpose of epidural to substantially block pain and the purpose of nitrous oxide to make pain manageable. A head to head comparison will always demonstrate greater effectiveness of epidural for reducing pain.

This section presents the results of the literature search and findings about the effectiveness of nitrous oxide as a labor analgesic compared with other pharmacologic and nonpharmacologic modalities. The pharmacologic modalities that were compared with nitrous oxide in the literature were other inhalational anesthetic gases, including methoxyflurane, isoflurane, enflurane, desflurane, sevoflurane, trichloroethylene, and cyclopropane; epidural anesthesia; the opioid pethidine/meperidine (Demerol<sup>®</sup>), which was sometimes used in conjunction with the antiemetic promazine; paracervical block; pudendal block; and varied combinations of the pharmacologic agents. Nonpharmacologic modalities included transcutaneous electrical nerve stimulation (TENS), hydrotherapy (bath or shower), sterile water papule blocks, acupuncture, and psychoprophylaxis.

## Overview of the Literature

Twenty-one publications representing 22 studies of distinct populations addressed the effectiveness of nitrous oxide.<sup>38, 40-41, 44-45, 47-49, 51, 53-54, 58, 62, 66, 68-70, 75-76, 78-79</sup> Eight of these studies were conducted in the United Kingdom,<sup>48, 38, 47, 53-54, 66, 78-79</sup> five in the United States,<sup>40, 45, 49, 68-69</sup> two in Sweden,<sup>70, 75</sup> two in Finland,<sup>58, 76</sup> two in Singapore,<sup>44</sup> and one each in Canada,<sup>41</sup> Ireland,<sup>62</sup> and Norway.<sup>51</sup> These studies included six RCTs,<sup>40, 44-45, 49, 53-54</sup> six crossover RCTs,<sup>38, 41, 44, 47-48, 51</sup> four cross-sectional studies,<sup>75-76, 78-79</sup> two nonrandomized clinical trials,<sup>66, 68</sup> two prospective cohort studies,<sup>58, 62</sup> one case series,<sup>69</sup> and one trend study.<sup>70</sup> One study included an RCT and a crossover RCT with two distinct populations.<sup>44</sup> Four studies were of fair quality,<sup>69-70, 75-76</sup> and 17 were of poor quality.<sup>38, 40-41, 44-45, 47-49, 51, 53-54, 58, 62, 66, 68, 78-79</sup>

## Detailed Synthesis

### Placebo

An RCT compared 50 percent nitrous oxide in oxygen with compressed air using a double-blind, crossover design.<sup>41</sup> Participants (n = 26) self-administered nitrous oxide or placebo for five consecutive contractions then were switched to the other option for the next five contractions. Visual analog scale (specific numerical values not reported) scores to rate pain were obtained after each contraction. No statistically significant differences in the mean visual analogue scores were found between the two groups.

### Inhalational Anesthetic Gases

Twelve studies compared nitrous oxide with various other inhalational anesthetic gases not currently used for management of labor pain in the United States, including six with methoxyflurane;<sup>51, 53-54, 66, 68-69</sup> two with isoflurane;<sup>45, 47</sup> two with enflurane;<sup>48-49</sup> and one each with desflurane,<sup>40</sup> sevoflurane,<sup>38</sup> trichloroethylene,<sup>66</sup> and cyclopropane.<sup>68</sup> These studies are summarized in Table 6, with the exception of one study that did not contribute additional data.<sup>69</sup> Studies are displayed in reverse chronological order.

**Table 6. Effectiveness of inhalational anesthetic gases**

Author Year Study Type N	Interventions	Other Labor Pain Management Method(s)	Findings
Yeo et al., <sup>38</sup> 2007 Crossover RCT N = 32	Entonox (nitrous oxide 50%)	None	<ul style="list-style-type: none"> <li>• Women used both gases.</li> <li>• Visual analogue scales with 100 mm rulers were used to assess pain relief, pain intensity, and sedation.</li> <li>• Pain relief significantly better with sevoflurane than Entonox in the first (<math>p = 0.01</math>) and second (<math>p &lt; 0.001</math>) crossovers.</li> <li>• Pain intensity significantly higher with Entonox than sevoflurane in the first crossover (<math>p = 0.04</math>) but not different in the second crossover.</li> <li>• Sedation significantly greater with sevoflurane than Entonox in both crossovers (<math>p &lt; 0.001</math>). 97% of participants preferred sevoflurane over nitrous oxide (<math>p &lt; 0.001</math>).</li> </ul>
	Sevoflurane 0.8%		
Abboud et al., <sup>40</sup> 1995 RCT N = 80	Nitrous oxide 30% to 60%, usually 46%	Not reported	<ul style="list-style-type: none"> <li>• Satisfactory analgesia scores were comparable among women, anesthesiologists, and obstetricians.</li> </ul>
	Desflurane 1% to 4.5%, usually 2%		
Abboud et al., <sup>45</sup> 1989 RCT N = 60	Nitrous oxide 30%-60%, usually 33%	Local infiltration, pudendal block, epidural	<ul style="list-style-type: none"> <li>• Proportion of satisfactory pain scores did not differ significantly between groups among mothers (87% for nitrous oxide, 83% for isoflurane), anesthesiologists (97% for nitrous oxide, 90% for isoflurane), and obstetricians (83% for nitrous oxide, 87% for isoflurane).</li> </ul>
	Isoflurane 0.2%-0.7%, usually 0.4%		
McLeod et al., <sup>47</sup> 1985 Crossover RCT N = 32	Entonox (nitrous oxide 50%)	None	<ul style="list-style-type: none"> <li>• Pain was assessed with a linear analogue scale (0-100). Mean pain scores were 63.0 (range 24-92) with Entonox and 46.6 (range 19-86) with isoflurane (<math>p &lt; 0.001</math>).</li> <li>• Drowsiness scores were higher with isoflurane than nitrous oxide.</li> <li>• When women asked which agent they preferred at the end of the study, 69% chose isoflurane, 25% chose Entonox, and 6% were undecided.</li> </ul>
	Isoflurane 0.75%		

**Table 6. Effectiveness of inhalational anesthetic gases (continued)**

Author Year Study Type N	Interventions	Other Labor Pain Management Method(s)	Findings
McGuinness et al., <sup>48</sup> 1984 Crossover RCT N = 20	Nitrous oxide 50%	Pethidine	<ul style="list-style-type: none"> <li>Women used both gases.</li> <li>Pain assessed with linear analogue scores (0-100). Scores with enflurane (median 50, range 13-79) were significantly lower than the scores with nitrous oxide use (median 52, range 29-79, <math>p &lt; 0.02</math>).</li> <li>Drowsiness scores for enflurane were significantly higher than the scores for nitrous oxide (<math>p &lt; 0.02</math>).</li> </ul>
	Enflurane 1%		
Abboud et al., <sup>49</sup> 1981 RCT N = 105	Nitrous oxide 30% to 60%, usually 40%	Narcotic analgesia, local infiltration, pudendal block	<ul style="list-style-type: none"> <li>Most women had satisfactory analgesia according to scores from the women, anesthesiologists, and obstetricians.</li> <li>The difference in satisfactory analgesia scores for the two gases was significant only for the obstetricians (<math>p &lt; 0.05</math>).</li> </ul>
	Enflurane 0.25% to 1.25%, usually 0.5%		
Bergsjö et al., <sup>51</sup> 1971 Crossover RCT N = 63	Nitrous oxide 50%	None	<ul style="list-style-type: none"> <li>After using both, a higher proportion of mothers chose nitrous oxide (63%) than methoxyflurane (35%) with 2% undecided (<math>p &lt; 0.05</math>).</li> <li>Analgesic effect of nitrous oxide (rated by physician): excellent for 8%, good for 82%, moderate for 4%, and poor for none.</li> <li>Analgesic effect of methoxyflurane (rated by physician): good for 95% and moderate for 5%.</li> </ul>
	Methoxyflurane 0.8%		
Jones et al., <sup>54</sup> 1969 RCT N = 48	Nitrous oxide calibrated in 5% steps from 20% to 100% oxygen	Pethidine	<ul style="list-style-type: none"> <li>Mean proportion of time the anesthetists assessed the women's reactions to contractions as satisfactory did not differ significantly between groups.</li> <li>Most midwives and women reported pain relief was complete or considerable.</li> </ul>
	Methoxyflurane with 40% oxygen		
Jones et al., <sup>53</sup> 1969 RCT N = 50	Nitrous oxide 50%	Pethidine	<ul style="list-style-type: none"> <li>Mean proportion of time the anesthetists assessed the women's reactions to contractions as satisfactory was significantly (<math>p &lt; 0.05</math>) higher for methoxyflurane (<math>79.3 \pm 20\%</math>) than nitrous oxide (<math>62.3 \pm 30\%</math>).</li> <li>Most midwives and women reported pain relief was complete or considerable.</li> </ul>
	Methoxyflurane 0.35%		

**Table 6. Effectiveness of inhalational anesthetic gases (continued)**

Author Year Study Type N	Interventions	Other Labor Pain Management Method(s)	Findings
Rosen et al., <sup>66</sup> 1969 Prospective cohort N = 1257	Nitrous oxide 50%	Pethidine, morphine	<ul style="list-style-type: none"> <li>No significant difference between groups in the women's assessment of their pain relief in interviews immediately after the birth and two days later.</li> <li>Midwives rated pain relief good or excellent more frequently with methoxyflurane (53%, <math>p &lt; 0.01</math>) and trichloroethylene (49%, <math>p &lt; 0.02</math>) than nitrous oxide (42%).</li> </ul>
	Trichloroethylene 0.35% or 0.5%		
	Methoxyflurane 0.35%		
Smith et al., <sup>68</sup> 1968 Prospective cohort N = 1616	Nitrous oxide 25% to 40%	Local or pudendal nerve block	<ul style="list-style-type: none"> <li>Participants and physician pain ratings did not differ significantly across groups.</li> </ul>
	Methoxyflurane 0.2% to 0.5%		
	Cyclopropane 1% to 5%		

## Transcutaneous Electric Nerve Stimulation

One publication comparing Entonox<sup>®</sup> with TENS reported two studies.<sup>44</sup> The first study was an RCT in which 101 women in early labor were randomized to Entonox or TENS as their initial pain management method. They could choose a different pain relief method if the initial method was inadequate, and the proportion of women who did this was comparable in the two groups (17% using Entonox vs. 19% using TENS, difference nonsignificant). On the first postpartum day, the woman rated her pain with Entonox or TENS on a scale of 0 to 10. The difference between groups was not statistically significant. The second study was a crossover RCT in which 20 nulliparous women undergoing induction of labor were randomized to Entonox or TENS for their first pain management method. When labor pain was no longer tolerable, the woman was asked to rate the pain relief as nil, partial, or complete then switched to the other method (Entonox or TENS). For their first method, women had more relief with TENS than Entonox, but this difference was not statistically significant and women in the Entonox group were having more frequent contractions. The difference in pain relief between groups was also nonsignificant for the second method used.

## Observational Studies of Multiple Pain Management Methods

Two prospective cohort studies assessed the effectiveness of multiple pain management methods in women who chose their methods.<sup>58, 62</sup> The first study ( $n = 170$ ) included women whose initial pain management method choice was Entonox, TENS, pethidine and promazine, or epidural.<sup>62</sup> Five-point scales were used to assess women's pain and midwives' evaluation of pain relief. Both groups rated epidural as providing the most pain relief, and pethidine and promazine as providing the least ( $p < 0.001$  for participant and midwife ratings). Additional pain management methods were used by 5 percent of women in the nitrous group, 82 percent in the TENS group, 80 percent in the pethidine and promazine group, and none of the women in the epidural group. The second study ( $n = 833$  with pain scores) included women who had 50 percent nitrous oxide, water blocks, pethidine, paracervical block, epidural, several methods, and

no analgesia.<sup>58</sup> During labor, a visual pain scale (0–10) was used. Median pain scores decreased significantly ( $p < 0.01$ ) from pre-analgesia values with epidural and paracervical block, and increased significantly ( $p < 0.01$ ) after water block, nitrous oxide, and pethidine. On their third day postpartum, women were asked to rate the adequacy of analgesia. None of the women who had epidural rated it as poor ( $p < 0.01$  for comparison with other groups) compared with 28 percent who used nitrous oxide.

Five cross-sectional studies retrospectively assessed the effectiveness of labor pain management methods.<sup>70, 75-76, 78-79</sup> In a study of 2,482 women, participants completed a questionnaire two months after their births that included assessment of their pain management methods as very effective, some effect, or no effect.<sup>70</sup> Epidural had the highest percentage of very effective responses (84% of primiparas, 72% of multiparas) followed by nitrous oxide (38% of primiparas, 49% of multiparas), psychoprophylaxis (39% of primiparas, 47% of multiparas), pethidine (41% of primiparas and multiparas), bath or shower (29% of primiparas, 35% of multiparas), and acupuncture (10% of primiparas, 23% of multiparas). In another study, 1,000 women were interviewed within 48 hours after giving birth and asked to identify how much pain they experienced using a 10 cm linear analogue scale graded between 0 and 100 mm.<sup>78</sup> Women who had epidurals had the lowest mean ( $\pm$  SD) pain score ( $29 \pm 3.7$ ) followed by pethidine plus epidural ( $30 \pm 3.8$ ), epidural plus Entonox ( $51 \pm 4.2$ ), pethidine plus Entonox ( $57 \pm 3.4$ ), pethidine ( $58 \pm 3.1$ ), Entonox ( $61 \pm 3.1$ ), pudendal block ( $68 \pm 1.9$ ), miscellaneous ( $69 \pm 3.3$ ), and no analgesia ( $70 \pm 2.6$ ). In one study, interviews were conducted 24 to 48 hours after birth in which women were asked to rate their pain relief with analgesia as complete, satisfactory, slight, or none.<sup>79</sup> When nitrous oxide ( $n = 130$ ) was compared with pethidine ( $n = 67$ ), more women had complete (4% vs. 0) or satisfactory (46% vs. 22%) pain relief with nitrous oxide. Nearly half of the women who used pethidine reported no pain relief compared with one-third of the women who used nitrous oxide. Two studies did not contribute additional data.<sup>75-76</sup>

## KQ2: Effect of Nitrous Oxide on Women's Satisfaction

### Key Points

- The measures used to assess women's satisfaction with their birth experience and pain management were unique to each study, which makes synthesis challenging.
- The strength of the evidence is low for equivalence or superiority of nitrous oxide compared with other pain management methods for women's satisfaction with their birth experience and pain management.

This section presents the results of the literature search and findings about women's satisfaction with nitrous oxide as a labor analgesic compared with other pharmacologic and nonpharmacologic modalities for labor pain management. The pharmacologic modalities that were compared with nitrous oxide in the literature were epidural anesthesia; the narcotic pethidine/meperidine, which was sometimes used in conjunction with the antiemetic promazine; other inhalational anesthetic gases, including isoflurane, enflurane, and desflurane; and paracervical block. Nonpharmacologic modalities included TENS and water blocks.

### Overview of the Literature

Nine studies addressed the effectiveness of nitrous oxide on women's satisfaction.<sup>40, 45, 49, 56, 58, 62, 71, 74, 79</sup> Three of these studies were conducted in the United States,<sup>40, 45, 49</sup> and one each in

Australia,<sup>71</sup> the United Kingdom,<sup>79</sup> Malaysia,<sup>56</sup> Sweden,<sup>74</sup> Ireland,<sup>62</sup> and Finland.<sup>58</sup> These studies included three RCTs,<sup>40, 45, 49</sup> three prospective cohorts,<sup>56, 58, 62</sup> and three cross-sectional studies.<sup>71, 74, 79</sup> One study was of good quality,<sup>56</sup> one of fair quality,<sup>74</sup> and seven of poor quality.<sup>40, 45, 49, 58, 62, 71, 79</sup>

## **Women's Satisfaction with Their Birth Experience**

Two studies assessed women's satisfaction with their birth experience.<sup>62, 74</sup> The first was a prospective cohort study in which 170 women who chose Entonox, epidural, pethidine and promazine, or TENS as their first choice of analgesia were asked in the first 24 hours if they would use the same method again.<sup>62</sup> The second was a cross-sectional study in which 1,111 women were asked about their birth experience at two months postpartum via questionnaire.<sup>74</sup> The results for these studies are grouped by comparator.

### **Epidural**

Of the women in the prospective cohort study who chose Entonox, 80 percent (16 of 20) would request Entonox again, compared with 88 percent (44 of 50) of women who chose epidural.<sup>62</sup> In the postpartum survey, 57 percent of women who had nitrous oxide (n = 362) reported a positive or very positive birth experience compared with 34 percent of the women (n = 129) who had epidural analgesia.<sup>74</sup>

### **Pethidine**

Eighty percent (16 of 20) of the women who chose Entonox in the prospective cohort study would request Entonox again compared with 38 percent (19 of 50) of women who chose pethidine and promazine.<sup>62</sup> Of 362 women who had nitrous oxide, 57 percent reported a positive or very positive birth experience at two months postpartum compared with 49 percent of 94 women who had pethidine.<sup>74</sup>

### **Transcutaneous Electric Nerve Stimulation**

Women in the prospective cohort study who chose Entonox more frequently (16 of 20, 80%) reported they would choose it again compared with women who chose TENS (30 of 50, 60%).<sup>62</sup>

## **Women's Satisfaction with Their Pain Management**

### **Epidural**

Four studies compared women's satisfaction with pain management with nitrous oxide or epidural.<sup>56, 58, 62, 71</sup> In a prospective cohort study, only 5.5 percent (3 of 55) of women who had an epidural were not satisfied with the pain relief compared with 45.6 percent (31 of 68) of women who had Entonox and pethidine.<sup>56</sup> Of the women who chose Entonox in another prospective cohort study, 60 percent (12 of 20) reported that the pain relief was adequate, compared with 98 percent (49 of 50) of women who chose epidural analgesia.<sup>62</sup> In a third prospective cohort study, 33 percent (66 of 200) of women who chose Entonox rated the pain relief adequacy as good, compared with 94 percent (75 of 80) of those who chose an epidural.<sup>58</sup> A cross-sectional study found 30 percent (40 of 115) of women who chose nitrous oxide were very satisfied with the relief of pain, compared with 49 percent (58 of 118) of those who chose an epidural.<sup>71</sup>

## **Pethidine**

Three studies compared women's satisfaction with the pain management of Entonox and pethidine. Of the women who chose Entonox in a prospective cohort study, 60 percent (12 of 20) reported that the pain relief was adequate, compared with 18 percent (9 of 50) of women who chose pethidine-promazine.<sup>62</sup> In another prospective cohort study, 33 percent (66 of 200) of women who chose Entonox rated the pain relief adequacy as good, compared with 60 percent (26 of 44) of those who chose pethidine.<sup>58</sup> Of the women in a cross-sectional study who received Entonox, 50 percent (65 of 130) reported satisfactory or complete pain relief, compared with 22 percent (15 of 67) of those receiving pethidine alone.<sup>79</sup>

## **Inhalational Anesthetic Gases**

Three RCTs (total n = 245) compared women's satisfaction with pain management with use of nitrous oxide (30% to 60% mix) with use of other inhalational anesthetic gases. The proportion of women who were satisfied or very satisfied with nitrous oxide was not statistically different than enflurane (76% vs. 89%),<sup>49</sup> isoflurane (87% vs. 83%),<sup>45</sup> and desflurane (63% for both).<sup>40</sup>

## **Paracervical Block**

In a prospective cohort study, a lower proportion of women who chose Entonox (33%, 66 of 200) reported good pain relief adequacy compared with women who chose to receive paracervical block (59%, 70 of 119).<sup>58</sup>

## **Transcutaneous Electric Nerve Stimulation**

An equal proportion of women in a prospective cohort study who chose Entonox (80%, 12 of 20) and TENS (80%, 40 of 50) reported that their pain relief was adequate.<sup>62</sup>

## **Water Blocks**

The proportion of women who rated their pain relief adequacy as good was lower with Entonox (33%, 66 of 200) than among those who chose to receive injections of water (water blocks) in their lower back (59%, 40/68) in one prospective cohort study.<sup>58</sup>

# **KQ3: Effect of Nitrous Oxide on the Route of Birth**

## **Key Points**

- The strength of the evidence is insufficient to determine the effect of nitrous oxide on the route of birth because the studies are predominately of poor quality, use heterogeneous outcome measures, and have inconsistent findings.

This section presents the results of the literature search and findings about the route of birth in women who used nitrous oxide as a labor analgesic compared with other pharmacologic and nonpharmacologic modalities for labor pain management. The pharmacologic modalities that were compared with nitrous oxide in the literature were epidural anesthesia; the narcotic pethidine/meperidine, which was sometimes used in conjunction with the antiemetic promazine; other inhalational anesthetic gases, including methoxyflurane, desflurane, and trichloroethylene; and paracervical block. Nonpharmacologic modalities included TENS and water blocks.



## Detailed Synthesis

Six studies compare the route of birth in women who used nitrous oxide with that in women who used other pain management methods.<sup>40, 54, 56, 58, 62, 66</sup> Two studies were conducted in the United Kingdom,<sup>54, 66</sup> one in Ireland,<sup>62</sup> one in Finland,<sup>58</sup> one in Malaysia,<sup>56</sup> and one in the United States.<sup>40</sup> Two studies are RCTs,<sup>40, 54</sup> three are prospective cohort studies,<sup>56, 58, 62</sup> and one is a nonrandomized clinical trial.<sup>66</sup> One study was of good quality<sup>56</sup> and five were of poor quality.<sup>40, 54, 58, 62, 66</sup> Findings for route of birth are presented in Table 7. Studies are presented in reverse chronological order. Only two of the studies<sup>56, 62</sup> had statistically significant findings. In one prospective cohort study the proportion who had an assisted vaginal birth was lower with Entonox plus pethidine (13%) than epidural (40%).<sup>56</sup> Another prospective cohort study found the operative birth rate (which combined forceps-assisted, vacuum-assisted, cesarean, and breech births) was higher among women whose initial choice for pain management was epidural than those who chose nitrous oxide, TENS, or pethidine plus promazine.<sup>62</sup>

**Table 7. Route of birth in women using nitrous oxide**

Author Year Study Type	Intervention (N)	Vaginal Birth N (%)	Assisted Vaginal Birth N (%)	Cesarean Birth N (%)
Leong et al., <sup>56</sup> 2000 Prospective cohort	Entonox plus IM pethidine (68)	56 (82.4)	9 (13.2)	3 (4.4)
	Bupivacaine epidural (55)	28 (50.9)	22 (40.1)*	5 (9.0)
Abboud et al., <sup>40</sup> 1995 RCT	Nitrous oxide, 30-60% oxygen (40)	35 (87.5)	5 (12.5)	0 <sup>^</sup>
	Desflurane 1-4.5% and oxygen (40)	31 (77.5)	9 (22.5)	0 <sup>^</sup>
Ranta et al., <sup>58</sup> 1994 Prospective cohort	Nitrous oxide 50% (210)	NR (95)	NR (2)	NR (3)
	Water blocks (69)	NR (90)	NR (3)	NR (7)
	Pethidine (50)	NR (91)	NR (2)	NR (7)
	Paracervical block (128)	NR (94)	NR (3)	NR (3)
	Epidural anesthesia (82)	NR (80)	NR (11)	NR (9)
	Several methods (339)	NR (86)	NR (7)	NR (7)
	No analgesia (213)	NR (94)	NR (1)	NR (5)

**Table 7. Route of birth in women using nitrous oxide (continued)**

Author Year Study Type	Intervention (N)	Vaginal Birth N (%)	Assisted Vaginal Birth N (%)	Cesarean Birth N (%)
Harrison et al., <sup>62</sup> 1987 Prospective cohort	Entonox (20) <sup>†</sup>	12 (60.0)	7 (35.0)	0
	TENS (50)	32 (64.0)	14 (28.0)	4 (8.0)
	Pethidine plus promazine (50)	32 (64.0)	18 (36.0)	0
	Lumbar epidural (50) <sup>†</sup>	13 (26.0)	31 (62.0) <sup>θ</sup>	3 (6.0) <sup>θ</sup>
Rosen et al., <sup>66</sup> 1969 Nonrandomized clinical trial	Nitrous oxide 50% (265)	235 (88.7)	30 (11.3)	0
	Trichloroethylene 0.35% or 0.5% (394)	345 (87.5)	46 (11.7)	3 (0.8)
	Methoxyflurane 0.35% (598)	525 (87.8)	68 (11.4)	5 (0.8)
Jones et al., <sup>54</sup> 1969 Quasi-RCT	Nitrous oxide calibrated in 5% steps from 20% to 100% oxygen (24)	19 (79.2)	5 (20.8)	0 <sup>^</sup>
	Methoxyflurane with 40% oxygen (24)	19 (79.2)	5 (20.8)	0 <sup>^</sup>

NR = not reported; RCT = randomized controlled trial

\*p < 0.01

<sup>^</sup>Study only included women with vaginal births.

<sup>†</sup>One woman in the Entonox group and three women in the lumbar epidural group had breech births that are not included in the table because the route of birth was not identified.

<sup>θ</sup>The operative birth rate (which included forceps- and vacuum-assisted births, cesarean births, and breech births) was higher for women whose initial choice was epidural than any of the other analgesia methods (p < 0.001).

## KQ4: Adverse Effects of Nitrous Oxide for Labor Pain Management

### Key Points

- When nitrous oxide was used as a sole agent, 0 to 28 percent of women experienced nausea and zero to 14 percent experienced vomiting.
- Three to 23 percent of women using nitrous oxide as a sole agent reported dizziness.
- Drowsiness occurred in 0 to 67 percent of women using nitrous oxide as a sole agent.
- Apgar scores in newborns whose mothers used nitrous oxide did not differ significantly from those of newborns whose mothers used other labor pain management methods or no analgesia.
- Limited data on occupational harms are available.

- The strength of evidence that adverse effects associated with nitrous oxide for labor pain management are primarily unpleasant side effects that affect tolerability is moderate.

In this section we present the results of the literature search and findings about maternal, fetal, neonatal, and occupational harms. Within each of these outcome categories we have organized the research findings by specific harms, with related or similar harms presented together.

## Overview of the Literature

Forty-nine publications addressed maternal, fetal, neonatal and occupational harms related to nitrous oxide for labor.<sup>12-13, 16, 26-30, 32-43, 45-61, 63-69, 72-73, 77, 80</sup> Twenty-two of these studies were conducted in the United Kingdom,<sup>12-13, 16, 26, 31-32, 38, 42, 46-48, 50, 52-55, 57, 59, 65-66, 73, 77</sup> ten in Sweden,<sup>27-30, 33-36, 39, 43</sup> six in the United States,<sup>40, 45, 49, 68-69, 80</sup> two in Australia,<sup>60, 72</sup> and one each in Germany,<sup>61</sup> Canada,<sup>41</sup> Finland,<sup>58</sup> Iran,<sup>37</sup> Ireland,<sup>63</sup> Japan,<sup>67</sup> Malaysia,<sup>56</sup> Nigeria,<sup>64</sup> and Norway.<sup>51</sup> These studies include 12 RCTs,<sup>12, 37, 39-40, 42, 45-46, 49-50, 52-54</sup> six crossover RCTs,<sup>38, 41, 43, 47-48, 51</sup> four case-control studies,<sup>33-36</sup> four nonrandomized clinical trials,<sup>13, 66, 68-69</sup> 13 prospective cohorts,<sup>16, 30, 32, 55-61, 63-64, 67</sup> one retrospective cohort,<sup>65</sup> three case series,<sup>73, 77, 80</sup> five cross-sectional studies,<sup>26-27, 29, 31, 72</sup> and one trend study.<sup>28</sup> Two were of good quality,<sup>36, 56</sup> seven of fair quality,<sup>26, 30-32, 42, 69, 72</sup> and forty of poor quality.<sup>12-13, 16, 27-29, 33-35, 37-41, 43, 45-55, 57-61, 63-68, 73, 77, 80</sup>

Where appropriate to specific harms, these studies are grouped according to co-administered agents given. The 49 studies include twenty studies of nitrous oxide administered as a sole analgesic agent,<sup>37-43, 45-48, 50, 55-60, 65, 72</sup> seven studies of nitrous oxide administered with opioids;<sup>16, 49, 52, 61, 64, 66, 77</sup> one study of nitrous oxide administered with another anesthetic gas;<sup>73</sup> seven studies of nitrous oxide administered with opioids and sedatives or hypnotics;<sup>12-13, 51, 53-54, 63, 68</sup> two studies of opioids and sedatives or hypnotics, or combination thereof;<sup>69, 80</sup> and one of nitrous unspecified.<sup>67</sup> Seven studies evaluated nitrous oxide as an occupational agent.<sup>26-32</sup> Four case-control studies evaluated nitrous oxide use during labor as an independent risk factor.<sup>33-36</sup>

In the past, nitrous oxide for labor was co-administered with other analgesic, anesthetic, anxiolytic, and sedative agents in various combinations titrated to induce sedation and amnesia. These co-agents have a significant impact on the rate and degree of harms associated with nitrous oxide for labor analgesia. To maintain consistency with contemporary practice, thirteen studies published prior to 1980 in which nitrous oxide was given in combination with unspecified doses of narcotics, tranquilizers and sedatives are not included in the tables.<sup>12-13, 16, 50-54, 66-69, 80</sup>

## Detailed Synthesis

### Maternal Harms

Thirty-two studies reported maternal harms related to nitrous oxide. The most clinically significant and frequently reported maternal harms were nausea, vomiting, dizziness, and drowsiness. These side effects are presented in Table 8. Within the table, studies are grouped by agent(s) administered. Studies of nitrous oxide as a sole agent are listed first, followed by nitrous/opioid, nitrous/other anesthetic, nitrous/opioid/sedatives, and nitrous/other anesthetic gases/opioids/sedatives or combinations thereof. Within each agent designation, RCTs are listed first followed by nonrandomized clinical trials and observational studies, and each group of study type is in reverse chronological order.

In addition to the harms presented in Table 8, other infrequently reported maternal harms included restlessness,<sup>12-13, 16, 53-54, 66</sup> dreams,<sup>12-13, 16, 53-54</sup> dry mouth or nose,<sup>16, 37, 46, 51</sup> tingling or pins and needles,<sup>37, 46</sup> numbness,<sup>51</sup> paresthesias,<sup>16</sup> reduced awareness of experience,<sup>72</sup> mask phobia,<sup>72</sup> bothersome smell,<sup>51, 54</sup> euphoria,<sup>51</sup> and hiccups.<sup>51</sup>

Clinically relevant harms reported in included studies but not typically associated with nitrous oxide were backache and/or headache,<sup>56, 72</sup> shivering,<sup>72</sup> difficulty moving,<sup>72</sup> and renal dysfunction.<sup>45, 49-50</sup>

Other findings associated with nitrous oxide of unknown clinical significance include inactivation of methionine synthase<sup>59</sup> and effects on maternal circulation.<sup>37, 43</sup>

## **Nausea and Vomiting**

Nausea and/or vomiting were reported in 17 studies,<sup>12-13, 16, 37-38, 42-43, 46-49, 51, 53-54, 64, 66, 68-69, 72</sup> ten of which are presented in Table 8. In these ten studies, rates of nausea ranged from zero to 45 percent.

Studies in women receiving nitrous oxide as a sole agent reported nausea rates from zero to 28 percent.<sup>37-38, 42-43, 47-48, 64, 72</sup> Three studies reported nausea data that include both nitrous oxide as a sole agent and an unmedicated control group.<sup>37, 43, 72</sup> Nausea rates with nitrous oxide ranged from zero to 13 percent with no incidence of nausea in control groups. Nausea was reported to be more common with nitrous oxide than sevoflurane in a crossover RCT<sup>38</sup> with a reported relative risk of 2.7 for nitrous oxide ( $p = 0.004$ ). Nitrous oxide was associated with less nausea than enflurane in one study,<sup>48</sup> and a comparable rate of nausea to isoflurane in another study.<sup>47</sup> A cross-sectional study reported similar rates of nausea and vomiting with nitrous oxide (13%), epidural (14%), and pethidine (16%).<sup>72</sup>

Vomiting was reported in six studies presented in Table 8 with rates ranging from zero to 14 percent.<sup>37-38, 43, 49, 64, 72</sup> Four studies using nitrous oxide as a sole agent reported vomiting data, with rates of 0 to 14 percent.<sup>37-38, 43, 72</sup> Two studies addressed aspiration specifically.<sup>13, 49</sup> One RCT reported no aspiration with one episode of vomiting in a woman receiving nitrous oxide.<sup>49</sup> One nonrandomized trial reported no incidences of aspiration after vomiting in a series of 501 women receiving 50 to 80 percent nitrous oxide in conjunction with injected analgesics who had a combined nausea and vomiting rate of 15 to 22 percent across nitrous oxide concentrations.<sup>13</sup>

## **Dizziness and Lightheadedness**

Dizziness was reported in seven studies,<sup>37, 42, 46-47, 51, 54, 72</sup> four of which are presented in Table 8. In these four studies, nitrous oxide was used as a sole agent with rates of dizziness from three to 23 percent. One RCT reported lightheadedness with Entonox and found it was more common with a mouthpiece compared with face mask.<sup>46</sup> Overall, 58 percent of women in the study had lightheadedness with Entonox, which some women were using in conjunction with pethidine.

## **Drowsiness and Sleepiness**

Thirteen studies reported drowsiness,<sup>12, 16, 37-38, 47-48, 51, 54, 61, 64, 66, 72-73</sup> of which six have outcomes presented in Table 8. Four studies reported drowsiness incidence rates of zero to 67 percent with nitrous oxide used as a sole agent.<sup>37-38, 64, 72</sup> Two studies reported drowsiness data based upon a visual analog scale and do not report incidence rates.<sup>47-48</sup> Three studies compared drowsiness reported with nitrous oxide with other inhalational anesthetic gases and found drowsiness with nitrous oxide was equal to sevoflurane<sup>38</sup> and less than with isoflurane<sup>47</sup> or

enflurane.<sup>48</sup> A cross-sectional study found nitrous oxide caused more drowsiness than epidural but less than pethidine.<sup>72</sup>

Sleepiness or sleep was reported as a side effect in older studies utilizing sedative analgesia.<sup>12, 53-54, 66</sup> No studies reported sleepiness as an outcome for nitrous oxide administered as a sole agent.

**Table 8. Maternal adverse effects associated with nitrous oxide use during labor, side effects**

Author Year Country Study Type	Intervention (N)	Nausea (%)	Vomiting (%)	Dizziness (%)	Drowsiness (%)
Talebi et al., <sup>37</sup> 2009 Iran RCT	50% nitrous in oxygen (260)	8.4	2.3	23.0	8.3
	50% oxygen (249)	0.0	0.0	0	0.0
Arora et al., <sup>42</sup> 1992 U.K. RCT	Entonox (39)	NR	NR	3.0	NR
	Entonox and 0.25% isoflurane (39)	5.0	NR	10.0	NR
Constantine et al., <sup>46</sup> 1989 U.K. RCT	Entonox, via mask (49) <sup>†</sup>	45.0	NR	NR	NR
	Entonox, via mask and humidifier (36) <sup>†</sup>	25.0	NR	NR	NR
	Entonox, via mouthpiece (37) <sup>†</sup>	36.0	NR	NR	NR
	Entonox, via mouthpiece and humidifier (27) <sup>†</sup>	41.0	NR	NR	NR
Yeo et al., <sup>38</sup> 2007 U.K. Crossover RCT	Entonox (22)	28.0	14.0	NR	0.0
	Sevoflurane (22)	3.0	0.0	NR	0.0
Westling et al., <sup>43</sup> 1992 Sweden Crossover RCT	40% nitrous oxide in oxygen, intermittent (24)	0.0	0.0	NR	NR
	70% nitrous oxide in oxygen, intermittent (24)	0.0	0.0	NR	NR
	40% nitrous oxide in oxygen, continuous (24)	4.0	0.0	NR	NR
	Oxygen, intermittent (24)	0.0	0.0	NR	NR
McGuiness et al., <sup>48</sup> 1984 U.K. Crossover RCT	50% nitrous in oxygen (20)	5.0	NR	NR	NR

**Table 8. Maternal adverse effects associated with nitrous oxide use during labor, side effects (continued)**

Author Year Country Study Type	Intervention (N)	Nausea (%)	Vomiting (%)	Dizziness (%)	Drowsiness (%)
Paech, <sup>72</sup> 1991 Australia Cross-sectional	Nitrous oxide (220)	13.0 <sup>θ</sup>	13.0 <sup>θ</sup>	5.0	4.0
	Epidural (112)	14.0 <sup>θ</sup>	14.0 <sup>θ</sup>	0.0	0.0
	Pethidine (83)	16.0 <sup>θ</sup>	16.0 <sup>θ</sup>	6.0	11.0
	Non-pharmacological (140)	0.0	0.0	0.0	0.0
	Enflurane in air (20)	15.0	NR	NR	NR
McLeod et al., <sup>47</sup> 1985 U.K. Prospective cohort	50% nitrous oxide in oxygen (32)	3.0	NR	6.0	More drowsy with Entonox: 9.7
	0.75% Isoflurane in oxygen (32)	3.0	NR	0.0	More drowsy with isoflurane: 58.1
Abboud et al., <sup>49</sup> 1981 U.S. RCT	30-60% nitrous in oxygen (50)*	NR	2.0	NR	NR
	0.25-1.25% Enflurane in oxygen (55)*	NR	0.0	NR	NR
Soyannwo, <sup>64</sup> 1985 Nigeria Prospective cohort	Entonox (114)	NR	4.0^	NR	Mild: 66.7 Moderate: 31.6 Severe: 1.7
	Entonox with 100mg pethidine or pethilorphan (36)	NR	4.0^	NR	Mild: 55.6 Moderate: 44.4 Severe: 0.0

NR = not reported, RCT= randomized clinical trial

Note: Studies published prior to 1980 are not included in this table. Numerous studies did not provide the N for these outcomes; therefore, only percentages are reported in this table.

\*Some patients used additional narcotics (meperidine or alphaprodine).

^Results combined for entire study population.

†Some patients used pethidine.

θNausea and vomiting results combined.

## Unconsciousness

Unconsciousness data were reported in eight studies, including one in which nitrous was the sole agent,<sup>43</sup> three with nitrous/opioid,<sup>16, 64, 66</sup> three with nitrous/opioid/sedatives,<sup>12-13, 53</sup> and one with nitrous/other anesthetic gas.<sup>73</sup> Studies published prior to 1980 report low rates (0-1%) of unconsciousness with sedative polypharmacy.<sup>12-13, 53, 66, 73</sup> In a study of 150 women, one woman became unconscious while breathing Entonox in conjunction with use of analgesics. No instances of unconsciousness were reported in a study of Entonox with and without continuous nitrous oxide supplement via nasal cannula,<sup>16</sup> and a study of women breathing up to 70 percent concentrations of nitrous oxide.<sup>43</sup>

## **Amnesia and Hazy Memory of Labor**

Amnesia or hazy memory of labor or birth was addressed in nine studies.<sup>12-13, 16, 40, 45, 49, 53-54, 68</sup> Overall rates of amnesia ranged from zero to 16 percent.<sup>40, 45, 49, 68</sup> Studies published since 1980 reported low to nonexistent rates of amnesia. In an RCT published in 1981, 10 percent of women receiving 30 to 60 percent nitrous oxide with narcotics reported amnesia for birth.<sup>49</sup> In two subsequent RCTs, none of the women who used nitrous oxide reported amnesia.<sup>40, 45</sup>

Hazy memory of labor and birth was an outcome reported in older studies, and incidence ranged from eight to 60 percent.<sup>12-13, 16, 53</sup> Hazy memory of labor was not reported as an outcome in any studies published since 1980.

## **Hypoxia, Maternal Oxygen Saturation, and Diffusion Hypoxia**

Hypoxia and/or maternal oxygen saturation was reported as an outcome in eight studies.<sup>38-39, 41, 57, 60-61, 77</sup> Hypoxia was not defined or inconsistently defined,<sup>39, 41, 57, 77</sup> and studies reporting oxygen saturation values were inconsistent in their reporting of mean, median, and average values. Where desaturations were reported, they occurred in all groups studied including control (no analgesia) and epidural.<sup>57, 60, 77</sup>

In a crossover placebo-controlled RCT, comparable rates of desaturation occurred in women receiving nitrous oxide and compressed air.<sup>41</sup> In another crossover RCT, there were no oxygen saturations less than 98 percent in women breathing Entonox or sevoflurane alone.<sup>38</sup> Hypoxic episodes exceeding 10 seconds to saturations less than 90 percent occurred at similar rates for all groups in a case series including women using nitrous oxide, nitrous oxide with pethidine, pethidine only, and epidural.<sup>77</sup> Maternal saturations did not differ between groups in an RCT comparing 50 and 70 percent nitrous oxide.<sup>39</sup> Median maternal oxygen saturation was not statistically different between Entonox and control in a prospective cohort study.<sup>57</sup> In another prospective cohort study, there were no significant difference in saturations between women using 50 percent nitrous oxide, epidural, pethidine, or no analgesia.<sup>60</sup> The same study found a significant decrease in maternal saturations in women breathing nitrous oxide 50 percent with co-administration of pethidine compared with women in the control group ( $p < 0.05$ ). The difference in mean lowest oxygen saturations between women receiving nitrous oxide with meperidine compared with peridural anesthesia was significant for primiparous, but not multiparous, women.<sup>61</sup>

Three studies evaluated diffusion hypoxia.<sup>16, 39, 41</sup> Women who used nitrous oxide had no evidence of diffusion hypoxia when compared with a control group based upon analysis of end tidal nitrous oxide and carbon dioxide.<sup>39</sup> Maternal end tidal nitrous oxide levels were assessed in a study of women breathing Entonox with and without a continuous supplement of nitrous oxide 50 percent via nasal cannula. Mean end tidal nitrous oxide levels were 14.8 percent in between contractions, and mean maximum end tidal nitrous oxide concentrations were 44 percent for all women.<sup>16</sup> There was no evidence of diffusion hypoxia in a study of nitrous oxide compared with compressed air.<sup>41</sup>

## **Effects on Maternal Circulation**

In a crossover RCT, nitrous oxide was reported to cause a clinically insignificant but statistically significant decrease in heart rate, cardiac output, and arterial pressure and increase in stroke volume ( $p < 0.01$  for all) in laboring women while breathing nitrous oxide at 70 percent concentration compared with control (oxygen only).<sup>43</sup>

## Biochemical Findings

Inhalational anesthetic gases have been associated with renal dysfunction. There was no significant difference in renal function indices in an RCT of women using methoxyflurane or nitrous oxide.<sup>50</sup> In another RCT comparing nitrous oxide with enflurane, serum electrolyte levels and renal function were not significantly affected.<sup>49</sup> Maternal and neonatal fluoride levels were assessed in an RCT comparing nitrous with isoflurane and were comparable.<sup>45</sup>

## Inactivation of Methionine Synthase

The use of nitrous oxide by inhalation has been shown to inactivate methionine synthase activity (MSA) by binding to cobalamin, which is the central component of vitamin B12. Clinical implications of inactivation of methionine synthase have not been established. Landon measured methionine synthase in placental samples reporting a negative correlation between placental MSA and duration of exposure to nitrous oxide ( $p = 0.01$ ).<sup>59</sup> There was a more rapid decrease in MSA in women with reduced B12 levels, although the regression coefficients were not significantly different.

## Restlessness

Restlessness was reported in six studies, including two with nitrous/opioid<sup>16, 66</sup> and four with nitrous/opioid/sedatives.<sup>12-13, 53-54</sup> No studies reporting restlessness included a group receiving nitrous oxide as a sole agent. All studies reporting restlessness data were published prior to 1980. Reported rates of restlessness for nitrous oxide with opioids with or without sedatives ranged from 5 percent to 59 percent.

## Dreams

Dreams were reported in five studies,<sup>12-13, 16, 53-54</sup> including four with nitrous/opioid/sedatives<sup>12-13, 53-54</sup> and one with nitrous/opioid.<sup>16</sup> All studies reporting dreams as a harm were published prior to 1980, and dreams were not reported in any studies of nitrous as a sole agent. Dreams were reported at rates of 10 percent to 26 percent of women breathing nitrous in combination with analgesic and sedative agents.

## Other Maternal Side Effects

Dry mouth or nose was reported in four studies.<sup>16, 37, 46, 51</sup> One study of nitrous oxide as a sole agent reported a rate of 8.3 percent for dry mouth in women breathing nitrous oxide alone.<sup>37</sup> In one RCT dry mouth and nose were found to be more common with use of a mask compared with mouthpiece, and incidence was lowered by use of a humidifier.<sup>46</sup> Dry nose was reported by 75 percent of women breathing nitrous oxide via nasal cannula in one study.<sup>16</sup>

In a crossover RCT, women reported a rate of dry mouth of 10 percent while using nitrous oxide combined with narcotics and sedatives.<sup>51</sup>

Tingling or “pins and needles” was reported in two RCTs with rates of 4.1 percent<sup>37</sup> and 25 percent<sup>46</sup> in women using nitrous oxide. In a crossover RCT, 1.6 percent of women using nitrous oxide reported numbness. In a prospective cohort study, 40 percent of women breathing Entonox alone and 33 percent of women breathing Entonox with a continuous supplement of nitrous oxide 50 percent via nasal cannula experienced paresthesia.

In a cross-sectional study, reduced awareness of experience was more frequently reported as a disliked side effect for nitrous (18%) and pethidine (16%) than epidural (2%) and control (zero).<sup>72</sup>



Backache and/or headache were reported in two studies.<sup>56, 72</sup> In one prospective cohort study, women receiving epidural analgesia had a 3.6 percent incidence of spinal headache and 3.6 percent rate of persistent backache compared with zero incidence in women using nitrous oxide.<sup>56</sup> No women in a cross-sectional study who used nitrous oxide reported back pain compared with 14 percent of those with an epidural.

Shivering was not reported as a side effect by women using nitrous oxide compared with eight percent of women receiving an epidural in a cross-sectional study.<sup>72</sup>

Fourteen percent of women with epidural analgesia reported difficulty moving as a disliked side effect compared with none of the women using nitrous oxide.<sup>72</sup> Other side effects infrequently reported include mask phobia,<sup>72</sup> bothersome smell,<sup>51, 54</sup> euphoria,<sup>51</sup> and hiccups.<sup>51</sup>

## **Fetal and Neonatal Harms**

Twenty-nine studies include outcomes on fetal and neonatal harms. The most clinically significant and frequently reported outcomes for fetal harms were umbilical cord gases and Apgar scores, which are presented in Tables 9, 10, and 11. Studies are presented in reverse chronological order. Additional fetal and neonatal outcomes reported include placental transfer of nitrous oxide, assessment of neurobehavioral status, neonatal fluoride levels, and long-term outcomes.

Neonatal intensive care unit (NICU) admission rates cannot be accurately reported because different countries vary in their definition of what constitutes a high acuity ward, and rates were not consistently reported. Three studies reported admission to a special care nursery<sup>56, 73</sup> or neonatal unit.<sup>55</sup> Other reported harms that suggest the need for NICU care included fetal resuscitation,<sup>64, 73</sup> asphyxia,<sup>67</sup> depressed babies,<sup>49</sup> sleepy babies,<sup>67</sup> prolonged time to sustained respiration,<sup>80</sup> and treatment for apnea.<sup>73</sup>

## **Umbilical Arterial and Venous Blood Gases**

Umbilical cord blood gases were reported in eight studies. Three of these reported neonatal outcomes presented in Table 9.<sup>45, 49, 61</sup> The only significant finding was a lower mean umbilical artery pH in primiparous women who used nitrous oxide and meperidine compared with epidural (p = 0.01).<sup>61</sup> The remaining five studies were excluded from the table because they reported data prior to 1980 with unspecified co-administration of narcotics and sedatives in all groups<sup>52, 68-69</sup> or did not report actual cord blood gas values.<sup>40, 58</sup>

**Table 9. Fetal adverse effects, cord blood gases\***

Author Year Country Study Type	Intervention (N)	Umbilical pH, Arterial	Umbilical pH, Venous	Base Excess, Arterial	Base Excess, Venous
Abboud et al., <sup>45</sup> 1989 U.S. RCT	30-60% nitrous oxide in oxygen (30)	7.27	7.33	-2.2	-2.8
	0.2-0.7% Isoflurane in oxygen (30)	7.28	7.34	-3.0	-3.0
Deckhart et al., <sup>61</sup> 1987 Germany Prospective cohort	50% nitrous oxide in oxygen with meperidine (16 primip, 9 multip)	Primip: 7.21 <sup>^</sup> Multip: 7.31	NR	Primip: -9.5 Multip: -5.1	NR
	Epidural (25 primip)	7.29 <sup>^</sup>	NR	-6.4	NR
Abboud et al., <sup>49</sup> 1981 U.S. RCT	30-60% nitrous oxide in oxygen (50)	7.27	7.27	-7.0	-5.6
	0.25-1.25% Enflurane in oxygen (55)	7.26	7.34	-6.3	-6.3

multip = multiparous, NR = not reported, primip - primiparous, RCT = randomized controlled trial

Note: Studies published prior to 1980 are not included in this table.

\*Umbilical pH < 7 and base deficit  $\geq$  12 indicate metabolic acidosis. Arterial values are the most accurate.<sup>81</sup>

<sup>^</sup>Significant (p = 0.001)

## Apgar Scores

The Apgar score is used to assess the general condition of a newborn at 1 minute and 5 minutes after birth. A score of 0, 1, or 2 is given for each of five categories: heart rate, breathing effort, muscle tone, reflex response, and color. The highest possible score is 10, and a 5-minute score of 7 to 10 is considered normal.<sup>82</sup> Pharmacologic labor pain management methods can affect the Apgar score.

Twenty-five studies reported Apgar score data,<sup>12-13, 16, 37, 40, 43, 45, 49, 51-56, 58-59, 61, 64-69, 73, 80</sup> and 12 of these are presented in Tables 10 and 11. Studies that reported mean and/or median Apgar scores are presented in Table 10 while Table 11 presents studies that reported categorical Apgar scores (i.e., 8-10 and < 8). None of the studies reported in Tables 10 and 11 found significant differences in Apgar scores with nitrous oxide compared with other pain management methods or no labor analgesia. Apgar data were not included in table format for studies conducted prior to 1980 in which nitrous oxide was co-administered with unspecified and uncontrolled narcotics and/or sedatives. Two other studies were excluded from the table, one because neither treatment nor control group could be defined in terms of analgesia given<sup>83</sup> and the other because the timing of the Apgar scores was not defined.<sup>64</sup>

**Table 10. Neonatal adverse effects, mean and median Apgar scores**

Author Year Country Study Type	Intervention (N)	1 Min, Mean	5 Min, Mean	10 Min, Mean	1 Min, Median
Talebi et al., <sup>37</sup> 2009 Iran RCT	50% nitrous oxide in oxygen (260)	8.5	9.5	NR	NR
	50% oxygen (249)	8.5	9.5	NR	NR
Stirk et al., <sup>55</sup> 2002 U.K. Prospective cohort	Entonox (45)	8.2	9.6	NR	NR
	Morphine (70)	8.3	9.4	NR	NR
Ross et al., <sup>73</sup> 1999 U.K. Case series	50% nitrous oxide in oxygen with 0.25% isoflurane (48)	NR	NR	NR	9.0
	50% nitrous oxide in oxygen with 0.25% isoflurane; narcotic given > 5 hours before delivery (85)	NR	NR	NR	9.0
	50% nitrous oxide in oxygen with 0.25% isoflurane, narcotic given < 5 hours before delivery (88)	NR	NR	NR	8.0
	Nitrous oxide stopped < 1 hour before delivery (174)	NR	NR	NR	9.0
	Nitrous oxide stopped > 1 hour before delivery (47)	NR	NR	NR	9.0
Westling et al., <sup>43</sup> 1992 Sweden Crossover RCT	40% intermittent nitrous oxide in oxygen (24)	9.2 (all groups)	10.0 (all groups)	10.0 (all groups)	NR
	70% intermittent nitrous oxide in oxygen (24)				
	40% continuous nitrous oxide in oxygen (24)				
	Intermittent oxygen only (24)				
Landon et al., <sup>59</sup> 1992 U.K. Prospective cohort	Entonox for vaginal delivery (45)	8.5	9.3	NR	NR
	Vaginal delivery without Entonox (13)	8.5	9.4	NR	NR
	Epidural for cesarean section (13)	8.1	9.0	NR	NR
	Cesarean section with general anesthesia and nitrous oxide (23)	7.5	9.3	NR	NR

**Table 10. Neonatal adverse effects, mean and median Apgar scores (continued)**

Author Year Country Study Type	Intervention (N)	1 Min, Mean	5 Min, Mean	10 Min, Mean	1 Min, Median
Deckardt et al., <sup>61</sup> 1987 Germany Prospective cohort	50% nitrous oxide in oxygen with meperidine (25)	8.1	9.7	10.0	NR
	Epidural (25)	8.9	10.0	10.0	NR
Arthurs et al., <sup>16</sup> 1979 U.K. Prospective cohort	50% nitrous oxide in oxygen intermittent with continuous nitrous 50% via nasal cannula* (24)	7.8	9.6	NR	NR
	50% nitrous oxide in oxygen, intermittent* (25)	7.7	9.3	NR	NR

NR = not reported, RCT = randomized controlled trial

Note: No studies reported 5 or 10 minute median Apgar scores.

\*Some participants used pethidine and/or epidural

**Table 11. Neonatal adverse effects, range of Apgar scores**

Author Year Country Study Type	Intervention (N)	8-10, 1 Min (%)	<8, 1 Min (%)	8-10, 5 Min (%)	<8, 5 Min (%)
Leong et al., <sup>56</sup> 2000 Malaysia Prospective cohort	Entonox with pethidine (68)	NR	NR	100	0
	Epidural (55)	NR	NR	100	0
Ross et al., <sup>73</sup> 1999 U.K. Case series	50% nitrous oxide in oxygen with 0.25% isoflurane (48)	83*	17.6*	97.3	2.7
	50% nitrous oxide in oxygen with 0.25% isoflurane; narcotic given > 5 hours before delivery (85)	69	31	NR	NR
	50% nitrous oxide in oxygen with 0.25% isoflurane, narcotic given < 5 hours before delivery (88)	55	46	NR	NR
	Nitrous oxide stopped < 1 hour before delivery (174)	67	33	NR	NR
	Nitrous oxide stopped > 1 hour before delivery (47)	67*	36*	NR	NR
Abboud et al., <sup>40</sup> 1995 U.S. RCT	30-60% nitrous oxide in oxygen (40)	92	8	100	0
	1-4.5% desflurane in oxygen (40)	87	13	100	0

**Table 11. Neonatal adverse effects, range of Apgar scores (continued)**

Author Year Country Study Type	Intervention (N)	8-10, 1 Min (%)	<8, 1 Min (%)	8-10, 5 Min (%)	<8, 5 Min (%)
Ranta et al., <sup>58</sup> 1994 Finland Prospective cohort	50% nitrous oxide in oxygen (210)	93	7	99	1
	Water block (69)	90	10	97	3
	IM pethidine (50)	91	9	100	0
	Paracervical block (128)	97	3	97	3
	Epidural (82)	94	6	96	4
	Several forms of analgesia (339)	94	6	97	3
	No analgesia (213)	89	11	99	1
Abboud et al., <sup>45</sup> 1989 U.S. RCT	30-60% nitrous oxide in oxygen (30)	93	7	100	0
	0.2-0.7% isoflurane in oxygen (30)	93	7	100	0
Murphy et al., <sup>65</sup> 1984 U.K. Retrospective cohort	Entonox, born 1970-1974 (3,697)	87.8	12.3	NR	NR
	Entonox, born 1975-1979 (4,448)	89.9	10.1	NR	NR
	Entonox and pethidine, born 1970-1974 (12,084)	78.5	21.5	NR	NR
	Entonox and pethidine, born 1975-1979 (85,860)	78.8	21.2	NR	NR
	Pethidine, born 1970-1975 (2,770)	74.4	25.6	NR	NR
	Pethidine, born 1975-1979 (874)	80.3	19.7	NR	NR
	Epidural, born 1970-1974 (1,223)	74.5	25.4	NR	NR
	Epidural, born 1975-1979 (3,084)	82.0	18.0	NR	NR
	No analgesia, born 1970-1974 (1,508)	86.1	13.8	NR	NR
	No analgesia, born 1975-1979 (852)	90.0	10.0	NR	NR

**Table 11. Neonatal adverse effects, range of Apgar scores (continued)**

Author Year Country Study Type	Intervention (N)	8-10, 1 Min (%)	<8, 1 Min (%)	8-10, 5 Min (%)	<8, 5 Min (%)
Abboud et al., <sup>49</sup> 1981 U.S. RCT	30-60% nitrous oxide in oxygen (50)	94	6	100	0
	0.25-1.25% enflurane in oxygen (55)	92	8	98	2

NR = not reported, RCT = randomized controlled trial

\*As reported by publication; percentages do not tally to 100.

## Assessment of Neonatal Neurobehavioral Status

Neurobehavioral status has been studied in four studies using a variety of assessment tools.<sup>40, 45, 63, 67</sup> Only one study compared newborns of women using nitrous oxide with a control group.<sup>63</sup> In this prospective cohort study, neonates of mothers receiving a variety of analgesic agents in labor were evaluated with the Neonatal Psychological Assessment profile. Neonatal scores with Entonox were comparable with all other methods, including epidural, pethidine, TENS, and no analgesia. Neonatal Adaptive Capacity Scores (NACS) at 2 and 24 hours did not differ significantly between newborns whose mothers used nitrous oxide and desflurane.<sup>40</sup> In another RCT, there were no significant differences in test item scores on the NACS between the nitrous oxide group and isoflurane group.<sup>45</sup> One study reported Perez and Moro reflexes became positive more rapidly in newborns after maternal administration of nitrous oxide compared with trichloroethylene and halothane (no test of statistical significance reported).<sup>67</sup>

## Long-Term Harms

Long-term offspring outcomes were addressed in four studies.<sup>33-36</sup> All studies reporting long-term outcomes were retrospective; no prospective studies with regard to long-term harms were identified. Three poor-quality case-control studies from Sweden conducted by the same investigators with overlapping populations have investigated nitrous oxide use during labor and later addiction in offspring.<sup>33-35</sup> One of these studies reported a risk ratio of 5.6 (95% CI 1.6 to 16.9,  $p = 0.005$ ) for amphetamine addiction after greater than 4.5 hours of nitrous oxide exposure in utero compared with less than 0.25 hours; however, many participants had missing data and women used pure nitrous oxide rather than a mix with oxygen as is current practice.<sup>35</sup> The fourth case-control study investigated possible risk factors for childhood leukemia reporting an increased risk for all leukemias with in utero exposure to nitrous oxide (odds ratio 1.3, 95% CI 1.0 to 1.6), although the risk was not observed in all subgroups.<sup>36</sup>

## Occupational Exposure

Occupational exposure in labor and birth settings was addressed in seven studies.<sup>26-32</sup> Three of these were Swedish studies that examined occupational exposure related harms in midwives.<sup>27-29</sup> One study focused on subfertility and found a decreased fecundability ratio in midwives who attended more than 30 births per month in which nitrous oxide was used (0.63, 95% CI 0.43 to 0.94).<sup>28</sup> Another study reported no increased risk of spontaneous abortion with nitrous oxide exposure.<sup>29</sup> In the third study, women exposed to nitrous oxide had newborns with

reduced birth weight (-77 grams, 95% CI -129 to -24) and an increase in odds for small for gestational age (odds ratio 1.8, 95 % CI 1.1 to 2.8).<sup>27</sup>

The measurement of nitrous oxide exposure is addressed in four studies, which report nitrous oxide levels but not specific harms.<sup>26, 30-32</sup> A study in the United Kingdom collected data on midwives wearing exposure badges for 242 shifts in labor wards without scavenging and with standard room ventilation only.<sup>32</sup> Shifts ranged from 7.5 to 11 hours. Midwives had exposure greater than 100 ppm (the Swedish limit) during 23 percent of shifts and greater than 25 ppm (the U.S. limit) during 53 percent of shifts. An evaluation of scavenging systems in Swedish labor wards found a 4-fold reduction in nitrous oxide levels with use of efficient scavenging systems. Nitrous oxide concentrations in diffusive air samplers varied from 2.5 to 260 mg/m<sup>3</sup>, and mean 8-hour time-weighted averages were 17mg/m<sup>3</sup> for midwives and 42mg/m<sup>3</sup> for assistant midwives.<sup>30</sup> The 8-hour-time-weighted-averages exceeded the American Conference of Industrial Hygienists' average threshold limit value (50 ppm or 90 mg/m<sup>3</sup>) in 16 percent of midwives and 45 percent of assistant midwives. The authors attribute these differences to the fact that assistant midwives have a longer average exposure time and are also working more closely with women earlier in labor when nitrous oxide is used more frequently.<sup>30</sup> Another study in the United Kingdom correlated nitrous oxide exposure to urine nitrous oxide levels in a descriptive study of unscavenged and poorly-ventilated delivery suites.<sup>26</sup> Environmental levels exceeded 100 ppm over 8-hour time-weighted averages in 35 of 46 midwife shifts monitored. It is notable that in this study 22 of 46 midwives had nonzero baseline values of nitrous oxide in their urine, which the authors propose may indicate tissue clearance occurs over a longer time period than previously thought. Newton et al evaluated 8-hour time-weighted average nitrous oxide exposure (in ppm) for 15 midwives at a newly built English hospital with a ventilation system incorporating six to ten air changes per hour, comparing the results with historical data from an older building in which ventilation did not exist (Entonox machines were unscavenged in both hospitals).<sup>31</sup> Levels in the new hospital were significantly lower, and none of the 15 midwives in the new hospital was exposed to levels of nitrous oxide greater than 100 ppm. Six of the 15 midwives were exposed to levels of nitrous oxide greater than 25 ppm (the U.S. limit).

## **KQ5: Effects of Provider and Health System Factors**

No studies addressed KQ5. It is discussed as a part of future research.

## **Grey Literature Search Results**

Grey literature search methods are described in the Methods chapter of this review. No relevant articles were located.

# Discussion

## State of the Literature

We identified a total of 59 distinct studies reported in 58 publications: two of good quality; 11 fair; and 46 poor. Thirty-three percent of the studies identified were randomized clinical trials (RCTs), a smaller proportion were clinical trials without clear evidence of randomization (7%), and the balance are observational research.

## Strength of Evidence

Overall the strength of evidence to answer the Key Questions (KQ) was insufficient for effectiveness in managing labor pain (KQ1), effect on route of birth (KQ3), and health system factors (KQ5); low for satisfaction (KQ2); and moderate for harms (KQ4) (Table 12). Deficiencies in the strength of evidence most often related to a preponderance of study designs with high risk of bias; inconsistent findings across studies and inconsistencies among outcomes that would be expected to show corresponding benefit; use of intermediate outcomes; and small studies with poor precision. In the summary below, we provide strength of evidence ratings by Key Question.

**Table 12. Strength of evidence for nitrous oxide for the management of labor pain**

Total Studies (Total Participants)	Domains Pertaining to Strength of Evidence				Strength of Evidence
	Risk of Bias	Consistency	Directness	Precision	
<b><i>Effectiveness of Nitrous Oxide vs. Other, Nonepidural Labor Pain Management Methods for the Management of Labor Pain (KQ1)</i></b>					
<b>25 (15,991)</b>	High	Inconsistent	Indirect	Imprecise	Insufficient; includes 6 RCTs; 5 studies of fair quality and 20 studies of poor quality total
<b><i>Equivalence or Superiority of Nitrous Oxide vs. Other Labor Pain Management Methods for Women's Satisfaction With Their Birth Experience (KQ2)</i></b>					
<b>2 (1,303)</b>	High	Consistent	Direct	Imprecise	Low; includes no RCTs; 1 study of fair quality and 1 study of poor quality total
<b><i>Equivalence or Superiority of Nitrous Oxide vs. Other Labor Pain Management Methods for Women's Satisfaction With Their Pain Management (KQ2)</i></b>					
<b>8 (2,825)</b>	High	Consistent	Direct	Imprecise	Low; includes 2 RCTs; 1 study of good quality and 7 studies of poor quality total
<b><i>Effect of Nitrous Oxide for the Management of Labor Pain on Route of Birth (KQ3)</i></b>					
<b>6 (33,031)</b>	High	Inconsistent	Direct	Imprecise	Insufficient; includes 2 RCTs; 1 study of good quality and 5 studies of poor quality total
<b><i>Adverse Effects Associated With Nitrous Oxide for the Management of Labor Pain are Primarily Unpleasant Side Effects That Affect Tolerability (KQ4)</i></b>					
<b>48 (27,530)*</b>	High	Consistent	Direct	Imprecise	Moderate; includes 18 RCTs; 2 studies of good quality, 6 studies of fair quality, and 40 studies of poor quality total

RCT = randomized controlled trial

Note: Domains pertaining to SOE are taken from the AHRQ Methods Guide<sup>25</sup> and are explained in the Methods chapter

\*One study did not provide an N and is not included in this calculation<sup>32</sup>.



## Principal Findings and Considerations

### KQ1: Effectiveness of Nitrous Oxide for Labor Pain Management

Twenty-one studies addressed the effectiveness of nitrous oxide using some measurement of pain or pain relief.<sup>38, 40-41, 44-45, 47-49, 51, 53-54, 58, 62, 66, 68-70, 75-76, 78-79</sup> Four studies were of fair quality,<sup>69-70, 75-76</sup> and 17 were of poor quality.<sup>38, 40-41, 44-45, 47-49, 51, 53-54, 58, 62, 66, 68, 78-79</sup> There was considerable variation across studies in many aspects including the concentration of nitrous oxide and frequency (continuous vs. intermittent) administered, additional pain management methods used, and methods and persons (i.e., women, obstetricians, midwives, and anesthesia providers) assessing pain and pain relief. The substantial variation in timing of assessment may have affected the reported outcomes because women's opinions about pain relief change with time lapsed after birth.<sup>53-54, 66</sup>

The majority of the effectiveness studies (12 of 21) had as comparators other inhalational anesthetic gases that are not used to manage labor pain in the United States. Only one study compared nitrous oxide with placebo and found no significant difference in pain scores. As expected, epidurals provide more effective pain relief than nitrous oxide. It may be counterproductive to evaluate pain scores, which require focusing on the level of pain, in women using nitrous oxide, which is intended to produce dissociation from pain. What these studies are unable to demonstrate is whether nitrous provided adequate pain relief for women who knowingly accept less effective pain relief in exchange for increased mobility, less intervention and monitoring, and avoidance of potential complications associated with epidurals. Generally speaking, therefore, pain relief is likely to be an inadequate measure of effectiveness for nitrous oxide in the absence of other outcomes such as women's satisfaction.

### KQ2: Effect of Nitrous Oxide on Women's Satisfaction

Nine studies addressed women's satisfaction with their birth experience or pain management.<sup>40, 45, 49, 56, 58, 62, 71, 74, 79</sup> One study was of good quality,<sup>56</sup> one of fair quality,<sup>74</sup> and seven of poor quality.<sup>40, 45, 49, 58, 62, 71, 79</sup> Measurements of satisfaction were not uniform making it impossible to synthesize studies. Satisfaction may be a more relevant measure of effectiveness than assessment of pain because nitrous oxide is not intended to provide complete pain relief.

### KQ3: Effect of Nitrous Oxide on the Route of Birth

Six studies compare the route of birth in women who used nitrous oxide with women who used other pain management methods.<sup>40, 54, 56, 58, 62, 66</sup> Two of these only included women who had vaginal births,<sup>40, 54</sup> and five were of poor quality.<sup>40, 54, 58, 62, 66</sup> The strength of the evidence is insufficient to determine the effect of nitrous oxide on the route of birth.

### KQ4: Adverse Effects of Nitrous Oxide for Labor Pain Management

Forty-nine studies addressed the maternal, fetal, neonatal, and occupational harms related to nitrous oxide use during labor.<sup>12-13, 16, 26-30, 32-43, 45-61, 63-69, 72-73, 77, 80</sup> Two were of good quality,<sup>36, 56</sup> seven of fair quality,<sup>26, 30-32, 42, 69, 72</sup> and forty of poor quality.<sup>12-13, 16, 27-29, 33-35, 37-41, 43, 45-55, 57-61, 63-68, 73, 77, 80</sup> Although these 49 studies report data from more than 27,000 women, only six of these studies were conducted in the United States (n = 2,445 women). In addition, one-third (16 of 49) of studies reporting harms were conducted prior to 1980 when nitrous oxide was often used in

combination with sedatives, tranquilizers, and other inhaled anesthetics in labor, a practice that has largely been abandoned. Studies reporting harms associated with sedative analgesic regimens may not translate effectively to contemporary labor analgesia practice. For example, in older studies amnesia in labor was considered to be a positive outcome.

Most maternal harms reported in the literature were unpleasant side effects that affect tolerability (e.g., nausea, vomiting, dizziness, and drowsiness). Some maternal harms (e.g., nausea and oxygen desaturation) are common in all laboring women regardless of the type of analgesia used. Study sizes were inadequate to assess for unusual or rare harms that might be more serious in terms of morbidity.

Nitrous oxide is transmitted via the placenta and is rapidly eliminated by the neonate following birth once breathing begins. Apgar scores in newborns whose mothers used nitrous oxide did not differ significantly from those of newborns whose mothers used other labor pain management methods or no analgesia. Followup of newborns was short, most frequently lasting only to birth or discharge of the neonate from the hospital.

Limited data on occupational harms are available thus it is difficult to draw conclusions regarding potential occupational harms as a result of exposure to nitrous oxide. Evidence about occupational levels of nitrous oxide is limited, and some studies were conducted prior to the use of room ventilation systems or scavenging systems. The implementation of these systems in clinical practice has reduced occupational exposure, which should mitigate potential risks of exposure.

## **KQ5: Effects of Provider and Health System Factors**

No studies addressed KQ5. It is discussed as a part of future research.

## **Applicability**

Applicability describes the extent to which study populations and characteristics in the literature reviewed apply to the larger population. In this report, the study populations were healthy women in labor who should be similar to the target population. The eligibility criteria and participant characteristics were not always explicitly detailed. Some participants were excluded due to choice of alternate pain management methods.

Most studies used a 50/50 mix of nitrous and oxygen, often premixed in the form of Entonox<sup>®</sup>. The 50/50 mix is available, although Entonox is not used in the United States and has not been reviewed by the U.S. Food and Drug Administration. In addition, mechanical equipment for administration of nitrous oxide in labor and delivery has very limited availability in the United States at the time of this writing. In the studies related to harms (Key Question 4), the intervention varied significantly in terms of dose, frequency, and duration. In many studies participants received unspecified amounts of narcotics and/or sedating agents. Studies prior to 1980 are not applicable to current guidelines for clinical use.

The comparators include standard pain management methods, such as epidural, narcotics, and nonpharmacologic methods such as transcutaneous electrical nerve stimulation (TENS). However, some comparators are not commonly used and/or available for laboring women, such as other inhalational anesthetic gases.

For KQ1, the most frequent outcome was an assessment of pain, generally during labor. Some studies retrospectively assessed pain in the immediate postpartum period and/or weeks to months after birth. The methods of pain assessment were heterogeneous. Those assessing outcomes included participants, obstetricians, midwives, and anesthesia providers. Satisfaction

with pain management and the birth experience, as reported by the women were the outcome measures for KQ2. The outcomes for KQ3 were vaginal birth, assisted vaginal birth, and cesarean. None of the studies had a cesarean birth rate greater than 10 percent, which is much lower than the most recently reported U.S. rate of 32 percent.<sup>1</sup> For KQ4, the most frequent outcomes were assessments of nausea, vomiting, dizziness, drowsiness, hypoxia, oxygen saturation, Apgar scores, and cord blood gases.

Only six of 58 studies were conducted in the United States. The options for labor pain management in the United States are somewhat dissimilar to those in other countries because nitrous oxide for laboring women is widely available outside of the United States, whereas in this country its availability is extremely limited. While setting was not a criterion for inclusion or exclusion, all of the studies were conducted in hospitals. Thus the effectiveness, women's satisfaction, route of birth, and harms associated with nitrous oxide in birth centers and the home setting have not been reported.

## **Future Research**

### **State of the Science**

Nitrous oxide has been used for labor pain management since the 1930s, primarily outside the United States.<sup>4</sup> Much of the literature on this topic is older with nearly half of the studies in this review published prior to 1990 and one-quarter before 1980. Over the past decade, there has been growing interest in the use of nitrous oxide for laboring women in the United States. As use of nitrous oxide for labor pain management increases, continued research is warranted. Topics that would benefit from consideration include:

### **Methodologic Priorities**

- Clearly documenting the mix of nitrous oxide used and the timing and mode of administration.
- Performing studies that use doses and equipment consistent with contemporary U.S. maternity care.
- Developing outcome measures that assess effectiveness as defined by women choosing nitrous oxide.
- Using standardized and validated outcome measures to assess pain and women's satisfaction.
- Including women's assessment of pain, rather than only providers', in all studies that report this outcome.
- Performing qualitative research in addition to quantitative studies.
- Conducting sequential analysis trials in which women can opt-in and opt-out of nitrous oxide.
- Conducting studies in out-of-hospital birth settings (i.e., freestanding birth centers and home births).
- Building consensus about critical maternal, fetal, neonatal, childhood, and occupational exposure outcomes, developing a minimal core data set for future research.
- Designing human studies that examine apoptosis, which has been observed in rodents exposed to high doses of systemic anesthetics.

- Developing electronic medical record approaches to long-term surveillance for adverse effects.

## **Content Priorities**

- Exploring anti-anxiety effects of nitrous oxide during labor.
- Examining the influence of nitrous oxide on whether and when women choose to use other labor pain management methods.
- Investigating the impact of nitrous oxide on use of cointerventions, route of birth, maternal-newborn bonding, and breastfeeding.
- Assessing fetal/neonatal clearance of nitrous oxide.
- Determining optimal methods for minimizing occupational exposures, such as room ventilation and scavenging measures.
- Assessing potential occupational harms, including nitrous oxide abuse and addiction.
- Identifying health system factors influencing the use of nitrous oxide for the management of labor pain, including but not limited to provider preferences, availability, setting, and resource utilization.
- Determining provider and patient education needed for nitrous oxide use in labor,
- Analyzing cost effectiveness of nitrous oxide and other labor pain management methods.

## **Current and Future Research**

Recently completed and ongoing research includes the following:

Completed:

- One study on the effect of labor analgesia on babies' movement after birth, with nitrous oxide use or no analgesia as the control group.

Ongoing:

- Zero studies.

Planned:

- One study on the comparison of the effects of Entonox and TENS in labor pain.

## **Conclusions**

The literature addressing nitrous oxide for the management of labor pain has few studies of good or fair quality. Synthesis of effectiveness and satisfaction studies was challenging because of heterogeneous interventions, comparators, and outcome measures. Satisfaction may be a more relevant measure of effectiveness than assessment of pain because nitrous oxide is not intended to provide complete pain relief. The strength of evidence for the effect of nitrous oxide on route of birth was insufficient. Most maternal harms reported in the literature were unpleasant side effects that affect tolerability (e.g., nausea, vomiting, dizziness, and drowsiness), and Apgar scores did not differ significantly across labor pain management methods. Data for occupational harms were limited. Research assessing nitrous oxide is needed across all of the Key Questions examined: effectiveness, women's satisfaction, route of birth, harms, and health system factors affecting use.

## References and Included Studies

1. Martin JA, Hamilton BE, Sutton PD, et al. Births: Final Data for 2008. National Vital Statistics Reports. Released December 8, 2010;59(1):1-72.
2. Marmor TR and Krol DM. Labor pain management in the United States: understanding patterns and the issue of choice. *Am J Obstet Gynecol.* 2002 May;186(5 Suppl Nature):S173-80.
3. Declercq ER, Sakala C, Corry MP, et al. Listening to Mothers II: Report of the Second National US Survey of Women's Childbearing Experiences. New York: Childbirth Connection. 2006.
4. Rosen MA. Nitrous oxide for relief of labor pain: A systematic review. *Am J Obst Gynecol.* 2002;186(5 SUPPL):S110-S126.
5. Irestedt L. Current status of nitrous oxide for obstetric pain relief. *Acta Anaesthesiol Scand.* 1994 Nov;38(8):771-2.
6. Oyston J. Obstetrical anaesthesia in Ontario. *Can J Anaesth.* 1995 Dec;42(12):1117-25.
7. Bishop JT. Administration of nitrous oxide in labor: expanding the options for women. *J Midwifery Womens Health.* 2007 May-Jun;52(3):308-9.
8. Smith WD. A history of nitrous oxide and oxygen anaesthesia. I. *Br J Anaesth.* 1965;37(10):790-798.
9. Fujinaga M and Maze M. Neurobiology of nitrous oxide-induced antinociceptive effects. *Mol Neurobiol.* 2002 Apr;25(2):167-89.
10. Sanders RD, Weimann J and Maze M. Biologic effects of nitrous oxide: a mechanistic and toxicologic review. *Anesthesiology.* 2008 Oct;109(4):707-22.
11. Camann W, Alexander K. Easy labor: Every woman's guide to choosing less pain and more joy during childbirth. New York: Ballantine Books; 2007.
12. Clinical trials of different concentrations of oxygen and nitrous oxide for obstetric analgesia. Report to the Medical Research Council of the Committee on Nitrous Oxide and Oxygen Analgesia in Midwifery. *Br Med J.* 1970 Mar 21;1(5698):709-13.
13. McAneny T and Doughty A. Self-administered nitrous-oxide/oxygen analgesia in obstetrics. *Anaesthesia.* 1963 1963;18(4):488-497.
14. Rooks JP. Safety and risks of nitrous oxide labor analgesia: A review. *J Midwifery Womens Health.* 2011;56(6):557-565.
15. Arthurs GJ and Rosen M. Acceptability of continuous nasal nitrous oxide during labour--a field trial in six maternity hospitals. *Anaesthesia.* 1981 Apr;36(4):384-8.
16. Arthurs GJ and Rosen M. Self-administered intermittent nitrous oxide analgesia for labour. Enhancement of effect with continuous nasal inhalation of 50 per cent nitrous oxide (Entonox). *Anaesthesia.* 1979 Apr;34(4):301-9.
17. Osterman MJ and Martin JA. Epidural and spinal anesthesia use during labor: 27-state reporting area, 2008. *Natl Vital Stat Rep.* 2011 Apr 6;59(5):1-13, 16.
18. Anim-Somuah M, Smyth RM and Jones L. Epidural versus non-epidural or no analgesia in labour. *Cochrane Database Syst Rev.* 2011;12:CD000331.
19. Anim-Somuah M, Smyth R and Howell C. Epidural versus non-epidural or no analgesia in labour. *Cochrane Database Syst Rev.* 2005(4):CD000331.
20. Hawkins JL. Epidural analgesia for labor and delivery. *N Engl J Med.* 2010;362(16):1503-1510.
21. From the American College of Nurse-Midwives. Nitrous oxide for labor analgesia. *J Midwifery Womens Health.* 2010 May-Jun;55(3):292-6.
22. Juni P, Hoenstein F, Sterne J, et al. Direction and impact of language bias in meta-analyses of controlled trials: empirical study. *Int J Epidemiol.* 2002 Feb;31(1):115-23.
23. Higgins JPT, Altman DG and Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT and Green S, editors. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0* (updated March 2011): The Cochrane Collaboration; 2011.

24. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp).
25. Agency for Healthcare Research and Quality. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville: AHRQ Publication; 2011 [updated 2011; cited]; 10: [www.effectivehealthcare.ahrq.gov/methodsguide.cfm](http://www.effectivehealthcare.ahrq.gov/methodsguide.cfm).
26. Henderson KA, Matthews IP, Adisesh A, et al. Occupational exposure of midwives to nitrous oxide on delivery suites. *Occup Environ Med*. 2003 Dec;60(12):958-61.
27. Bodin L, Axelsson G and Ahlborg G, Jr. The association of shift work and nitrous oxide exposure in pregnancy with birth weight and gestational age. *Epidemiology*. 1999 Jul;10(4):429-36.
28. Ahlborg G, Jr., Axelsson G and Bodin L. Shift work, nitrous oxide exposure and subfertility among Swedish midwives. *Int J Epidemiol*. 1996 Aug;25(4):783-90.
29. Axelsson G, Ahlborg G, Jr. and Bodin L. Shift work, nitrous oxide exposure, and spontaneous abortion among Swedish midwives. *Occup Environ Med*. 1996 Jun;53(6):374-8.
30. Westberg H, Egelrud L, Ohlson CG, et al. Exposure to nitrous oxide in delivery suites at six Swedish hospitals. *Int Arch Occup Environ Health*. 2008;81(7):829-836.
31. Newton C, Fitz-Henry J and Bogod D. The occupational exposure of midwives to nitrous oxide - a comparison between two labour suites. *Int J Obstet Anesth*. 1999 Jan;8(1):7-10.
32. Mills GH, Singh D, Longan M, et al. Nitrous oxide exposure on the labour ward. *Int J Obstet Anesth*. 1996 Jul;5(3):160-4.
33. Nyberg K, Allebeck P, Eklund G, et al. Socio-economic versus obstetric risk factors for drug addiction in offspring. *Br J Addict*. 1992 Dec;87(12):1669-76.
34. Jacobson B, Nyberg K, Gronbladh L, et al. Opiate addiction in adult offspring through possible imprinting after obstetric treatment. *BMJ*. 1990 Nov 10;301(6760):1067-70.
35. Jacobson B, Nyberg K, Eklund G, et al. Obstetric pain medication and eventual adult amphetamine addiction in offspring. *Acta Obstet Gynecol Scand*. 1988;67(8):677-82.
36. Zack M, Adami HO and Ericson A. Maternal and perinatal risk factors for childhood leukemia. *Cancer Res*. 1991 Jul 15;51(14):3696-701.
37. Talebi H, Nourozi A, Jamilian M, et al. Entonox for labor pain: a randomized placebo controlled trial. *Pak J Biol Sci*. 2009 Sep 1;12(17):1217-21.
38. Yeo ST, Holdcroft A, Yentis SM, et al. Analgesia with sevoflurane during labour: ii. Sevoflurane compared with Entonox for labour analgesia. *Br J Anaesth*. 2007 Jan;98(1):110-5.
39. Einarsson S, Stenqvist O, Bengtsson A, et al. Gas kinetics during nitrous oxide analgesia for labour. *Anaesthesia*. 1996 May;51(5):449-52.
40. Abboud TK, Swart F, Zhu J, et al. Desflurane analgesia for vaginal delivery. *Acta Anaesthesiol Scand*. 1995 Feb;39(2):259-61.
41. Carstoniu J, Levytam S, Norman P, et al. Nitrous oxide in early labor. Safety and analgesic efficacy assessed by a double-blind, placebo-controlled study. *Anesthesiology*. 1994 Jan;80(1):30-5.
42. Arora S, Tunstall M and Ross J. Self-administered mixture of Entonox and isoflurane in labour. *Int J Obstet Anesth*. 1992 Sep;1(4):199-202.
43. Westling F, Milsom I, Zetterstrom H, et al. Effects of nitrous oxide/oxygen inhalation on the maternal circulation during vaginal delivery. *Acta Anaesthesiol Scand*. 1992 Feb;36(2):175-81.
44. Chia YT, Arulkumaran S, Chua S, et al. Effectiveness of transcutaneous electric nerve stimulator for pain relief in labour. *Asia Oceania J Obstet Gynaecol*. 1990 Jun;16(2):145-51.
45. Abboud TK, Gangolly J, Mosaad P, et al. Isoflurane in obstetrics. *Anesth Analg*. 1989 Mar;68(3):388-91.

46. Constantine G, Luesley DM, O'Connor A, et al. The use of Entonox in conjunction with a rebreathing humidifier. *J Obstet Gynaecol.* 1989;10(1):23-25.
47. McLeod DD, Ramayya GP and Tunstall ME. Self-administered isoflurane in labour. A comparative study with Entonox. *Anaesthesia.* 1985 May;40(5):424-6.
48. McGuinness C and Rosen M. Enflurane as an analgesic in labour. *Anaesthesia.* 1984 Jan;39(1):24-6.
49. Abboud TK, Shnider SM, Wright RG, et al. Enflurane analgesia in obstetrics. *Anesth Analg.* 1981 Mar;60(3):133-7.
50. Rosen M, Latto P and Asscher AW. Kidney function after methoxyflurane analgesia during labour. *Br Med J.* 1972 Jan 8;1(5792):81-3.
51. Bergsjö P and Lindbaek E. Comparison between nitrous oxide and methoxyflurane for obstetrical analgesia. *Acta Obstet Gynecol Scand.* 1971;50(3):285-90.
52. Phillips TJ and Macdonald RR. Comparative effect of pethidine, trichloroethylene, and Entonox on fetal and neonatal acid-base and PO<sub>2</sub>. *Br Med J.* 1971 Sep 4;3(5774):558-60.
53. Jones PL, Rosen M, Mushin WW, et al. Methoxyflurane and nitrous oxide as obstetric analgesics. II. A comparison by self-administered intermittent inhalation. *Br Med J.* 1969 Aug 2;3(5665):259-62.
54. Jones PL, Rosen M, Mushin WW, et al. Methoxyflurane and nitrous oxide as obstetric analgesics. I. A comparison by continuous administration. *Br Med J.* 1969 Aug 2;3(5665):255-9.
55. Stirk P, Staines J and Brown DW. Maternal diamorphine administration during labour: the effect on neonate admissions to NNU. *J Neonatal Nurs.* 2002;8(2):56-7.
56. Leong EW, Sivanesaratnam V, Oh LL, et al. Epidural analgesia in primigravidae in spontaneous labour at term: a prospective study. *J Obstet Gynaecol Res.* 2000 Aug;26(4):271-5.
57. Arfeen Z, Armstrong PJ and Whitfield A. The effects of Entonox and epidural analgesia on arterial oxygen saturation of women in labour. *Anaesthesia.* 1994 Jan;49(1):32-4.
58. Ranta P, Jouppila P, Spalding M, et al. Parturients' assessment of water blocks, pethidine, nitrous oxide, paracervical and epidural blocks in labour. *International Journal of Obstetric Anesthesia.* 1994;3(4):193-198.
59. Landon MJ, Creagh-Barry P, McArthur S, et al. Influence of vitamin B12 status on the inactivation of methionine synthase by nitrous oxide. *Br J Anaesth.* 1992 Jul;69(1):81-6.
60. Zelcer J, Owers H and Paull JD. A controlled oximetric evaluation of inhalational, opioid and epidural analgesia in labour. *Anaesth Intensive Care.* 1989 Nov;17(4):418-21.
61. Deckardt R, Fembacher PM, Schneider KT, et al. Maternal arterial oxygen saturation during labor and delivery: pain-dependent alterations and effects on the newborn. *Obstet Gynecol.* 1987 Jul;70(1):21-5.
62. Harrison RF, Shore M, Woods T, et al. A comparative study of transcutaneous electrical nerve stimulation (TENS), Entonox, pethidine + promazine and lumbar epidural for pain relief in labor. *Acta Obstet Gynecol Scand.* 1987;66(1):9-14.
63. Harrison RF and Cullen R. A comparative study of the behaviour of the neonate following various forms of maternal intrapartum analgesia and anaesthesia. *Ir J Med Sci.* 1986;155(1):12-18.
64. Soyannwo OA. Self-administered Entonox (50% nitrous oxide in oxygen) in labour: report of the experience in Ibadan. *Afr J Med Med Sci.* 1985 Mar-Jun;14(1-2):95-8.
65. Murphy JF, Dauncey M and Rees GAD. Obstetric analgesia, anaesthesia and the Apgar score. *Anaesthesia.* 1984;39(8):760-763.
66. Rosen M, Mushin WW, Jones PL, et al. Field trial of methoxyflurane, nitrous oxide, and trichloroethylene as obstetric analgesics. *Br Med J.* 1969 Aug 2;3(5665):263-7.
67. Beppu K. Transmission of the anesthetic agents through the placenta in painless delivery and their effects on newborn infants. *Keio J Med.* 1968 Jun;17(2):81-107.

68. Smith BE and Moya F. Inhalational analgesia with methoxyflurane for vaginal delivery. *South Med J*. 1968 Apr;61(4):386-90.
69. Clark RB, Cooper JO, Brown WE, et al. An evaluation of methoxyflurane analgesia and anesthesia for obstetrics. *South Med J*. 1968 Jul;61(7):687-91.
70. Waldenstrom U and Irestedt L. Obstetric pain relief and its association with remembrance of labor pain at two months and one year after birth. *J Psychosom Obstet Gynaecol*. 2006 Sep;27(3):147-56.
71. Henry A and Nand SL. Intrapartum pain management at the Royal Hospital for Women. *Aust N Z J Obstet Gynaecol*. 2004 Aug;44(4):307-13.
72. Paech MJ. The King Edward Memorial Hospital 1,000 mother survey of methods of pain relief in labour. *Anaesth Intensive Care*. 1991 Aug;19(3):393-9.
73. Ross JA, Tunstall ME, Campbell DM, et al. The use of 0.25% isoflurane premixed in 50% nitrous oxide and oxygen for pain relief in labour. *Anaesthesia*. 1999 Dec;54(12):1166-72.
74. Waldenstrom U. Experience of labor and birth in 1111 women. *J Psychosom Res*. 1999 Nov;47(5):471-82.
75. Waldenstrom U, Bergman V and Vasell G. The complexity of labor pain: Experiences of 278 women. *J Psychosom Obstet Gynaecol*. 1996;17(4):215-228.
76. Ranta P, Spalding M, Kangas-Saarela T, et al. Maternal expectations and experiences of labour pain — options of 1091 Finnish parturients. *Acta Anaesthesiol Scand*. 1995;39(1):60-66.
77. Reed PN, Colquhoun AD and Hanning CD. Maternal oxygenation during normal labour. *Br J Anaesth*. 1989 Mar;62(3):316-8.
78. Morgan B, Bulpitt CJ, Clifton P, et al. Effectiveness of pain relief in labour: survey of 1000 mothers. *Br Med J (Clin Res Ed)*. 1982 Sep 11;285(6343):689-90.
79. Holdcroft A and Morgan M. An assessment of the analgesic effect in labour of pethidine and 50 per cent nitrous oxide in oxygen (Entonox). *J Obstet Gynaecol Br Commonw*. 1974 Aug;81(8):603-7.
80. Marx GF, Joshi CW and Orkin LR. Placental transmission of nitrous oxide. *Anesthesiology*. 1970 May;32(5):429-32.
81. ACOG Committee Opinion No. 348, November 2006: Umbilical cord blood gas and acid-base analysis. *Obstet Gynecol*. 2006 Nov; 108(5): 1319-22
82. The Apgar Score. *Adv Neonatal Care*. 2006 Aug;6(4):220-3.
83. Grant D and Haas C. Nitrous nightmares? Hygienists compare notes on N2O, pregnancy. *RDH*. 2009;29(12):40-4.



## Acronyms/Abbreviations/Symbols

±	plus or minus
≤	less than or equal to
≥	greater than or equal to
%	percent
ACGIH	American Conference of Governmental Industrial Hygienists
AE	adverse events
AHRQ	Agency for Healthcare Research and Quality
ANSI	American National Standard Institute
BUN	blood urea nitrogen
CGA	Compressed Gas Association
CI	confidence interval(s)
CINAHL	Cumulative Index to Nursing and Allied Health Literature
cm	centimeter
DHHS	Department of Health and Human Services
etc.	et cetera
EPA	United States Environmental Protection Agency
EPC	Evidence-based Practice Center
FDA	United States Food and Drug Administration
fl	fluid liter
g	gram(s)
g/dl	gram per decaliter
g/ml	grams per milliliter
Hb	hemoglobi n
IM	intramuscular
Kg	kilogram
KQ	Key Question
mcM/L	micrometer per liter
mmol/L	micromolar
mEq/L	milliequivalents per liter
Mg	milligram
mg/dl	milligrams per deciliter
min	minute(s)
ml	milliliter
mm	millimeter
mmHg	millimeters of mercury
mOsm/kg	milliosmoles per kilogram of water
mU/min	milliunits per minute
n, N	number
NACS	Neonatal Adaptive Capacity Scores
NFPA	National Fire Protection Association
NIOSH	National Institute for Occupational Health and Safety
NR	not reported

NS	not significant
N <sub>2</sub> O	nitrous oxide
OSHA	Occupational Safety and Health Administration
O <sub>2</sub>	oxygen
P, p	p value
pH	power of hydrogen
PICOTS	Population(s), Intervention(s), Comparator(s), Outcome(s), Timing, Setting(s)
PCO <sub>2</sub>	partial pressure of carbon dioxide
PO <sub>2</sub>	oxygen partial pressure
ppm	parts per million
pt	patient
RCT	randomized controlled trial
REL	recommended exposure limit
RR	relative risk
SD	standard deviation
SE	standard error
SGA	small for gestational age
TENS	transcutaneous electric nerve stimulation
TEP	technical expert panel
TLV	threshold limit value
torr	non-SI unit of pressure
TSCA	Toxic Substances Control Act
UCSF	University of California, San Francisco
U.S.	United States
USP	United States Pharmacopeia
VAS	visual analogue scale
vs.	versus
w/	with
wk(s)	week(s)
yr(s)	year(s)
µg/l	micrograms per liter

## Appendix A. Exact Search Strings and Results

**Table 1: Preliminary PubMed search strategies**

Preliminary Search Terms		Preliminary Search Results
#1	"Nitrous Oxide"[Mesh] OR "nitrous oxide"[tw] OR "N2O"[tw] OR "laughing gas"[tw] OR "Entonox "[Substance Name] OR Entonox[tw] OR Equanox[tw] OR Kalinox[tw] OR Medimix[tw] OR "Dinitrogen Monoxide"[tw] OR Kalinox[tw] OR Medimix[tw] OR "Dinitrogen Monoxide"[tw]	19,052
#2	"Labor Pain"[Mesh] OR "Labor, Obstetric"[Mesh] OR labor[tw] OR "parturition"[MeSH Terms] OR "pregnancy"[MeSH Terms] OR "pregnancy"[tw] OR "Analgesia, Obstetrical"[mh] OR "obstetric"[tw] OR birth[tw] OR childbirth[tw] OR labour[tw] OR intrapartum[tw] OR delivery, obstetric[mh]	867,187
#3	#1 AND #2 AND eng[la] AND humans[mh]	646
#4	#3 AND letter[pt]	27
#5	#3 AND comment[pt]	14
#6	#3 AND case reports[pt]	50
#7	#3 AND review[pt]	72
#8	#3 AND news[pt]	2
#9	#3 AND editorial[pt]	5
#10	#3 AND historical article[pt]	6
#11	#3 AND meta-analysis[pt]	1
#12	#3 NOT (#4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11)	495*

**Table 2: EMBASE search strategies**

<b>Preliminary Search Terms</b>		<b>Preliminary Search Results</b>
<b>#1</b>	nitrous oxide.mp. or nitrous oxide/ or entonox.mp. or nitrous oxide plus oxygen/ or n20.mp. or laughing gas.mp. or equanox.mp. or kalinox.mp. or medimix.mp. or dinitrogen monoxide.mp.	30,451
<b>#2</b>	pregnancy/ or pregnancy.mp. or CHILDBIRTH/ or childbirth.mp. or labor pain.mp. or labor pain/ or obstetric analgesia.mp. or obstetric analgesia/ or delivery/ or delivery.mp. or INTRAPARTUM CARE/ or intrapartum.mp. or LABOR/ or labor.mp.	537,234
<b>#3</b>	#1 AND #2	1,789
<b>#4</b>	Limit #3 to (human and english language)	1,178
<b>#5</b>	Limit #4 to (editorial or letter or "review")	319
<b>#6</b>	#4 NOT #5	859*

**Table 3: CINAHL search strategies**

<b>Preliminary Search Terms</b>		<b>Preliminary Search Results</b>
<b>#1</b>	(MH "Nitrous Oxide") OR "nitrous oxide" OR "N2O" OR "laughing gas" OR Entonox OR Equanox OR Kalinox OR Medimix OR "Dinitrogen Monoxide"	925
<b>#2</b>	(MH "Pregnancy") OR (MH "Childbirth") OR (MH "Labor") OR (MH "Labor Pain") OR "labor pain" OR pregnancy OR childbirth OR birth OR labour OR intrapartum OR (MH "Analgesia, Obstetrical") OR (MH "Delivery")	100,226
<b>#3</b>	#1 AND #2	90
<b>#4</b>	#3 AND PT ( Commentary OR Editorial OR Letter OR Review )	21
<b>#5</b>	#3 NOT #4	69

# Appendix B. Sample Data Abstraction Forms

## Nitrous Oxide for the Management of Labor Pain CER

### Abstract Review Form

First Author, Year: \_\_\_\_\_

EndNote Ref ID #: \_\_\_\_\_

Abstractor Initials: \_\_\_\_

Primary Inclusion/Exclusion Criteria			
1. Original research (exclude reviews, editorials, commentaries, letters to editor, etc.)	Yes	No	Cannot Determine
2. Study size $\geq$ 20 pregnant women in labor (record N if study size < 20: _____) OR addresses harms or occupational exposures	Yes	No	Cannot Determine
3. Relevant to CER topic If "No", select at least one of the following reasons: a. ____ Other pain management b. ____ Termination of pregnancy c. ____ Retained placenta and perineal repairs d. ____ Other _____	Yes	No	Cannot Determine
4. Study published in English	Yes	No	Cannot Determine

Retain for:

\_\_\_\_ BACKGROUND/DISCUSSION

\_\_\_\_ REVIEW OF REFERENCES

\_\_\_\_ OTHER \_\_\_\_\_

COMMENTS:

# Nitrous Oxide for the Management of Labor Pain Full-text Review Form

First Author, Year: \_\_\_\_\_

EndNote Ref ID #: \_\_\_\_\_

Abstractor Initials: \_\_\_\_\_

Primary Inclusion/Exclusion Criteria		
<p>5. Original research (exclude reviews, editorials, commentaries, letters to editor, etc.) If yes, record the following:</p> <div style="display: flex; justify-content: space-between;"> <div> <p>Comparison group:</p> <p><input type="checkbox"/> Yes</p> <p><input type="checkbox"/> No</p> <p><input type="checkbox"/> Not reported</p> </div> <div> <p>Randomized (NA if no comparison group):</p> <p><input type="checkbox"/> Yes</p> <p><input type="checkbox"/> No</p> <p><input type="checkbox"/> Not reported/NA</p> </div> </div>	Yes	No
<p>6. Study size ≥ 20 pregnant women in labor (record N if study size &lt; 20: ____)</p> <p>OR addresses harms or occupational exposure during labor</p>	Yes	No
<p>7. Relevant to CER topic</p> <p>If “No”, select at least one of the following reasons:</p> <ul style="list-style-type: none"> <li>a. ___ Other pain management</li> <li>b. ___ Termination of pregnancy</li> <li>c. ___ Retained placenta and perineal repairs</li> <li>d. ___ Other _____</li> </ul>	Yes	No
8. Study published in English	Yes	No
9. Does study answer any of the following key questions? (circle applicable questions)	Yes	No
<p><b>KQ1.</b> What is the effectiveness of nitrous oxide when compared to other methods for the management of labor pain among women intending a vaginal birth?</p> <p><b>KQ2.</b> What is the comparative effectiveness of nitrous oxide on women’s satisfaction with their birth experience and pain management?</p> <p><b>KQ3.</b> What is the comparative effectiveness of nitrous oxide on the route of birth?</p> <p><b>KQ4.</b> What is the nature and frequency of adverse effects associated with the use of nitrous oxide for the management of labor pain, including but not limited to:</p> <ul style="list-style-type: none"> <li>○ Maternal adverse effects, such as nausea and vomiting, dizziness, unconsciousness, and postpartum complications.</li> <li>○ Fetal/neonatal adverse effects, such as low Apgar scores and abnormal fetal cord blood gases.</li> <li>○ Childhood adverse effects, such as drug dependency and developmental complications.</li> <li>○ Adverse effects on health care providers and other individuals present for labor.</li> </ul> <p><b>KQ5.</b> What are the health system factors influencing the use of nitrous oxide for the management of labor pain, including but not limited to provider preferences, availability, setting, and resource utilization?</p>		
10. If you answered YES to all questions, please review references and note relevant citation numbers below:		

Retain for: BACKGROUND/DISCUSSION REVIEW OF REFERENCES OTHER

**COMMENTS:**

## **Appendix C. Evidence Tables**

Tables are sorted by last name of first author.



**Evidence Table 1: Nitrous oxide for management of labor pain**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Abboud et al., 1995 <b>Country:</b> U.S. <b>Participant source:</b> Academic single site <b>Setting:</b> Hospital <b>Enrollment period:</b> NR <b>Design:</b> RCT ***** <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>Healthy parturients undergoing normal vaginal delivery</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>Clinically significant history of gastro-intestinal, hepatic, renal, endocrine or respiratory disease, convulsive or neurological disorders</li> <li>Fetal distress or any history of chronic alcohol or drug use</li> </ul>	<b>Groups:</b> <b>G1:</b> N <sub>2</sub> O in 30-60% O <sub>2</sub> , mixed and administered by an anesthesiologist and initiated during the second stage of labor <b>G2:</b> Desflurane 1-4.5% and O <sub>2</sub> , mixed and administered by an anesthesiologist and initiated during the second stage of labor <b>N at enrollment:</b> <b>G1:</b> 40 <b>G2:</b> 40 <b>N at followup:</b> (24 hours) <b>G1:</b> 40 <b>G2:</b> 40 <b>Age, mean yrs ± SD:</b> <b>G1:</b> 25.7 ± 5.7 <b>G2:</b> 26.3 ± 5.7 <b>Race/ethnicity:</b> NR <b>Parous, n (%):</b> <b>G1:</b> 27 (67.5) <b>G2:</b> 28 (70.0)	<b>Provider preferences:</b> NR <b>Provider specialty:</b> NR <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> NR <b>Pain management:</b> NR	<b>Pain, %:</b> (5 point scale from 0-4) Satisfactory (3 or 4): <sup>1</sup> Maternal report: <b>G1:</b> 63 <b>G2:</b> 63 Anesthesiologist report: <b>G1:</b> 63 <b>G2:</b> 58 Obstetrician report: <b>G1:</b> 55 <b>G2:</b> 50 <b>Labor progress:</b> NR <b>Fetal status:</b> NR <b>Timeliness:</b> NR <b>Labor co-interventions:</b> NR <b>Adverse effects, n (%):</b> Maternal: Birth amnesia: <b>G1:</b> 0 <b>G2:</b> 9 (22.5) <b>G1/G2:</b> <i>P</i> < 0.05 Neonatal: NR Occupational: NR <b>Route of birth, n (%):</b> Vaginal: <b>G1:</b> 35 (87.5) <b>G2:</b> 31 (77.5) Assisted: <sup>2</sup> <b>G1:</b> 5 (12.5) <b>G2:</b> 9 (22.5) Cesarean: <b>G1:</b> 0 <b>G2:</b> 0	<b>Satisfaction with pain management, %:</b> Participant would accept same treatment again: <b>G1:</b> 90 <b>G2:</b> 93 <b>Satisfaction with birth experience:</b> NR <b>Maternal status:</b> Blood loss, ml, mean: <b>G1:</b> 335 <b>G2:</b> 364 <b>Neonatal status, n (%):</b> Apgar score < 7: 1 minute: <b>G1:</b> 3 (8) <b>G2:</b> 5 (13) 5 minutes: <b>G1:</b> 0 <b>G2:</b> 0 NACS < 35: 2 hours: <b>G1:</b> 7 (18) <b>G2:</b> 4 (10) 24 hours: <b>G1:</b> 3 (8) <b>G2:</b> 0 <b>Adverse effects:</b> NR

**Comments:**

<sup>1</sup> Physician scale ranges from 0 (no demonstrable analgesia) to 4 (no observable signs of pain); patient scale ranges from 0 (none or worse) to 4 (absolutely no pain).

<sup>2</sup> Includes forceps and vacuum

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
<b>Author:</b> Abboud et al., 1989 <b>Country:</b> U.S. <b>Participant source:</b> Academic single site <b>Setting:</b> Hospital <b>Enrollment period:</b> NR <b>Design:</b> RCT ***** <b>Inclusion criteria:</b> • Women undergoing normal vaginal delivery <b>Exclusion criteria:</b> • See inclusion criteria	<b>Groups:</b> <b>G1:</b> N <sub>2</sub> O 30-60% in O <sub>2</sub> administered continuously by an anesthesiologist until moment of birth <b>G2:</b> Isoflurane 0.2-0.7% in O <sub>2</sub> administered continuously by an anesthesiologist until moment of birth ***** <b>N at enrollment:</b> <b>G1:</b> 30 <b>G2:</b> 30 <b>N at followup:</b> <b>G1:</b> 30 <b>G2:</b> 30 <b>Age:</b> NR <sup>1</sup> <b>Race/ethnicity:</b> NR <b>Parous:</b> NR	<b>Provider preferences:</b> NR <b>Provider specialty:</b> NR <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> <b>G1:</b> NR <b>G2:</b> 20 mg ketamine (for difficult forceps delivery) <b>Pain management, %:</b> No local anesthetic for delivery: <b>G1:</b> 53 <b>G2:</b> 47 Local infiltration: <b>G1:</b> 3 <b>G2:</b> 0 Pudendal nerve block: <b>G1:</b> 27 <b>G2:</b> 20 Epidural: <b>G1:</b> 7 <b>G2:</b> 7 Epidural and pudendal: <b>G1:</b> 10 <b>G2:</b> 26 Duration of prepartum analgesia, minutes, mean ± SD: <b>G1:</b> 14.7 ± 2.2 <b>G2:</b> 13 ± 2.4	<b>Pain, %:</b> (scale from 0 to 4) <sup>2</sup> Satisfactory (3 or 4): Mother: <b>G1:</b> 87 <b>G2:</b> 83 Anesthesiologist: <b>G1:</b> 97 <b>G2:</b> 90 Obstetrician: <b>G1:</b> 83 <b>G2:</b> 87 Labor progress : NR Fetal status : NR Timeliness : NR <b>Labor co-interventions:</b> NR <b>Adverse effects:</b> NR <b>Route of birth, %<sup>3</sup></b> Vaginal: <b>G1:</b> > 83 <b>G2:</b> > 83 Assisted: <b>G1:</b> < 17 <b>G2:</b> < 17 Cesarean: <b>G1:</b> 0 <b>G2:</b> 0	<b>Satisfaction with pain management, %:</b> Shortly after delivery, answered "yes" to "would you have the same agent again?": <b>G1:</b> 93 <b>G2:</b> 93 <b>Satisfaction with birth experience:</b> NR <b>Maternal status:</b> Blood loss estimated ml, mean ± SD: <b>G1:</b> 350 ± 22 <b>G2:</b> 320 ± 24 Hemoglobin, g/100 ml, mean ± SD: Antepartum: <b>G1:</b> 12.7 ± 0.2 <b>G2:</b> 13.2 ± 0.2 12-24 hours postpartum: <b>G1:</b> 11.0 ± 0.3 <b>G2:</b> 11.6 ± 0.2 Hematocrit, mean % ± SD: Antepartum: <b>G1:</b> 38.2 ± 0.6 <b>G2:</b> 39.3 ± 0.7 12-24 hours postpartum: <b>G1:</b> 33.1 ± 0.8 <b>G2:</b> 35.1 ± 0.7 Serum fluoride level < 5.6 mcmol/L, n (%): Before anesthesia, <b>G1:</b> 30 (100) <b>G2:</b> 30 (100) 12-24 hours postpartum: <b>G1:</b> 30 (100) <b>G2:</b> 30 (100) Urine fluoride level, mcmol/L, mean ± SD: Before anesthesia: <b>G1:</b> 38.9 ± 5.8 <b>G2:</b> 41.4 ± 4.6

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
Abboud et al., 1989 (continued)				<p>12-24 hours postpartum:  <b>G1:</b> 23.62 ± 2.2  <b>G2:</b> 36.5 ± 3.1  <b>G1/G2:</b> <math>P &lt; 0.05</math></p> <p><b>Neonatal status:</b>  Apgar score, 1 minute, %:  0-4:  <b>G1:</b> 0  <b>G2:</b> 0  5-7:  <b>G1:</b> 7  <b>G2:</b> 7  8-10:  <b>G1:</b> 93  <b>G2:</b> 93</p> <p>Apgar score, 5 minutes, %:  0-4:  <b>G1:</b> 0  <b>G2:</b> 0  5-7:  <b>G1:</b> 0  <b>G2:</b> 0  8-10:  <b>G1:</b> 100  <b>G2:</b> 100</p> <p>pH, mean ± SD:  Umbilical vein:  <b>G1:</b> 7.33 ± 0.01  <b>G2:</b> 7.34 ± 0.01  Umbilical artery:  <b>G1:</b> 7.27 ± 0.01  <b>G2:</b> 7.28 ± 0.01</p> <p>PCO<sub>2</sub> mmHg, mean ± SD:  Umbilical vein:  <b>G1:</b> 42.4 ± 1.2  <b>G2:</b> 41 ± 1.3  Umbilical artery:  <b>G1:</b> 51.5 ± 1.5  <b>G2:</b> 50 ± 1.9</p> <p>Base excess mEq/L, mean ± SD:  Umbilical vein:  <b>G1:</b> -2.8 ± 0.4  <b>G2:</b> -3 ± 0.3  Umbilical artery:  <b>G1:</b> -2.2 ± 0.5  <b>G2:</b> -3 ± 0.5</p>

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
Abboud et al., 1989 (continued)				<p>PO<sub>2</sub> mmHg, mean ± SD:  Umbilical vein:  <b>G1:</b> 32.1 ± 1.4  <b>G2:</b> 33 ± 1.4  Umbilical artery:  <b>G1:</b> 20.1 ± 1.1  <b>G2:</b> 20 ± 0.9</p> <p>O<sub>2</sub> saturation, mean % ± SD:  Umbilical vein:  <b>G1:</b> 55.7 ± 2.4  <b>G2:</b> 58 ± 2.9  Umbilical artery:  <b>G1:</b> 26.1 ± 2.2  <b>G2:</b> 26 ± 2.4</p> <p>Urine fluoride levels from first voided urine &lt; 5.6 mcmol/L, n (%):  <b>G1:</b> 30 (100)  <b>G2:</b> 30 (100)</p> <p><b>Adverse effects:</b>  Maternal:  Partial amnesia, n:  <b>G1:</b> 0  <b>G2:</b> 1<sup>4</sup></p> <p>Neonatal: NR</p> <p>Childhood: NR</p> <p>Occupational: NR</p>

**Comments:**

<sup>1</sup> Authors state maternal age was slightly higher in G1.

<sup>2</sup> Physician scale ranges from 0 (no demonstrable analgesia) to 4 (no observable signs of pain); patient scale ranges from 0 (none or worse) to 4 (absolutely no pain).

<sup>3</sup> Authors report that more than 83% of parturients in both groups had spontaneous vaginal deliveries; the rest were delivered by forceps.

<sup>4</sup> Parturient had difficult forceps delivery and 20 mg of ketamine.

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
<b>Author:</b> Abboud et al., 1981 <b>Country:</b> U.S. <b>Participant source:</b> NR <b>Setting:</b> Hospital <b>Enrollment period:</b> NR <b>Design:</b> RCT ***** <b>Inclusion criteria:</b> • Normal vaginal delivery <b>Exclusion criteria:</b> • See inclusion criteria	<b>Groups:</b> <b>G1:</b> N <sub>2</sub> O, 30% to 60% and O <sub>2</sub> administered by anesthesiologist <b>G2:</b> Enflurane, 0.25% to 1.25% and O <sub>2</sub> <b>N at enrollment:</b> <b>G1:</b> 50 <b>G2:</b> 55 <b>N at followup:</b> <b>G1:</b> 50 <b>G2:</b> 55 <b>Age, mean yrs (SE):</b> <b>G1:</b> 25.1 (0.9) <b>G2:</b> 23.4 (0.7) <b>Race/ethnicity:</b> NR <b>Parous, %:</b> Primipara: <b>G1:</b> 38 <b>G2:</b> 51 Multipara: <b>G1:</b> 62 <b>G2:</b> 49	<b>Provider preferences:</b> NR <b>Provider specialty, %:</b> Obstetrician: <b>Total:</b> 100 <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> Single- or multiple-dose meperidine intramuscular (IM), single-dose alphaprodine subcutaneous (SC), local infiltration; pudendal block <b>Pain management, %:</b> Narcotic analgesia: < 1 hour before delivery: <b>G1:</b> 10 <b>G2:</b> 7 1-2 hours before delivery: <b>G1:</b> 12 <b>G2:</b> 14.5 > 2 hours before delivery: <b>G1:</b> 22 <b>G2:</b> 14.5 None: <b>G1:</b> 56 <b>G2:</b> 64 Single-dose meperidine IM: <b>G1:</b> 10 <b>G2:</b> 4 Multiple-dose meperidine IM: <b>G1:</b> 10 <b>G2:</b> 6 Single-dose alphaprodine SC:	<b>Pain:</b> (5 point scale 0-4) <sup>1</sup> Satisfactory (3 or 4), shortly after delivery, %: Mother: <b>G1:</b> 76 <b>G2:</b> 89 Anesthesiologist: <b>G1:</b> 70 <b>G2:</b> 80 Obstetrician: <b>G1:</b> 58 <b>G2:</b> 84 <b>G1/G2:</b> <i>P</i> < 0.05 <b>Labor progress:</b> NR <b>Fetal status:</b> NR <b>Timeliness:</b> NR <b>Labor co-interventions:</b> NR <b>Adverse effects:</b> Maternal: Estimated blood loss, ml, mean (SE): <b>G1:</b> 327 (13) <b>G2:</b> 321 (15) Neonatal: NR Occupational: NR <b>Route of birth, %:</b> Vaginal spontaneous: <b>G1:</b> 82 <b>G2:</b> 82 Assisted: Outlet forceps: <b>G1:</b> 10 <b>G2:</b> 14 Mid-forceps: <b>G1:</b> 2 <b>G2:</b> 2 Vacuum:	<b>Satisfaction with pain management:</b> (asked shortly after delivery) "Would you have the same agent again?", %: Yes: <b>G1:</b> 86 <b>G2:</b> 96 No: <b>G1:</b> 12 <b>G2:</b> 2 Maybe: <b>G1:</b> 2 <b>G2:</b> 2 <b>Satisfaction with birth experience:</b> NR <b>Maternal status:</b> Hemoglobin, g/100 ml, mean (SE): Antepartum: <b>G1:</b> 12.8 (0.2) <b>G2:</b> 12.9 (0.2) 12-24 hrs postpartum: <b>G1:</b> 12.0 (0.2) <b>G2:</b> 11.5 (0.2) Hematocrit, mean % (SE): Antepartum: <b>G1:</b> 38.0 (0.6) <b>G2:</b> 38.2 (0.5) 12-24 hrs postpartum: <b>G1:</b> 35.4 (0.6) <b>G2:</b> 34.4 (0.6) Blood sodium, meq/L, mean (SE): Before anesthesia: <b>G1:</b> 137 (0.3) <b>G2:</b> 137 (0.3) 12-24 hrs postpartum: <b>G1:</b> 138 (0.2) <b>G2:</b> 138 (0.3) Blood potassium, meq/L, mean

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
		<b>G1:</b> 24 <b>G2:</b> 27  Local anesthesia: None: <b>G1:</b> 56	<b>G1:</b> 6 <b>G2:</b> 2  Cesarean: Not applicable	(SE): Before anesthesia: <b>G1:</b> 4.0 (0.04) G 2: 3.9 (0.04) 12-24 hrs postpartum: <b>G1:</b> 4.0 (0.1) G 2: 4.0 (0.1)

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Abboud et al., 1981 (continued)		<b>G2:</b> 51  Local infiltration: <b>G1:</b> 14 <b>G2:</b> 16  Pudendal block: <b>G1:</b> 30 <b>G2:</b> 33  Duration of prepartum analgesia, minutes, mean (SE): <b>G1:</b> 13.5 (1.5) <b>G2:</b> 14.7 (1.2)		Blood chloride, meq/L, mean (SE): Before anesthesia: <b>G1:</b> 103 (0.3) G2: 103 (0.3) 12-24 hrs postpartum: <b>G1:</b> 102 (0.2) G2: 103 (0.3)  Blood bicarbonate, meq/L, mean (SE): Before anesthesia: <b>G1:</b> 17.7 (0.3) G2: 18.6 (0.3) G1/G2: $P < 0.05$ 12-24 hrs postpartum: <b>G1:</b> 22.7 (0.3) G2: 22.4 (0.3)  Blood BUN, mg/100 ml, mean (SE): Before anesthesia: <b>G1:</b> 8.1 (0.4) G2: 8.2 (0.3) 12-24 hrs postpartum: <b>G1:</b> 8.1 (0.3) G2: 7.9 (0.3)  Blood creatinine, mg/100 ml, mean (SE): Before anesthesia: <b>G1:</b> 0.7 (0.02) G2: 0.7 (0.01) 12-24 hrs postpartum: <b>G1:</b> 0.7 (0.01) G2: 0.7 (0.02)  Blood uric acid, mg/100 ml, mean (SE): Before anesthesia: <b>G1:</b> 5.1 (0.1) G2: 5.3 (0.1) 12-24 hrs postpartum: <b>G1:</b> 5.3 (0.2) G2: 5.4 (0.1)



**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
				Blood osmolality, mOsm/kg, mean (SE): Before anesthesia: <b>G1:</b> 281 (0.8) G2: 280 (0.6) 12-24 hrs postpartum: <b>G1:</b> 284 (0.6) G2: 282 (0.6)

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Abboud et al., 1981 (continued)				<p>Serum fluoride, mcM/L, mean (SE): Before anesthesia: <b>G1:</b> 1.6 (0.1) G2: 1.4 (0.1)</p> <p>12-24 hrs postpartum: <b>G1:</b> 1.5 (0.1) G2: 1.6 (0.1)</p> <p>Urine sodium, meq/L, mean (SE): Before anesthesia: <b>G1:</b> 142 (8.5) G2: 130 (6.8) 12-24 hrs postpartum: <b>G1:</b> 93.7 (7.7) G2: 88.2 (5.3)</p> <p>Blood potassium, meq/L, mean (SE): Before anesthesia: <b>G1:</b> 76.4 (6.5) G2: 83.7 (7.5) 12-24 hrs postpartum: <b>G1:</b> 39.3 (2.9) G2: 39.0 (3.4)</p> <p>Urine osmolality, mOsm/kg, mean (SE): Before anesthesia: <b>G1:</b> 599 (36.0) G2: 615 (32.7) 12-24 hrs postpartum: <b>G1:</b> 468 (28.8) G2: 480 (28.3)</p> <p>Urine fluoride, mcM/L, mean (SE): Before anesthesia: <b>G1:</b> 18.3 (2.2) G2: 20.0 (2.1) 12-24 hrs postpartum: <b>G1:</b> 15.9 (3.4) G2: 34.4 (4.0) G1/G2: <math>P &lt; 0.05</math></p>

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
				<b>Neonatal status:</b> Birth weight, g, mean (SE): <b>G1:</b> 3,304 (61) <b>G2:</b> 3,461 (57)

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Abboud et al., 1981 (continued)				<p>Apgar score, 1 minute, %:</p> <p>0-4: <b>G1:</b> 0 <b>G2:</b> 2</p> <p>5-7: <b>G1:</b> 6 <b>G2:</b> 6</p> <p>8-10: <b>G1:</b> 94 <b>G2:</b> 92</p> <p>Apgar score, 5 minutes, %:0-4: <b>G1:</b> 0 <b>G2:</b> 0</p> <p>5-7: <b>G1:</b> 6 <b>G2:</b> 6</p> <p>8-10: <b>G1:</b> 94 <b>G2:</b> 92</p> <p>Blood gases pH, mean (SE): Umbilical vein: <b>G1:</b> 7.34 (0.01) G 2: 7.34 (0.01) Umbilical artery: <b>G1:</b> 7.27 (0.01) G 2: 7.26 (0.01)</p> <p>Blood gases PCO<sub>2</sub>, torr, mean (SE): Umbilical vein: <b>G1:</b> 35.6 (0.9) G 2: 35.5 (0.7) Umbilical artery: <b>G1:</b> 42.5 (1.6) G 2: 44.5 (1.1)</p> <p>Blood gases PO<sub>2</sub>, torr, mean (SE): Umbilical vein: <b>G1:</b> 28.1 (0.9) G 2: 30.5 (1.0) Umbilical artery: <b>G1:</b> 16.9 (0.7) G 2: 17.9 (0.7)</p> <p>Blood gases base excess, meq/L, mean (SE): Umbilical vein: <b>G1:</b> -5.6 (0.4) G 2: -6.3 (0.3) Umbilical artery: <b>G1:</b> -7.0 (0.6)</p>

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
				G2: -6.3 (0.5)

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Abboud et al., 1981 (continued)				<p>Blood gases calculated O<sub>2</sub> saturation, mean %: Umbilical vein: <b>G1:</b> 63.5 G 2: 69 Umbilical artery: <b>G1:</b> 28 G 2: 31</p> <p>Urine sodium, meq/L, mean (SE): <b>G1:</b> 17.9 (2.1) G 2: 17.9 (2.0)</p> <p>Blood potassium, meq/L, mean (SE): <b>G1:</b> 23.3 (1.6) G 2: 22.7 (1.7)</p> <p>Urine osmolality, mOsm/kg, mean (SE): <b>G1:</b> 167 (16.6) G 2: 164 (19.9)</p> <p>Serum fluoride levels, umbilical cord, mM/L, mean (SE): <b>G1:</b> 1.8 (0.1) <b>G2:</b> 2.4 (0.2) <b>G1/G2:</b> <math>P &lt; 0.05</math></p> <p>Urine fluoride levels first voided urine, mM/L, mean (SE): <b>G1:</b> 3.5 (0.3) G 2: 4.0 (0.5)</p> <p><b>Adverse effects:</b> Maternal: Complete amnesia for delivery, %: <b>G1:</b> 10 <b>G2:</b> 7</p> <p>Neonatal: NR</p>

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
------------------------------	--	------------------------	--	---

Childhood: NR

Occupational: NR

---

**Comments:**

<sup>1</sup> Physician scale ranges from 0 (no demonstrable analgesia) to 4 (no observable signs of pain); patient scale ranges from 0 (none or worse) to 4 (absolutely no pain).

**Evidence Table 1: Nitrous Oxide for the Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
<b>Author:</b> Ahlborg et al., 1996 <b>Country:</b> Sweden <b>Participant source:</b> Community <b>Setting:</b> NR <b>Enrollment period:</b> 01/1989 to 12/1989 <b>Design:</b> Trend ***** <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>• Women born in 1940 or after</li> <li>• Found in membership files of the Swedish Midwives Association in 1989</li> <li>• Most recent pregnancy only</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>• Termination prior to 1983</li> </ul>	<b>Groups:</b> <b>G1:</b> Midwives exposed to N <sub>2</sub> O during deliveries <b>Ga:</b> > 30 N <sub>2</sub> O deliveries per month <b>Gb:</b> 21-30 N <sub>2</sub> O deliveries per month <b>Gc:</b> 11-20 N <sub>2</sub> O deliveries per month. <b>Gd:</b> 1-10 N <sub>2</sub> O deliveries per month <b>Ge:</b> 0 N <sub>2</sub> O deliveries per month <b>N at enrollment:</b> (questionnaires returned) G1a: 41 G1b: 43 G1c: 136 G1d: 160 G1e: 346  <b>N at followup:</b> G1a: 41 G1b: 43 G1c: 136 G1d: 160 G1e: 346  <b>Age, yrs:</b> ≤ 29: Total: 196 30-34: Total: 386 ≥ 35: Total: 169  <b>Race/ethnicity:</b> NR  <b>Parous:</b> NR	<b>Provider preferences:</b> NR <b>Provider specialty:</b> NR <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> NR <b>Pain management:</b> NR	<b>Pain:</b> NR <b>Labor progress:</b> NR <b>Fetal status:</b> NR <b>Timeliness:</b> NR <b>Labor co-interventions:</b> NR <b>Adverse effects:</b> NR	<b>Satisfaction with pain management:</b> NR <b>Satisfaction with birth experience:</b> NR <b>Maternal status:</b> NR <b>Neonatal status:</b> NR <b>Adverse effects:</b> Maternal: NR Neonatal: NR Childhood: NR Occupational: Became pregnant in first cycle, %: G1a: 14.6 G1b-d: 37.3 <b>G1e:</b> 42.8 Number of cycles to conception, women pregnant within 13 cycles, mean: G1a: 4.6 G1b: 3.1 G1c: 3.0 G1d: 2.8 <b>G1e:</b> 3.1 > 13 cycles to pregnancy, %: G1a: 29 G1b: 7 G1c: 8 G1d: 6 <b>G1e:</b> 10 Fecundability ratio, crude: G1a: 0.51 G1b: 1.10 G1c: 0.98 G1d: 1.10 <b>G1e:</b> 1.0 Fecundability ratio, adjusted



**Evidence Table 1: Nitrous Oxide for the Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long- Term Outcomes
				(95% CI): G 1a: 0.63 (0.43- 0.94) G 1b: 1.19 (0.89- 1.59) G 1c: 1.05 (0.86- 1.28) G 1d: 1.18 (0.98- 1.41) G 1e: 1.0

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Arfeen et al., 1994  <b>Country:</b> Scotland  <b>Participant source:</b> NR  <b>Setting:</b> NR  <b>Enrollment period:</b> NR  <b>Design:</b> Prospective cohort ***** <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>• Healthy mothers</li> <li>• Normal medical and obstetric history</li> <li>• In first stage of labor</li> <li>• Cervical dilation &gt; 2 cm</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>• See inclusion criteria</li> </ul>	<b>Groups:</b> <b>G1:</b> Entonox. Breathed during contractions. <b>G2:</b> Epidural analgesia. Maintained with infusion of 20 ml/hr of 0.1% plain bupivacaine, bolus injections of 0.25% bupivacaine if needed.  <b>N at enrollment:</b> (1 <sup>st</sup> stage of labor) <b>G1:</b> 20 <b>G2:</b> 20  <b>N at followup:</b> (completed study) <b>G1:</b> 19 <b>G2:</b> 18  <b>Age, median yrs (range):</b> <b>G1:</b> 26.0 (20-36) <b>G2:</b> 27.5 (21-45)  <b>Race/ethnicity:</b> NR  <b>Parity, median (range):</b> <b>G1:</b> 1 (0-3) <b>G2:</b> 0 (0-4) <b>G1/G2:</b> $P = 0.02^1$	<b>Provider preferences:</b> NR  <b>Provider specialty:</b> NR  <b>Cost of intervention:</b> NR  <b>Other pain management methods available:</b> NR  <b>Pain management:</b> NR	<b>Pain, n:</b> <b>G1:</b> NR <b>G2:</b> 0  <b>Labor progress:</b> NR  <b>Fetal status:</b> NR  <b>Timeliness:</b> NR  <b>Labor co-interventions:</b> NR  <b>Adverse effects:</b> Maternal: At least 1 desaturation, n (%): <b>G1:</b> 8 (42) <b>G2:</b> 6 (33) <b>G1/G2:</b> $P = NS$ Total number of desaturations, n (% of time): <b>G1:</b> 74 (2.37) <b>G2:</b> 31 (1.08) <b>G1/G2:</b> $P = 0.002^2$ Hypoxic episodes, n: <b>G1:</b> 29 <b>G2:</b> 21 Duration of hypoxic episodes, seconds, mean: <b>G1:</b> 30.6 <b>G2:</b> 17.7 <b>G1/G2:</b> $P = 0.002^1$ Hypoxic episodes, median severity, % (range): <b>G1:</b> 88 (84-89) <b>G2:</b> 89 (86-89) <b>G1/G2:</b> $P = 0.03^1$  Neonatal: NR  Occupational: NR  <b>Route of birth:</b> NR	<b>Satisfaction with pain management:</b> NR  <b>Satisfaction with birth experience:</b> NR  <b>Maternal status:</b> Median SpO <sub>2</sub> (range): <b>G1:</b> 96.0 (84-100) <b>G2:</b> 95.0 (86-99) <b>G1/G2:</b> $P = NS$  <b>Neonatal status:</b> NR  <b>Adverse effects:</b> NR

**Comments:**

<sup>1</sup> Mann-Whitney test.

<sup>2</sup> Chi-squared test.

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Arora et al., 1992 <b>Country:</b> United Kingdom <b>Participant source:</b> Community <b>Setting:</b> Hospital <b>Enrollment period:</b> NR <b>Design:</b> RCT ***** <b>Inclusion criteria:</b> •Normal labor with regular painful uterine contractions •Required inhalational analgesia <b>Exclusion criteria:</b> •See inclusion criteria	<b>Groups:</b> <b>G1:</b> Participants received Entonox or Entonox-isoflurane for five contractions, room air for one contraction, then the other agent for five contractions <b>G1a:</b> Received Entonox first <b>G1b:</b> Received Entonox-isoflurane first <b>N at enrollment:</b> (In labor) G 1: 41 <b>N at followup:</b> G 1: 39 <b>G1a:</b> 19 <b>G1b:</b> 20 <b>Age, mean yrs:</b> G 1: 28.7 <b>Race/ethnicity:</b> NR <b>Parous, n (%):</b> G 1: 16 (41.0)	<b>Provider preferences:</b> NR <b>Provider specialty:</b> NR <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> Oxytocin, diamorphine, epidural <b>Pain management, n (%):</b> Oxytocin: G 1:13 (33.3) Diamorphine: G 1:19 (48.7) Epidural: G 1:2 (5.1)	<b>Pain, mean <math>\pm</math> SD (median):</b> Linear visual analog scale G 1a: 5.8 $\pm$ 1.5 (5.0) G 1b: 7.0 $\pm$ 1.5 (7.0) Entonox-isoflurane provided significantly more pain relief <b>G1a/G1b: <math>P = 0.001</math></b> <b>Labor progress:</b> NR <b>Fetal status:</b> NR <b>Timeliness:</b> NR <b>Labor co-interventions:</b> NR <b>Adverse effects:</b> Maternal, n (%): Dizziness: <b>G1:</b> 5 (12.8) <b>G1a:</b> 1 (5.2) <b>G1b:</b> 4 (20.0) Unpleasant or nauseating odor: <b>G1a:</b> NR <b>G1b:</b> 6 (30.0) Neonatal: NR Occupational: NR <b>Route of birth, n (%):</b> Vaginal: G 1: 25 (64.1) Assisted: G 1: 9 (23.1) Cesarean: G 1: 5 (12.8)	<b>Satisfaction with pain management:</b> NR <b>Satisfaction with birth experience:</b> NR <b>Maternal status:</b> NR <b>Neonatal status:</b> NR <b>Adverse effects, n (%):</b> Maternal: NR Neonatal: Agpar-minus-color score < 8: G 1: 20 (51.3) Childhood: NR Occupational: NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Arthurs et al., 1979 <b>Country:</b> United Kingdom <b>Participant source:</b> NR <b>Setting:</b> Hospital <b>Enrollment period:</b> NR <b>Design:</b> Prospective cohort ***** <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>Women in labor who chose to use nitrous oxide</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>See inclusion criteria</li> </ul>	<b>Groups:</b> <b>G1:</b> N <sub>2</sub> O mix 50/50 administered inter-mittently by mask plus continuous N <sub>2</sub> O mix 50/50 via nasal cannula <b>G2:</b> N <sub>2</sub> O 50/50 administered inter-mittently by mask  <b>N at enrollment:</b> <b>G1:</b> 24 <b>G2:</b> 25  <b>N at followup:</b> <b>G1:</b> 22 <b>G2:</b> 22  <b>Age :</b> NR  <b>Race/ethnicity:</b> NR  <b>Parous, n:</b> <b>G1:</b> 13 <b>G2:</b> 10	<b>Provider preferences:</b> NR  <b>Provider specialty:</b> NR  <b>Cost of intervention:</b> NR  <b>Other pain management methods available:</b> Pethidine, epidural  <b>Pain management, n (%):</b> Pethidine: <b>G1:</b> 19 (79) <b>G2:</b> 22 (88) Epidural: <b>G1:</b> 3 (NR) <b>G2:</b> 4 (NR)	<b>Pain:</b> (0% to 100%) <sup>1</sup> Linear analogue score, mean increase $\pm$ SD: After 2 contractions: <b>G1:</b> 0.3 $\pm$ 16.2 <b>G2:</b> 11.5 $\pm$ 14.6 After 4 contractions: <b>G1:</b> 5.7 $\pm$ 17.0 <b>G2:</b> 17.9 $\pm$ 12.1 Pain relief, after 4 contractions, n (%): Pain had increased: <b>G1:</b> 21 (84) <b>G2:</b> 4 (17) No change: <b>G1:</b> 4 (16) <b>G2:</b> 7 (29) Pain had decreased: <b>G1:</b> 0 <b>G2:</b> 13 (54) <b>G1/G2:</b> $P < 0.0005$ Pain relief, midwife report: Complete: <b>G1:</b> 7 (29) <b>G2:</b> 1 (4) Considerable: <b>G1:</b> 15 (63) <b>G2:</b> 15 (60) Slight: <b>G1:</b> 2 (8) <b>G2:</b> 9 (36) <b>G1/G2:</b> $P = 0.02$ None: <b>G1:</b> 0 <b>G2:</b> 0  <b>Labor progress:</b> Duration of labor, hours:minutes, mean (SE): <b>G1:</b> 7:54 (0:48) <b>G2:</b> 8:42 (1:07)  <b>Fetal status:</b> NR	<b>Satisfaction with pain management:</b> NR  <b>Satisfaction with birth experience:</b> NR  <b>Maternal status, n (%):</b> Too drowsy, midwife report: <b>G1:</b> 2 (8) <b>G2:</b> 2 (8) Restless, midwife report: <b>G1:</b> 2 (8) <b>G2:</b> 8 (32) Noncooperative, midwife report: <b>G1:</b> 0 <b>G2:</b> 1 (4)  <b>Neonatal status:</b> Apgar score, mean $\pm$ SD: 1 minute: <b>G1:</b> 7.8 $\pm$ 1.9 <b>G2:</b> 7.7 $\pm$ 1.9 5 minutes: <b>G1:</b> 9.6 $\pm$ 0.7 <b>G2:</b> 9.3 $\pm$ 1.1  <b>Adverse effects:</b> Maternal: Hazy memory of labor: <b>G1:</b> 13 (54) <b>G2:</b> 7 (28) Memory of delivery: Hazy: <b>G1:</b> 2 (8) <b>G2:</b> 4 (16) None: <b>G1:</b> 1 (4) <b>G2:</b> 0  Neonatal: NR  Childhood: NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
			<b>Timeliness:</b> NR	Occupational: NR
			<b>Labor co-interventions:</b> NR	

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Arthurs et al., 1979 (continued)			<b>Adverse effects, n (%)</b> :Maternal: Nausea during labor: <b>G1:</b> 8 (33) <b>G2:</b> 9 (36) Vomiting during labor: <b>G1:</b> 6 (25) <b>G2:</b> 11 (44) Dreams: <b>G1:</b> 6 (25) <b>G2:</b> 7(28) Paraesthesia: <b>G1:</b> 8 (33) <b>G2:</b> 10 (40)  Neonatal: NR Occupational: NR  <b>Route of birth:</b> Vaginal: NR  Assisted: NR Cesarean: <b>G1:</b> 1 <b>G2:</b> 1	

**Comments:**

<sup>1</sup> 0% = no pain, 100% = max pain

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Axelsson et al., 1996 <b>Country:</b> Sweden <b>Participant source:</b> Community <b>Setting:</b> NR <b>Enrollment period:</b> 01/1989 to 12/1989 <b>Design:</b> Cross-sectional  <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>Female members of Swedish midwives association</li> <li>Born 1940 or later</li> <li>Worked more than half the time during first trimester</li> <li>Information on background variables was complete</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>Ongoing pregnancy at time of questionnaire</li> <li>Pregnancies before 1980</li> <li>Ectopic pregnancies</li> <li>Women with five or more spontaneous abortions</li> </ul>	<b>Groups:</b> <b>G1:</b> Midwives exposed to N <sub>2</sub> O during deliveries <b>G1a:</b> Midwives using N <sub>2</sub> O for > 50% of deliveries <b>G1b:</b> Midwives using N <sub>2</sub> O for ≤ 50% of deliveries <b>G2:</b> Midwives not using N <sub>2</sub> O  <b>N at enrollment:</b> NR <b>N at followup, n (%):</b> <b>G1a:</b> 705 <b>G1b:</b> 538 <b>G2:</b> 1,262 <b>Age:</b> NR <b>Race/ethnicity:</b> NR <b>Parous:</b> NR	<b>Provider preferences:</b> NR <b>Provider specialty:</b> NR <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> NR <b>Pain management:</b> NR	<b>Pain:</b> NR <b>Labor progress:</b> NR <b>Fetal status:</b> NR <b>Timeliness:</b> NR <b>Labor co-interventions:</b> NR <b>Adverse effects, n (%):</b> Maternal: NR Neonatal: NR Occupational: Spontaneous abortions: <b>G1a:</b> 111/705 (15.7) <b>G1b:</b> 71/538 (13.2) <b>G2:</b> 168/1,262 (13.3) Spontaneous abortions, women who worked as a midwife during the first trimester: <sup>1</sup> <b>G1a:</b> 98/624 (15.7) <b>G1b:</b> 65/495 (13.1) <b>G2:</b> 89/598 (14.8) <b>Route of birth:</b> NR	<b>Satisfaction with pain management:</b> NR <b>Satisfaction with birth experience:</b> NR <b>Maternal status:</b> NR <b>Neonatal status:</b> NR <b>Adverse effects:</b> Maternal: NR Neonatal: NR Childhood: NR Occupational: Spontaneous abortion, nitrous oxide exposure odds ratio, crude: <b>G1a:</b> 1.22 <b>G1b:</b> 0.99 G2: 1.0 Spontaneous abortion, nitrous oxide exposure odds ratio, adjusted (95% CI): <b>G1a:</b> 1.17 (0.84-1.62) <b>G1b:</b> 0.95 (0.66-1.35) G2: 1.0 Spontaneous abortions, women who worked as a midwife during the first trimester, n: <sup>1</sup> All: <b>G1a:</b> 98 <b>G1b:</b> 65 <b>G2:</b> 89 Early: <b>G1a:</b> 77 <b>G1b:</b> 50 <b>G2:</b> 73 Late: <b>G1a:</b> 21 <b>G1b:</b> 15 <b>G2:</b> 19



**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Axelsson et al., 1996 (continued)				<p>Spontaneous abortion, nitrous oxide exposure odds ratio, women who worked as a midwife during the first trimester, crude:*</p> <p>All:  <b>G1a:</b> 1.07  <b>G1b:</b> 0.86  <b>G2:</b> 1.0</p> <p>Early:  <b>G1a:</b> 1.02  <b>G1b:</b> 0.81  <b>G2:</b> 1.0</p> <p>Late:  <b>G1a:</b> 1.27  <b>G1b:</b> 1.11  <b>G2:</b> 1.0</p> <p>Spontaneous abortion, nitrous oxide exposure odds ratio, women who worked as a midwife during the first trimester, adjusted (95% CI):<sup>1</sup></p> <p>All:  <b>G1a:</b> 0.95 (0.62-1.47)  <b>G1b:</b> 0.75 (0.48-1.19)  <b>G2:</b> 1.0</p> <p>Early:  <b>G1a:</b> 0.94 (0.58-1.53)  <b>G1b:</b> 0.70 (0.42-1.17)  <b>G2:</b> 1.0</p> <p>Late:  <b>G1a:</b> 1.05 (0.44-2.52)  <b>G1b:</b> 1.02 (0.41-2.53)  <b>G2:</b> 1.0</p>

**Comments:**

<sup>1</sup> About a third of the pregnancies occurred when the woman had an occupation other than midwife (e.g., nurse).

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Beppu, 1968 <b>Country:</b> Japan <b>Participant source:</b> Community <b>Setting:</b> Hospital <b>Enrollment period:</b> NR <b>Design:</b> Prospective cohort ***** <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>• Fit volunteers in normal labor</li> <li>• Uncomplicated pregnancies and onset of labor between the 38th and 42nd weeks</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>• See inclusion criteria</li> </ul>	<b>Groups:</b> <b>G1:</b> N <sub>2</sub> O (50-80%) and O <sub>2</sub> , delivery method <b>G1a:</b> Vaginal delivery <b>G1b:</b> Caesarean delivery <b>N at enrollment:</b> <b>G1:</b> 26 <b>G1a:</b> 20 <b>G1b:</b> 6 <b>N at followup:</b> <b>G1:</b> 26 <b>G1a:</b> 20 <b>G1b:</b> 6 <b>Age:</b> NR <b>Race/ethnicity:</b> NR <b>Parous:</b> NR	<b>Provider preferences:</b> NR <b>Provider specialty:</b> NR <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> <b>G1a:</b> NR <b>G1b:</b> 0.5 mg atropine, 50 mg meperidine for premedication of anesthesia; halothane <b>Pain management:</b> Inhalation time, minutes, mean (range): <b>G1a:</b> 28 (4-108) <b>G1b:</b> 24 (18-36)	<b>Pain:</b> NR <b>Labor progress:</b> NR <b>Fetal status:</b> NR <b>Timeliness:</b> NR <b>Labor co-interventions:</b> NR <b>Adverse effects:</b> NR <b>Route of birth, n (%):</b> Vaginal: <b>G1:</b> 20 (76.9) Assisted: NR Cesarean: <b>G1:</b> 6 (23.1)	<b>Satisfaction with pain management:</b> NR <b>Satisfaction with birth experience:</b> NR <b>Maternal status:</b> Nitrous oxide concentration, mg/dl, mean ± SD: Cubital artery: <b>G1a:</b> 23.82 ± 14.55 <b>G1b:</b> 26.25 ± 13.40 Cubital vein: <b>G1a:</b> 16.85 ± 10.60 <b>G1b:</b> 25.76 ± 10.70 <b>Neonatal status:</b> Nitrous oxide concentration, mg/dl, mean ± SD: Intravillous space: <b>G1a:</b> NR <b>G1b:</b> 24.50 ± 8.90 Umbilical artery: <b>G1a:</b> 7.51 ± 3.67 <b>G1b:</b> 18.43 ± 3.46 Umbilical vein: <b>G1a:</b> 11.02 ± 7.25 <b>G1b:</b> 18.50 ± 6.00 Apgar score, mean (range): <b>G1a:</b> 8.8 (6-9) <b>G1b:</b> 8.8 (6-9) <b>Adverse effects:</b> Maternal: NR Neonatal, n: Asphyxia: <b>G1a:</b> 0 <b>G1a:</b> 0 Sleepy baby: <b>G1a:</b> 2 <b>G1a:</b> 0 Childhood: NR Occupational: NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Beppu, 1968 <b>Country:</b> Japan <b>Participant source:</b> Community <b>Setting:</b> Hospital <b>Enrollment period:</b> NR <b>Design:</b> Prospective cohort ***** <b>Inclusion criteria:</b> NR <b>Exclusion criteria:</b> NR	<b>Groups:</b> <b>G1:</b> Infant of mother who received N <sub>2</sub> O mix (% and delivery method NR) <b>G2:</b> Infant of mother who received trichloroethylene <b>G3:</b> Infant of mother who received halothane  <b>N at enrollment:</b> <b>G1:</b> 148 <b>G2:</b> 210 <b>G3:</b> 283  <b>N at followup:</b> <b>G1:</b> 148 <b>G2:</b> 210 <b>G3:</b> 283  <b>Age:</b> NR <b>Race/ethnicity:</b> NR <b>Parous:</b> NR	<b>Provider preferences:</b> NR <b>Provider specialty:</b> NR <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> NR <b>Pain management:</b> NR	<b>Pain:</b> NR <b>Labor progress:</b> NR <b>Fetal status:</b> NR <b>Timeliness:</b> NR <b>Labor co-interventions:</b> NR <b>Adverse effects:</b> NR <b>Route of birth:</b> NR	<b>Satisfaction with pain management:</b> NR <b>Satisfaction with birth experience:</b> NR <b>Maternal status:</b> NR <b>Neonatal status, n (%):</b> Asphyxia, Cazean's classification: None: <b>G1:</b> 141 (95.27) <b>G2:</b> 199 (94.76) <b>G3:</b> 267 (95.06) First degree: <b>G1:</b> 5 (3.38) <b>G2:</b> 8 (3.81) <b>G3:</b> 10 (3.53) Second degree: <b>G1:</b> 2 (1.35) <b>G2:</b> 3 (1.43) <b>G3:</b> 4 (1.41)  Asphyxia, Flagg's classification: None: <b>G1:</b> 139 (93.91) <b>G2:</b> 196 (93.34) <b>G3:</b> 267 (94.36) First degree: <b>G1:</b> 6 (4.05) <b>G2:</b> 10 (4.76) <b>G3:</b> 10 (3.53) Second degree: <b>G1:</b> 2 (1.35) <b>G2:</b> 2 (0.95) <b>G3:</b> 4 (1.41) Third degree: <b>G1:</b> 1 (0.69) <b>G2:</b> 2 (0.95) <b>G3:</b> 2 (0.70)  Asphyxia, Lund's classification: None: <b>G1:</b> 138 (93.24) <b>G2:</b> 196 (93.34) <b>G3:</b> 265 (93.64) Slight: <b>G1:</b> 7 (4.72) <b>G2:</b> 10 (4.76) <b>G3:</b> 12 (4.24) :

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Beppu, 1968 (continued)				<p>Moderate  <b>G1:</b> 2 (1.35)  <b>G2:</b> 2 (0.95)  <b>G3:</b> 3 (1.06)</p> <p>Severe:  <b>G1:</b> 1 (0.69)  <b>G2:</b> 2 (0.95)  <b>G3:</b> 3 (1.06)</p> <p>Asphyxia, Silverman's classification:  0 point:  <b>G1:</b> 128 (86.50)  <b>G2:</b> 190 (90.49)  <b>G3:</b> 269 (91.53)  1 point:  <b>G1:</b> 12 (8.10)  <b>G2:</b> 14 (6.66)  <b>G3:</b> 17 (6.00)  2 points:  <b>G1:</b> 6 (4.05)  <b>G2:</b> 4 (1.90)  <b>G3:</b> 4 (1.41)  ≥ 3 points:  <b>G1:</b> 2 (1.35)  <b>G2:</b> 2 (0.95)  <b>G3:</b> 3 (1.06)</p> <p><b>Adverse effects:</b>  NR</p>

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
<b>Author:</b> Bergsjø and Lindbaek, 1971 <b>Country:</b> Norway <b>Participant source:</b> Academic single site <b>Setting:</b> Hospital <b>Enrollment period:</b> NR <b>Design:</b> Crossover RCT ***** <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>Women with established labor with obvious pain</li> <li>Delivery was expected to be normal</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>Women with a history of liver and kidney disease</li> <li>Anticipated difficult delivery</li> </ul>	<b>Groups:</b> <b>G1:</b> N <sub>2</sub> O 50% /O <sub>2</sub> 50% (Entonox) inhaled through face mask working by demand flow used first <b>G2:</b> Methoxyflurane used first <b>Ga:</b> N <sub>2</sub> O chosen as preferred drug <b>Gb:</b> Methoxyflurane chosen as preferred drug <b>Gc:</b> Undecided on drug preference All patients tried both N <sub>2</sub> O and methoxy-flurane, the order decided at random; patients then selected the preferred agent to use during labor.  <b>N at enrollment:</b> <b>G1:</b> 26 <b>G2:</b> 37  <b>N at followup:</b> <b>G1:</b> 26 <b>G1a:</b> 14 <b>G1b:</b> 12 <b>G1c:</b> 0 <b>G2:</b> 37 <b>G2a:</b> 26 <b>G2b:</b> 10 <b>G2c:</b> 1  <b>Age, n (%):</b> < 20: <b>G1:</b> 0 <b>G2:</b> 4 (10.8) 20-29:	<b>Provider preferences:</b> NR <b>Provider specialty:</b> NR <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> Diazepam 10 mg intramuscularly (IM) or pethidine 100 mg IM <b>Pain management, n:</b> Diazepam < 30 min after trial start: <b>Ga:</b> 1 <b>Gb:</b> 1 <b>Gc:</b> NR Diazepam ≥ 30 min after trial start: <b>Ga:</b> 1 <b>Gb:</b> 4 <b>Gc:</b> NR Pethidine < 30 min after trial start: <b>Ga:</b> 8 <b>Gb:</b> 0 <b>Gc:</b> NR Pethidine ≥ 30 min after trial start: <b>Ga:</b> 6 <b>Gb:</b> 3 <b>Gc:</b> NR Diazepam and/or pethidine < 30 min after trial start: <b>Ga:</b> 9 <b>Gb:</b> 1 <b>Gc:</b> NR Diazepam and/or pethidine ≥ 30 min after trial start: <b>Ga:</b> 7 <b>Gb:</b> 6 <b>Gc:</b> NR	<b>Pain:</b> NR Labor progress : Dilation of cervix at start of trial, n (%): 1-2 cm: <b>G1:</b> 7 (26.9) <b>G2:</b> 9 (24.3) 3 cm: <b>G1:</b> 7 (26.9) <b>G2:</b> 10 (27.1) 4 cm: <b>G1:</b> 6 (23.1) <b>G2:</b> 10 (27.1) 5 cm: <b>G1:</b> 2 (7.7) <b>G2:</b> 3 (8.0) ≥ 6 cm: <b>G1:</b> 4 (15.4) <b>G2:</b> 4 (10.8) Not stated: <b>G1:</b> 0 <b>G2:</b> 1 (2.7)  Duration of labor, n: ≤ 6 hours: <b>Ga:</b> 19 <b>Gb:</b> 5 > 6 hours: <b>Ga:</b> 21 <b>Gb:</b> 17  <b>Fetal status:</b> NR  <b>Timeliness:</b> NR  <b>Labor co-interventions:</b> NR  <b>Adverse effects:</b> NR  <b>Route of birth:</b> NR	<b>Satisfaction with pain management:</b> Satisfaction with preferred drug, n: Excellent: <b>Ga:</b> 3 <b>Gb:</b> 0 <b>Gc:</b> 0 Good: <b>Ga:</b> 33 <b>Gb:</b> 21 <b>Gc:</b> 1 Moderate: <b>Ga:</b> 4 <b>Gb:</b> 1 <b>Gc:</b> 0 Poor: <b>Ga:</b> 0 <b>Gb:</b> 0 <b>Gc:</b> 0  <b>Satisfaction with birth experience:</b> NR  <b>Maternal status:</b> NR  <b>Neonatal status:</b> Apgar score, patients who continued with preferred drug, n: ≤ 4: <b>Ga:</b> 0 <b>Gb:</b> 0 5: <b>Ga:</b> 1 <b>Gb:</b> 1 6: <b>Ga:</b> 0 <b>Gb:</b> 0 7: <b>Ga:</b> 2 <b>Gb:</b> 3 8: <b>Ga:</b> 5 <b>Gb:</b> 2 9: <b>Ga:</b> 21 <b>Gb:</b> 12 10: <b>Ga:</b> 4 <b>Gb:</b> 2  <b>Adverse effects, n:<sup>1</sup></b> Maternal, patient

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
	<b>G1:</b> 16 (61.5) <b>G2:</b> 27 (73.0) ≥ 30: <b>G1:</b> 10 (38.5) <b>G2:</b> 6 (16.2)  <b>Race/ethnicity:</b> NR  <b>Parous, n (%):</b> Primigravidae: <b>G1:</b> 16 (61.5) <b>G2:</b> 23 (62.2)	No additional drugs: <b>Ga:</b> 17 <b>Gb:</b> 12 <b>Gc:</b> NR		report:

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Bergsjö and Lindbaek, 1971 (continued)	Multiparae: <b>G1:</b> 10 (38.5) <b>G2:</b> 14 (37.8)			<p>Nausea, by cause: N<sub>2</sub>O: <b>Total:</b> 4 Methoxyflurane: <b>Total:</b> 2</p> <p>Dizziness and similar sensations, by cause: N<sub>2</sub>O: <b>Total:</b> 11 Methoxyflurane: <b>Total:</b> 11</p> <p>Dry mouth, mask unpleasant, by cause: N<sub>2</sub>O: <b>Total:</b> 6 Methoxyflurane: <b>Total:</b> 0</p> <p>Bad smell or taste, by cause: N<sub>2</sub>O: <b>Total:</b> 0 Methoxyflurane: <b>Total:</b> 9</p> <p>Numbness, by cause: N<sub>2</sub>O: <b>Total:</b> 1 Methoxyflurane: <b>Total:</b> 0</p> <p>No reported side effect, by cause: N<sub>2</sub>O: <b>Total:</b> 42 Methoxyflurane: <b>Total:</b> 44</p> <p>Maternal, objective/observed: Drowsiness, by cause: N<sub>2</sub>O: <b>Total:</b> 7 Methoxyflurane: <b>Total:</b> 8</p> <p>Euphoria, by cause: N<sub>2</sub>O:</p>

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
				<b>Total: 4</b> Methoxyflurane: <b>Total: 0</b>  Hiccups, by cause: N <sub>2</sub> O: <b>Total: 1</b> Methoxyflurane: <b>Total: 0</b>  Vomiting, by cause:



**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Bergsjö and Lindbaek, 1971 (continued)				N <sub>2</sub> O: <b>Total:</b> 3 Methoxyflurane: <b>Total:</b> 1  Neonatal: NR Childhood: NR Occupational: NR

---

**Comments:**

<sup>1</sup> Adverse effect numbers may exceed total number as some patients reported more than one side effect.

**Evidence Table 1: Nitrous Oxide for the Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Bodin et al., 1999  <b>Country:</b> Swedeb  <b>Participant source:</b> Community  <b>Setting:</b> Other  <b>Enrollment period:</b> 01/1989 to 12/1989  <b>Design:</b> Cross-sectional *****  <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>Members of Swedish Midwives Association</li> <li>Born in 1940 or later</li> <li>In second trimester between 1980 and 1987 that ended as single birth in the Swedish Medical Birth Register</li> <li>Working more than half time (greater than 20 hours per week)</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>See inclusion criteria</li> </ul>	<b>Groups:</b> <b>G1:</b> N <sub>2</sub> O used at assisted deliveries <b>G1a:</b> N <sub>2</sub> O used in ≥ 50% of all deliveries <b>G1b:</b> N <sub>2</sub> O used in < 50% of all deliveries <b>G2:</b> Did not work with N <sub>2</sub> O  <b>N at enrollment:</b> <b>Total:</b> 1,781 <sup>1</sup>  <b>N at followup:</b> <b>G1a:</b> 454 <b>G1b:</b> 357 <b>G2:</b> 931  <b>Age, yrs:</b> ≤ 29: <b>Total:</b> 960 30-34: <b>Total:</b> 642 ≥ 35: <b>Total:</b> 179  <b>Race/ethnicity:</b> NR  <b>Parous, n (%):</b> 1: <b>Total:</b> 694 (38.9) 2: <b>Total:</b> 679 (38.1) 3: <b>Total:</b> 320 (17.9) 4: <b>Total:</b> 72 (4.0) ≥ 5: <b>Total:</b> 16 (0.8)	<b>Provider preferences:</b> NR  <b>Provider specialty:</b> NR  <b>Cost of intervention:</b> NR  <b>Other pain management methods available:</b> NR  <b>Pain management:</b> NR	<b>Pain:</b> NR  <b>Labor progress:</b> NR  <b>Fetal status:</b> NR  <b>Timeliness:</b> NR  <b>Labor co-interventions:</b> NR  <b>Adverse effects:</b> Maternal: NR  Neonatal: NR  Preterm birth rate, %: <b>G1a:</b> 4.2 <b>G1b:</b> 4.2 <b>G2:</b> 4.2  Occupational: NR  <b>Route of birth:</b> NR	<b>Satisfaction with pain management:</b> NR  <b>Satisfaction with birth experience:</b> NR  <b>Maternal status:</b> NR  <b>Neonatal status:</b> Birth weight, grams, mean ± SD: <b>G1a:</b> 3,516 ± 534 <b>G1b:</b> 3,524 ± 527 <b>G2:</b> 3,588 ± 519  Birth weight in term births, adjusted difference (95% CI): <b>G1/G2:</b> -77 (-112,-8)  Birth weight, linear regression effect differences, adjusted (95% CI): <b>G1/G2:</b> -102 (-183,-22)  Low birth weight (LBW) rate, %: <b>G1a:</b> 3.5 <b>G1b:</b> 3.1 <b>G2:</b> 1.9  Low birth weight odds ratio, adjusted (95% CI): <b>G1:</b> 1.5 (0.7,3.3) <b>G2:</b> 1.0  Low birth weight,

**Evidence Table 1: Nitrous Oxide for the Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
				logistic regression effect difference, adjusted (95% CI): <b>G1:</b> 3.4 (0.9,13.4)
				Gestational age at delivery, weeks, mean $\pm$ SD: <b>G1a:</b> 39.7 $\pm$ 1.9 <b>G1b:</b> 39.6 $\pm$ 1.8 <b>G2:</b> 39.7 $\pm$ 1.9
				Gestational age in term births, adjusted difference (95% CI): <b>G1/G2:</b> 0.02 (-0.20, 0.23)

**Evidence Table 1: Nitrous Oxide for the Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Bodin et al., 1999 (continued)				<p>Gestational age, linear regression effect difference, adjusted (95% CI): G1: 0.30 (-0.03,0.63)</p> <p>Small for gestational age (SGA) rate, %: <b>G1a:</b> 13.4 <b>G1b:</b> 11.5 <b>G2:</b> 9.7</p> <p>SGA odds ratio, adjusted (95% CI): <b>G1:</b> 1.8 (1.1,2.8) G2: 1.0</p> <p>Logistic regression effect differences of SGA, adjusted (95% CI): <b>G1:</b> 3.0 (1.2,7.2)</p> <p><b>Adverse effects:</b> NR</p>

**Comments:**

<sup>1</sup> 1,781 pregnancies linked to 1,302 women.

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Carstoniu et al., 1994 <b>Country:</b> Canada <b>Participant source:</b> Academic single site <b>Setting:</b> Hospital <b>Enrollment period:</b> NR <b>Design:</b> Crossover RCTs ***** <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>Admitted in labor and delivery suite at Toronto Hospital</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>Age &lt; 18 yrs</li> <li>Maternal cardiorespiratory disease</li> <li>Evidence of fetal distress or abnormal heart rate pattern</li> <li>Any condition affecting accuracy of pulse oximetry</li> <li>Use of opioid or analgesia</li> </ul>	<b>Groups:</b> <b>G1:</b> NC (cross-over) <b>G2:</b> CN (cross-over) <b>Ga:</b> 50% N <sub>2</sub> O in O <sub>2</sub> (N) <b>Gb:</b> Compressed air (C) <b>N at enrollment:</b> (admission to labor and delivery) <b>Total:</b> 29 <b>N at followup:</b> G1: 14 G2: 12 <b>Age, mean yrs ± SD:</b> <b>G1:</b> 31.1 ± 5.8 <b>G2:</b> 28.4 ± 5.0 <b>Race/ethnicity:</b> NR <b>Parous, n:</b> Primipara: <b>G1:</b> 7 <b>G2:</b> 7 Multipara: <b>G1:</b> 7 <b>G2:</b> 5	<b>Provider preferences:</b> NR <b>Provider specialty:</b> NR <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> NR <b>Pain management:</b> NR	<b>Pain:</b> VAS score, baseline, mean ± SD: Contraction 1: <b>G1:</b> 5.6 ± 2.1 <b>G2:</b> 4.9 ± 2.5 Contraction 2: <b>G1:</b> 5.2 ± 2.2 <b>G2:</b> 5.8 ± 2.7 VAS score, trial, mean: Contraction 1: <b>Ga:</b> 5.1 <b>Gb:</b> 4.9 Contraction 2: <b>Ga:</b> 5.2 <b>Gb:</b> 5.2 Contraction 3: <b>Ga:</b> 5.7 <b>Gb:</b> 6.1 Contraction 4: <b>Ga:</b> 5.2 <b>Gb:</b> 5.6 Contraction 5: <b>Ga:</b> 5.6 <b>Gb:</b> 5.7 <b>Ga/Gb:</b> <i>P</i> = NS SpO <sub>2</sub> , baseline, mean % ± SD: Contraction 1: <b>G1:</b> 97 ± 2.0 <b>G2:</b> 97 ± 2.0 Contraction 2: <b>G1:</b> 97 ± 2.0 <b>G2:</b> 96 ± 2.0 SpO <sub>2</sub> , trial, mean %: Contraction 1: <b>Ga:</b> 97 <b>Gb:</b> 97 Contraction 2: <b>Ga:</b> 97 <b>Gb:</b> 96 Contraction 3: <b>Ga:</b> 97	<b>Satisfaction with pain management:</b> NR <b>Satisfaction with birth experience:</b> NR <b>Maternal status:</b> NR <b>Neonatal status:</b> NR <b>Adverse effects:</b> NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
			<b>Gb:</b> 96 Contraction 4: <b>Ga:</b> 97 <b>Gb:</b> 96 Contraction 5: <b>Ga:</b> 97 <b>Gb:</b> 96 <b>Ga/Gb:</b> $P < 0.05$	

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Carstoniu et al., 1994 (continued)			<p><b>Labor progress:</b> Cervical dilation, cm, mean <math>\pm</math> SD:  <b>G1:</b> 3 <math>\pm</math> 1.4  <b>G2:</b> 3 <math>\pm</math> 1.3</p> <p>Duration of labor, hours, mean <math>\pm</math> SD:  <b>G1:</b> 7.9 <math>\pm</math> 3.8  <b>G2:</b> 7.6 <math>\pm</math> 4.9</p> <p><b>Fetal status:</b> NR</p> <p><b>Timeliness:</b> NR</p> <p><b>Labor co-interventions:</b> NR</p> <p><b>Adverse effects:</b> NR</p> <p><b>Route of birth:</b> NR</p>	

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
<p><b>Author:</b> Chia et al., 1990</p> <p><b>Country:</b> Singapore</p> <p><b>Participant source:</b> Academic single site</p> <p><b>Setting:</b> Hospital</p> <p><b>Enrollment period:</b> NR</p> <p><b>Design:</b> 2 RCTs</p> <p>*****</p> <p><b>Inclusion criteria:</b></p> <ul style="list-style-type: none"> <li>• Patients admitted in the morning to labor suite in early labor or for induction of labor</li> <li>• Consented to use TENS or Entonox for pain relief</li> </ul> <p><b>Exclusion criteria:</b></p> <ul style="list-style-type: none"> <li>• Expressed desire for epidural analgesia</li> <li>• Admitted in advanced labor</li> <li>• Previously given other forms of analgesia</li> <li>• For groups G3 and G4, delivered without requesting further anesthesia</li> </ul>	<p><b>Groups:</b> <b>G1:</b> Entonox (50% N<sub>2</sub>O in O<sub>2</sub>) as first method pain relief in patients in early labor, instructed by midwife on breathing technique on admission to labor ward. <b>G2:</b> Transcutaneous electric nerve stimulation (TENS). Patient controlled flow of current using control box after demonstration of equipment. <b>G3:</b> Entonox (50% N<sub>2</sub>O in O<sub>2</sub>) in nulliparous patients scheduled for surgical induction. Patients switched to TENS when Entonox was not sufficient for pain relief. Same administration method as above for G1. <b>G4:</b> TENS at a first method in patients scheduled for surgical induction. Patients switched to</p>	<p><b>Provider preferences:</b> NR</p> <p><b>Provider specialty:</b> NR</p> <p><b>Cost of intervention:</b> NR</p> <p><b>Other pain management methods available:</b> <b>G1+G2:</b> Pethidine alone, pethidine combined with TENS or Entonox, or epidural <b>G3:</b> TENS (at first switch), if inadequate then combined Entonox and either TENS or 75 mg IM pethidine <b>G4:</b> Entonox (at first switch), if inadequate then combined TENS and either Entonox or 75 mg IM pethidine</p> <p><b>Pain management, additional methods, n (%):</b> No additional relief: <b>G1:</b> 9 (17) <b>G2:</b> 9 (18.8) <b>G3:</b> NR <b>G4:</b> NR</p> <p>Pethidine: <b>G1:</b> 38 (71.7) <b>G2:</b> 28 (58.3) <b>G3:</b> NR <b>G4:</b> NR</p> <p>Other modalities: <b>G1:</b> 6 (11.3) <b>G2:</b> 11 (22.9) <b>G3:</b> NR <b>G4:</b> NR</p>	<p><b>Pain, n (%):</b> (patient described intensity on 1-10 scale the day after delivery) 1-5: <b>G1:</b> 2 (3.2) <b>G2:</b> 4 (8.3) 6-10: <b>G1:</b> 51 (96.2) <b>G2:</b> 44 (91.7)</p> <p>Description of pain, time of request for pain relief in early labor: Mild: <b>G3:</b> 3 (30) <b>G4:</b> 7 (78) <b>G3/G4:</b> <i>P</i> = NS Moderate: <b>G3:</b> 4 (40) <b>G4:</b> 0 <b>G3/G4:</b> <i>P</i> = NS Severe: <b>G3:</b> 3 (30) <b>G4:</b> 2 (22) <b>G3/G4:</b> <i>P</i> = NS</p> <p>Type of relief from first method of pain relief: Nil: <b>G3:</b> 5 (50) <b>G4:</b> 1 (11) <b>G3/G4:</b> <i>P</i> = NS Partial: <b>G3:</b> 5 (50) <b>G4:</b> 8 (89) <b>G3/G4:</b> <i>P</i> = NS Complete: <b>G3:</b> 3 (30) <b>G4:</b> 0 <b>G3/G4:</b> <i>P</i> = NS</p> <p>After switching to second method: Mild: <b>G3:</b> 0 <b>G4:</b> 0 <b>G3/G4:</b> <i>P</i> = NS Moderate: <b>G3:</b> 5 (56) <b>G4:</b> 4 (40) <b>G3/G4:</b> <i>P</i> = NS Severe:</p>	<p><b>Satisfaction with pain management:</b> NR</p> <p><b>Satisfaction with birth experience:</b> NR</p> <p><b>Maternal status:</b> NR</p> <p><b>Neonatal status:</b> NR</p> <p><b>Adverse effects:</b> NR</p>



**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
	<p>Entonox when TENS was not sufficient for pain relief. Same methods as listed above for G2.</p> <p><b>N at enrollment:</b> (admitted in early labor or for surgical induction) <b>G1:</b> 53 <b>G2:</b> 48 <b>G3:</b> 10 <b>G4:</b> 10</p> <p><b>N at followup:</b> <b>G1:</b> 53 <b>G2:</b> 48 <b>G3:</b> 9<sup>1</sup> <b>G4:</b> 10</p> <p><b>Age, mean yrs ± SD:</b> <b>G1:</b> 28.3 ± 4.3 <b>G2:</b> 28.4 ± 4.2 <b>G3:</b> NR</p>		<p><b>G3:</b> 4 (44) <b>G4:</b> 5 (50)</p>	

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Chia et al., 1990 (continued)	<b>G4:</b> NR <b>Race/ethnicity:</b> NR <b>Parous, n (%):</b> Nulliparous: <b>G1:</b> 33 (62.3) <b>G2:</b> 26 (54.2) <b>G3:</b> 9 (100) <b>G4:</b> 10 (100)		<b>G3/G4:</b> $P = NS$ Type of relief with second method, n: Same as before: <b>G3:</b> 4 <b>G4:</b> 1 <b>G3/G4:</b> $P = NS$ Worse than before: <b>G3:</b> 6 <b>G4:</b> 2 <b>G3/G4:</b> $P = NS$ Partial: <b>G3:</b> 4 <b>G4:</b> 6 <b>G3/G4:</b> $P = NS$ Complete: <b>G3:</b> 0 <b>G4:</b> 0 <b>G3/G4:</b> $P = NS$ <b>Labor progress, n (%):</b> Observed length of first stage of labor: ≤ 8 hours: <b>G1:</b> 30 (56.6) <b>G2:</b> 35 (72.9) <b>G1/G2:</b> $P = NS$ > 8 hours: <b>G1:</b> 23 (43.4) <b>G2:</b> 13 (27.1) <b>G1/G2:</b> $P = NS$ Length of labor, hours:minutes, mean: <b>G1b:</b> 6:16 <b>G2b:</b> 4:48 <b>G1/G2:</b> $P = NS$ <b>Fetal status:</b> NR <b>Timeliness:</b> NR <b>Labor co-interventions, n (%):</b> Augmented or induced: <b>G1:</b> 16 (30.2) <b>G2:</b> 23 (47.9) <b>G3:</b> 9 (100)	

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
			G4: 10 (100)	
			Adverse effects:	
			NR	
			Route of birth:	
			NR	

---

**Comments:**

<sup>1</sup> One patient in G3 did not switch to TENS.

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
<b>Author:</b> Clark et al., 1967  <b>Country:</b> U.S.  <b>Participant source:</b> Academic single site  <b>Setting:</b> Hospital  <b>Enrollment period:</b> NR  <b>Design:</b> Nonrandomized trial  ***** <b>Inclusion criteria:</b> NR  <b>Exclusion criteria:</b> NR	<b>Groups:</b> <b>G1:</b> Methoxyflurane analgesia with the inhaler and anesthesia with N <sub>2</sub> O and methoxyflurane <b>G2:</b> Anesthesia with N <sub>2</sub> O and methoxyflurane <b>G3:</b> Methoxyflurane analgesia with the inhaler or some type of regional block  <b>N at enrollment:</b> <b>G1:</b> 42 <b>G2:</b> 11 <b>G3:</b> 41  <b>N at followup:</b> (infant blood gas and pH obtained) <b>G1:</b> 17 <b>G2:</b> 0 <b>G3:</b> 4  <b>Age, mean yrs:</b> <b>G1:</b> 24.5 <b>G2:</b> 18.6 <b>G3:</b> 26.4  <b>Race/ethnicity:</b> NR  <b>Parous, n (%):</b> <b>G1:</b> 9 (21.4) <b>G2:</b> 5 (45.4) <b>G3:</b> 6 (14.6)	<b>Provider preferences:</b> NR  <b>Provider specialty:</b> NR  <b>Cost of intervention:</b> NR  <b>Other pain management methods available:</b> <b>G1:</b> Meperidine <b>G2:</b> Meperidine, oxytocin (after delivery) <b>G3:</b> Meperidine, conduction anesthesia (epidural)  <b>Pain management, n (%):</b> Meperidine: <b>G1:</b> 7 (16.6*) <b>G2:</b> 1 (9.0*) <b>G3:</b> 5 (12.1*)  Oxytocin (after delivery): <b>G2:</b> 11 (100)  Conduction anesthesia (epidural): <b>G3:</b> 11 (26.8)	<b>Pain, %:<sup>1</sup></b> Excellent: <b>G1:</b> 20 <b>G2:</b> NR <b>G3:</b> 14 Good: <b>G1:</b> 37 <b>G2:</b> NR <b>G3:</b> 46 Fair: <b>G1:</b> 32 <b>G2:</b> NR <b>G3:</b> 24 Poor: <b>G1:</b> 11 <b>G2:</b> NR <b>G3:</b> 16  <b>Labor progress:</b> NR  <b>Fetal status:</b> NR  <b>Timeliness:</b> NR  <b>Labor co-interventions:</b> NR  <b>Adverse effects:</b> NR  <b>Route of birth:</b> NR	<b>Satisfaction with pain management:</b> NR  <b>Satisfaction with birth experience:</b> NR  <b>Maternal status:</b> NR  <b>Neonatal status:—</b> Apgar score < 7, 1 minute, n: <b>G1:</b> 14/42 <b>G2:</b> 4/11 <sup>2</sup> <b>G3:</b> 2/42  Umbilical artery pH, mean (range): <b>G1:</b> 7.27 (7.17-7.38) <b>G2:</b> NR <b>G3:</b> 7.29 (7.25-7.33)  Umbilical artery pO <sub>2</sub> , mean (range): <b>G1:</b> 29.0 (13.40-52.6) <b>G2:</b> NR <b>G3:</b> 26.40 (21.7-31.2)  Umbilical artery pCO <sub>2</sub> , mean (range): <b>G1:</b> 56.7 (34.0-90.0) <b>G2:</b> NR <b>G3:</b> 43.33 (40-50)  Umbilical artery Neg BE, mean (range): <b>G1:</b> -3.07 (-11.0,0.80) <b>G2:</b> NR <b>G3:</b> -6.06 (-9.8,-2.1)  Femoral vein pH, 1 hour, mean (range): <b>G1:</b> 7.31 (7.19-7.39) <b>G2:</b> NR <b>G3:</b> 7.27 (7.23-7.34)  Femoral vein pO <sub>2</sub> , 1 hour, mean (range): <b>G1:</b> 42.8 (22.9-80.7) <b>G2:</b> NR <b>G3:</b> 41.87 (32.8-60.2)  Femoral vein pCO <sub>2</sub> , 1 hour, mean (range): <b>G1:</b> 42.5 (26.0-58) <b>G2:</b> NR <b>G3:</b> 53.87 (45-75)

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Clark et al., 1967 (continued)				<p>Femoral Vein Neg BE, 1 hour, mean (range):  <b>G1:</b> -5.2 (-11.4,-2.0)  <b>G2:</b> NR  <b>G3:</b> -3.82 (-9.0,-0.10)</p> <p><b>Adverse effects, n (%):</b>  Maternal:  Nausea and vomiting:  <b>G1:</b> 6 (14.2)<sup>3</sup>  <b>G2:</b> 0  <b>G3:</b> 2 (4.8)</p> <p>Neonatal:  Stillborn:  <b>G1:</b> 0  <b>G2:</b> 0  <b>G3:</b> 1 (2.4)</p> <p>Pneumonitis:  <b>Total:</b> 3</p> <p>Apneic spells:  <b>Total:</b> 1</p> <p>Ocular discharge:  <b>Total:</b> 1</p> <p>Respiratory distress syndrome:  <b>Total:</b> 1</p> <p>Diarrhea:  <b>Total:</b> 1</p> <p>Childhood: NR</p> <p>Occupational: NR</p>

**Comments:**

\* Calculated by reviewer.

<sup>1</sup> Pain Relief Scale: Excellent — patient lay quietly during contractions in a tranquil state; Good — appreciable relief of pain, but still some discomfort; Fair — some, but not satisfactory relief of pain; Poor — little or no relief of pain.

<sup>2</sup> All breech

<sup>3</sup> Six in this group had nausea and/or vomiting during or after the analgesia and anesthesia. In addition, two additional participants vomited during labor, before the inhaler was started.

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Constantine et al., 1989 <b>Country:</b> United Kingdom <b>Participant source:</b> Community <b>Setting:</b> Hospital <b>Enrollment period:</b> NR <b>Design:</b> RCT ***** <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>Pregnant women using Entonox either alone or in combination with pethidine during labor</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>See inclusion criteria</li> </ul>	<b>Groups:</b> <b>G1:</b> Entonox (50% O <sub>2</sub> , 50% N <sub>2</sub> O) <b>Ga:</b> Mask alone <b>Gb:</b> Mask with humidifier <b>Gc:</b> Mouthpiece alone <b>Gd:</b> Mouthpiece with humidifier <b>N at enrollment:</b> <b>G1:</b> 149 <b>G1a:</b> 49 <b>G1b:</b> 36 <b>G1c:</b> 37 <b>G1d:</b> 27 <b>N at followup:</b> <b>G1:</b> 149 <b>G1a:</b> 49 <b>G1b:</b> 36 <b>G1c:</b> 37 <b>G1d:</b> 27 <b>Age:</b> NR <b>Race/ethnicity:</b> NR <b>Parous:</b> NR	<b>Provider preferences:</b> NR <b>Provider specialty:</b> NR <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> NR <b>Pain management, %:</b> Required further analgesia: <b>G1:</b> 52 Length of nitrous use, hours, mean $\pm$ SD: G 1a-b: 3.3 $\pm$ 2.5 G 1c-d: 3.3 $\pm$ 2.1	<b>Pain, n (%):</b> Rated good: <b>G1:</b> 80 (53) G 1a-b: 43 (50.5) G 1c-d: 37 (57.8) Rated moderate: <b>G1:</b> 42 (28) G 1a-b: 25 (29.4) G 1c-d: 17 (26.5) Rated poor: <b>G1:</b> 20 (14) G 1a-b: 11 (12.9) G 1c-d: 9 (14.1) Rated useless: <b>G1:</b> 7 (5) G 1a-b: 6 (7.0) G 1c-d: 1 (1.5) <b>Labor progress:</b> NR <b>Fetal status:</b> NR <b>Timeliness:</b> NR <b>Labor co-interventions:</b> NR <b>Adverse effects, n (%):</b> Maternal: Nausea: <b>G1:</b> 55 (37) <b>G1a:</b> 22 (45) <b>G1b:</b> 9 (25) <b>G1c:</b> 13 (36) <b>G1d:</b> 11 (41) Dry nose: <b>G1:</b> 23 (15) <b>G1a:</b> 11 (31) <b>G1b:</b> 5 (18) <b>G1c:</b> 6 (17) <b>G1d:</b> 1 (4)	<b>Satisfaction with pain management:</b> NR <b>Satisfaction with birth experience:</b> NR <b>Maternal status:</b> NR <b>Neonatal status:</b> NR <b>Adverse effects:</b> NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
			Dry mouth: <b>G1:</b> 116 (78) <b>G1a:</b> 37 (75) <b>G1b:</b> 26 (72) <b>G1c:</b> 31 (86) <b>G1d:</b> 22 (81)  Light headed: <b>G1:</b> 87 (58) <b>G1a:</b> 16 (33) <b>G1b:</b> 20 (56)	



**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Constantine et al., 1989 (continued)			<b>G1c:</b> 28 (76) <b>G1d:</b> 23 (85) <b>G1c/G1a:</b> $P < 0.05$ <b>G1c-d/G1a-b:</b> $P < 0.01$  Tingling: <b>G1:</b> 37 (25) <b>G1a:</b> 15 (31) <b>G1b:</b> 5 (18) <b>G1c:</b> 11 (31) <b>G1d:</b> 6 (22)  Neonatal: NR  Occupational: NR  <b>Route of birth:</b> NR	

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
<p><b>Author:</b> Deckardt et al., 1987</p> <p><b>Country:</b> (West) Germany</p> <p><b>Participant source:</b> Academic single site</p> <p><b>Setting:</b> Hospital</p> <p><b>Enrollment period:</b> NR</p> <p><b>Design:</b> Prospective cohort</p> <ul style="list-style-type: none"> <li>Patients assigned to pain managements according to their own request</li> </ul> <p>*****</p> <p><b>Inclusion criteria:</b></p> <ul style="list-style-type: none"> <li>Healthy pregnant women</li> <li>Singleton pregnancy</li> <li>Received training in prepared childbirth</li> </ul> <p><b>Exclusion criteria:</b></p> <ul style="list-style-type: none"> <li>Patients with premature rupture of membranes</li> </ul>	<p><b>Groups:</b><sup>1</sup></p> <p><b>G1:</b> N<sub>2</sub>O with O<sub>2</sub> 1:1 breathed at irregular intervals and meperidine 50-100 mg intramuscularly 2-4 hours before delivery</p> <p><b>G2:</b> Patients received lumbar peridural anesthesia (9-12 ml bupivacaine 0.25%)</p> <p><b>G3:</b> No analgesic drugs</p> <p><b>G4:</b> Control/women at term but not in labor</p> <p><b>Ga:</b> Primiparas</p> <p><b>Gb:</b> Multiparas</p> <p><b>N at enrollment:</b> (admitted to study as soon as true labor had began and progressive dilation to 3-4 cm was ascertained)</p> <p><b>G1:</b> 25 <b>G1a:</b> 16 <b>G1b:</b> 9 <b>G2:</b> 15 <b>G2a:</b> 15 <b>G2b:</b> 0 <b>G3:</b> 6 <b>G3a:</b> 0 <b>G3b:</b> 6 <b>G4:</b> 9</p> <p><b>N at followup:</b> <b>G1:</b> 25 <b>G1a:</b> 16 <b>G1b:</b> 9 <b>G2:</b> 15 <b>G2a:</b> 15 <b>G2b:</b> 0</p>	<p><b>Provider preferences:</b> NR</p> <p><b>Provider specialty:</b> NR</p> <p><b>Cost of intervention:</b> NR</p> <p><b>Other pain management methods available:</b> <b>G1:</b> Lumbar peridural anesthesia <b>G2:</b> N<sub>2</sub>O and meperidine <b>G3:</b> Lumbar peridural anesthesia, N<sub>2</sub>O, and meperidine</p> <p><b>Pain management:</b> NR</p>	<p><b>Pain, mean ± SD (range):</b> (VAS 0-10): <b>G1a:</b> 7.1 ± 1.2 (5-9) <b>G2a:</b> 3.5 ± 2.0 (1-8) <b>Gb:</b> 4.9 ± 1.7 (NR) <b>G1a/G2a:</b> <i>P</i> &lt; 0.001</p> <p>Labor progress: Labor duration, hours, mean ± SD: <b>G1a:</b> 3.3 ± 1.7 <b>G2a:</b> 4.5 ± 1.5 <b>Gb:</b> NR <b>G1a/G2a:</b> <i>P</i> &lt; 0.05</p> <p>Uterine contraction rate during labor, mean ± SD: <b>G1a:</b> 21.8 ± 4.13 <b>G2a:</b> 20.2 ± 4.27 <b>Gb:</b> NR</p> <p><b>Fetal status:</b> NR</p> <p><b>Timeliness:</b> NR</p> <p><b>Labor co-interventions, n (%):</b> Oxytocin stimulation (infusion rate 1-3.6 mU/min): <b>G1a:</b> 11 (68.7) <b>G2b:</b> 11 (73.3) <b>Gb:</b> NR</p> <p><b>Adverse effects:</b> NR</p> <p><b>Arterial oxygen saturation, % mean ± SD (range):</b> <b>G1a:</b> 88.8 ± 3.9 (74-100) <b>G2a:</b> 94.3 ± 1.3 (85-100) <b>Gb:</b> 93.9 ± 2.0 (NR) <b>G4:</b> 96 (NR)</p> <p><b>Route of birth, n (%):</b></p>	<p><b>Satisfaction with pain management:</b> NR</p> <p><b>Satisfaction with birth experience:</b> NR</p> <p><b>Maternal status:</b> NR</p> <p><b>Neonatal status:</b> Umbilical artery pH, mean ± SD: <b>G1a:</b> 7.21 ± 0.10 <b>G2a:</b> 7.29 ± 0.06 <b>Gb:</b> 7.31 ± 0.05 <b>G1a/G2a:</b> <i>P</i> = 0.01</p> <p>Umbilical artery base excess, mean ± SD: <b>G1a:</b> -9.5 ± 4.5 <b>G2a:</b> -6.4 ± 2.2 <b>Gb:</b> -5.1 ± 3.5</p> <p>Apgar score, 1 minute, mean ± SD: <b>G1a:</b> 8.1 ± 0.9 <b>G2a:</b> 8.5 ± 0.7 <b>Gb:</b> NR</p> <p>Apgar score, 5 minutes, mean ± SD: <b>G1a:</b> 9.7 ± 0.5 <b>G2a:</b> 10.0 ± 0 <b>Gb:</b> NR</p> <p>Apgar score, 10 minutes, mean ± SD: <b>G1a:</b> 10.0 ± 0 <b>G2a:</b> 10.0 ± 0 <b>Gb:</b> NR</p> <p>Birth weight, g, mean ± SD: <b>G1a:</b> 3,424 ± 395 <b>G2a:</b> 3,256 ± 726 <b>Gb:</b> 3,358 ± 361</p> <p>Gestational age, weeks, mean ± SD: <b>G1a:</b> 39.7 ± 0.68 <b>G2a:</b> 39.3 ± 1.23 <b>Gb:</b> 239.7 ± 0.70</p> <p><b>Adverse effects:</b> NR</p>

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
	<b>G3:</b> 6 <b>G3a:</b> 0 <b>G3b:</b> 6 <b>G4:</b> 9  <b>Age, mean yrs <math>\pm</math> SD:</b> <b>G1a:</b> 24.3 $\pm$ 4.40 <b>G1b:</b> NR <b>G2a:</b> 27.4 $\pm$ 4.85 <b>G3:</b> NR <b>Gb:</b> 27.6 $\pm$ 3.62 <b>G4:</b> NR		Vaginal spontaneous: <b>Total:</b> 40  Assisted forceps: <b>Total:</b> 5  Cesarean: <b>Total:</b> 1	

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Deckardt et al., 1987 (continued)	<b>Race/ethnicity:</b> NR  <b>Parous, n (%):</b> <b>G1:</b> 9 (36) <b>G2:</b> 0 <b>G3:</b> 6 (100) <b>G4:</b> NR			

---

**Comments:**

<sup>1</sup> Results are reported for groups G1a, G2a and Gb, but not separately for groups G1b and G3b.

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Einarsson et al., 1996 <b>Country:</b> Sweden <b>Participant source:</b> Academic single site <b>Setting:</b> Hospital <b>Enrollment period:</b> NR <b>Design:</b> RCT ***** <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>• Women undergoing vaginal delivery</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>• Maternal cardiorespiratory disease</li> <li>• Pre-eclampsia</li> <li>• Evidence of fetal distress</li> <li>• Used opioids</li> <li>• Used regional analgesia</li> </ul>	<b>Groups:</b> <b>G1:</b> 70% N <sub>2</sub> O in O <sub>2</sub> <sup>1</sup> <b>G2:</b> 50% N <sub>2</sub> O in O <sub>2</sub> <sup>1</sup> <b>N at enrollment:</b> <b>G1:</b> 12 <b>G2:</b> 12 <b>N at followup:</b> <b>G1:</b> 12 <b>G2:</b> 12 <b>Age, median yrs (range):</b> <b>G1:</b> 28 (19-41) <b>G2:</b> 29 (21-37) <b>Race/ethnicity:</b> NR <b>Parous, n (%):</b> Primiparous: <b>G1:</b> 6 (50) <b>G2:</b> 8 (66.7) Multiparous: <b>G1:</b> 6 (50) <b>G2:</b> 4 (33.3)	<b>Provider preferences:</b> NR <b>Provider specialty:</b> NR <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> NR <b>Pain management:</b> NR	<b>Pain:</b> NR <b>Labor progress:</b> Cervical dilation at time of study, cm, median (range): <b>G1:</b> 4.5 (3.0-8.0) <b>G2:</b> 5.0 (4.0-7.0) <b>Fetal status, n (%):</b> Decline in fetal heart rate: <b>G1:</b> 0 <b>G2:</b> 1 (8.3)* <b>Timeliness:</b> NR <b>Labor co-interventions:</b> NR <b>End-tidal CO<sub>2</sub>, median %:</b> Before N <sub>2</sub> O inhalation: <b>G1:</b> 3.7 <b>G2:</b> 3.5 At end of N <sub>2</sub> O inhalation: <b>G1:</b> 3.6 <b>G2:</b> 3.6 30 seconds after N <sub>2</sub> O: <b>G1:</b> 3.6 <b>G2:</b> 3.5 60 seconds after N <sub>2</sub> O: <b>G1:</b> 3.8 <b>G2:</b> 3.5 120 seconds after N <sub>2</sub> O: <b>G1:</b> 3.8 <b>G2:</b> 3.8 <b>End-tidal O<sub>2</sub>, median %:</b> Before N <sub>2</sub> O inhalation: <b>G1:</b> 16.0 <b>G2:</b> 16.2 At end of N <sub>2</sub> O inhalation:	<b>Satisfaction with pain management:</b> NR <b>Satisfaction with birth experience:</b> NR <b>Maternal status:</b> NR <b>Neonatal status:</b> NR <b>Adverse effects:</b> NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
			<b>G1:</b> 25.4 <b>G2:</b> 43.7 30 seconds after N <sub>2</sub> O: <b>G1:</b> 17.5 <b>G2:</b> 18.4 <b>G1/G2:</b> $P < 0.05$	

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Einarsson et al., 1996 (continued)			<p>60 seconds after N<sub>2</sub>O:  <b>G1:</b> 16.3  <b>G2:</b> 16.9  <b>G1/G2:</b> <i>P</i> = NS</p> <p>120 seconds after N<sub>2</sub>O:  <b>G1:</b> 15.4  <b>G2:</b> 15.4  <b>G1/G2:</b> <i>P</i> = NS</p> <p><b>Oxygen saturation, median %:</b>  Before N<sub>2</sub>O inhalation:  <b>G1:</b> 96.3  <b>G2:</b> 97.0  At end of N<sub>2</sub>O inhalation:  <b>G1:</b> 98.0  <b>G2:</b> 98.8  <b>G1/BL:</b> <i>P</i> &lt; 0.01  <b>G1/BL:</b> <i>P</i> &lt; 0.01  <b>G1/G2:</b> <i>P</i> = NS  30 seconds after N<sub>2</sub>O:  <b>G1:</b> 97.5  <b>G2:</b> 98.0  <b>G1/BL:</b> <i>P</i> &lt; 0.01  <b>G1/BL:</b> <i>P</i> &lt; 0.01  <b>G1/G2:</b> <i>P</i> = NS  60 seconds after N<sub>2</sub>O:  <b>G1:</b> 97.0  <b>G2:</b> 97.0  120 seconds after N<sub>2</sub>O:  <b>G1:</b> 97.0  <b>G2:</b> 97.0</p> <p><b>Expiratory ventilation volume, L/min, median:</b>  Before N<sub>2</sub>O inhalation:  <b>G1:</b> 13.7  <b>G2:</b> 11.1  At end of N<sub>2</sub>O inhalation:  <b>G1:</b> 13.9  <b>G2:</b> 11.3  30 seconds after N<sub>2</sub>O:  <b>G1:</b> 12.2  <b>G2:</b> 11.0  60 seconds after N<sub>2</sub>O:  <b>G1:</b> 10.8  <b>G2:</b> 9.9</p>	

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
			120 seconds after N <sub>2</sub> O: <b>G1:</b> 8.7 <b>G2:</b> 9.8	



**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Einarsson et al., 1996 (continued)			<b>Nitrous inhalation time per contraction, seconds, median:</b> <b>G1:</b> 33 <b>G2:</b> 58 <b>G1/G2:</b> $P = 0.01$ <b>Uterine contraction time, seconds, median:</b> <b>G1:</b> 87 <b>G2:</b> 90 <b>Adverse effects, n (%):</b> Maternal: Hypoxemia: <b>G1:</b> 1 (8.3) <b>G2:</b> 1 (8.3) Neonatal: NR Occupational: NR <b>Route of birth, n (%):</b> Vaginal: <b>G1:</b> 12 (100) <b>G2:</b> 12 (100) Assisted: NR Cesarean: Not applicable	

---

**Comments:**

<sup>1</sup> For all participants, administered via a nonrebreathing system with a demand valve; parturients breathed through mouthpiece while using a nose clip and switched on or off as desired.

\* Calculated by reviewer

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
<b>Author:</b> Harrison et al., 1987 <b>Country:</b> Ireland <b>Participant source:</b> Academic single site <b>Setting:</b> Hospital <b>Enrollment period:</b> 06/1983 to 12/1983 <b>Design:</b> Prospective cohort <ul style="list-style-type: none"> <li>Patients selected at random</li> </ul> <p>*****</p> <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>Primigravid</li> <li>Initial choice of analgesia was transcutaneous electrical nerve stimulation, Entonox, pethidine and promazine, or lumbar epidural</li> <li>Admitted to main labor ward</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>See inclusion criteria</li> </ul>	<b>Groups:</b> <b>G1:</b> Entonox: 50% N <sub>2</sub> O, 50% O <sub>2</sub> self-administered, usually towards the end of first stage of labor and during second stage <b>G2:</b> Transcutaneous electrical nerve stimulation (TENS) <b>G3:</b> Pethidine and promazine 50 mg each combined when deemed necessary by mutual consent <b>G4:</b> Lumbar epidural <b>N at enrollment:</b> <b>G1:</b> 20 <b>G2:</b> 50 <b>G3:</b> 50 <b>G4:</b> 50 <b>N at followup:</b> <b>G1:</b> 20 <b>G2:</b> 50 <b>G3:</b> 50 <b>G4:</b> 50 <b>Age:</b> NR <b>Race/ethnicity:</b> NR <b>Parous, n:</b> <b>Total:</b> 0	<b>Provider preferences:</b> NR <b>Provider specialty, %:</b> Midwives and medical personnel: 100 <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> <b>G1:</b> TENS, pethidine and promazine, epidural <b>G2:</b> Entonox, pethidine and promazine, epidural <b>G3:</b> Entonox, TENS, epidural <b>G4:</b> Entonox, TENS, pethidine and promazine <b>Pain management, n (%):</b> Initial choice alone: <b>G1:</b> 19 (95) <b>G2:</b> 9 (18) <b>G3:</b> 10 (20) <b>G4:</b> 50 (100) Initial choice + Entonox: <b>G1:</b> NA <b>G2:</b> 15 (30) <b>G3:</b> 25 (50) <b>G4:</b> 0 Initial choice + pethidine and promazine: <b>G1:</b> 1 (5) <b>G2:</b> 8 (16) <b>G3:</b> NA <b>G4:</b> 0 Initial choice + epidural: <b>G1:</b> 0 <b>G2:</b> 8 (16)	<b>Pain, n (%):</b> (5 point scale 0-4) <sup>1</sup> Degree of pain relief: Nil (pain score 4): <b>G1:</b> 2 (10) <b>G2:</b> 2 (4) <b>G3:</b> 23 (46) <b>G4:</b> 0 Partial (score 1-3): <b>G1:</b> 18 (90) <b>G2:</b> 48 (96) <b>G3:</b> 27 (54) <b>G4:</b> 6 (12) Complete (score 0): <b>G1:</b> 0 <b>G2:</b> 0 <b>G3:</b> 0 <b>G4:</b> 44 (88) Degree of pain relief, midwife report: Nil: <b>G1:</b> 0 <b>G2:</b> 1 (2) <b>G3:</b> 16 (32) <b>G4:</b> 0 Poor: <b>G1:</b> 4 (20) <b>G2:</b> 1 (2) <b>G3:</b> 10 (20) <b>G4:</b> 0 Fair: <b>G1:</b> 9 (45) <b>G2:</b> 14 (28) <b>G3:</b> 21 (42) <b>G4:</b> 1 (2) Good: <b>G1:</b> 7 (35) <b>G2:</b> 34 (68) <b>G3:</b> 3 (6) <b>G4:</b> 8 (16) Excellent: <b>G1:</b> 0 <b>G2:</b> 0 <b>G3:</b> 0 <b>G4:</b> 41 (82)	<b>Satisfaction with pain management, n (%):</b> Positive comments, 1 hour after delivery: <b>G1:</b> 18 (90) <b>G2:</b> 46 (92) <b>G3:</b> 26 (52) <b>G4:</b> 50 (100) Efficacy was yes, 24 hours after delivery: <b>G1:</b> 16 (80) <b>G2:</b> 46 (92) <b>G3:</b> 24 (48) <b>G4:</b> 49 (98) Adequacy was yes, 24 hours after delivery: <b>G1:</b> 12 (60) <b>G2:</b> 40 (80) <b>G3:</b> 9 (18) <b>G4:</b> 49 (98) <b>Satisfaction with birth experience, n (%):</b> (1-24 hours after delivery) Would request same analgesia again: Yes: <b>G1:</b> 16 (80) <b>G2:</b> 30 (60) <b>G3:</b> 19 (38) <b>G4:</b> 44 (88) Qualified yes: <b>G1:</b> 0 <b>G2:</b> 7 (14) <b>G3:</b> 0 <b>G4:</b> 0 No: <b>G1:</b> 3 (15) <b>G2:</b> 10 (20) <b>G3:</b> 24 (48) <b>G4:</b> 1 (2) Don't know: <b>G1:</b> 1 (5) <b>G2:</b> 3 (6) <b>G3:</b> 7 (14) <b>G4:</b> 5 (10) <b>Maternal status:</b> NR <b>Neonatal status:</b> NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
		<b>G3:</b> 15 (30) <b>G4:</b> NA Initial choice + pethidine and	<b>Labor progress:</b> Hours in labor, mean $\pm$ SD: Initial choice alone: <b>G1:</b> 5.2 $\pm$ 1.7 (n=19) <b>G2:</b> 6.3 $\pm$ 2.4 (n=9) <b>G3:</b> 6.2 $\pm$ 1.4 (n=10) <b>G4:</b> 7.7 $\pm$ 2.4 (n=50)	

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Harrison et al., 1987 (continued)		<p>promazine + Entonox:  <b>G1:</b> NA  <b>G2:</b> 7 (14)  <b>G3:</b> NA  <b>G4:</b> 0</p> <p>Initial choice +  pethidine and  promazine + epidural:  <b>G1:</b> 0  <b>G2:</b> 3 (6)  <b>G3:</b> NA  <b>G4:</b> NA</p>	<p>Including other  analgesia:  <b>G1:</b> 5.4 ± 1.7 (n=1)  <b>G2:</b> 8.2 ± 3.0 (n=41)  <b>G3:</b> 7.7 ± 2.8 (n=40)  <b>G4:</b> NA</p> <p><b>Fetal status:</b>  NR</p> <p><b>Timeliness:</b>  NR</p> <p><b>Labor co-interventions:</b>  NR</p> <p><b>Adverse effects:</b>  NR</p> <p><b>Route of birth, n (%):</b>  Vaginal (normal):  <b>G1:</b> 12 (60)  <b>G2:</b> 32 (64)  <b>G3:</b> 32 (64)  <b>G4:</b> 13 (26)</p> <p>Assisted (forceps and  vacuum):  <b>G1:</b> 7 (35)  <b>G2:</b> 14 (28)  <b>G3:</b> 18 (36)  <b>G4:</b> 31 (62)</p> <p>Cesarean:  <b>G1:</b> 0  <b>G2:</b> 4 (8)  <b>G3:</b> 0  <b>G4:</b> 3 (6)</p> <p>Breech:  <b>G1:</b> 1 (5)  <b>G2:</b> 0  <b>G3:</b> 0  <b>G4:</b> 3 (6)</p>	<b>Adverse effects:</b> NR

**Comments:**

<sup>1</sup> 0 (no pain) to 4 (very severe pain)

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Harrison and Cullen, 1986 <b>Country:</b> Ireland <b>Participant source:</b> Community <b>Setting:</b> Hospital <b>Enrollment period:</b> 08/1983 to 12/1983 <b>Design:</b> Prospective cohort ***** <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>Born at selected hospital between August and December 1983</li> <li>Mothers had taken part in study evaluating different forms of analgesia in labor</li> <li>Birth weight between 2.65 kg and 4.66 kg</li> <li>≥ 36 weeks gestation</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>See inclusion criteria</li> </ul>	<b>Groups:</b> <b>G1:</b> Babies whose mothers received one or more forms of analgesia during labor <b>Ga:</b> N <sub>2</sub> O 50% and O <sub>2</sub> 50% (Entonox) self administered as required by patient <b>Gb:</b> Pethidine/promazine <b>Gc:</b> Epidural <b>Gd:</b> Transcutaneous electrical nerve stimulation (TENS) <b>Ge:</b> TENS placebo <b>Gf:</b> General anesthesia <b>N at enrollment:</b> (3-5 days postdelivery) <b>G1:</b> 110 <b>G1a:</b> 46 <b>G1b:</b> 46 <b>G1c:</b> 48 <b>G1d:</b> 27 <b>G1e:</b> 31 <b>G1f:</b> 4 <b>N at followup:</b> <b>G1:</b> 110 <b>Age:</b> NR <b>Race/ethnicity:</b> NR <b>Parous:</b> NR <sup>1</sup>	<b>Provider preferences:</b> NR <b>Provider specialty:</b> NR <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> NR <b>Pain management, n:</b> Initial analgesic choice: Entonox: <b>G1:</b> 7 Pethidine/promazine: <b>G1:</b> 45 Epidural: <b>G1:</b> 26 TENS: <b>G1:</b> 15 TENS placebo: <b>G1:</b> 17 General anesthesia: <b>G1:</b> 0	<b>Pain:</b> NR <b>Labor progress:</b> Duration of labor, hours, mean (range): <b>G1:</b> 6 (2-12) <b>Fetal status:</b> NR <b>Timeliness:</b> NR <b>Labor co-interventions:</b> NR <b>Adverse effects:</b> NR <b>Route of birth, n:</b> Vaginal: <b>G1:</b> 65 Assisted: <b>G1:</b> 38 <sup>2</sup> Cesarean: <b>G1:</b> 7	<b>Satisfaction with pain management:</b> NR <b>Satisfaction with birth experience:</b> NR <b>Maternal status:</b> NR <b>Neonatal status:</b> Birth weight, kg, mean (range): <b>G1:</b> 3.488 (2.65-4.66) Gestational age, weeks, mean (range): <b>G1:</b> 40.2 (36-43) Neonatal Psychological Assessment Profile raw scores, mean: <sup>3</sup> Habituation to light: <b>G1a:</b> 2.92 <b>G1b:</b> 2.95 <b>G1c:</b> 3.15 <b>G1d:</b> 3.41 <b>G1e:</b> 3.11 <b>G1f:</b> 3.50 Habituation to sound: <b>G1a:</b> 3.29 <b>G1b:</b> 2.86 <b>G1c:</b> 3.03 <b>G1d:</b> 2.64 <b>G1e:</b> 3.35 <b>G1f:</b> 3.75 Auditory inanimate orientation: <b>G1a:</b> 2.53 <b>G1b:</b> 2.43 <b>G1c:</b> 2.15 <b>G1d:</b> 2.37 <b>G1e:</b> 2.48 <b>G1f:</b> 2.00 Visual inanimate orientation: <b>G1a:</b> 1.65 <b>G1b:</b> 1.58 <b>G1c:</b> 1.68 <b>G1d:</b> 1.56 <b>G1e:</b> 1.59 <b>G1f:</b> 1.00

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Harrison and Cullen, 1986 (continued)				<p>Auditory animate: orientation</p> <p><b>G1a:</b> 2.57</p> <p><b>G1b:</b> 2.62</p> <p><b>G1c:</b> 2.23</p> <p><b>G1d:</b> 2.35</p> <p><b>G1e:</b> 2.44</p> <p><b>G1f:</b> 1.00</p> <p>Visual animate orientation:</p> <p><b>G1a:</b> 2.45</p> <p><b>G1b:</b> 2.34</p> <p><b>G1c:</b> 2.22</p> <p><b>G1d:</b> 2.29</p> <p><b>G1e:</b> 2.45</p> <p><b>G1f:</b> 2.00</p> <p>Auditory and visual animate orientation:</p> <p><b>G1a:</b> 2.80</p> <p><b>G1b:</b> 2.61</p> <p><b>G1c:</b> 2.66</p> <p><b>G1d:</b> 2.61</p> <p><b>G1e:</b> 2.83</p> <p><b>G1f:</b> 2.00</p> <p>Alertness:</p> <p><b>G1a:</b> 2.37</p> <p><b>G1b:</b> 2.13</p> <p><b>G1c:</b> 2.08</p> <p><b>G1d:</b> 2.00</p> <p><b>G1e:</b> 2.29</p> <p><b>G1f:</b> 1.00</p> <p>Peak of excitement:</p> <p><b>G1a:</b> 3.23</p> <p><b>G1b:</b> 3.44</p> <p><b>G1c:</b> 3.17</p> <p><b>G1d:</b> 3.11</p> <p><b>G1e:</b> 3.12</p> <p><b>G1f:</b> 1.50</p> <p>Irritability:</p> <p><b>G1a:</b> 2.21</p> <p><b>G1b:</b> 2.37</p> <p><b>G1c:</b> 2.23</p> <p><b>G1d:</b> 2.33</p> <p><b>G1e:</b> 2.51</p> <p><b>G1f:</b> 1.50</p> <p>Consolability:</p> <p><b>G1a:</b> 2.84</p> <p><b>G1b:</b> 2.97</p> <p><b>G1C:</b> 2.91</p> <p><b>G1D:</b> 2.77</p> <p><b>G1E:</b> 3.38</p> <p><b>G1F:</b> 1.75</p>

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Harrison and Cullen, 1986 (continued)				Cuddliness: <b>G1a:</b> 2.60 <b>G1b:</b> 2.40 <b>G1c:</b> 2.47 <b>G1d:</b> 2.44 <b>G1e:</b> 2.50 <b>G1f:</b> 2.50  Self-quieting activity: <b>G1a:</b> 2.00 <b>G1b:</b> 1.40 <b>G1c:</b> 2.20 <b>G1d:</b> 2.00 <b>G1e:</b> 1.50 <b>G1f:</b> 1.00  Suckling time, %: 1 minute: <b>G1a:</b> 67.58 <b>G1b:</b> 62.00 <b>G1c:</b> 64.45 <b>G1d:</b> 66.13 <b>G1e:</b> 64.92 <b>G1f:</b> NR 5 minutes: <b>G1a:</b> 70.63 <b>G1b:</b> 65.83 <b>G1c:</b> 77.46 <b>G1d:</b> 68.25 <b>G1e:</b> 77.14 <b>G1f:</b> NR  <b>Adverse effects:</b> NR

---

**Comments:**

<sup>1</sup> The authors state mothers were either primigravid or women of the second parity.

<sup>2</sup> 34 forceps, 3 vacuum, 1 assisted breech



<sup>3</sup> Babies were assessed with the Neonatal Psychological Assessment Profile, which combines sections from the Neonatal Behavioural Assessment Scale, items from the Neurological Assessment of preterm and full-term infants, and two measures of suckling behaviors. The scale ranges from 1-5.

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Henderson et al., 2003  <b>Country:</b> United Kingdom  <b>Participant source:</b> Academic multiple sites  <b>Setting:</b> Hospital  <b>Enrollment period:</b> NR  Design: Prospective cohort *****  <b>Inclusion criteria:</b> NR  <b>Exclusion criteria:</b> NR	<b>Groups:</b> <b>G1:</b> Midwives exposed to N <sub>2</sub> O mix as delivery attendants. Midwives wore passive sampling tube for the first four hours (first half) of their shift, placed on lapel “within the breathing zone.” They also completed questionnaires and provided urine samples.  <b>N at enrollment:</b> <b>G1:</b> 46 <sup>1</sup>  <b>N at followup:</b> <b>G1:</b> 50 shifts of data <sup>1</sup>  <b>Age:</b> NR  <b>Race/ethnicity:</b> NR  <b>Parous:</b> NR	<b>Provider preferences:</b> NR  <b>Provider specialty, n (%):</b> Midwives: <b>G1:</b> 46 (100)  <b>Cost of intervention:</b> NR  <b>Other pain management methods available:</b> NR  <b>Pain management:</b> All were exposed to N <sub>2</sub> O, concentration not noted.	<b>Pain:</b> NR  <b>Labor progress:</b> NR  <b>Fetal status:</b> NR  <b>Timeliness:</b> NR  <b>Labor co-interventions:</b> NR  <b>Adverse effects, n:</b> Maternal: NR Neonatal: NR  Occupational: Time-weighted average of nitrous exposure, n: 10 times the occupational exposure limits: <b>G1:</b> 5/46 5 times the occupational exposure limits: <b>G1:</b> 5/46 2 times the occupational exposure limits: <b>G1:</b> 13/46 Below the occupational exposure limits: <b>G1:</b> 13/46  Interindividual environmental concentrations, ppm, mean ± SD	<b>Satisfaction with pain management:</b> NR  <b>Satisfaction with birth experience:</b> NR  <b>Maternal status:</b> NR  <b>Neonatal status:</b> NR  <b>Adverse effects:</b> Maternal: NR Neonatal: NR Childhood: NR Occupational: See labor and immediate outcomes.

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
			(range): <b>G1:</b> 313 ± 358 (2.4-1300)	
			No nitrous oxide present in urine after 4 hours: <b>G1:</b> 3	
			Nonzero values of nitrous oxide in baseline urine prior to starting shift: <b>G1:</b> 22	

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
Henderson et al., 2002 (continued)			<p>Nonzero baseline urinary concentrations of nitrous oxide, <math>\mu\text{g/l}</math>, mean <math>\pm</math> SD (range):  <b>G1:</b> <math>44 \pm 51</math> (3-174) (n=22)</p> <p>Urinary nitrous oxide concentrations in excess of <math>27 \mu\text{g/l}</math> (biological exposure limit in Italy) before starting their shift:  <b>G1:</b> 12</p> <p>Urinary nitrous oxide concentrations, second sample, <math>\mu\text{g/l}</math>, mean <math>\pm</math> SD (range):  <b>G1:</b> <math>114 \pm 191</math> (0-1103)</p> <p><b>Route of birth:</b>  NR</p>	

**Comments:**

<sup>1</sup> All shifts where midwives were monitored (shifts were 4 hours in length); some participants were monitored more than once. In hospital 1, 15 midwife shifts were monitored, 2 of which were on the same midwife. In hospital 2, 35 midwife shifts were monitored, with 20 monitored only on one shift, and 4 monitored on 2 shifts, 1 on 3 shifts, and 1

on 4 shifts. Text variously describes 46 midwives and 46 shifts, although some midwives were monitored more than once.

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Henry et al., 2004  <b>Country:</b> Australia  <b>Participant source:</b> Academic single site  <b>Setting:</b> Hospital  <b>Enrollment period:</b> 10/2002 to 01/2003  <b>Design:</b> Cross-sectional  *****  <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>• Women in labor</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>• Age &lt; 17 years</li> <li>• Non-English speaking</li> <li>• Women undergoing elective or urgent cesarean where no labor occurred</li> <li>• Women with stillbirth/neonatal deaths, major congenital anomaly/major neonatal morbidity</li> <li>• Homebirths</li> <li>• Active psychiatric illness at time of labor</li> </ul>	<b>Groups:</b> <sup>1</sup> <b>G1:</b> N <sub>2</sub> O <b>G2:</b> Pethidine <b>G3:</b> Epidural anesthesia <b>G4:</b> Local anesthesia (infiltration of the perineum) <b>G5:</b> "Natural" methods which included massage, hot pack, bath/shower, or any other nonpharmacologic method <b>G6:</b> No N <sub>2</sub> O  <b>N at enrollment:</b> (survey given in the first 24 hours postpartum, completed within 1 <sup>st</sup> postpartum week) Total: 496  <b>N at followup, n (%):</b> (included surveys) <b>G1:</b> 268 (54) <b>G2:</b> 132 (27) <b>G3:</b> 217 (44) <b>G4:</b> 190 (38) <b>G5:</b> 367 (74) <b>G6:</b> 228 (46) Total: 496  <b>Age, mean yrs (range):</b> <b>Total:</b> 32 (18-44)  <b>Race/ethnicity:</b> NR  <b>Parous, %:</b> Nulliparous: <b>Total:</b> 56	<b>Provider preferences:</b> NR  <b>Provider specialty:</b> NR  <b>Cost of intervention:</b> NR  <b>Other pain management methods available:</b> NR  <b>Pain management, n (%):</b> N <sub>2</sub> O: <b>Total:</b> 268 (54) Pethidine: <b>Total:</b> 132 (27) Epidural anesthesia: <b>Total:</b> 217 (44) Local anesthesia: <b>Total:</b> 190 (38) "Natural" methods: <b>Total:</b> 367 (74) "Natural" methods only: <b>Total:</b> 46 (9.3)  Number of pain management methods used, %: At least one: <b>Total:</b> 93 Two methods: <b>Total:</b> 24 Three methods: <b>Total:</b> 33  Pain management, normal vaginal deliveries, %: N <sub>2</sub> O: <b>Total:</b> 49 Pethidine: <b>Total:</b> 22 Epidural anesthesia: <b>Total:</b> 26	<b>Pain:</b> NR <sup>2</sup>  <b>Labor progress:</b> NR  <b>Fetal status:</b> NR  <b>Timeliness:</b> NR  <b>Effect of place of "booking in" vs. place of delivery, %:</b> Booked and gave birth in delivery suite or operating theatre (n = 398): <b>G1:</b> 59 <b>G2:</b> 29 <b>G3:</b> 49 <b>G4:</b> NR <b>G5:</b> 70  Booked into birth center, but gave birth in delivery suite or operating theatre (n=44): <b>G1:</b> 43 <b>G2:</b> 27 <b>G3:</b> 46 <b>G4:</b> NR <b>G5:</b> 93  Booked and gave birth in birth center (n=51): <b>G1:</b> 20 <b>G2:</b> 5 <b>G3:</b> 0 <b>G4:</b> NR <b>G5:</b> 86  <b>Labor co-interventions:</b> NR	<b>Satisfaction with pain management:</b> (survey given in the first 24 hours postpartum, to be completed within 1 <sup>st</sup> postpartum week) Very satisfied, %: <b>G1:</b> 35 <b>G6:</b> 57 <b>G1/G6:</b> <i>P</i> < 0.01  Pain management method, probably or definitely would use again, %: <b>G1:</b> 65 <b>G2:</b> 49 <b>G3:</b> 82 <b>G4:</b> NR <b>G5:</b> 79  <b>Satisfaction with birth experience:</b> NR  <b>Maternal status:</b> NR  <b>Neonatal status:</b> NR  <b>Adverse effects:</b> NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
		Local anesthesia: <b>Total:</b> NR “Natural methods”: <b>Total:</b> 72 Any pharmacologic: <b>Total:</b> 75	<b>Adverse effects:</b> NR  <b>Route of birth:</b> NR	

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Henry et al., 2004 (continued)		Pain management, “other” deliveries, %: N <sub>2</sub> O: <b>Total:</b> 66 Pethidine: <b>Total:</b> 40 Epidural anesthesia: <b>Total:</b> 92 Local anesthesia: <b>Total:</b> NR “Natural” methods: <b>Total:</b> 80 Any pharmacologic: <b>Total:</b> 99		

---

**Comments:**

<sup>1</sup> Groups are not exclusive.



<sup>2</sup> Utility of pain management methods only displayed graphically. Epidural analgesia recieved the highest utility scores, with 194/217 (89) rating it 'very useful' in relieving their pain.

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Holdcroft and Morgan, 1974 <b>Country:</b> United Kingdom <b>Participant source:</b> Academic single site <b>Setting:</b> Hospital <b>Enrollment period:</b> 7 month period <b>Design:</b> Cross-sectional ***** <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>• See exclusion criteria</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>• Those receiving epidurals</li> <li>• Having a cesarean</li> <li>• Non-English speaking</li> </ul>	<b>Groups:</b> <b>G1:</b> Entonox alone (50% mixture of N <sub>2</sub> O and O <sub>2</sub> ) <b>G2:</b> Entonox and pethidine <b>G3:</b> Pethidine alone <b>G4:</b> No analgesia <b>N at enrollment:</b> (interviewed) <b>G1:</b> 130 <b>G2:</b> 466 <b>G3:</b> 67 <b>G4:</b> 42 <b>N at followup:</b> (24-48 hours after delivery) <b>G1:</b> 130 <b>G2:</b> 466 <b>G3:</b> 67 <b>G4:</b> 42 <b>Age:</b> NR <b>Race/ethnicity:</b> NR <b>Parous:</b> NR	<b>Provider preferences:</b> NR <b>Provider specialty:</b> NR <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> NR <b>Pain management:</b> NR	<b>Pain, n (%):</b> (scale developed by investigators) Pain relief from Entonox: None: <b>G1:</b> 39 (30.0) <b>G2:</b> 157 (33.7) Slight analgesia: <b>G1:</b> 23 (17.7) <b>G2:</b> 80 (17.2) Satisfactory analgesia: <b>G1:</b> 60 (46.2) <b>G2:</b> 212 (45.5) Complete analgesia: <b>G1:</b> 5 (3.8) <b>G2:</b> 8 (1.7) Amnesia: <b>G1:</b> 1 (0.8) <b>G2:</b> 5 (1.1) No pain to relieve: <b>G1:</b> 2 (1.5) <b>G2:</b> 4 (0.9)  Pain relief from Entonox by duration of labor, primagravid: Less than 4 hours: None: <b>G1+G2:</b> 9 (30) Slight: <b>G1+G2:</b> 4 (13.3) Satisfactory: <b>G1+G2:</b> 14 (46.6) Complete: <b>G1+G2:</b> 0 Amnesia: <b>G1+G2:</b> 1 (3.3) No pain to relieve: <b>G1+G2:</b> 2 (6.7)  4 to 12 hours: None: <b>G1+G2:</b> 72 (38.9) Slight: <b>G1+G2:</b> 29 (15.7) Satisfactory: <b>G1+G2:</b> 75 (40.5) Complete: <b>G1+G2:</b> 4 (2.2) Amnesia: <b>G1+G2:</b> 2 (1.1) No pain to relieve: <b>G1+G2:</b> 3 (1.6)	<b>Satisfaction with pain management:</b> NR <b>Satisfaction with birth experience:</b> NR <b>Maternal status:</b> NR <b>Neonatal status:</b> NR <b>Adverse effects:</b> NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Holdcroft and Morgan, 1974 (continued)			<p>More than 12 hours:</p> <p>None:  <b>G1+G2:</b> 32 (38.6)</p> <p>Slight:  <b>G1+G2:</b> 15 (18.1)</p> <p>Satisfactory:  <b>G1+G2:</b> 35 (42.2)</p> <p>Complete:  <b>G1+G2:</b> 0</p> <p>Amnesia:  <b>G1+G2:</b> 1 (1.2)</p> <p>No pain to relieve:  <b>G1+G2:</b> 0</p> <p>Pain relief from Entonox by duration of labor, multipara:</p> <p>Less than 4 hours:</p> <p>None:  <b>G1+G2:</b> 27 (30.3)</p> <p>Slight:  <b>G1+G2:</b> 13 (14.6)</p> <p>Satisfactory:  <b>G1+G2:</b> 45 (50.6)</p> <p>Complete:  <b>G1+G2:</b> 3 (3.4)</p> <p>Amnesia:  <b>G1+G2:</b> 0</p> <p>No pain to relieve:  <b>G1+G2:</b> 1 (1.1)</p> <p>4 to 12 hours:</p> <p>None:  <b>G1+G2:</b> 51 (29.1)</p> <p>Slight:  <b>G1+G2:</b> 33 (18.8)</p> <p>Satisfactory:  <b>G1+G2:</b> 84 (48.0)</p> <p>Complete:  <b>G1+G2:</b> 5 (2.9)</p> <p>Amnesia:  <b>G1+G2:</b> 2 (1.1)</p> <p>No pain to relieve:  <b>G1+G2:</b> 0</p> <p>More than 12 hours:</p> <p>None:  <b>G1+G2:</b> 5 (14.7)</p> <p>Slight:  <b>G1+G2:</b> 9 (26.5)</p> <p>Satisfactory:  <b>G1+G2:</b> 19 (55.9)</p> <p>Complete:  <b>G1+G2:</b> 1 (2.9)</p> <p>Amnesia:  <b>G1+G2:</b> 0</p> <p>No pain to relieve:</p>	

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
			<b>G1+G2: 0</b>	

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Holdcroft and Morgan, 1974 (continued)			<p>Pain relief from pethidine:</p> <p>No analgesia:  <b>G2:</b> 224 (48.1)  <b>G3:</b> 32 (47.7)</p> <p>Slight analgesia:  <b>G2:</b> 163 (35.0)  <b>G3:</b> 15 (22.4)</p> <p>Satisfactory analgesia:  <b>G2:</b> 65 (13.9)  <b>G3:</b> 15 (22.4)</p> <p>Complete analgesia:  <b>G2:</b> 5 (1.1)  <b>G3:</b> 0</p> <p>Amnesia:  <b>G2:</b> 5 (1.1)  <b>G3:</b> 4 (6.0)</p> <p>No pain to relieve:  <b>G2:</b> 4 (0.9)  <b>G3:</b> 1 (1.5)</p> <p><b>Labor progress:</b>  NR</p> <p><b>Fetal status:</b>  NR</p> <p><b>Timeliness:</b>  NR</p> <p><b>Labor co-interventions:</b>  NR</p> <p><b>Adverse effects, n:</b></p> <p>Maternal:  Vomiting:  <b>Total:</b> 22<sup>1</sup></p> <p>Altered consciousness:  <b>Total:</b> 27</p> <p>Loss of control:  <b>Total:</b> 7</p> <p>Neonatal: NR</p> <p>Occupational: NR</p> <p><b>Route of birth:</b>  NR</p>	

**Comments:**

<sup>1</sup> Ascribed to pethidine in 10 patients.

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Jacobson et al., 1990  <b>Country:</b> Sweden  <b>Participant source:</b> Community  <b>Setting:</b> Review of data for addicts from county jail, forensic medicine institute, and hospital  <b>Enrollment period:</b> Addicts born from 1945 to 1966  <b>Design:</b> Case control  ***** <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>• Opiate addict and siblings from one of three sources</li> <li>• Birth records available</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>• Siblings who were also drug addicts or brought up outside family</li> </ul>	<b>Groups:</b> <sup>1</sup> <b>G1a:</b> Opiate addicts whose mothers received N <sub>2</sub> O during labor <b>G1b:</b> Nonaddict siblings of addicts, whose mothers may also have received N <sub>2</sub> O during labor <b>G2a<sup>2</sup>:</b> Addicts whose mothers may have received opiates and/or barbiturates during labor <b>G2b<sup>2</sup>:</b> Nonaddict siblings of addicts, whose mothers may have received opiates and/or barbiturates during labor.  <b>N at enrollment:</b> <b>G1a:</b> 145 <b>G1b:</b> 174 <b>G2a:</b> 200 <b>G2b:</b> 230  <b>N at followup:</b> <b>G1a:</b> 145 <b>G1b:</b> 174 <b>G2a:</b> 200 <b>G2b:</b> 230  <b>Age:</b> NR  <b>Race/ethnicity:</b> NR  <b>Parous:</b> NR	<b>Provider preferences:</b> NR  <b>Provider specialty:</b> NR  <b>Cost of intervention:</b> NR  <b>Other pain management methods available:</b> NR  <b>Pain management:</b> NR	<b>Pain:</b> NR  <b>Labor progress:</b> NR  <b>Fetal status:</b> NR  <b>Timeliness:</b> NR  <b>Labor co-interventions:</b> NR  <b>Adverse effects:</b> NR  <b>Route of birth:</b> NR	<b>Satisfaction with pain management:</b> NR  <b>Satisfaction with birth experience:</b> NR  <b>Maternal status:</b> NR  <b>Neonatal status:</b> NR  <b>Adverse effects:</b> Maternal: NR  Neonatal: NR  Childhood: Duration of N <sub>2</sub> O exposure of mothers during labor, hours, n (%): ≤ 0.25 hours: <b>G1a:</b> 22 (15.2) <b>G1b:</b> 44 (25.3) > 0.25 to ≤ 1 hour: <b>G1a:</b> 30 (20.7) <b>G1b:</b> 46 (26.4) > 1.0 to < 2.5 hours: <b>G1a:</b> 32 (22.1) <b>G1b:</b> 32 (18.4) ≥ 2.5 to < 4.5 hours: <b>G1a:</b> 30 (20.7) <b>G1b:</b> 30 (17.2) ≥ 4.5 hours: <b>G1a:</b> 31 (21.4) <b>G1b:</b> 22 (12.6)  Opiate addiction in offspring, relative risk for N <sub>2</sub> O exposure of > 1 to < 2.5

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
				hours (95% CI): Matched: <b>G1a/G1b:</b> 1.6 (0.95, 2.6) Unmatched: <b>G1a/G1b:</b> 1.7 (1.2, 2.3)



**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Jacobson et al., 1990 (continued)				<p>Time between last administration of opiates and/or barbiturates and delivery, hours, n (%):</p> <p>≤ 0.5 hours:  <b>G2a:</b> 1 (0.5)  <b>G2b:</b> 2 (0.9)</p> <p>&gt; 0.5 to ≤ 1.5 hours:  <b>G2a:</b> 6 (3)  <b>G2b:</b> 2 (0.9)</p> <p>&gt; 1.5 to ≤ 4.5 hours:  <b>G2a:</b> 23 (11.5)  <b>G2b:</b> 16 (7)</p> <p>&gt; 4.5 to ≤ 10 hours:  <b>G2a:</b> 13 (6.5)  <b>G2b:</b> 6 (2.6)</p> <p>&gt; 10 hours:  <b>G2a:</b> 18 (9)  <b>G2b:</b> 16 (7)</p> <p>No administration, n (%):  <b>G2a:</b> 150 (75)  <b>G2b:</b> 194 (84.3)</p> <p>Opiate addiction in offspring, relative risk for single dose of opiates, (95% CI):  Matched:  <b>G2a/G2b:</b> 1.6 (0.75, 3.6)  Unmatched:  <b>G2a/G2b:</b> 1.8 (0.94, 3.5)</p> <p>Opiate addiction in offspring, relative risk for single dose of barbiturates, (95% CI):  Matched:  <b>G2a/G2b:</b> 1.7 (0.97, 3.0)</p>

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
				Unmatched: <b>G2a/G2b:</b> 1.6 (0.97, 2.6) Occupational: NR

---

**Comments:**

<sup>1</sup> Those subjects in G2 not in G1 were missing data for administration of nitrous oxide.

<sup>2</sup> Opiate doses were 0.01-0.02g morphine or 0.05-0.1 g pethidine hydrochloride, barbiturates doses as 0.05-2g phenobarbitone (and some other barbiturates not described)

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Jacobson et al., 1988 <b>Country:</b> Sweden <b>Participant source:</b> Community <b>Setting:</b> Other (custody center for arrests) <b>Enrollment period:</b> 11/1986 to 09/1987 <b>Design:</b> Case control ***** ***** <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>• Adult amphetamine addicts born between 1945 and 1966</li> <li>• Born in any of the seven largest hospitals in Stockholm</li> <li>• Brought up at home by biological mother</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>• See inclusion criteria</li> </ul>	<b>Groups:</b> <b>G1:</b> Addicts whose mothers were given N <sub>2</sub> O during delivery (mix and administration NR) <b>G2:</b> Nonaddicted siblings as controls <b>N at enrollment:</b> <b>G1:</b> 200 <b>G2:</b> 195 <b>N at followup:</b> NR <b>Age:</b> NR <b>Race/ethnicity:</b> NR <b>Parous:</b> NR	<b>Provider preferences:</b> NR <b>Provider specialty:</b> NR <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> NR <b>Pain management, %:</b> Duration of nitrous oxide analgesia: ≥ 4.5 hours: <b>G1:</b> 18.4 G2: 7.1 ≥ 2.5 to < 4.5 hours: <b>G1:</b> 21.3 <b>G2:</b> 20.8 > 1 to < 2.5 hours: <b>G1:</b> 19.9 <b>G2:</b> 16.9 > 0.25 to ≤ 1 hour: <b>G1:</b> 23.4 <b>G2:</b> 27.3 ≤ 0.25 hour: <b>G1:</b> 17.0 <b>G2:</b> 27.9	<b>Pain:</b> NR <b>Labor progress:</b> NR <b>Fetal status:</b> NR <b>Timeliness:</b> NR <b>Labor co-interventions:</b> NR <b>Adverse effects:</b> NR <b>Route of birth, n:</b> Vaginal: NR Assisted: NR Cesarean: <b>G1:</b> 0 <b>G2:</b> 0	<b>Satisfaction with pain management:</b> NR <b>Satisfaction with birth experience:</b> NR <b>Adverse effects:</b> Maternal: NR Neonatal: NR Childhood: Amphetamine addiction in offspring, relative risk for N <sub>2</sub> O exposure ≥ 4.5 hours (95% CI): Males: <b>G1/G2:</b> 8.2 (1.2, 55.2) Females: <b>G1/G2:</b> 3.6 (0.96, 15.8) Amphetamine addiction in offspring, relative risk for N <sub>2</sub> O exposure: ≥ 4.5 hours: <b>G1/G2:</b> 5.6 <sup>1</sup> ≥ 2.5 to < 4.5 hours: <b>G1/G2:</b> NR <sup>1</sup> > 1 to < 2.5 hours: <b>G1/G2:</b> NR <sup>1</sup> > 0.25 to ≤ 1 hour: <b>G1/G2:</b> NR <sup>1</sup> ≤ 0.25 hour: <b>G1/G2:</b> 1.0 Occupational: NR

**Comments:**

<sup>1</sup> Data only displayed graphically. Observed relative risks for all exposure levels fall within the 95% confidence intervals of estimated risks determined from logistic regression analysis.

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Jones et al., 1969 <b>Country:</b> United Kingdom <b>Participant source:</b> NR <b>Setting:</b> Hospital <b>Enrollment period:</b> 05/1962 to 11/1967 <b>Design:</b> RCT ***** <b>Inclusion criteria:</b> • Normal delivery <b>Exclusion criteria:</b> • Those who had received instruction in psychoprophylaxis or hypnosis	<b>Groups:</b> <b>G1:</b> N <sub>2</sub> O in O <sub>2</sub> (calibrated in 5% steps from 20% to 100% O <sub>2</sub> and checked at continuous flows up to 40 liters/minute) <b>G2:</b> Methoxyflurane in O <sub>2</sub> enriched air (40% O <sub>2</sub> with a flow of about 30 liters/minute) Both administered by observer <b>N at enrollment:</b> <b>G1:</b> 24 <b>G2:</b> 24 <b>Age, mean yrs ± SD:</b> <b>G1:</b> 25.0 ± 5.0 <b>G2:</b> 24.4 ± 5.9 <b>Race/ethnicity:</b> NR <b>Parous, n (%):</b> <b>G1:</b> 13 (54) <b>G2:</b> 13 (54)	<b>Provider preferences:</b> NR <b>Provider specialty, %:</b> Midwife: 100 <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> Pethidine given within 4 hours of inhalation <b>Pain management, n (%):</b> Pethidine: <b>G1:</b> 11 (45.8) <b>G2:</b> 14 (58.3) Duration of inhalation, minutes, mean ± SD: <b>G1:</b> 83 ± 66.3 <b>G2:</b> 82.5 ± 72.8	<b>Pain:</b> Anesthetist's assessment of analgesia, mean % of time satisfactory ± SD: All factors: <b>G1:</b> 70.9 ± 17.6 <b>G2:</b> 73.8 ± 26.3 All factors, pethidine within 4 hours of inhalation: <b>G1:</b> 72.9 ± 19.0 <b>G2:</b> 67.5 ± 29.6 All factors, no pethidine: <b>G1:</b> 69.3 ± 16.0 <b>G2:</b> 82.6 ± 18.8 Reactions to contractions: <b>G1:</b> 77.2 ± 14.7 <b>G2:</b> 81.4 ± 22.3 Level of consciousness: <b>G1:</b> 94.5 ± 7.2 <b>G2:</b> 94.0 ± 8.7 Restlessness: <b>G1:</b> 97.2 ± 6.4 <b>G2:</b> 92.1 ± 14.7 Anesthetist's assessment of analgesia, all factors, mean % of time satisfactory, n (%): 0-59: <b>G1:</b> 2 (8) <b>G2:</b> 3 (13) 60-69: <b>G1:</b> 4 (17) <b>G2:</b> 3 (13) 70-79: <b>G1:</b> 8 (33) <b>G2:</b> 2 (8) 80-89: <b>G1:</b> 5 (21) <b>G2:</b> 4 (16) 90-100: <b>G1:</b> 5 (21) <b>G2:</b> 12 (50) <b>G1/G2:</b> <i>P</i> < 0.05	<b>Satisfaction with pain management, n (%):</b> Midwife report: Complete pain relief: <b>G1:</b> 2 (9) <b>G2:</b> 9 (38) <b>G1/G2:</b> <i>P</i> < 0.05 Complete or considerable pain relief: <b>G1:</b> 15 (65) <b>G2:</b> 20 (83) Maternal report, immediately after delivery: Complete pain relief: <b>G1:</b> 4 (18) <b>G2:</b> 7 (29) Considerable pain relief: <b>G1:</b> 15 (68) <b>G2:</b> 12 (50) Slight pain relief: <b>G1:</b> 3 (14) <b>G2:</b> 4 (17) No pain relief: <b>G1:</b> 0 <b>G2:</b> 1 (4) Pain relief complete or considerable, 48 hours post delivery: <b>G1:</b> 19 (83) <b>G2:</b> 22 (92) <b>Satisfaction with birth experience, n (%):</b> Better than previous labour, multiparae: <b>G1:</b> 6 (46) <b>G2:</b> 8 (62) <b>Neonatal status:</b> Apgar score, 1 minute: <b>G1:</b> NR <b>G2:</b> NR <b>G1/G2:</b> <i>P</i> = NS

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
				<b>Adverse effects:</b> Maternal: Too drowsy, midwife report, n (% *) <b>G1:</b> 3 (12.5) <b>G2:</b> 3 (12.5)

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Jones et al., 1969 (continued)			<p>Anesthetist's assessment of analgesia, all factors, mean % of time satisfactory: First stage: <b>G1:</b> 71.2 <b>G2:</b> 73.8 Second stage: <b>G1:</b> 73.8 <b>G2:</b> 71.2 Third stage: <b>G1:</b> 67.5 <b>G2:</b> 62.0 30 minutes before delivery: <b>G1:</b> 66.7 <b>G2:</b> 73.1</p> <p><b>Labor progress:</b> Duration of second stage labor, minutes, mean <math>\pm</math> SD: <b>G1:</b> 32.0 <math>\pm</math> 23.4 <b>G2:</b> 36.7 <math>\pm</math> 25.3</p> <p><b>Fetal status:</b> NR</p> <p><b>Timeliness:</b> NR</p> <p><b>Labor co-interventions:</b> NR</p> <p><b>Adverse effects:</b> NR</p> <p><b>Route of birth, n (%):</b> Vaginal: <b>G1:</b> 19 (79) <b>G2:</b> 19 (79) Assisted: <b>G1:</b> 5 (21) <b>G2:</b> 5 (21) Cesarean: <b>G1:</b> 0 <b>G2:</b> 0</p>	<p>Blood loss, midwife estimate, ml, mean (range): <b>G1:</b> 160 (25-500) <b>G2:</b> 176 (30-500)</p> <p>Vomiting, n (%): During labor (assessed immediately after delivery): <b>G1:</b> 4 (17) <b>G2:</b> 0</p> <p>At some point during labor or in succeeding 24 hours (assessed 36-48 hours after delivery): <b>G1:</b> 6 (25) <b>G2:</b> 4 (17)</p> <p>Nausea, n (%): During labor (assessed immediately after delivery): <b>G1:</b> 8 (35) <b>G2:</b> 2 (8)</p> <p>At some point during labor or in succeeding 24 hours (assessed 36-48 hours after delivery): <b>G1:</b> 13 (54) <b>G2:</b> 5 (21) <b>G1/G2:</b> <math>P &lt; 0.05</math></p> <p>Memory of labor and delivery (assessed 36-48 hours after delivery): <b>G1:</b> NR</p>



**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
				<b>G2:</b> NR <b>G1/G2:</b> $P = NS$ Neonatal, n: Fetal distress: <b>G1:</b> 1 <b>G2:</b> 0 Neonatal deaths: <b>Total:</b> 2 Childhood: NR Occupational: NR

---

**Comments:**

\* Calculated by reviewer.

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Jones et al., 1969 <b>Country:</b> United Kingdom <b>Participant source:</b> NR <b>Setting:</b> Hospital <b>Enrollment period:</b> NR <b>Design:</b> RCT  <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>• Normal delivery</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>• Received instruction in psychoprophylaxis or hypnosis</li> </ul>	<b>Groups:</b> <b>G1:</b> N <sub>2</sub> O in O <sub>2</sub> (50%/50%) <b>G2:</b> Methoxyflurane (0.35%) in air  Both self-administered intermittently.  <b>N at enrollment:</b> <b>G1:</b> 25 <b>G2:</b> 25  <b>N at followup:</b> NR  <b>Age, mean yrs ± SD:</b> <b>G1:</b> 26.5 ± 7.2 <b>G2:</b> 24.1 ± 5.1  <b>Race/ethnicity:</b> NR  <b>Primiparous, n (%):</b> <b>G1:</b> 9 (36) <b>G2:</b> 11 (44)	<b>Provider preferences:</b> NR  <b>Provider specialty:</b> NR  <b>Cost of intervention:</b> NR  <b>Other pain management methods available:</b> Other analgesic (pethidine) or sedative drugs were given by the midwife on her usual indications.  <b>Pain management n (%)*:</b> Pethidine: <b>G1:</b> 17 (68) <b>G2:</b> 16 (64)  Mean duration of inhalation, minutes, mean ± SD: <b>G1:</b> 66.1 ± 39.2 <b>G2:</b> 90.1 ± 67.5 <b>G1/G2:</b> <i>P</i> = NS	<b>Pain, n:</b> Anesthetist's assessment of analgesia, mean % of time satisfactory ± SD: All factors: <b>G1:</b> 61.5 ± 29.9 <b>G2:</b> 78.1 ± 20.1 <b>G1/G2:</b> <i>P</i> < 0.05 All factors, pethidine within 4 hours of inhalation: <b>G1:</b> 61.3 ± 30.8 <b>G2:</b> 85.4 ± 12.8 <b>G1/G2:</b> <i>P</i> < 0.01 All factors, no pethidine: <b>G1:</b> 60.5 ± 32.7 <b>G2:</b> 65.1 ± 24.6 <b>G1/G2:</b> <i>P</i> = NS Reactions to contractions: <b>G1:</b> 62.3 ± 30 <b>G2:</b> 79.3 ± 20 <b>G1/G2:</b> <i>P</i> < 0.05 Level of consciousness: <b>G1:</b> 98.9 ± 2.2 <b>G2:</b> 98.7 ± 3.7 Restlessness: <b>G1:</b> 98.5 ± 4.2 <b>G2:</b> 99.4 ± 1.4  Anesthetist's assessment of analgesia, all factors, mean % of time satisfactory, n (%): 0-59: <b>G1:</b> 11(44) <b>G2:</b> 4 (16) 60-69: <b>G1:</b> 2 (8) <b>G2:</b> 4 (16) 70-79: <b>G1:</b> 2 (8) <b>G2:</b> 2 (8) 80-89: <b>G1:</b> 6 (24) <b>G2:</b> 5 (20) 90-100: <b>G1:</b> 4 (15) <b>G2:</b> 10 (40)	<b>Satisfaction with pain management, n (%):</b> Midwife report: Complete pain relief: <b>G1:</b> 2 (8) <b>G2:</b> 4 (16) Complete or considerable pain relief: <b>G1:</b> 18 (72) <b>G2:</b> 21 (84) Adequately cooperative: <b>G1:</b> 24 (96) <b>G2:</b> 24 (96) Satisfactory (restless assessment): <b>G1:</b> 15 (60) <b>G2:</b> 17 (68)  Maternal report, immediately after delivery: Complete pain relief: <b>G1:</b> 4 (16) <b>G2:</b> 7 (28) Considerable pain relief: <b>G1:</b> 16 (64) <b>G2:</b> 14 (56) Slight pain relief: <b>G1:</b> 5 (20) <b>G2:</b> 4 (16) No pain relief: <b>G1:</b> 0 <b>G2:</b> 0  Labor worse than expected, n (%): (36 to 48 hours after delivery) Time 1: <b>G1:</b> 10 (40) <b>G2:</b> 4 (16) <b>G1/G2:</b> <i>P</i> = NS Time 2: <b>G1:</b> 9 (36) <b>G2:</b> 2 (8) <b>G1/G2:</b> <i>P</i> < 0.05
			<b>Labor progress:</b>	

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
			G1: NR <sup>1</sup> G2: NR <sup>1</sup>	

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Jones et al., 1969 (continued)			<p>Fetal status : NR</p> <p><b>Timeliness:</b> NR</p> <p><b>Labor co-interventions:</b> NR</p> <p><b>Adverse effects:</b> NR</p> <p><b>Route of birth:</b> NR</p>	<p><b>Labor better than previous labors, multiparae, n (%):</b> (36 to 48 hours after delivery)</p> <p>Time 1: <b>G1:</b> 4 (25) <b>G2:</b> 9 (64) <b>G1/G2:</b> <i>P</i> = NS</p> <p>Time 2: <b>G1:</b> 12 (86) <b>G2:</b> 5 (31) <b>G1/G2:</b> <i>P</i> &lt; 0.01</p> <p><b>Maternal Status, n (%):</b> Remembered labor clearly (vs. hazily): <b>G1:</b> 17 (68) <b>G2:</b> 17 (68)</p> <p>Remembered actual delivery clearly: <b>G1:</b> 10 (40) <b>G2:</b> 17 (68)</p> <p>Thought they had fallen asleep during inhalation: <b>G1:</b> 8 (32) <b>G2:</b> 4 (16)</p> <p>Smell noted with inhalation: <b>G1:</b> 4 (16) <b>G2:</b> 25 (100)</p> <p>Dreams experienced: <b>G1:</b> 6 (24) <b>G2:</b> 4 (16)</p> <p>Other sensations: <b>G1:</b> 9 (36) <b>G2:</b> 2 (8) <b>G1/G2:</b> <i>P</i> &lt; 0.05</p> <p><b>Neonatal status:</b> Apgar scores, 1-10 minutes after delivery: <b>G1:</b> NR<sup>2</sup> <b>G2:</b> NR<sup>2</sup></p>

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Jones et al., 1969 (continued)				<p><b>Adverse effects:</b></p> <p>Maternal:</p> <p>Blood loss, midwife estimate, ml, mean <math>\pm</math> SD:  <b>G1:</b> 144.0 <math>\pm</math> 149  <b>G2:</b> 186.7 <math>\pm</math> 101</p> <p>Vomiting during labor (assessed immediately after delivery), n (%):  <b>G1:</b> 2 (8)  <b>G2:</b> 0</p> <p>Nausea during labor (assessed immediately after delivery), n (%):  <b>G1:</b> 8 (32)  <b>G2:</b> 0  <b>G1/G2:</b> <math>P &lt; 0.01</math></p> <p>Nausea or vomiting at some point during labor (assessed subsequently), n (%):  <b>G1:</b> 8 (32)  <b>G2:</b> 4 (16)  <b>G1/G2:</b> <math>P = NS</math></p> <p>Neonatal: NR</p> <p>Childhood: NR</p> <p>Occupational: NR</p>

**Comments:**

\* Calculated by reviewer.

<sup>1</sup> The progress of labor in the two groups was similar, though the first stage of labor was shorter in G1.

<sup>2</sup> There were no differences between the agents as demonstrated by the Apgar scores at 1, 2, 5, or 10 minutes.

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Landon et al., 1992 <b>Country:</b> United Kingdom <b>Participant source:</b> NR <b>Setting:</b> Hospital <b>Enrollment period:</b> NR <b>Design:</b> Prospective cohort ***** <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>• Healthy</li> <li>• Uncomplicated pregnancy</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>• Preeclampsia</li> <li>• Metabolic or haematological disease</li> <li>• IUGR</li> <li>• Abnormalities of the placenta</li> <li>• Pregnancy did not progress normally to full-term delivery</li> </ul>	<b>Groups:</b> <b>G1:</b> Vaginal birth and Entonox <b>G2:</b> Vaginal birth without N <sub>2</sub> O <b>N at enrollment:</b> <b>G1:</b> 45 <b>G2:</b> 13 <b>N at followup:</b> <b>G1:</b> 45 <b>G2:</b> 13 <b>Age, mean yrs:</b> <b>G1:</b> 27.5 <b>G2:</b> 29.4 <b>Race/ethnicity, n:</b> Asian: <b>G1:</b> 16 <b>G2:</b> 3 <b>Parous, n:</b> <b>G1:</b> 21 <b>G2:</b> 8	<b>Provider preferences:</b> NR <b>Provider specialty:</b> NR Cost of intervention: NR <b>Other pain management methods available:</b> NR <b>Pain management:</b> NR	<b>Pain:</b> NR <b>Labor progress, Duration of labor, hours, mean ± SD:</b> <b>G1:</b> 6.2 ± 2.8 <b>G2:</b> 5.5 ± 3.0 <b>Fetal status:</b> NR <b>Timeliness:</b> NR <b>Labor co-interventions:</b> NR <b>Adverse effects:</b> NR <b>Route of birth, n (%):</b> Vaginal: <b>G1:</b> 45 (100) <b>G2:</b> 13 (100) Assisted: <b>G1:</b> 0 <b>G2:</b> 0 Cesarean: <b>G1:</b> 0 <b>G2:</b> 0	<b>Satisfaction with pain management:</b> NR <b>Satisfaction with birth experience:</b> NR <b>Maternal status:</b> Hb, g/dl, mean ± SD: <b>G1:</b> 12.8 ± 1.2 <b>G2:</b> 12.7 ± 0.67 Mean cell volume, fl, mean ± SD: <b>G1:</b> 86.8 ± 14.5 <b>G2:</b> 90.4 ± 3.1 <b>Neonatal status:</b> Birth weight, kg, mean ± SD: <b>G1:</b> 3.3 ± 0.45 <b>G2:</b> 3.1 ± 0.45 Apgar score, mean ± SD: 1 minute: <b>G1:</b> 8.5 ± 1.1 <b>G2:</b> 8.5 ± 0.9 5 minutes: <b>G1:</b> 9.3 ± 0.5 <b>G2:</b> 9.4 ± 0.5 <b>Adverse effects:</b> NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
<b>Author:</b> Leong et al., 2000 <b>Country:</b> Malaysia <b>Participant source:</b> Academic single setting <b>Setting:</b> Hospital <b>Enrollment period:</b> NR <b>Design:</b> Prospective cohort <sup>1</sup> ***** <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>Randomly selected healthy primigravid women at term (37-41 weeks)</li> <li>Cervical dilation not exceeding 4 cm</li> <li>Cephalic presentation</li> <li>Presenting to labor between 0800 and 1000 hours</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>Complications such as previous uterine surgery</li> <li>Pre-existing illness</li> <li>Hypertension</li> <li>Abnormal admission cardiotocography</li> <li>Contraindications to an epidural</li> </ul>	<b>Groups:</b> <b>G1:</b> Inhalational Entonox (nitrous) and IM pethidine routine; 75-100 mg IM pethidine every 4-6 hours with Entonox (these patients declined an epidural) <b>G2:</b> Epidural with initial dose of 4-6 ml of 0.25% bupivacaine followed by maintenance dose of 6-10 ml/hour of 0.125% bupivacaine with 0.0002% fentanyl (selected by patients) <b>N at enrollment:</b> (enrolled in labor between 0800 and 1000 hours) <b>G1:</b> 68 <b>G2:</b> 55 <b>N at followup:</b> <b>G1:</b> 68 <b>G2:</b> 50 <b>Age, mean yrs:</b> <b>G1:</b> 24.9 <b>G2:</b> 25.5 <b>Race/ethnicity, %:</b> Chinese: <b>G1:</b> 20.6 <b>G2:</b> 30.9 Indian: <b>G1:</b> 11.8 <b>G2:</b> 14.6 Malay: <b>G1:</b> 67.7 <b>G2:</b> 54.6 <b>Parous:</b>	<b>Provider preferences:</b> NR <b>Provider specialty:</b> NR <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> NR <b>Pain management:</b> NR	<b>Pain:</b> NR <b>Labor progress, mean duration of labor, min, mean:</b> First stage: <b>G1:</b> 483.4 (n=65) <b>G2:</b> 565.8 <b>G1/G2:</b> $P < 0.02$ Second stage: <b>G1:</b> 36.3 (n=65) <b>G2:</b> 60.2 <b>G1/G2:</b> $P < 0.03$ Third stage: <b>G1:</b> 5.8 (n=65) <b>G2:</b> 6.3 <b>G1/G2:</b> $P = NS$ Total duration of labor: <b>G1:</b> 525.5 (n=65) <b>G2:</b> 631.6 <b>G1/G2:</b> $P < 0.03$ <b>Fetal status:</b> NR <b>Timeliness:</b> NR <b>Labor co-interventions, n (%):</b> Oxytocin augmentation: <b>G1:</b> 38 (55.9) <b>G2:</b> 48 (87.3) <b>G1/G2:</b> $P < 0.01$ Continuous cardiotocography: <b>G1:</b> 68 (100) <b>G2:</b> 55 (100) <b>Adverse effects, n (%):</b>	<b>Satisfaction with pain management, n (%):</b> (day after birth) Happy with method and would repeat in next pregnancy: <b>G1:</b> NR (35.3) <b>G2:</b> NR (69) Unhappy and unsatisfied with pain method: <b>G1:</b> 31 (45.6) <b>G2:</b> 3 (5.5) <b>Satisfaction with birth experience:</b> NR <b>Maternal status:</b> NR <sup>2</sup> <b>Neonatal status:</b> NR <sup>3</sup> <b>Adverse effects, n:</b> Maternal: Voiding difficulties requiring repeat catheterization: <b>G1:</b> 0 <b>G2:</b> 2 Neonatal: NR Childhood: NR Occupational: NR



**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
	NR		Maternal: Ascension of epidural block to T3/T4: <b>G1:</b> 0 (NR) <b>G2:</b> 1 (NR) Spinal headache requiring blood patch: <b>G1:</b> 0 <b>G2:</b> 2 (3.6) Backache requiring oral analgesics: <b>G1:</b> 0 <b>G2:</b> 2 (3.6)	

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Leong et al., 2000 (continued)			<p>Neonatal:</p> <p>Occipito-transverse position in second stage of labor:</p> <p><b>G1:</b> 0</p> <p><b>G2:</b> 8 (1.8)</p> <p>Occupational: NR</p> <p><b>Route of birth, n (%):</b></p> <p>Vaginal:</p> <p><b>G1:</b> 56 (82.4)</p> <p><b>G2:</b> 28 (50.9)</p> <p>Forceps assisted:</p> <p><b>G1:</b> 5 (7.3)</p> <p><b>G2:</b> 13 (23.6)</p> <p>Vacuum assisted:</p> <p><b>G1:</b> 4 (5.9)</p> <p><b>G2:</b> 9 (16.5)</p> <p>Cesarean:</p> <p><b>G1:</b> 3 (4.4)</p> <p><b>G2:</b> 5 (9.0)</p> <p>G 1/G 2: <math>P = NS</math></p> <p>Total instrumental delivery rate:</p> <p><b>G1:</b> NR (13.2)</p> <p><b>G2:</b> NR (40.1)</p> <p>G 1/G 2: <math>P &lt; 0.01</math></p>	

**Comments:**

<sup>1</sup> Patients were randomly selected from those meeting inclusion criteria, but chose whether to be in epidural group.

<sup>2</sup> No significant difference in time to full ambulation or time to spontaneously void urine.

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Marx et al., 1970  <b>Country:</b> U.S.  <b>Participant source:</b> Academic single site  <b>Setting:</b> Hospital  <b>Enrollment period:</b> NR  <b>Design:</b> Prospective cohort *****  <b>Inclusion criteria:</b> • Parturients with unremarkable prenatal courses  <b>Exclusion criteria:</b> • See inclusion criteria	<b>Groups:</b> <b>G1:</b> Vaginal delivery <b>G2:</b> Elective repeat cesarean section  <b>N at enrollment:</b> <b>G1:</b> 26 <b>G2:</b> 14  <b>N at followup:</b> <b>G1:</b> 26 <b>G2:</b> 14  <b>Age:</b> NR  <b>Race/ethnicity:</b> NR  <b>Parous:</b> NR	<b>Provider preferences:</b> NR  <b>Provider specialty:</b> NR  <b>Cost of intervention:</b> NR  <b>Other pain management methods available:</b> NR  <b>Pain management:</b> <b>G1:</b> N <sub>2</sub> O (ranging from 50-70%) and O <sub>2</sub> by mask in a semiclosed system with circle absorber plus local anesthesia <b>G2:</b> Anesthetized with 150-250 mg thiopental followed by N <sub>2</sub> O-O <sub>2</sub> via endotracheal tube and 0.1% succinylcholine by IV infusion	<b>Pain:</b> NR  <b>Labor progress:</b> NR  <b>Fetal status:</b> NR  <b>Timeliness:</b> NR  <b>Labor co-interventions:</b> NR  <b>Adverse effects:</b> NR  <b>Route of birth, n:</b> Vaginal: <b>G1:</b> 16 <b>G2:</b> 0  Assisted, forceps: <b>G1:</b> 10 <b>G2:</b> 0  Cesarean: <b>G1:</b> 0 <b>G2:</b> 14	<b>Satisfaction with pain management:</b> NR  <b>Satisfaction with birth experience:</b> NR  <b>Maternal status:</b> NR  <b>Neonatal status:</b> Umbilical vein blood N <sub>2</sub> O levels, vol % range: <b>Total:</b> 11.2-28.8  Apgar score < 6, 1 minute, n: 6 or less: <b>G1:</b> 3 <b>G2:</b> 1  Apgar score 9-10, 5 minutes, n (%): <b>Total:</b> 40 (100)  <b>Adverse effects:</b> Maternal: NR  Neonatal, n: Severe fetal acidosis: <b>G1:</b> 3 <b>G2:</b> 0 High fetal N <sub>2</sub> O level with normal acid-base values: <b>G1:</b> 0 <b>G2:</b> 1  Childhood: NR  Occupational: NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> McAneny and Doughty 1963 <b>Country:</b> United Kingdom <b>Participant source:</b> Community <b>Setting:</b> Hospital <b>Enrollment period:</b> NR <b>Design:</b> Nonrandomized trial ***** <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>English speaking women in labor</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>See inclusion criteria</li> </ul>	<b>Groups:</b> <b>G1:</b> 50% N <sub>2</sub> O in O <sub>2</sub> <b>G2:</b> 60% N <sub>2</sub> O in O <sub>2</sub> <b>G3:</b> 70% N <sub>2</sub> O in O <sub>2</sub> <b>G4:</b> 75% N <sub>2</sub> O in O <sub>2</sub> <b>G5:</b> 80% N <sub>2</sub> O in O <sub>2</sub>  <b>N at enrollment:</b> <b>G1:</b> 101 <b>G2:</b> 101 <b>G3:</b> 100 <b>G4:</b> 101 <b>G5:</b> 98 <b>Total:</b> 501  <b>N at followup:</b> <b>G1:</b> 101 <b>G2:</b> 101 <b>G3:</b> 100 <b>G4:</b> 101 <b>G5:</b> 98  <b>Age:</b> NR  <b>Race/ethnicity:</b> NR  <b>Parous, n (%):</b> Primigravidae: <b>Total:</b> 342 (68.3)  Multigravidae: <b>Total:</b> 159 (31.7)	<b>Provider preferences:</b> NR  <b>Provider specialty:</b> NR  <b>Cost of intervention:</b> NR  <b>Other pain management methods available:</b> NR  <b>Pain management, %:</b> Multiple analgesics by injection: <b>G1:</b> 30.0 <b>G2:</b> 26.0 <b>G3:</b> 22.0 <b>G4:</b> 29.0 <b>G5:</b> 33.0	<b>Pain, %:</b> Considerable and complete relief, mothers report: <b>G1:</b> 52.0 <b>G2:</b> 64.0 <b>G3:</b> 74.0 <b>G4:</b> 76.0 <b>G5:</b> 75.5 <b>G1/G3:</b> $P < 0.01$  First stage, midwife report: Complete relief: <b>G1:</b> 8.0 <b>G2:</b> 6.0 <b>G3:</b> 14.0 <b>G4:</b> 12.0 <b>G5:</b> 7.0 Complete or adequate relief: <b>G1:</b> 92.0 <b>G2:</b> 92.0 <b>G3:</b> 90.0 <b>G4:</b> 88.0 <b>G5:</b> 92.0  Second stage, midwife report: Complete relief: <b>G1:</b> 18.0 <b>G2:</b> 10.0 <b>G3:</b> 12.0 <b>G4:</b> 9.0 <b>G5:</b> 11.0 Complete or adequate relief: <b>G1:</b> 94.0 <b>G2:</b> 92.0 <b>G3:</b> 94.0 <b>G4:</b> 92.0 <b>G5:</b> 93.0  <b>Labor progress:</b> NR  <b>Fetal status:</b> NR  <b>Timeliness:</b> NR  <b>Labor co-interventions:</b> NR	<b>Satisfaction with pain management:</b> One day after labor: Only 2 mothers reported no pain during labor  About 40% of mothers reported that the pain was worse than expected  <b>Satisfaction with birth experience, %:</b> One day after labor: Would tolerate the same labor again: <b>G1:</b> 82.0 <b>G2:</b> 81.0 <b>G3:</b> 89.0 <b>G4:</b> 87.0 <b>G5:</b> 75.5 <b>G3/G5:</b> $P < 0.02$  Were comfortable late in 1 <sup>st</sup> stage of labor: <b>G1:</b> 55.0 <b>G2:</b> 66.0 <b>G3:</b> 63.0 <b>G4:</b> 56.0 <b>G5:</b> 60.0  Were comfortable while pushing in 2 <sup>nd</sup> stage: <b>G1:</b> 72.0 <b>G2:</b> 74.0 <b>G3:</b> 74.0 <b>G4:</b> 73.0 <b>G5:</b> 74.0  Were comfortable at the actual birth: <b>G1:</b> 76.0 <b>G2:</b> 82.0 <b>G3:</b> 86.0 <b>G4:</b> 88.0 <b>G5:</b> 83.0  <b>Maternal status:</b> NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
			Adverse effects: Maternal, (%):	

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
McAenny and Doughty 1963 (continued)			<p>Unconsciousness:</p> <p><b>G1:</b> 1.0  <b>G2:</b> 3.0  <b>G3:</b> 1.0  <b>G4:</b> 5.0  <b>G5:</b> 5.0</p> <p>Restless or noisy:</p> <p><b>G1:</b> 21.0  <b>G2:</b> 14.0  <b>G3:</b> 15.0  <b>G4:</b> 16.0  <b>G5:</b> 23.0</p> <p>Any complications:</p> <p><b>G1:</b> 25.0  <b>G2:</b> 27.0  <b>G3:</b> 20.0  <b>G4:</b> 19.0  <b>G5:</b> 24.5</p> <p>Hemorrhage:</p> <p><b>G1:</b> 8.5  <b>G2:</b> 8.5  <b>G3:</b> 6.5  <b>G4:</b> 4.0  <b>G5:</b> 5.0</p> <p>Hazy or no memory of labor:</p> <p><b>G1:</b> 43.0  <b>G2:</b> 53.0  <b>G3:</b> 57.0  <b>G4:</b> 53.0  <b>G5:</b> 49.0</p> <p>Hazy or no memory of birth:</p> <p><b>G1:</b> 15.0  <b>G2:</b> 25.0  <b>G3:</b> 26.0  <b>G4:</b> 31.0  <b>G5:</b> 26.0  <b>G1/G4:</b> <math>P &lt; 0.02</math></p> <p>Dreamed while breathing gas:</p> <p><b>G1:</b> 8.0  <b>G2:</b> 12.0  <b>G3:</b> 18.0  <b>G4:</b> 21.0  <b>G5:</b> 26.0  <b>G1/G5:</b> <math>P &lt; 0.001</math></p> <p>Nausea or vomiting:</p> <p><b>G1:</b> 16.0  <b>G2:</b> 15.0  <b>G3:</b> 22.0  <b>G4:</b> 22.0  <b>G5:</b> 18.5</p> <p>Neonatal: NR</p>	<p><b>Neonatal status:</b></p> <p>Mean Apgar score:</p> <p><b>G1:</b> 9.1  <b>G2:</b> 8.6  <b>G3:</b> 8.9  <b>G4:</b> 8.6  <b>G5:</b> 8.9</p> <p><b>Adverse effects:</b></p> <p>Maternal: NR</p> <p>Neonatal:</p> <p>Death:</p> <p><b>G1:</b> One neonatal death 9 hours after delivery</p> <p>Childhood: NR</p> <p>Occupational: NR</p>

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
			Occupational: NR	

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
McAenny and Doughty 1963 (continued)			<b>Route of birth, %:</b> Vaginal: NR Assisted: <sup>1</sup> <b>G1:</b> 15.0 <b>G2:</b> 18.0 <b>G3:</b> 11.5 <b>G4:</b> 10.5 <b>G5:</b> 17.0  Cesarean: NR	

---

**Comments:**

<sup>1</sup> Forceps



**Evidence Table1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> McGuiness and Rosen, 1984 <b>Country:</b> United Kingdom <b>Participant source:</b> Academic single site <b>Setting:</b> Hospital <b>Enrollment period:</b> NR <b>Design:</b> Crossover RCT At onset of regular uterine contractions, each participant was randomly administered one agent during 3 consecutive uterine contractions, followed by the other agent for 3 further contractions (the agent was concealed to the operator). ***** <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>• Fit women</li> <li>• Age 20 to 33</li> <li>• Early normal labor</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>• See inclusion criteria</li> </ul>	<b>Groups:</b> <b>G1:</b> Women delivered two gas mixtures via the same tubing and mouthpiece <b>Ga:</b> Entonox (50% N <sub>2</sub> O in O <sub>2</sub> ) <b>Gb:</b> Enflurane 1% in air (delivered from a low resistance drawover Cyprane vaporizer) <b>Gc:</b> No analgesia <b>N at enrollment:</b> (during early normal labor) <b>G1:</b> 20 <b>N at followup:</b> <b>G1:</b> 20 <b>Age, range yrs:</b> <b>G1:</b> 20-33 <b>Race/ethnicity:</b> NR <b>Parous:</b> NR	<b>Provider preferences:</b> NR <b>Provider specialty:</b> NR <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> NR <b>Pain management:</b> NR	<b>Pain:</b> Linear analog score, median (range): <b>G1a:</b> 52 (29-79) <b>G1b:</b> 50 (13-79) <b>G1c:</b> 61 (47-87) <b>G1a/G1b:</b> $P < 0.02$ <b>G1a/G1c:</b> $P = \text{NR}^1$ <b>G1b/G1c:</b> $P = \text{NR}^1$ Linear analog score, n (%): 0-20: <b>G1a:</b> 0 <b>G1b:</b> 1 (5.0) <b>G1c:</b> 0 20-40: <b>G1a:</b> 4 (20.0) <b>G1b:</b> 7 (35.0) <b>G1c:</b> 0 40-60: <b>G1a:</b> 10 (50.0) <b>G1b:</b> 6 (30.0) <b>G1c:</b> 10 (50.0) 60-80: <b>G1a:</b> 6 (30.0) <b>G1b:</b> 6 (30.0) <b>G1c:</b> 6 (30.0) 80-100: <b>G1a:</b> 0 <b>G1b:</b> 0 <b>G1c:</b> 4 (20.0) <b>Labor progress:</b> NR <b>Fetal status:</b> NR <b>Timeliness:</b> NR <b>Labor co-interventions:</b> NR <b>Adverse effects:</b>	<b>Satisfaction with pain management:</b> NR <b>Satisfaction with birth experience:</b> NR <b>Maternal status:</b> NR <b>Neonatal status:</b> NR <b>Adverse effects:</b> NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
			Maternal: Drowsiness, linear analog score, median (range): <b>G1a:</b> 26 (0-68) <b>G1b:</b> 38 (0-88) <b>G1a/G1b:</b> $P < 0.02$ Slightly nauseous, n (%): <b>G1a:</b> 1 (5.0) <b>G1b:</b> 3 (15.0)	

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
McGuinness and Rosen, 1984 (continued)			Neonatal: NR Occupational: NR <b>Route of birth, n (%):</b> Vaginal: <b>G1:</b> 15 (75.0) Assisted, forceps: <b>G1:</b> 2 (10.0) Cesarean: <b>G1:</b> 3 (15.0)	

---

**Comments:**

<sup>1</sup> The authors state that the difference is significant, but do not report the significance level used.

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> McLeod et al., 1985 <b>Country:</b> United Kingdom <b>Participant source:</b> Community <b>Setting:</b> Hospital <b>Enrollment period:</b> NR <b>Design:</b> Crossover RCT ***** <b>Inclusion criteria:</b> • Women aged 18-38 • ASA group I • Normal labor <b>Exclusion criteria:</b> • Use of any other analgesic or sedative agent during labor	<b>Groups:</b> <b>G1:</b> Women given both agents in random sequence during 5 consecutive uterine contractions, with a break of 2 contractions to allow for elimination of first agent <b>Ga:</b> Entonox (50% N <sub>2</sub> O in O <sub>2</sub> ) <b>Gb:</b> Isoflurane (0.75% in O <sub>2</sub> ) <b>Both self-administered using separate facemasks</b> <b>N at enrollment:</b> (in established labor) <b>G1:</b> 32 <b>N at followup:</b> (end of trial) <b>G1:</b> 32 <b>Age, range yrs:</b> <b>G1:</b> 18-38 <b>Race/ethnicity:</b> NR <b>Parous:</b> NR	<b>Provider preferences:</b> NR <b>Provider specialty:</b> NR <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> NR <b>Pain management:</b> NR	<b>Pain:</b> Linear analog scores, mean (range): Prior to analgesia: <b>G1:</b> 75.4 (44-99) Post analgesia: <b>G1a:</b> 63.0 (24-92) <b>G1b:</b> 46.6 (19-86) <b>G1a/G1b:</b> $P < 0.001$ <b>Labor progress:</b> NR <b>Fetal status:</b> NR <b>Timeliness:</b> NR <b>Labor co-interventions:</b> NR <b>Adverse effects, n (%):</b> Maternal: <sup>1</sup> Drowsiness, assessed by midwife and patient: More drowsy when using Entonox: <b>G1:</b> 3 (9.7) More drowsy when using isoflurane: <b>G1:</b> 18 (58.1) Equal between agents: <b>G1:</b> 10 (32.2) Nausea, n: <b>G1a:</b> 1 <b>G1b:</b> 1 Dizziness, n: <b>G1a:</b> 2 <b>G1b:</b> 0 Neonatal: NR Occupational: NR <b>Route of birth, n (%):</b> Vaginal: <b>G1:</b> 32 (100)	<b>Satisfaction with pain management, n (%):</b> Preference at the end of the trial: Entonox: <b>G1:</b> 8 (25.0) Isoflurane: <b>G1:</b> 22 (68.8) No preference: <b>G1:</b> 2 (6.3) <b>Satisfaction with birth experience:</b> NR <b>Maternal status:</b> NR <b>Neonatal status:</b> NR <b>Adverse effects:</b> NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
-------------------	---------------------------	-----------------	---------------------------------	------------------------------

Assisted:

**G1:** 0

Cesarean:

**G1:** 0

---

**Comments:**

<sup>1</sup>Results of 31 participants included.

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Mills et al., 1996  <b>Country:</b> United Kingdom  <b>Participant source:</b> Multisite  <b>Setting:</b> Hospital  <b>Enrollment period:</b> NR  <b>Design:</b> Prospective cohort  ***** <b>Inclusion criteria:</b> •Midwives working in labor wards in one of two selected UK hospitals  <b>Exclusion criteria:</b> •See inclusion criteria	<b>Groups:</b> Midwives working in labor wards at one of two hospitals (DRI and BDGH) and wearing N <sub>2</sub> O personal sampling devices  <b>N at enrollment:</b> DRI: 5 midwives/shift BDGH: 4 midwives/shift  <b>N at followup:</b> 242 total shifts analyzed  <b>Age:</b> NR  <b>Race/ethnicity:</b> NR  <b>Parous:</b> NR	<b>Provider preferences:</b> NR  <b>Provider specialty, %:</b> Midwives: 100  <b>Cost of intervention:</b> NR  <b>Other pain management methods available:</b> NR  <b>Pain management:</b> NR	<b>Pain:</b> NR  <b>Labor progress:</b> NR  <b>Fetal status:</b> NR  <b>Timeliness:</b> NR  <b>Labor co-interventions:</b> NR  <b>Adverse effects:</b> Maternal: NR  Neonatal: NR  Occupational: N <sub>2</sub> O exposure, mean pp m (range): <b>DRI:</b> 45 (0-413) <b>BDGH:</b> 124 (0-1638) <b>Total:</b> 86 (0-1638)  In 111 shifts worked in rooms where Entonox was not used: Mean pp m (range): <b>Total:</b> 22 (0-233)  Exceed exposure level, n (%): > 100 ppm: <b>Total:</b> 4 (3.6) > 25 ppm: <b>Total:</b> 21 (18.9)  <b>Route of birth:</b> NR	<b>Satisfaction with pain management:</b> NR  <b>Satisfaction with birth experience:</b> NR  <b>Maternal status:</b> NR  <b>Neonatal status:</b> NR  <b>Adverse effects:</b> NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Morgan et al., 1982 <b>Country:</b> United Kingdom <b>Participant source:</b> Community <b>Setting:</b> Hospital <b>Enrollment period:</b> NR <b>Design:</b> Cross-sectional ***** <b>Inclusion criteria:</b> • Vaginal delivery of a live child <b>Exclusion criteria:</b> • See inclusion criteria	<b>Groups:</b> <b>G1:</b> Entonox, self administered <b>G2:</b> 100 mg Pethidine and 25 mg promethazine IM <b>G3:</b> Entonox and pethidine <b>G4:</b> Pudendal block <b>G5:</b> Epidural <b>G6:</b> Epidural and Entonox <b>G7:</b> Epidural and pethidine <b>G8:</b> Miscellaneous (ineffective epidural blocks or other analgesia, various IM and IV opiates, and regional blocks) <b>G9:</b> None <b>N at enrollment:</b> <b>Total:</b> 1,000 <b>G1:</b> 128 <b>G2:</b> 120 <b>G3:</b> 88 <b>G4:</b> 24 <b>G5:</b> 423 <b>G6:</b> 38 <b>G7:</b> 47 <b>G8:</b> 52 <b>G9:</b> 80 <b>N at followup:</b> (within 48 hours of delivery) <b>Total:</b> 1,000 <b>Age, mean yrs ± SD:</b> <b>Total:</b> 28 ± 4.8	<b>Provider preferences:</b> NR <b>Provider specialty:</b> NR <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> NR <b>Pain management, n (%):</b> <b>Entonox:</b> <b>Total:</b> 128 (12.8) <b>Pethidine:</b> <b>Total:</b> 120 (12.0) <b>Entonox and pethidine:</b> <b>Total:</b> 88 (8.8) <b>Pudendal block:</b> <b>Total:</b> 24 (2.4) <b>Epidural:</b> <b>Total:</b> 423 (42.3) <b>Epidural and Entonox:</b> <b>Total:</b> 38 (3.8) <b>Epidural and pethidine:</b> <b>Total:</b> 47 (4.7) <b>Miscellaneous:</b> <b>Total:</b> 52 (5.2) <b>None:</b> <b>Total:</b> 80 (8.0)	<b>Pain:</b> (linear analogue scale 0-100 mm) <sup>1</sup> Linear analogue score, mean ± SD: <b>G1:</b> 61 ± 3.1 <b>G2:</b> 58 ± 3.1 <b>G3:</b> 57 ± 3.4 <b>G4:</b> 68 ± 1.9 <b>G5:</b> 29 ± 3.7 <b>G6:</b> 51 ± 4.2 <b>G7:</b> 30 ± 3.8 <b>G8:</b> 69 ± 3.3 <b>G9:</b> 70 ± 2.6 Painless labor, n (%): <b>G1:</b> 15 (11.7) <b>G2:</b> 15 (12.5) <b>G3:</b> 16 (18.2) <b>G4:</b> 2 (8.3) <b>G5:</b> 251 (59.3) <b>G6:</b> 13 (34.2) <b>G7:</b> 29 (61.7) <b>G8:</b> 7 (13.5) <b>G9:</b> 6 (7.5) Duration of pain, minutes, mean: <b>G1:</b> 47 <b>G2:</b> 66 <b>G3:</b> 71 <b>G4:</b> 73 <b>G5:</b> 35 <b>G6:</b> 66 <b>G7:</b> 56 <b>G8:</b> 75 <b>G9:</b> 50 <b>Labor progress, n (%):</b> Induced:	<b>Satisfaction with pain management:</b> NR <b>Satisfaction with birth experience:</b> NR <b>Maternal status:</b> NR <b>Neonatal status:</b> NR <b>Adverse effects:</b> NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
	<b>Race/ethnicity:</b> NR		<b>G1:</b> 21 (16.4)	
			<b>G2:</b> 22 (18.3)	
	<b>Parous, n (%):</b>		<b>G3:</b> 16 (18.2)	
	<b>Total:</b> 496 (49.6)		<b>G4:</b> 4 (16.7)	
			<b>G5:</b> 148 (35.0)	
			<b>G6:</b> 12 (31.6)	
			<b>G7:</b> 12 (25.5)	
			<b>G8:</b> 21 (40.4)	
			<b>G9:</b> 9 (11.3)	



**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Morgan et al., 1982 (continued)			<p>Duration, hours, mean <math>\pm</math> SD:</p> <p><b>G1:</b> 6.7 <math>\pm</math> 3.0  <b>G2:</b> 7.3 <math>\pm</math> 3.2  <b>G3:</b> 7.6 <math>\pm</math> 4.1  <b>G4:</b> 5.6 <math>\pm</math> 4.2  <b>G5:</b> 10.5 <math>\pm</math> 4.6  <b>G6:</b> 8.6 <math>\pm</math> 4.7  <b>G7:</b> 13.1 <math>\pm</math> 6.1  <b>G8:</b> 10.7 <math>\pm</math> 4.9  <b>G9:</b> 5.2 <math>\pm</math> 3.5</p> <p><b>Fetal status:</b> NR</p> <p><b>Timeliness:</b> NR</p> <p><b>Labor co-interventions:</b> NR</p> <p><b>Adverse effects:</b> NR</p> <p><b>Route of birth, n (%):</b>  Vaginal:*  <b>G1:</b> 120 (93.7)  <b>G2:</b> 111 (92.5)  <b>G3:</b> 83 (94.3)  <b>G4:</b> 20 (83.3)  <b>G5:</b> 206 (48.7)  <b>G6:</b> 23 (60.5)  <b>G7:</b> 22 (46.8)  <b>G8:</b> 11 (21.2)  <b>G9:</b> 79 (98.7)</p> <p>Assisted:  <b>G1:</b> 8 (6.3)  <b>G2:</b> 9 (7.5)  <b>G3:</b> 5 (5.7)  <b>G4:</b> 4 (16.7)  <b>G5:</b> 217 (51.3)  <b>G6:</b> 15 (39.5)  <b>G7:</b> 25 (53.2)  <b>G8:</b> 41 (78.8)  <b>G9:</b> 1 (1.3)</p>	

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
----------------------	------------------------------	-----------------	---------------------------------------	---------------------------------

Cesarean:

Total: 0

---

**Comments:**

\* Calculated by reviewer.

<sup>1</sup> 0 (no pain) to 100 mm (as much pain as is possible to imagine).

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Murphy et al., 1984 <b>Country:</b> United Kingdom <b>Participant source:</b> Academic single site <b>Setting:</b> Hospital <b>Enrollment period:</b> 1970 to 1979 <b>Design:</b> Retrospective cohort ***** <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>• Live births from 1970-1979</li> <li>• Data from Cardiff Births Survey</li> <li>• Residents of South Glamorgan</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>• See inclusion criteria</li> </ul>	<b>Groups:</b> <b>G1:</b> N <sub>2</sub> O 50%/O <sub>2</sub> 50% (Entonox) used for maternal analgesia, administration not specified <b>G2:</b> Drugs and N <sub>2</sub> O (Entonox) used for maternal analgesia <b>G3:</b> Drugs only (mainly pethidine) used for maternal analgesia <b>G4:</b> Epidural block used for maternal analgesia <b>G5:</b> No analgesia used <b>Ga:</b> Gave birth from 1970-1974 <b>Gb:</b> Gave birth from 1975-1979  <b>N at enrollment:</b> <b>G1:</b> 8,392 <b>G1a:</b> 3,798 <b>G1b:</b> 4,594 <b>G2:</b> 21,121 <b>G2a:</b> 12,375 <b>G2b:</b> 8,746 <b>G3:</b> 3,749 <b>G3a:</b> 2,855 <b>G3b:</b> 894 <b>G4:</b> 4,435 <b>G4a:</b> 1,235 <b>G4b:</b> 3,200 <b>G5:</b> 2,440 <b>G5a:</b> 1,562 G5b: 878  <b>N at followup:</b> <b>G1:</b> 8,392	<b>Provider preferences:</b> NR <b>Provider specialty:</b> NR <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> NR <b>Pain management:</b> NR	<b>Pain:</b> NR <b>Labor progress:</b> NR <b>Fetal status:</b> NR <b>Timeliness:</b> NR <b>Labor co-interventions:</b> NR <b>Adverse effects:</b> NR <b>Route of birth, singletons with no congenital anomalies, n:</b> Vaginal (vertex): <b>Total:</b> 30,172 <b>Ga:</b> 16,619 Gb: 13,553 Assisted, forceps: <b>Total:</b> 5,737 <b>Ga:</b> 2,752 Gb: 2,985 Cesarean: <b>Total:</b> 2,482 Ga: 1,038 G1b: 1,444 Elective: <b>Total:</b> 856 Ga: 411 Gb: 445 Emergency: <b>Total:</b> 1,626 Ga: 627 Gb: 999	<b>Satisfaction with pain management:</b> NR <b>Satisfaction with birth experience:</b> NR <b>Maternal status:</b> NR <b>Neonatal status, n (%):</b> Lower of 1 and 5 minute Apgar scores, singletons with no congenital anomalies: 1-3: <b>G1a:</b> 66 (1.8) <b>G1b:</b> 63 (1.4) <b>G2a:</b> 330 (2.7) <b>G2b:</b> 220 (2.6) <b>G3a:</b> 121 (4.4) <b>G3b:</b> 25 (2.7) <b>G4a:</b> 38 (3.1) <b>G4b:</b> 48 (1.5) <b>G5a:</b> 26 (1.7) G5b: 13 (1.5) 4-7: <b>G1a:</b> 389 (10.5) <b>G1b:</b> 388 (8.7) <b>G2a:</b> 2270 (18.8) <b>G2b:</b> 1594 (18.6) <b>G3a:</b> 586 (21.2) <b>G3b:</b> 149 (17.0) <b>G4a:</b> 274 (22.4) <b>G4b:</b> 509 (16.5) <b>G5a:</b> 183 (121) G5b: 72 (8.5) 8-10: <b>G1a:</b> 3242 (87.7) <b>G1b:</b> 3997 (89.9) <b>G2a:</b> 9484 (78.5) <b>G2b:</b> 6772 (78.8) <b>G3a:</b> 2063 (74.4) <b>G3b:</b> 700 (80.3) <b>G4a:</b> 911 (74.5) <b>G4b:</b> 2527 (82.0)

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
	<b>G2:</b> 21,121 <b>G3:</b> 3,749 <b>G4:</b> 4,435 <b>G5:</b> 2,440  <b>Age:</b> NR  <b>Race/ethnicity:</b> NR  <b>Parous, n:<sup>1</sup></b> Primiparae: <b>G1a:</b> 642 <b>G1b:</b> 894 <b>G2a:</b> 5,667			<b>G5a:</b> 1299 (86.1) G 5b: 767 (90.0)  <b>Adverse effects:</b> NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Murphy et al., 1984 (continued)	<b>G2b:</b> 3,806 <b>G3a:</b> 1,211 <b>G3b:</b> 313 <b>G4a:</b> 837 <b>G4b:</b> 2,101 <b>G5a:</b> 315 G 5b: 125 <b>Ga:</b> 8,672 <b>Gb:</b> 7,239  Multiparae: <b>G1a:</b> 3,120 <b>G1b:</b> 3,644 <b>G2a:</b> 6,599 <b>G2b:</b> 4,893 <b>G3a:</b> 1,616 <b>G3b:</b> 577 <b>G4a:</b> 397 <b>G4b:</b> 1,048 <b>G5a:</b> 1,185 G 5b: 753 <b>Ga:</b> 12,917 Gb: 10,915		Singleton births: <b>G1:</b> 8,145 <b>G1a:</b> 3,697 <b>G1b:</b> 4,448 <b>G2:</b> 20,670 <b>G2a:</b> 12,084 <b>G2b:</b> 8,586 <b>G3:</b> 3,644 <b>G3a:</b> 2,770 <b>G3b:</b> 874 <b>G4:</b> 4,307 <b>G4a:</b> 1,223 <b>G4b:</b> 3,084 <b>G5:</b> 2,360 <b>G5a:</b> 1,508 G 5b: 852	

**Comments:**

<sup>1</sup> Parity was not known for 236 of women in Ga and 158 women in Gb.

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Newton et al., 1999 <b>Country:</b> United Kingdom <b>Participant source:</b> Community <b>Setting:</b> Hospital <b>Enrollment period:</b> NR <b>Design:</b> Cross-sectional ***** <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>Midwife participating in the care of women using Entonox during labor in a specific UK hospital</li> </ul> <b>Exclusion criteria:</b> See inclusion criteria	<b>Groups:</b> <b>G1:</b> Midwives participating in the care of women wearing samplers to measure N <sub>2</sub> O levels over 8 hrs <b>N at enrollment:</b> 16 <b>N at followup:</b> 15 <b>Age, mean yrs :</b> NR <b>Race/ethnicity:</b> NR <b>Parous:</b> NR	<b>Provider preferences:</b> NR <b>Provider specialty:</b> Midwife: 16 (100) <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> NR <b>Pain management:</b> NR	<b>Pain:</b> NR <b>Labor progress:</b> NR <b>Fetal status:</b> NR <b>Timeliness:</b> NR <b>Labor co-interventions:</b> NR <b>Adverse effects:</b> Maternal: NR Neonatal: NR Occupational: No midwife was exposed to levels of N <sub>2</sub> O greater than 100ppm <b>Route of birth:</b> NR	<b>Satisfaction with pain management:</b> NR <b>Satisfaction with birth experience:</b> NR <b>Maternal status:</b> NR <b>Neonatal status:</b> NR <b>Adverse effects:</b> NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Nyberg et al., 1992 <b>Country:</b> Sweden <b>Participant source:</b> Other (see inclusion criteria) <b>Setting:</b> Other (see inclusion criteria) <b>Enrollment period:</b> 1945 to 1966 <b>Design:</b> Case control ***** <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>• Amphetamine or opiate addict</li> <li>• Brought to Stockholm City Custody</li> <li>• Opiate addict from autopsy victims at the State Institute of Forensic Medicine in Stockholm</li> <li>• Opiate addict accepted for the methadone program at Ulleraker Hospital</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>• See inclusion criteria</li> </ul>	<b>Groups:</b> <b>G1a:</b> Amphetamine addicts <b>G1b:</b> Control siblings <b>G2a:</b> Opiate addicts <b>G2b:</b> Control siblings <b>N at enrollment:</b> <b>G1a:</b> 200 <b>G1b:</b> NR <b>G2a:</b> 200 <b>G2b:</b> NR <b>N at followup:</b> <b>G1a:</b> 73 <b>G1b:</b> 109 <b>G2a:</b> 139 <b>G2b:</b> 230 <b>Age:</b> NR <b>Race/ethnicity:</b> NR <b>Parous:</b> NR	<b>Provider preferences:</b> NR <b>Provider specialty:</b> NR <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> NR <b>Pain management:</b> NR	<b>Pain:</b> NR <b>Labor progress:</b> NR <b>Fetal status:</b> NR <b>Timeliness:</b> NR <b>Labor co-interventions:</b> NR <b>Adverse effects:</b> NR <b>Route of birth:</b> NR	<b>Satisfaction with pain management:</b> NR <b>Satisfaction with birth experience:</b> NR <b>Maternal status:</b> NR <b>Neonatal status:</b> NR <b>Adverse effects:</b> Maternal: NR Neonatal: NR Childhood: Amphetamine addiction in offspring, relative risk for exposure to N <sub>2</sub> O (95% CI): ≥ 4.5 hrs: <b>G1:</b> 4.4 (1.2, 15.8) ≥ 2.5 to < 4.5 hrs: <b>G1:</b> 3.1 (1.2, 7.9) > 1 to < 2.5 hrs: <b>G1:</b> 2.1 (1.11, 4.0) > 0.25 to ≤ 1 hr: <b>G1:</b> 1.5 (1.06, 2.0) 0 to ≤ 0.25 hr: <b>G1:</b> 1.0 Opiate addiction in offspring, relative risk for exposure to N <sub>2</sub> O (95% CI): <b>G2:</b> NR <sup>1</sup> Occupational: NR

**Comments:**

<sup>1</sup> In group G2, nitrous oxide is combined with opiate and barbiturate exposure. After controlling for socio-economic level and civil status of the mother at time of delivery, the conditional logistic regression analysis confirms that administration of opiate or barbiturate or nitrous oxide during delivery is a risk factor for adult amphetamine addiction in offspring, and that the number



of administrations of either opiates, barbiturates or nitrous oxide for >1 hour, or any combination thereof, is a risk factor for opiate addiction.

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Paech, 1991  <b>Country:</b> Australia  <b>Participant source:</b> NR  <b>Setting:</b> Hospital  <b>Enrollment period:</b> NR  <b>Design:</b> Cross-sectional  ***** <b>Inclusion criteria:</b> • Vaginal birth  <b>Exclusion criteria:</b> • See inclusion criteria	<b>Groups:*</b> <b>G1:</b> N <sub>2</sub> O alone <b>G2:</b> Pethidine and N <sub>2</sub> O <b>G3:</b> N <sub>2</sub> O and epidural <b>G4:</b> Pethidine alone <b>G5:</b> Pethidine and epidural <b>G6:</b> Epidural alone <b>G7:</b> Several methods <sup>1</sup> <b>G8:</b> Nonpharmacological <b>Ga:</b> N <sub>2</sub> O <b>Gb:</b> Pethidine <b>Gc:</b> Epidural <b>Gd:</b> No epidural  <b>N at enrollment:</b> (day after vaginal birth) <b>G1:</b> 220 <b>G2:</b> 175 <b>G3:</b> 84 <b>G4:</b> 83 <b>G5:</b> 86 <b>G6:</b> 112 <b>G7:</b> 100 <b>G8:</b> 140 <b>Ga:</b> NR* <b>Gb:</b> NR* <b>Gc:</b> NR* <b>Gd:</b> NR*  <b>N at followup:</b> <b>G1:</b> 220 <b>G2:</b> 175 <b>G3:</b> 84 <b>G4:</b> 83 <b>G5:</b> 86 <b>G6:</b> 112 <b>G7:</b> 100 <b>G8:</b> 140 <b>Ga:</b> NR <sup>1</sup>	<b>Provider preferences:</b> NR  <b>Provider specialty:</b> NR  <b>Cost of intervention:</b> NR  <b>Other pain management methods available:</b> Antenatal preparation classes, on-demand epidural service, along with noted available treatments <b>G8:</b> Transcutaneous nerve stimulation (TENS)  <b>Pain management:</b> NR	<b>Pain, n (%):</b> VAS < 25: <b>G1:</b> NR <sup>2</sup> <b>G4:</b> NR <sup>2</sup> <b>G6:</b> NR <sup>2</sup> <b>G8:</b> NR <sup>2</sup> <b>G6/G1:</b> $P < 0.0001$ <b>G6/G4:</b> $P < 0.0001$ <b>G6/G8:</b> $P < 0.0001$ <b>Gc/Gd:</b> $P < 0.0001$  VAS < 50: <b>G1:</b> NR <sup>2</sup> <b>G4:</b> NR <sup>2</sup> <b>G6:</b> NR <sup>2</sup> <b>G8:</b> NR <sup>2</sup> <b>G6/G1:</b> $P < 0.0001$ <b>G6/G4:</b> $P < 0.0001$ <b>G6/G8:</b> $P < 0.0001$ <b>Gc/Gd:</b> $P < 0.0001$  More than expected: <b>G1:</b> 93 (42) <b>G2:</b> 97 (55) <b>G3:</b> 38 (45) <b>G4:</b> 47 (57) <b>G5:</b> 40 (47) <b>G6:</b> 33 (29) <b>G7:</b> 60 (60) <b>G8:</b> 46 (33)  <b>Labor progress:</b> Duration of labor, minutes, mean $\pm$ SD:	<b>Satisfaction with pain management:</b> VAS > 75: <b>G1:</b> NR <sup>2</sup> <b>G4:</b> NR <sup>2</sup> <b>G6:</b> NR <sup>2</sup> <b>G8:</b> NR <sup>2</sup> <b>Gc:</b> NR <sup>2</sup> <b>Gd:</b> NR <sup>2</sup> <b>G6/G1:</b> $P < 0.0001$ <b>G6/G4:</b> $P < 0.0001$ <b>G6/G8:</b> $P < 0.0001$ <b>Gc/Gd:</b> $P < 0.0001$  VAS = 100: <b>G1:</b> NR <sup>2</sup> <b>G4:</b> NR <sup>2</sup> <b>G6:</b> NR <sup>2</sup> <b>G8:</b> NR <sup>2</sup> <b>Gc:</b> NR <sup>2</sup> <b>Gd:</b> NR <sup>2</sup> <b>G6/G1:</b> $P < 0.0001$ <b>G6/G4:</b> $P < 0.0001$ <b>G6/G8:</b> $P < 0.0001$ <b>Gc/Gd:</b> $P < 0.0001$  <b>Satisfaction with birth experience, n (%):</b> (day after birth) Dissatisfied: <b>Total:</b> 51 (5.1) <b>Gc:</b> NR (7) <b>Gd:</b> NR (4) <b>Gc/Gd:</b> $P = NS$  <b>Maternal status:</b> NR  <b>Neonatal status:</b> NR  <b>Adverse effects:</b>

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
	<b>Gb:</b> NR <sup>1</sup> <b>Gc:</b> NR <sup>1</sup> <b>Gd:</b> NR <sup>1</sup>  <b>Age:</b> NR  <b>Race/ethnicity:</b> NR		First stage: <b>G1:</b> 291 ± 191 <b>G2:</b> 338 ± 200 <b>G3:</b> 397 ± 189 <b>G4:</b> 328 ± 195 <b>G5:</b> 501 ± 250 <b>G6:</b> 397 ± 223 <b>G7:</b> 507 ± 292 <b>G8:</b> 244 ± 155  Second stage: <b>G1:</b> 29 ± 32 <b>G2:</b> 40 ± 37 <b>G3:</b> 79 ± 60 <b>G4:</b> 36 ± 35 <b>G5:</b> 98 ± 70 <b>G6:</b> 73 ± 58 <b>G7:</b> 87 ± 67 <b>G8:</b> 24 ± 31  <b>Fetal status:</b> NR	NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Paech, 1991 (continued)	<p><b>Parous, n (%):</b>  Primipara:  <b>G1:</b> 50 (23)  <b>G2:</b> 86 (49)  <b>G3:</b> 40 (48)  <b>G4:</b> 38 (46)  <b>G5:</b> 66 (77)  <b>G6:</b> 56 (50)  <b>G7:</b> 82 (82)  <b>G8:</b> 22 (16)</p> <p>Multipara:  <b>G1:</b> 170 (77)  <b>G2:</b> 89 (51)  <b>G3:</b> 44 (52)  <b>G4:</b> 45 (54)  <b>G5:</b> 20 (23)  <b>G6:</b> 56 (50)  <b>G7:</b> 18 (18)  <b>G8:</b> 118 (84)</p>		<p><b>Timeliness:</b>  NR</p> <p><b>Labor co-interventions, n (%):</b>  Induced or augmented:  <b>G1:</b> 91 (41)  <b>G2:</b> 99 (57)  <b>G3:</b> 65 (77)  <b>G4:</b> 31 (37)  <b>G5:</b> 69 (80)  <b>G6:</b> 90 (80)  <b>G7:</b> 80 (80)  <b>G8:</b> 43 (31)</p> <p><b>Adverse effects, %:</b>  Maternal:  Inadequate pain relief:  <b>Ga:</b> 21  <b>Gb:</b> 27  <b>Gc:</b> 7  <b>G8:</b> 6  <b>Gc/Ga:</b> <math>P &lt; 0.0001</math>  <b>Gc/Gb:</b> <math>P &lt; 0.0001</math>  <b>G8/Ga:</b> <math>P &lt; 0.0001</math>  <b>G8/Gb:</b> <math>P &lt; 0.0001</math>  Reduced awareness of experience:  <b>Ga:</b> 18  <b>Gb:</b> 16  <b>Gc:</b> 2  <b>G8:</b> 0  Nausea and vomiting:  <b>Ga:</b> 13  <b>Gb:</b> 16</p>	

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
			<b>Gc:</b> 14 <b>G8:</b> 0 Dizziness: <b>Ga:</b> 5 <b>Gb:</b> 6 <b>Gc:</b> 0 <b>G8:</b> 0 Drowsiness <b>Ga:</b> 4 <b>Gb:</b> 11 <b>Gc:</b> 0 <b>G8:</b> 0 Mask phobia: <b>Ga:</b> 5 <b>Gb:</b> 0 <b>Gc:</b> 0 <b>G8:</b> 0 Shivering: <b>Ga:</b> 0 <b>Gb:</b> 0 <b>Gc:</b> 19 <b>G8:</b> 0	

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Paech, 1991 (continued)			<p>Back pain:  <b>Ga:</b> 0  <b>Gb:</b> 0  <b>Gc:</b> 14  <b>G8:</b> 0</p> <p>Difficulty moving:  <b>Ga:</b> 0  <b>Gb:</b> 0  <b>Gc:</b> 14  <b>G8:</b> 0</p> <p>Pruritus:  <b>Ga:</b> 0  <b>Gb:</b> 0  <b>Gc:</b> 8  <b>G8:</b> 0</p> <p>Neonatal: NR</p> <p>Occupational: NR</p> <p><b>Route of birth, n (%):</b>  Vaginal:  <b>G1:</b> 204 (93)  <b>G2:</b> 152 (87)  <b>G3:</b> 49 (58)  <b>G4:</b> 76 (92)  <b>G5:</b> 47 (55)  <b>G6:</b> 58 (52)  <b>G7:</b> 56 (56)  <b>G8:</b> 135 (96)</p> <p>Assisted:  <b>G1:</b> 16 (7)  <b>G2:</b> 23 (13)  <b>G3:</b> 35 (42)  <b>G4:</b> 7 (8)  <b>G5:</b> 39 (45)  <b>G6:</b> 54 (48)  <b>G7:</b> 44 (44)  <b>G8:</b> 5 (4)</p> <p>Cesarean:  <b>Total:</b> 0</p>	

**Comments:**

<sup>1</sup> The author states that almost all women in G7 had pethidine and nitrous oxide, followed by epidural analgesia. If this was the case for all women in G7, then the number of women in Ga, Gb, and Gc would be 579, 444 and 382, respectively.

<sup>2</sup> Results only displayed graphically.

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
<b>Author:</b> Phillips and Macdonald, 1971  <b>Country:</b> United Kingdom  <b>Participant source:</b> Academic single site  <b>Setting:</b> Hospital  <b>Enrollment period:</b> NR  <b>Design:</b> RCT  *****  <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>Fetus at extra risk of intrapartum hypoxia during labor</li> <li>Primigravidae aged <math>\geq 35</math> or multigravidae aged <math>\geq 40</math></li> <li>Previous stillbirth due to intrauterine hypoxia</li> <li>Pregnancy prolonged beyond 41 weeks</li> <li>Maternal diabetes, preeclampsia, threatened abortion or antepartum hemorrhage during current pregnancy</li> <li>Small-for-dates fetus, or</li> <li>Low urinary estrogen excretion</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>See inclusion criteria</li> </ul>	<b>Groups:</b> <b>G1:</b> 50% N <sub>2</sub> O/50% O <sub>2</sub> (Entonox; delivery NR) and pethidine <b>G2:</b> Pethidine alone (no inhaled analgesia) <b>G3:</b> Trichloroethylene and pethidine  <b>N at enrollment:</b> <b>G1:</b> 50 <b>G2:</b> 51 <b>G3:</b> 51  <b>N at followup:</b> (neonatal capillary blood collected) <b>G1:</b> 30 <b>G2:</b> 30 <b>G3:</b> 28  <b>Age:</b> NR  <b>Race/ethnicity:</b> NR  <b>Parous:</b> NR	<b>Provider preferences:</b> NR  <b>Provider specialty:</b> NR  <b>Cost of intervention:</b> NR  <b>Other pain management methods available:</b> NR  <b>Pain management:</b> NR	<b>Pain:</b> NR  <b>Labor progress:</b> NR  <b>Fetal status:</b> Fetal scalp blood pH, mean $\pm$ SD: Before inhaled analgesia: <b>G1:</b> $7.253 \pm 0.065$ (n=49) <b>G2:</b> $7.256 \pm 0.064$ (n=50) <b>G3:</b> $7.256 \pm 0.053$ After inhaled analgesia: <b>G1:</b> $7.244 \pm 0.071$ (n=49) <b>G2:</b> $7.241 \pm 0.066$ (n=50) <b>G3:</b> $7.216 \pm 0.057$  Fetal scalp blood PCO <sub>2</sub> , mean $\pm$ SD: Before inhaled analgesia: <b>G1:</b> $37.0 \pm 8.1$ (n=49) <b>G2:</b> $39.8 \pm 6.1$ <b>G3:</b> $34.9 \pm 5.9$ After inhaled analgesia: <b>G1:</b> $35.0 \pm 7.0$ (n=49) <b>G2:</b> $41.8 \pm 4.8$ <b>G3:</b> $41.3 \pm 7.7$  Fetal scalp blood base deficit, mean $\pm$ SD: Before inhaled analgesia: <b>G1:</b> $-9.3 \pm 3.7$	<b>Satisfaction with pain management:</b> NR  <b>Satisfaction with birth experience:</b> NR  <b>Maternal status:</b> NR  <b>Neonatal status:</b> Apgar score, mean: 1 minute: <b>G1:</b> 7.42 <b>G2:</b> 6.70 <b>G3:</b> 6.17 5 minutes: <b>G1:</b> 9.20 <b>G2:</b> 8.85 <b>G3:</b> 8.43  Apgar score, 1 minute, n: 4: <b>G1:</b> 0 <b>G2:</b> 3 <b>G3:</b> 9 5: <b>G1:</b> 0 <b>G2:</b> 0 <b>G3:</b> 1 6: <b>G1:</b> 21 <b>G2:</b> 27 <b>G3:</b> 27 7: <b>G1:</b> 0 <b>G2:</b> 0 <b>G3:</b> 0 8: <b>G1:</b> 20 <b>G2:</b> 21 <b>G3:</b> 14 9: <b>G1:</b> 5 <b>G2:</b> 0 <b>G3:</b> 0 10: <b>G1:</b> 4 <b>G2:</b> 0



**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
			<b>G2:</b> $-10.2 \pm 2.1$ <b>G3:</b> $-8.6 \pm 2.2$ After inhaled analgesia: <b>G1:</b> $-9.7 \pm 2.4$ <b>G2:</b> $-11.6 \pm 1.9$ <b>G3:</b> $-10.7 \pm 1.6$	<b>G3:</b> 0

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Phillips and Macdonald, 1971 (continued)			<p>Fetal scalp blood PO<sub>2</sub>, mean <math>\pm</math> SD:</p> <p>Before inhaled analgesia:</p> <p><b>G1:</b> 27.8 <math>\pm</math> 4.6</p> <p><b>G2:</b> 26.1 <math>\pm</math> 6.5 (n=50)</p> <p><b>G3:</b> 30.0 <math>\pm</math> 5.8</p> <p>After inhaled analgesia:</p> <p><b>G1:</b> 28.7 <math>\pm</math> 6.2</p> <p><b>G2:</b> 22.7 <math>\pm</math> 5.7 (n=50)</p> <p><b>G3:</b> 24.6 <math>\pm</math> 4.0</p> <p><b>Timeliness:</b></p> <p>NR</p> <p><b>Labor co-interventions:</b></p> <p>NR</p> <p><b>Adverse effects:</b></p> <p>NR</p> <p><b>Route of birth:</b></p> <p>NR</p>	<p>Apgar score, 5 minutes, n:</p> <p>4-5:</p> <p><b>G1:</b> 0</p> <p><b>G2:</b> 0</p> <p><b>G3:</b> 0</p> <p>6:</p> <p><b>G1:</b> 0</p> <p><b>G2:</b> 1</p> <p><b>G3:</b> 5</p> <p>7:</p> <p><b>G1:</b> 0</p> <p><b>G2:</b> 1</p> <p><b>G3:</b> 0</p> <p>8:</p> <p><b>G1:</b> 19</p> <p><b>G2:</b> 18</p> <p><b>G3:</b> 30</p> <p>9:</p> <p><b>G1:</b> 2</p> <p><b>G2:</b> 15</p> <p><b>G3:</b> 0</p> <p>10:</p> <p><b>G1:</b> 29</p> <p><b>G2:</b> 16</p> <p><b>G3:</b> 16</p> <p>Fetal and neonatal capillary blood pH, mean (SE):</p> <p>Before treatment:</p> <p><b>G1:</b> 7.249 (0.012)</p> <p><b>G2:</b> 7.233 (0.011)</p> <p><b>G3:</b> 7.259 (0.011)</p> <p>After treatment:</p> <p><b>G1:</b> 7.246 (0.011)</p> <p><b>G2:</b> 7.226 (0.009)</p> <p><b>G3:</b> 7.235 (0.010)</p> <p>45/60 minutes after birth:</p> <p><b>G1:</b> 7.274 (0.009)</p> <p><b>G2:</b> 7.250 (0.007)</p> <p><b>G3:</b> 7.188 (0.012)</p>

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Phillips and Macdonald, 1971 (continued)				<p>Fetal and neonatal capillary blood base excess, mean (SE):</p> <p>Before treatment:</p> <p><b>G1:</b> -8.8 (0.06)</p> <p><b>G2:</b> -11.0 (0.4)</p> <p><b>G3:</b> -8.2 (0.3)</p> <p>After treatment:</p> <p><b>G1:</b> -9.1 (0.5)</p> <p><b>G2:</b> -12.2 (0.3)</p> <p><b>G3:</b> -10.7 (0.3)</p> <p>45/60 minutes after birth:</p> <p><b>G1:</b> -9.1 (0.5)</p> <p><b>G2:</b> -8.2 (0.3)</p> <p><b>G3:</b> -11.4 (0.3)</p> <p>Fetal and neonatal capillary blood PO<sub>2</sub>, mean (SE):</p> <p>Before treatment:</p> <p><b>G1:</b> 27.0 (1.1)</p> <p><b>G2:</b> 26.8 (1.1)</p> <p><b>G3:</b> 31.7 (1.2)</p> <p>After treatment:</p> <p><b>G1:</b> 29.3 (0.9)</p> <p><b>G2:</b> 21.6 (0.8)</p> <p><b>G3:</b> 25.3 (1.1)</p> <p>45/60 minutes after birth:</p> <p><b>G1:</b> 64.0 (2.0)</p> <p><b>G2:</b> 46.4 (1.2)</p> <p><b>G3:</b> 44.8 (0.9)</p> <p><b>Adverse effects:</b></p> <p>NR</p>

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Ranta et al., 1995  <b>Country:</b> Finland  <b>Participant source:</b> Academic multisite Community  <b>Setting:</b> Hospitals  <b>Enrollment period:</b> 04/1992 to 07/1992  <b>Design:</b> Cross-sectional *****  <b>Inclusion criteria:</b> • All pregnant women admitted for vaginal delivery during the study period  <b>Exclusion criteria:</b> • Elective cesareans	<b>Groups:</b> <b>G1:</b> 50/50 N <sub>2</sub> O/O <sub>2</sub> mix by face mask <b>G2:</b> Pethidine 50-75 mg IM administered by midwife <b>G3:</b> Paracervical block with 0.25% bupivacaine 5 ml on each side of cervix, administered by obstetrician <b>G4:</b> Segmental epidural analgesia administered by an anesthetist; initially bupivacaine 0.25% 5-10 ml with intermittent top-ups in 42% and continuous infusion in 52%. <b>G5:</b> No analgesia <b>Ga:</b> Primiparous <b>Gb:</b> Multiparous, 2-4 <b>Gc:</b> Multiparous, 5-17  <b>N at enrollment:</b> (admitted to delivery room at the beginning of labor) <b>Total:</b> 1,091 <b>G1:</b> NR <sup>1</sup> <b>G2:</b> NR <sup>1</sup> <b>G3:</b> NR <sup>1</sup> <b>G4:</b> NR <sup>1</sup> <b>G5:</b> 213 <b>Ga:</b> 360 <b>Gb:</b> 468 <b>Gc:</b> 45  <b>N at followup:</b> (pain score measurements were obtained in the delivery room) <b>Total:</b> 833 (postpartum followup) <b>Total:</b> 1,024	<b>Provider preferences:</b> NR  <b>Provider specialty, %:</b> Midwife: <b>Total:</b> 100  <b>Cost of intervention:</b> NR  <b>Other pain management methods available:</b> NR  <b>Pain management, %:</b> N <sub>2</sub> O/O <sub>2</sub> mix: <b>Ga:</b> 20 <b>Gb:</b> 23 <b>Gc:</b> 18  Pethidine: <b>Ga:</b> 2 <b>Gb:</b> 0.4 <b>Gc:</b> 0  Paracervical block: <b>Ga:</b> 24 <b>Gb:</b> 24 <b>Gc:</b> 20  Epidural: <b>Ga:</b> 39 <b>Gb:</b> 5.3 <b>Gc:</b> 1  No analgesia: <b>Ga:</b> 17 <b>Gb:</b> 48 <b>Gc:</b> 61	<b>Pain, %:</b> (11-point Box Scale 1-10) High pain score (8-10) after analgesia in first stage of labor: <b>G1:</b> 46 <b>G2:</b> 5 <b>G3:</b> 23 <b>G4:</b> 5  Low pain score (0-2) after analgesia in first stage of labor: <b>G1:</b> 35 <b>G2:</b> 4 <b>G3:</b> 27 <b>G4:</b> 57  <b>Labor progress:</b> NR  <b>Fetal status:</b> NR  <b>Timeliness:</b> NR  <b>Labor co-interventions, %:</b> Induction of labor: <b>Total:</b> 8.7  <b>Adverse effects, %:</b> Maternal: Episiotomy: <b>Total:</b> 45  Perineal laceration: <b>Total:</b> 29  Neonatal: NR  Occupational: NR  <b>Route of birth, %:</b> Vaginal, normal: <b>Total:</b> 80  Assisted: <b>Total:</b> 4.2  Cesarean, nonelective: <b>Total:</b> 7	<b>Satisfaction with pain management, %:</b> First stage: Very Good: <b>Total:</b> 45 Moderate: <b>Total:</b> 37 Poor: <b>Total:</b> 18  Second stage: Satisfied: <b>Total:</b> 53  <b>Satisfaction with birth experience, %:</b> Satisfied: <b>Total:</b> 95 Dissatisfaction to some degree: <b>Total:</b> 4 Compete dissatisfaction: <b>Total:</b> 1  <b>Maternal status:</b> NR  <b>Neonatal status:</b> NR  <b>Adverse effects:</b> NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
	<b>Age:</b> NR  <b>Race/ethnicity:</b> NR			

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Ranta et al., 1995 (continued)	<b>Parous:</b> Primiparous: <b>Total: 360</b> <b>G5: 30</b>  Multiparous, 2-4: <b>Total: 360</b>  Multiparous, 5-17: <b>Total: 360</b>			

---

**Comments:**

<sup>1</sup> Numbers of patients in groups G1-4 can be calculated (approximately) from the percentages for pain management by parity group.

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
<b>Author:</b> Ranta et al., 1994  <b>Country:</b> Finland  <b>Participant source:</b> Academic single site  <b>Setting:</b> Hospital  <b>Enrollment period:</b> 1992  <b>Design:</b> Prospective cohort  Patients selected pain relief methods in agreement with obstetric staff.  *****  <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>Intended to deliver vaginally</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>Elective cesarean</li> </ul>	<b>Groups:</b> <b>G1:</b> 50% N <sub>2</sub> O and O <sub>2</sub> administered by midwife <b>G2:</b> Water block using 0.1 ml intracutaneous injections of sterile water at four points in lower back administered by midwife <b>G3:</b> IM pethidine 1 mg/kg administered by midwife <b>G4:</b> Paracervical block with bilateral injection of 0.25% bupivacaine 5 ml <b>G5:</b> Epidural catheter induced with initial doses of 5-7 ml 0.25% bupivacaine (divided doses) and continued with 5 ml/hour infusion of same solution or further 5 ml top-ups, withheld after cervix was 8-10 cm dilated. <b>G6:</b> Several forms of analgesia <sup>1</sup> <b>G7:</b> No analgesia  <b>N at enrollment:</b> (patients who had attended antenatal	<b>Provider preferences:</b> NR  <b>Provider specialty:</b> <b>G1:</b> Midwives administered N <sub>2</sub> O <b>G2:</b> Midwives administered water blocks <b>G3:</b> Midwives administered pethidine <b>G4:</b> Obstetricians administered paracervical blocks <b>G5:</b> Anesthetists administered epidural <b>G6:</b> NR <b>G7:</b> NR  <b>Cost of intervention:</b> NR  <b>Other pain management methods available:</b> NR  <b>Pain management:</b> NR	<b>Pain, median (IQR):</b> (VAS from 0=no pain to 10=intolerable pain) First stage, before treatment (baseline): <b>G1:</b> 6 (5-7) <b>G2:</b> 6 (5-7) <b>G3:</b> 5 (4-7) <b>G4:</b> 7 (6-8) <b>G5:</b> 7 (6-8) <b>G6:</b> 7 (5-8) <b>G7:</b> 6 (5-7) <b>G4/G1-3:</b> $P < 0.01$ <b>G4/G7:</b> $P < 0.01$ <b>G5/G1-3:</b> $P < 0.01$ <b>G5/G7:</b> $P < 0.01$ <b>G6/G1-3:</b> $P < 0.01$ <b>G6/G7:</b> $P < 0.01$ First stage, after treatment: <b>G1:</b> 8 (6-9) <b>G2:</b> 7 (6-8) <b>G3:</b> 8 (7-8) <b>G4:</b> 6 (4-8) <b>G5:</b> 2 (1-4) <b>G6:</b> 7 (5-7) <b>G7:</b> NR <b>G1/BL:</b> $P < 0.01$ <b>G2/BL:</b> $P < 0.01$ <b>G3/BL:</b> $P < 0.01$ <b>G4/BL:</b> $P < 0.01$ <b>G5/BL:</b> $P < 0.0001$ Second stage: <b>G1:</b> 8 (6-9) <b>G2:</b> 7 (5-9) <b>G3:</b> 8 (5-9) <b>G4:</b> 8 (5-9) <b>G5:</b> 7 (4-9) <b>G6:</b> 7 (5-9) <b>G7:</b> 7 (5-9) Third stage: <b>G1:</b> 3 (1-5) <b>G2:</b> 2 (1-4) <b>G3:</b> 2 (1-4) <b>G4:</b> 2 (1-4) <b>G5:</b> 2 (1-5) <b>G6:</b> 2 (1-4)	<b>Satisfaction with pain management, %:</b> (Verbal scale 0-5) Total pain experience, reported on the third day after delivery: No or mild (0-1): <b>G1:</b> 3 <b>G2:</b> 4 <b>G3:</b> 0 <b>G4:</b> 4 <b>G5:</b> 5 <b>G6:</b> 2 <b>G7:</b> 4 Moderate to severe (2-3): <b>G1:</b> 50 <b>G2:</b> 78 <b>G3:</b> 67 <b>G4:</b> 57 <b>G5:</b> 36 <b>G6:</b> 47 <b>G7:</b> 74 Very severe to intolerable (4-5): <b>G1:</b> 49 <b>G2:</b> 28 <b>G3:</b> 34 <b>G4:</b> 39 <b>G5:</b> 60 <b>G6:</b> 51 <b>G7:</b> 22 <b>G5/G1-4:</b> $P < 0.01$ <b>G5/G6-7:</b> $P < 0.01$  Adequacy of pain relief method: Good: <b>G1:</b> 33 <b>G2:</b> 59 <b>G3:</b> 60 <b>G4:</b> 59 <b>G5:</b> 94 <b>G6:</b> 32 <b>G7:</b> Not applicable Moderate: <b>G1:</b> 39 <b>G2:</b> 26 <b>G3:</b> 23 <b>G4:</b> 26 <b>G5:</b> 6 <b>G6:</b> 43 <b>G7:</b> Not applicable

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
	clinics, selected pain relief method and consented to participation) <b>G1:</b> 210 <b>G2:</b> 69 <b>G3:</b> 50 <b>G4:</b> 128 <b>G5:</b> 82 <b>G6:</b> 339 <b>G7:</b> 213  <b>N at followup:</b> (during first, second and third stage) <b>G1:</b> 200 <b>G2:</b> 68 <b>G3:</b> 44 <b>G4:</b> 119 <b>G5:</b> 80 <b>G6:</b> 151 <b>G7:</b> 171		<b>G7:</b> 2 (0-4)	



**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Ranta et al., 1994 (continued)	<b>Age, mean yrs (range):</b> <b>Total:</b> 28.6 (16-47)  <b>Race/ethnicity:</b> NR  <b>Parous, %:</b> Primiparous: <b>G1:</b> 27 <b>G2:</b> 14 <b>G3:</b> 26 <b>G4:</b> 23 <b>G5:</b> 71 <b>G6:</b> 49 <b>G7:</b> 13		<b>Labor progress:</b> Duration of labor, hours, mean $\pm$ SD: <b>G1:</b> 6.0 $\pm$ 3.3 <b>G2:</b> 5.8 $\pm$ 3.2 <b>G3:</b> 7.1 $\pm$ 4.5 <b>G4:</b> 6.7 $\pm$ 3.9 <b>G5:</b> 10.8 $\pm$ 4.9 <b>G6:</b> 9.3 $\pm$ 4.9 <b>G7:</b> 6.5 $\pm$ 2.9  <b>Fetal status:</b> pH < 7.15, umbilical artery, % (N=616): <b>G1:</b> 9 <b>G2:</b> 15 <b>G3:</b> 6 <b>G4:</b> 6 <b>G5:</b> 4 <b>G6:</b> 4 <b>G7:</b> 9  <b>Timeliness, %:</b> Received analgesia within ½ hour of request: <b>G1-4:</b> 72 <b>G5:</b> 63  Had to wait more than one hour for analgesia after requesting it: <b>G1:</b> 19 <b>G2:</b> 10 <b>G3:</b> 5 <b>G4:</b> 9 <b>G5:</b> 26 <b>G6:</b> NR  <b>Labor co-interventions, %:</b> Induced labor: <b>G1:</b> 10 <b>G2:</b> 3 <b>G3:</b> 9 <b>G4:</b> 13 <b>G5:</b> 15 <b>G6:</b> 11 <b>G7:</b> 5  <b>Adverse effects:</b> NR	Poor: <b>G1:</b> 28 <b>G2:</b> 15 <b>G3:</b> 17 <b>G4:</b> 15 <b>G5:</b> 0 <b>G6:</b> 15 <b>G7:</b> Not applicable <b>G5/G1-4:</b> $P < 0.01$ <b>G5/G6-7:</b> $P < 0.01$  <b>Satisfaction with birth experience:</b> NR  <b>Maternal status:</b> NR  <b>Neonatal status, %:</b> Apgar score $\leq$ 7: 1 minute: <b>G1:</b> 7 <b>G2:</b> 10 <b>G3:</b> 9 <b>G4:</b> 3 <b>G5:</b> 6 <b>G6:</b> 6 <b>G7:</b> 11 5 minutes: <b>G1:</b> 1 <b>G2:</b> 3 <b>G3:</b> 0 <b>G4:</b> 3 <b>G5:</b> 4 <b>G6:</b> 3 <b>G7:</b> 1  <b>Adverse effects:</b> NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Ranta et al., 1994 (continued)			<b>Route of birth, %:</b> Vaginal: <b>G1:</b> 95 <b>G2:</b> 90 <b>G3:</b> 91 <b>G4:</b> 93 <b>G5:</b> 80 <b>G6:</b> 86 <b>G7:</b> 94  Assisted, vacuum extraction: <b>G1:</b> 2 <b>G2:</b> 3 <b>G3:</b> 2 <b>G4:</b> 4 <b>G5:</b> 11 <b>G6:</b> 7 <b>G7:</b> 1  Cesarean: <b>G1:</b> 3 <b>G2:</b> 7 <b>G3:</b> 7 <b>G4:</b> 3 <b>G5:</b> 9 <b>G6:</b> 7 <b>G7:</b> 5	

**Comments:**

\* Calculated by reviewer.

<sup>1</sup> Authors state that almost all patients in G6 first received water blocks and/or pethidine and/or N<sub>2</sub>O followed by a paracervical (n=123, 36%) or epidural (n=84, 25%) block.

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Reed et al., 1989 <b>Country:</b> United Kingdom <b>Participant source:</b> Academic single site <b>Setting:</b> Hospital <b>Enrollment period:</b> NR <b>Design:</b> Case series  ***** <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>• Caucasian</li> <li>• Normal medical and obstetric histories</li> <li>• Did not intend to request extradural analgesia</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>• Those who subsequently received extradural analgesia</li> <li>• Those who delivered within one hour</li> </ul>	<b>Groups:</b> <sup>1</sup> <b>G1a:</b> N <sub>2</sub> O (Entonox, 50% N <sub>2</sub> O in O <sub>2</sub> ) only in the first stage of labor <b>G1b:</b> Pethidine plus N <sub>2</sub> O (Entonox) in the first stage of labor <b>G2:</b> Pethidine only in first stage of labor <b>G3:</b> No analgesia  <b>N at enrollment:</b> <b>Total:</b> 41  <b>N at followup:</b> <b>G1a:</b> 6 <b>G1b:</b> 20 <b>G2:</b> 7 <b>G3:</b> 0  <b>Age:</b> NR  <b>Race/ethnicity, %:</b> Caucasian: <b>Total:</b> 100  <b>Parous:</b> NR	<b>Provider preferences:</b> NR <b>Provider specialty:</b> NR  <b>Cost of intervention:</b> NR  <b>Other pain management methods available:</b> NR  <b>Pain management:</b> See groups.	<b>Pain:</b> NR  <b>Labor progress:</b> NR  <b>Fetal status:</b> NR  <b>Timeliness:</b> NR  <b>Labor co-interventions:</b> NR  <b>Adverse effects:</b> Maternal: Hypoxic episodes: <b>G1a:</b> 5/6 <b>G1b:</b> 9/20 <b>G2:</b> 2/7 Duration of monitoring, minutes:* <b>G1a:</b> 520 <b>G1b:</b> 1,819 <b>G2:</b> 1,677 <b>G3:</b> 2,452 Hypoxic episodes per hour of monitoring:* <b>G1a:</b> 0.57 <b>G1b:</b> 1.4 <b>G2:</b> 0.43 <b>G3:</b> 0.049  Neonatal: NR Occupational: NR  <b>Route of birth:</b> NR	<b>Satisfaction with pain management:</b> NR  <b>Satisfaction with birth experience:</b> NR  <b>Maternal status:</b> NR  <b>Neonatal status:</b> NR  <b>Adverse effects:</b> NR

**Comments:**

<sup>1</sup> Participants assigned to groups *a posteriori*. Indicated results refer to total minutes in which analgesia was nitrous oxide, pethidine, nitrous oxide plus pethidine, or no analgesia.

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Rosen et al., 1972 <b>Country:</b> United Kingdom <b>Participant source:</b> Academic multisite <b>Setting:</b> Hospital <b>Enrollment period:</b> NR <b>Design:</b> RCT ***** <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>NR for either study within this paper</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>NR for either study in the paper</li> </ul>	<b>Groups:</b> <b>G1:</b> Study 1 <b>G2:</b> Study 2 <b>Ga:</b> N <sub>2</sub> O mix and delivery 50% N <sub>2</sub> O and 50% O <sub>2</sub> (Entonox) <b>Gb:</b> Methoxyflurane 0.35% <b>N at enrollment:</b> (day prior to labor) <b>G1a:</b> 25 <b>G1b:</b> 25 (day of discharge from labor ward) <b>G2a:</b> 100 <b>G2b:</b> 100 <b>N at followup:</b> (entire 6 days) <b>G1a:</b> 19 <b>G1b:</b> 20 <b>G2a:</b> 100 <b>G2b:</b> 100 <b>Age, mean yrs ± SD:</b> <b>G1a:</b> 23.6 ± 5.4 <b>G1b:</b> 26.9 ± 7.1 <b>G2a:</b> 25.5 ± 5.9 <b>G2b:</b> 24.5 ± 5.3 <b>Race/ethnicity:</b> NR <b>Parous, n:</b> Primagravidas: <b>G1a:</b> 18 <b>G1b:</b> 15 <b>G2a:</b> 36 <b>G2b:</b> 47	<b>Provider preferences:</b> NR <b>Provider specialty:</b> NR <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> NR <b>Pain management:</b> NR	<b>Pain:</b> NR <b>Labor progress:</b> NR <b>Fetal status:</b> NR <b>Timeliness:</b> NR <b>Labor co-interventions:</b> NR <b>Adverse effects, mean ± SD:</b> Maternal: Blood urea, mg/100 ml, before delivery: <b>G1a:</b> 16.0 ± 4.5 <b>G1b:</b> 16.3 ± 7.3 <b>G1a/G1b:</b> P = NS Urinary/blood urea ratio, before delivery: <b>G1a:</b> 71.0 ± 22.3 <b>G1b:</b> 80.8 ± 43.2 <b>G1a/G1b:</b> P = NS Serum osmolality, before delivery, mOsm/kg: <b>G1a:</b> 289.7 ± 7.7 <b>G1b:</b> 290.7 ± 7.5 <b>G1a/G1b:</b> P = NS Urinary/serum osmolality ratio, before delivery: <b>G1a:</b> 1.88 ± 0.68 <b>G1b:</b> 1.92 ± 0.93 <b>G1a/G1b:</b> P = NS Packed cell volume, before delivery, mean % ± SD: <b>G1a:</b> 38.6 ± 2.5 <b>G1b:</b> 37.5 ± 3.1 <b>G1a/G1b:</b> P = NS Neonatal: NR Occupational: NR	<b>Satisfaction with pain management:</b> NR <b>Satisfaction with birth experience:</b> NR <b>Maternal status, n (%):</b> Blood urea, mg/100 ml, mean ± SD: 1st day after delivery: <b>G1a:</b> 20.0 ± 6.9 <b>G1b:</b> 16.6 ± 5.2 <b>G1a/G1b:</b> P = NS 2nd-3rd day after delivery: <b>G1a:</b> 21.4 ± 5.7 <b>G1b:</b> 21.3 ± 6.3 <b>G1a/G1b:</b> P = NS 4th-6th day after delivery: <b>G1a:</b> 21.0 ± 5.2 <b>G1b:</b> 20.8 ± 4.4 <b>G1a/G1b:</b> P = NS Day of discharge: <b>G2a:</b> NR* <b>G2b:</b> NR* <b>G2a/G2b:</b> P = NS Urinary/blood urea ratio, mean ± SD: 1st day after delivery: <b>G1a:</b> 57.3 ± 27.1 <b>G1b:</b> 55.2 ± 31.8 <b>G1a/G1b:</b> P = NS 2nd-3rd day after delivery: <b>G1a:</b> 73.4 ± 27.3 <b>G1b:</b> 70.5 ± 28.6 <b>G1a/G1b:</b> P = NS 4th-6th day after delivery: <b>G1a:</b> 81.4 ± 24.9 <b>G1b:</b> 67.2 ± 29.1 <b>G1a/G1b:</b> P = NS Day of discharge: <b>G2a:</b> NR <sup>1</sup> <b>G2b:</b> NR <sup>1</sup> <b>G2a/G2b:</b> P = NS Serum osmolality, mOsm/kg, mean ± SD: 1st day after delivery: <b>G1a:</b> 288.5 ± 7.1

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
----------------------	------------------------------	-----------------	---------------------------------------	---------------------------------

Route of birth:  
NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Rosen et al., 1972 (continued)				<p><b>G1b:</b> 291.8 ± 5.7  <b>G1a/G1b:</b> <i>P</i> = NS  2nd-3rd day after delivery:  <b>G1a:</b> 294.5 ± 4.4  <b>G1b:</b> 294.6 ± 5.9  <b>G1a/G1b:</b> <i>P</i> = NS  4th-6th day after delivery:  <b>G1a:</b> 294.7 ± 3.8  <b>G1b:</b> 295.4 ± 5.0  <b>G1a/G1b:</b> <i>P</i> = NS</p> <p>Urinary/serum osmolality ratio, mean ± SD:  1st day after delivery:  <b>G1a:</b> 1.69 ± 0.85  <b>G1b:</b> 1.49 ± 0.62  <b>G1a/G1b:</b> <i>P</i> = NS  2nd-3rd day after delivery:  <b>G1a:</b> 2.17 ± 0.75  <b>G1b:</b> 2.09 ± 0.66  <b>G1a/G1b:</b> <i>P</i> = NS  4th-6th day after delivery:  <b>G1a:</b> 2.22 ± 0.59  <b>G1b:</b> 2.04 ± 0.61  <b>G1a/G1b:</b> <i>P</i> = NS</p> <p>Packed cell volume, mean % ± SD:  1st day after delivery:  <b>G1a:</b> 38.5 ± 4.8  <b>G1b:</b> 37.8 ± 3.8  <b>G1a/G1b:</b> <i>P</i> = NS  2nd-3rd day after delivery:  <b>G1a:</b> 35.5 ± 4.4  <b>G1b:</b> 34.6 ± 5.2  <b>G1a/G1b:</b> <i>P</i> = NS  4th-6th day after delivery:  <b>G1a:</b> 37.2 ± 3.1  <b>G1b:</b> 35.2 ± 5.7  <b>G1a/G1b:</b> <i>P</i> = NS</p> <p>Mean hospital stay, days:  <b>G2a:</b> 5.5  <b>G2b:</b> 5.3</p> <p><b>Neonatal status:</b>  NR</p> <p><b>Adverse effects:</b>  NR</p>

**Comments:**

<sup>1</sup> Results only displayed graphically.



**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Rosen et al., 1969 <b>Country:</b> United Kingdom <b>Participant source:</b> Community <b>Setting:</b> Maternity units <b>Enrollment period:</b> NR <b>Design:</b> Nonrandomized trial Choice of drug for the day was randomized on a calendar present in labor room, with Sundays labeled as open choice of midwife. ***** <b>Inclusion criteria:</b> • Mothers <b>Exclusion criteria:</b> • See inclusion criteria	<b>Groups:</b> <b>G1:</b> N <sub>2</sub> O 50% /O <sub>2</sub> 50% given by Entonox apparatus <b>G2:</b> Trichloroethylene (0.5% and 0.35% in air) <b>G3:</b> Methoxyflurane (0.35% in air) <b>N at enrollment:</b> <b>G1:</b> 265 <b>G2:</b> 394 <b>G3:</b> 598 <b>N at followup:</b> <b>G1:</b> 265 <b>G2:</b> 394 <b>G3:</b> 598 <b>Age:</b> NR <b>Race/ethnicity:</b> NR <b>Parous, n (%):</b> Multiparae: <b>G1:</b> 130 (49) <b>G2:</b> 226 (57.5) <b>G3:</b> 347 (58)	<b>Provider preferences:</b> Choice of agent on Sundays, n (%): <b>G1:</b> 47/180 (26) <b>G2:</b> 32/180 (18) <b>G3:</b> 101/180 (56) Midwives response to questionnaire (n=77): In favour of use, before trial began, %: <b>G1:</b> 85 <b>G2:</b> 50 <b>G3:</b> NR Methoxyflurane is improvement over chosen agent, after experience of trial, %: <b>G1:</b> 53 <b>G2:</b> 78 <b>G3:</b> NA <b>Provider specialty, %:</b> Midwife: <b>Total:</b> 100 <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> NR <b>Pain management, n (%):</b> No additional drugs: <b>G1:</b> 87 (33) <b>G2:</b> 151 (38) <b>G3:</b> 238 (40) Pethidine: <b>G1:</b> 166 (63) <b>G2:</b> 228 (58) <b>G3:</b> 333 (56) Others: <b>G1:</b> 12 (4) <b>G2:</b> 15 (4) <b>G3:</b> 27 (4)	<b>Pain relief, n (%):</b> (scale NR) Maternal report, immediately after delivery: Complete: <b>G1:</b> 29 (11) <b>G2:</b> 47 (12) <b>G3:</b> 69 (11.5) Considerable: <b>G1:</b> 161 (61) <b>G2:</b> 235 (60) <b>G3:</b> 352 (59) Slight: <b>G1:</b> 66 (25) <b>G2:</b> 98 (25) <b>G3:</b> 154 (26) None: <b>G1:</b> 9 (3) <b>G2:</b> 14 (3) <b>G3:</b> 23 (3.5) Midwife report: Excellent: <sup>1</sup> <b>G1:</b> 19 (7) <b>G2:</b> 43 (11) <b>G3:</b> 81 (14) <b>G1/G3:</b> <i>P</i> < 0.01 Good: <sup>1</sup> <b>G1:</b> 92 (35) <b>G2:</b> 148 (38) <b>G3:</b> 235 (39) Adequate: <b>G1:</b> 129 (49) <b>G2:</b> 161 (41) <b>G3:</b> 225 (38) Inadequate: <b>G1:</b> 25 (9) <b>G2:</b> 42 (10) <b>G3:</b> 57 (9) <b>Labor progress:</b> NR <b>Fetal status:</b> NR <b>Timeliness:</b> NR <b>Labor co-interventions:</b> NR <b>Adverse effects:</b>	<b>Satisfaction with pain management:</b> NR <b>Satisfaction with birth (labor) experience, n (%):</b> Maternal report, multiparous: Better: <b>G1:</b> 45 (35) <b>G2:</b> 94 (42) <b>G3:</b> 189 (55) <b>G1/G3:</b> <i>P</i> < 0.001 <b>G2/G3:</b> <i>P</i> < 0.01 Same: <b>G1:</b> 33 (25) <b>G2:</b> 66 (29) <b>G3:</b> 62 (18) Worse: <b>G1:</b> 18 (14) <b>G2:</b> 29 (22) <b>G3:</b> 32 (9) Don't know: <b>G1:</b> 9 (3) <b>G2:</b> 44 (19) <b>G3:</b> 34 (26) <b>Maternal status:</b> NR <b>Neonatal status:</b> Apgar score, 1 minute, pethidine within 4 hours of inhalation: <b>G1:</b> NR <sup>2</sup> <b>G2:</b> NR <sup>2</sup> <b>G3:</b> NR <sup>2</sup> <b>Adverse effects:</b> Maternal: Nausea/felt sick, %: <b>G1:</b> 19 <b>G2:</b> 22 <b>G3:</b> 23 Vomited, %: <b>G1:</b> 7.5 <b>G2:</b> 6 <b>G3:</b> 7.5 Restlessness, midwife report, n (%): Never: <b>G1:</b> 95 (36)

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
		Duration of inhalation, minutes, mean: <b>G1:</b> 103.14 <b>G2:</b> 97.15 <b>G3:</b> 91.19	NR <b>Route of birth, n (%):</b> Vaginal:	<b>G2:</b> 153 (39) <b>G3:</b> 242 (41) Short periods:

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
Rosen et al., 1969 (continued)		<p><b>G1/G3:</b> <math>P &lt; 0.02</math></p> <p>Midwives opinion on concentration of agents, n (%):</p> <p>Satisfied:</p> <p><b>G1:</b> 213 (79)</p> <p><b>G2:</b> 299 (76)</p> <p><b>G3:</b> 412 (69)</p> <p><b>G1/G3:</b> <math>P &lt; 0.001</math></p> <p><b>G2/G3:</b> <math>P &lt; 0.05</math></p> <p>Requested stronger:</p> <p><b>G1:</b> 36 (14)</p> <p><b>G2:</b> 42 (11)</p> <p><b>G3:</b> 72 (12)</p> <p>Requested weaker:</p> <p><b>G1:</b> 5 (3)</p> <p><b>G2:</b> 35 (9)</p> <p><b>G3:</b> 64 (11)</p> <p>Don't know:</p> <p><b>G1:</b> 11 (4)</p> <p><b>G2:</b> 18 (4)</p> <p><b>G3:</b> 50 (8)</p> <p>Reasons and incidence of inhalation abandoned, n (%):</p> <p>Ineffective:</p> <p><b>G1:</b> 6 (2)</p> <p><b>G2:</b> 6 (1.5)</p> <p><b>G3:</b> 18 (9)</p> <p>Too powerful:</p> <p><b>G1:</b> 1 (0.6)</p> <p><b>G2:</b> 9 (2.2)</p> <p><b>G3:</b> 12 (2)</p> <p>Obstetric reason:</p> <p><b>G1:</b> 2 (0.8)</p> <p><b>G2:</b> 6 (1.5)</p> <p><b>G3:</b> 9 (1.5)</p> <p>Other:</p> <p><b>G1:</b> 5 (1.8)</p> <p><b>G2:</b> 33 (8)</p> <p><b>G3:</b> 45 (7.5)</p> <p>Reasons and incidence of inhalation abandoned, also took pethidine, n (%):</p> <p>Ineffective:</p> <p><b>G1:</b> 6/12 (50)</p> <p><b>G2:</b> 4/37 (10.8)</p> <p><b>G3:</b> 14/49 (28.5)</p> <p>Too powerful:</p> <p><b>G1:</b> 1/12 (8.3)</p> <p><b>G2:</b> 9/37 (24.3)</p> <p><b>G3:</b> 5/49 (10.2)</p> <p>Obstetric reason:</p>	<p><b>G1:</b> 235 (88.7)</p> <p><b>G2:</b> 345 (87.6)</p> <p><b>G3:</b> 525 (87.8)</p> <p>Assisted:</p> <p><b>G1:</b> 30 (11.3)</p> <p><b>G2:</b> 46 (11.7)</p> <p><b>G3:</b> 68 (11.4)</p> <p>Cesarean:</p> <p><b>G1:</b> 0</p> <p><b>G2:</b> 3 (0.8)</p> <p><b>G3:</b> 5 (0.8)</p>	<p><b>G1:</b> 157 (59)</p> <p><b>G2:</b> 206 (52)</p> <p><b>G3:</b> 310 (52)</p> <p>Long periods:</p> <p><b>G1:</b> 13 (5)</p> <p><b>G2:</b> 35 (9)</p> <p><b>G3:</b> 46 (7)</p> <p>Cooperation, midwife report, n (%):</p> <p>Satisfactory:</p> <p><b>G1:</b> 213 (81)</p> <p><b>G2:</b> 298 (76)</p> <p><b>G3:</b> 413 (69)</p> <p><b>G1/G3:</b> <math>P &lt; 0.001</math></p> <p><b>G2/G3:</b> <math>P &lt; 0.05</math></p> <p>Drowsy:</p> <p><b>G1:</b> 38 (14)</p> <p><b>G2:</b> 68 (17)</p> <p><b>G3:</b> 135 (23)</p> <p>Too drowsy:</p> <p><b>G1:</b> 6 (2)</p> <p><b>G2:</b> 14 (4)</p> <p><b>G3:</b> 29 (5)</p> <p>Asleep:</p> <p><b>G1:</b> 1 (1)</p> <p><b>G2:</b> 5 (1)</p> <p><b>G3:</b> 13 (2)</p> <p>Uncooperative:</p> <p><b>G1:</b> 7 (2)</p> <p><b>G2:</b> 9 (2)</p> <p><b>G3:</b> 8 (1)</p> <p>Neonatal, n (%):</p> <p>Apnoea, treatment:</p> <p>Artificial ventilation alone:</p> <p><b>G1:</b> 8 (3.5)</p> <p><b>G2:</b> 15 (3.5)</p> <p><b>G3:</b> 13 (2.5)</p> <p>Artificial ventilation and tracheal intubation:</p> <p><b>G1:</b> 6 (2)</p> <p><b>G2:</b> 7 (2)</p> <p><b>G3:</b> 19 (3)</p> <p>Apnoea, mortality:</p>

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
		G1: 1/12 (8.3) G2: 3/37 (8.1)		G1: 2 (0.5) G2: 3 (0.5) G3: 3 (0.5)  Childhood: NR  Occupational: NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Rosen et al., 1969 (continued)		G3: 5/49 (10.2) Other: <b>G1:</b> 4/12 (33.3) <b>G2:</b> 34/37 (64.8) <b>G3:</b> 25/49 (51.0)		

---

**Comments:**

<sup>1</sup> **G3/G2:**  $P < 0.01$  (excellent or good)

<sup>2</sup> Data only represented graphically. There were a significantly higher percentage of babies with a low Apgar score in G1 than in G2 ( $P < 0.01$ ) or G3 ( $P < 0.05$ ).

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Ross et al., 1999 <b>Country:</b> Scotland <b>Participant source:</b> Academic single site <b>Setting:</b> Hospital <b>Enrollment period:</b> NR <b>Design:</b> Uncontrolled trial ***** <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>• Mother in labor</li> <li>• Selection of mothers for isoflurane with nitrous left to discretion of midwives</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>• See inclusion criteria</li> </ul>	<b>Groups:</b> <b>G1:</b> 50% N <sub>2</sub> O / 50% O <sub>2</sub> (Entonox) mixed with isoflurane (IN <sub>2</sub> O), given through a gas scavenging system <b>Ga:</b> Apgar score < 8 at 1 minute <b>Gb:</b> Apgar score 8-10 at 1 minute <b>Gc:</b> No resuscitation required <b>Gd:</b> Resuscitation required <b>N at enrollment:</b> (consented early in labor prior to need for a stronger agent than Entonox) <b>G1:</b> 221 <b>N at followup:</b> <b>G1:</b> 221 <b>Ga:</b> 74 <b>Gb:</b> 147 <b>Gc:</b> 162 <b>Gd:</b> 59 <b>Age, median yrs (range):</b> <b>G1:</b> 29 (16-43) <b>Race/ethnicity:</b> NR <b>Parous, n (%):</b> Primiparous: <b>G1:</b> 126 (57) Multiparous: <b>G1:</b> 93 (43) <b>Gestation, median weeks (range):</b> <b>G1:</b> 40 (34-42)	<b>Provider preferences:</b> NR <b>Provider specialty:</b> NR <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> Opioids (either diamorphine 10 mg or morphine 15 mg given by intramuscular injection), pethidine <b>Pain management, n (%):</b> Epidural: <b>G1:</b> 32 (14.8) Opioids: <b>G1:</b> 173 (78.3) Pethidine: <b>G1:</b> 4 (1.8)	<b>Pain:</b> NR <b>Labor progress:</b> Duration of first stage, hours, median (IQR): <b>G1:</b> 9.13 (5.62-13.13) Duration of second stage, hours, median (IQR): <b>G1:</b> 0.70 (0.25-1.86) <b>Fetal status:</b> NR <b>Timeliness:</b> NR Labor co-interventions: NR <b>Adverse effects, n (%):</b> Maternal: Smelled: <b>G1:</b> 5 (2.3) Disliked: <b>G1:</b> 1 (0.4) Nausea: <b>G1:</b> 2 (0.9) Dizziness: <b>G1:</b> 2 (0.9) Drowsiness: <b>G1:</b> 2 (0.9) Neonatal: NR Occupational: NR <b>Route of birth, n:</b> Vaginal: <b>G1:</b> 151 Assisted (forceps or ventouse): Primiparous: <b>G1:</b> 49 Multiparous: <b>G1:</b> 9 Cesarean: Primiparous: <b>G1:</b> 12 Multiparous: <b>G1:</b> 0	<b>Satisfaction with pain management:</b> NR <b>Satisfaction with birth experience:</b> NR <b>Maternal status:</b> NR <b>Neonatal status:</b> Apgar score < 8, 1 minute: <b>G1:</b> 74 Apgar score < 8, 5 minutes: <b>G1:</b> 6 Duration of IN <sub>2</sub> O use, hours, median (IQR): <b>G1a:</b> 2.41 (1.15-4.12) <b>G1b:</b> 2.22 (0.90-4.23) <b>G1c:</b> 2.38 (0.92-4.38) <b>G1d:</b> 2.0 (1.15-4.0) IN <sub>2</sub> O stopped less than 1 hour before delivery, n (%): <b>G1a:</b> 57 (33) <b>G1b:</b> 117 (67) <b>G1c:</b> 127 (73) <b>G1d:</b> 47 (27) IN <sub>2</sub> O stopped more than 1 hour before delivery, n (%): <b>G1a:</b> 17 (36) <b>G1b:</b> 30 (67) <b>G1c:</b> 35 (75) <b>G1d:</b> 12 (25) Opioid use by mother, n (%): No opioid: <b>G1a:</b> 8 (17.6) <b>G1b:</b> 40 (83) <b>G1c:</b> 45 (94) <b>G1d:</b> 3 (6) Opioid less than 5 hrs before delivery, n (%): <b>G1a:</b> 40 (46) <b>G1b:</b> 48 (55) <b>G1c:</b> 48 (55) <b>G1d:</b> 40 (45)

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
----------------------	------------------------------	-----------------	---------------------------------------	---------------------------------

Opioid more than 5  
hrs before delivery, n



**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Ross et al., 1999 (continued)				<p>(%):  <b>G1a:</b> 26 (31)  <b>G1b:</b> 59 (69)  <b>G1c:</b> 69 (81)  <b>G1d:</b> 16 (19)</p> <p><b>Adverse effects:</b>  <b>Maternal:</b>  Blood loss, ml,  median (IQR):  <b>G1:</b> 200 (100-300)  Blood loss, mean ml:  <b>G1:</b> 241  Blood loss, n (%):  500-999 ml:  <b>G1:</b> 26 (11.1)  &gt; 1000 ml:  <b>G1:</b> 3 (1.3)</p> <p><b>Neonatal:</b>  Admission to  special care baby  unit, n:  <b>G1:</b> 2  Tracheal tube, n:  <b>G1:</b> 1  Mild respirator  depression:  <b>G1:</b> 1</p> <p>Childhood: NR  Occupational: NR</p>

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
<b>Author:</b> Smith et al., 1968 <b>Country:</b> U.S. <b>Participant source:</b> Academic single site <b>Setting:</b> Hospital <b>Enrollment period:</b> 08/1966 to 08/1967 <b>Design:</b> Nonrandomized trial ***** <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>• Multiparous (except for comparison group)</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>• See inclusion criteria</li> </ul>	<b>Groups:</b> <b>G1:</b> N <sub>2</sub> O (individualized, usual amount 2-4 L of 25-40% concentration) <b>G2:</b> Methoxyflurane (usual amount 12-30 ml, 0.2-0.5% setting on a Pentec vaporizer) <b>G3:</b> Cyclopropane (usual amount 60-300 ml, 1-5% concentration) <b>G4:</b> Pudendal <b>G5:</b> Spinal  <b>N at enrollment:</b> (during labor if analgesia needed in addition to local or pudendal nerve block) <b>G1:</b> 553 <b>G2:</b> 525 <b>G3:</b> 279 <b>G4:</b> 259 <b>G5:</b> 450  <b>N at followup:</b> NR <sup>1</sup>  <b>Age, mean yrs:</b> NR  <b>Race/ethnicity:</b> NR  <b>Parous, n (%):</b> Primiparous: <b>G1:</b> 0 <b>G2:</b> 0 <b>G3:</b> 0 <b>G4:</b> 0 <b>G5:</b> 450 (100)  Multiparous: <b>G1:</b> 553 (100) <b>G2:</b> 525 (100) <b>G3:</b> 279 (100) <b>G4:</b> 259 (100) <b>G5:</b> 0	<b>Provider preferences:</b> NR <b>Provider specialty:</b> NR <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> NR <b>Pain management:</b> NR	<b>Pain, %:</b> (5 point scale 0-4) <sup>2</sup> Patient report: Score 0: <b>G1:</b> 4 <b>G2:</b> 4 <b>G3:</b> 4 Score 1: <b>G1:</b> 8 <b>G2:</b> 7 <b>G3:</b> 8 Score 2: <b>G1:</b> 10 <b>G2:</b> 16 <b>G3:</b> 14 Score 3: <b>G1:</b> 27 <b>G2:</b> 35 <b>G3:</b> 33 Score 4: <b>G1:</b> 50 <b>G2:</b> 38 <b>G3:</b> 40  Patient report, < 5 minutes administration: Score 0: <b>G1:</b> 9 <b>G2:</b> 8 <b>G3:</b> 10 Score 1: <b>G1:</b> 13 <b>G2:</b> 12 <b>G3:</b> 10 Score 2: <b>G1:</b> 17 <b>G2:</b> 17 <b>G3:</b> 25 Score 3: <b>G1:</b> 20	<b>Satisfaction with pain management:</b> NR  <b>Satisfaction with birth experience:</b> NR  <b>Maternal status:</b> NR  <b>Neonatal status, mean:</b> Apgar score, 1 and 5 minutes: <sup>3</sup> NR  pO <sub>2</sub> : <b>G1:</b> 19 (n=23) <b>G2:</b> 20 (n=30) <b>G3:</b> 23 (n=7) <b>G4:</b> 20 (n=17)  pH: <b>G1:</b> 7.23 (n=23) <b>G2:</b> 7.25 (n=30) <b>G3:</b> 7.25 (n=7) <b>G4:</b> 7.29 (n=17)  pCO <sub>2</sub> : <b>G1:</b> 62 (n=23) <b>G2:</b> 55 (n=30) <b>G3:</b> 49 (n=7) <b>G4:</b> 46 (n=17)  Buffer base: <b>G1:</b> 39 (n=23) <b>G2:</b> 38 (n=30) <b>G3:</b> 39 (n=7) <b>G4:</b> 40 (n=17)  Standard bicarbonate: <b>G1:</b> 17 (n=23) <b>G2:</b> 17 (n=30) <b>G3:</b> 18 (n=7) <b>G4:</b> 18 (n=17)  <b>Adverse effects:</b> NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
			<b>G2:</b> 32 <b>G3:</b> 30 Score 4: <b>G1:</b> 41 <b>G2:</b> 31 <b>G3:</b> 25  Patient report, $\geq 5$ minutes administration: Score 0: <b>G1:</b> 1 <b>G2:</b> 1 <b>G3:</b> 3 Score 1: <b>G1:</b> 4	

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Smith et al., 1968 (continued)			<b>G2:</b> 5 <b>G3:</b> 7 Score 2: <b>G1:</b> 6 <b>G2:</b> 16 <b>G3:</b> 11 Score 3: <b>G1:</b> 32 <b>G2:</b> 36 <b>G3:</b> 34 Score 4: <b>G1:</b> 57 <b>G2:</b> 42 <b>G3:</b> 44  <b>Labor progress:</b> NR  <b>Fetal status:</b> NR  <b>Timeliness:</b> NR  <b>Labor co-interventions:</b> NR  <b>Adverse effects, %:</b> Maternal: Amnesia: <b>G1:</b> 11 <b>G2:</b> 8 <b>G3:</b> 11  Amnesia, < 5 minutes administration: <b>G1:</b> 16 <b>G2:</b> 4 <b>G3:</b> 5  Amnesia, ≥ 5 minutes administration: <b>G1:</b> 7 <b>G2:</b> 10 <b>G3:</b> 13	

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
			<p>Nausea and vomiting:  <b>G1:</b> 3  <b>G2:</b> 13  <b>G3:</b> 0.5  <b>G1/G2:</b> <math>P &lt; 0.05</math>  <b>G2/G3:</b> <math>P &lt; 0.001</math></p> <p>Neonatal: NR</p> <p>Occupational: NR</p> <p><b>Route of birth, n (%):</b>  Vaginal:  <b>G1:</b> 505 (91.3)  <b>G2:</b> 441 (84.0)</p>	

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Smith et al., 1968 (continued)			<p>G3: 185 (66.3)  <b>G4:</b> 241 (93.1)  <b>G5:</b> 0</p> <p>Assisted, low forceps:  <b>G1:</b> 36 (6.5)  <b>G2:</b> 76 (14.5)  <b>G3:</b> 73 (26.2)  <b>G4:</b> 12 (4.6)  <b>G5:</b> 448 (99.6)</p> <p>Assisted, breech:  <b>G1:</b> 12 (2.2)  <b>G2:</b> 8 (1.5)  <b>G3:</b> 21 (7.5)  <b>G4:</b> 6 (2.3)  <b>G5:</b> 2 (0.4)</p> <p>Cesarean:  <b>Total:</b> 0</p>	

---

**Comments:**

<sup>1</sup> Results for analgesia and amnesia scores note they include “all vaginal vertex deliveries in multiparous patients” so presumably these results exclude breech births.

<sup>2</sup> Patient analgesia score scale: 0=didn't help or made it worse, 1=only helped a little, 2=the anesthetic helped, 3=only a little pain, 4=no pain at all.

<sup>3</sup> Apgar scores at 1 and 5 minutes only displayed graphically.

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
<b>Author:</b> Soyannwo, 1985 <b>Country:</b> Nigeria <b>Participant source:</b> Academic single site <b>Setting:</b> Hospital <b>Enrollment period:</b> NR <b>Design:</b> Prospective cohort ***** <b>Inclusion criteria:</b> • Participants in established labor <b>Exclusion criteria:</b> • See inclusion criteria	<b>Groups:</b> <b>G1:</b> Entonox administered via portable demand apparatus <b>G2:</b> 100 mg injection of pethidine or pethilorphan in early labor followed by Entonox inhalation  <b>N at enrollment:</b> (during established labor) <b>G1:</b> 114 <b>G2:</b> 36  <b>N at followup:</b> (after labor) <b>G1:</b> 114 <b>G2:</b> 36  <b>Age, mean yrs:</b> <b>Total:</b> 27.2  <b>Race/ethnicity:</b> NR  <b>Parous, n (%):</b> <b>Total:</b> 114 (76.0)	<b>Provider preferences:</b> NR  <b>Provider specialty, n (%):</b> Resident anesthetist or midwife: <b>Total:</b> 150 (100)  <b>Cost of intervention:</b> NR  <b>Other pain management methods available:</b> NR  <b>Pain management:</b> NR	<b>Pain, n (%):</b> Excellent relief: <b>G1:</b> 24 (21.1) <b>G2:</b> 12 (33.3) Good relief: <b>G1:</b> 74 (64.9) <b>G2:</b> 24 (66.7) Fair relief: <b>G1:</b> 14 (12.3) <b>G2:</b> 0 Poor relief: <b>G1:</b> 2 (1.7) <b>G2:</b> 0  <b>Labor progress:</b> NR  <b>Fetal status:</b> NR  <b>Timeliness:</b> NR  <b>Labor co-interventions:</b> NR  <b>Adverse effects, n (%):</b> Maternal: Drowsiness: Mild: <b>G1:</b> 76 (66.7) <b>G2:</b> 20 (55.6) Moderate: <b>G1:</b> 36 (31.6) <b>G2:</b> 16 (44.4) Severe: <b>G1:</b> 2 (1.7) <b>G2:</b> 0  Time for inhalation of Entonox, minutes, mean (range): Mild drowsiness: <b>Total:</b> 210 (45-320) Moderate drowsiness: <b>Total:</b> 340 (60-480) Vomiting: <sup>1</sup>	<b>Satisfaction with pain management, n (%):</b> (after delivery) Willing to use Entonox in subsequent deliveries: <b>Total:</b> 135 (90.0)  <b>Satisfaction with birth experience:</b> NR  <b>Maternal status:</b> NR  <b>Neonatal status, n (%):</b> Apgar score 8-10, vaginal deliveries: <b>Total:</b> 136 (97.1)  <b>Adverse effects:</b> Maternal: NR  Neonatal: Apgar score < 5, vaginal deliveries: <b>Total:</b> 4 (2.9) <sup>2</sup> Childhood: NR Occupational: NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
			Total: 4 (2.7)	
			Unconsciousness: <sup>1</sup>	
			Total: 1 (0.7)	
			Neonatal: NR	
			Occupational: NR	



**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Soyannwo, 1985 (continued)			<b>Route of birth, n (%):</b> Vaginal: <b>Total:</b> 130 (86.7)  Assisted, forceps or breech delivery: <b>Total:</b> 10 (6.7)  Cesarean: <b>Total:</b> 10 (6.7)	

---

**Comments:**

<sup>1</sup> Groups unspecified but adverse effects due to Entonox inhalation.

<sup>2</sup> All breech deliveries and all resuscitated.

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Stirk et al., 2002  <b>Country:</b> United Kingdom  <b>Participant source:</b> Community  <b>Setting:</b> Hospital  <b>Enrollment period:</b> 02/1998 to 10/1998  <b>Design:</b> Prospective cohort ***** <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>• Primigravida</li> <li>• ≥ 36 weeks' gestation</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>• Caesarean sections</li> </ul>	<b>Groups:</b> <b>G1:</b> Entonox (mix and delivery method NR) <b>G2:</b> Diamorphine only  <b>N at enrollment:</b> (chart review) <b>G1:</b> 45 <b>G2:</b> 70  <b>N at followup:</b> <b>G1:</b> 45 <b>G2:</b> 70  <b>Age:</b> NR  <b>Race/ethnicity:</b> NR  <b>Parous, n (%):</b> Primigravida: <b>G1:</b> 45 (100) <b>G2:</b> 70 (100)	<b>Provider preferences:</b> NR  <b>Provider specialty:</b> NR  <b>Cost of intervention:</b> NR  <b>Other pain management methods available:</b> None  <b>Pain management:</b> NR	<b>Pain:</b> NR  <b>Labor progress:</b> Duration of labor, hours:minutes, mean (range): <sup>1</sup> <b>G1:</b> 5:00 (0:45-12:15) <b>G2:</b> 8:40 (1:45-20:15)  <b>Fetal status:</b> NR  <b>Timeliness:</b> NR  <b>Labor co-interventions:</b> NR  <b>Adverse effects:</b> NR  <b>Route of birth, n:</b> Vaginal: NR  Assisted: NR  Cesarean: <b>Total:</b> 0	<b>Satisfaction with pain management:</b> NR  <b>Satisfaction with birth experience:</b> NR  <b>Maternal status:</b> NR  <b>Neonatal status:</b> Apgar score, mean: 1 minute: <b>G1:</b> 8.2 <b>G2:</b> 8.3 5 minutes: <b>G1:</b> 9.6 <b>G2:</b> 9.4  Length of hospital stay, days, mean: <b>G1:</b> 3 <b>G2:</b> 2  <b>Adverse effects, n (%):</b> Maternal: NR  Neonatal: Neonatal unit admission: <b>G1:</b> 7 (18.4) <sup>2</sup> <b>G2:</b> 2 (2.8) <b>G1/G2:</b> $P < 0.027$  Given Narcan: <b>G1:</b> 5 (7) <b>G2:</b> 0  Given facial oxygen and intermittent positive pressure ventilation: <b>G1:</b> 3 (4.2) <b>G2:</b> 0  Childhood: NR  Occupational: NR

**Comments:**

<sup>1</sup> The text reports the mean duration of labor for G2 as 8:20, but Figure 3 reports the value as 8:40.

<sup>2</sup> Text notes 7 out of 38 in G1 (18.4%) group were admitted, but the Figure 1 indicates that 38 were *not* admitted, so the correct value could be 7 out of 45 (15.6%).

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
------------------------------	--	------------------------	--	---

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Talebi et al., 2009 <b>Country:</b> Iran <b>Participant source:</b> Academic single site <b>Setting:</b> Hospital <b>Enrollment period:</b> 09/2004 to 09/2006 <b>Design:</b> RCT ***** <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>• ASA I and II</li> <li>• 16 to 35 yrs old</li> <li>• Primigravid or second gravid, term (38 to 42 wks GA) parturients in active phase of labor (dilation &gt; 4 cm)</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>• Evidence of fetal distress or abnormal heart rate pattern</li> <li>• GA &lt; 37 wks or &gt; 42 wks</li> <li>• Maternal cardiorespiratory disease or any condition affecting the accuracy of pulse oximetry</li> <li>• History of taking opioids, administration of sedatives or regional analgesia</li> <li>• Unable to tolerate Entonox</li> <li>• Cesarean or forceps delivery</li> </ul>	<b>Groups:</b> <b>G1:</b> 50% N <sub>2</sub> O and O <sub>2</sub> , self administered via facemask <b>G2:</b> 50% O <sub>2</sub> , self administered via facemask <b>N at enrollment:</b> <sup>1</sup> (first request for analgesia) <b>Total:</b> 523 <b>N at followup:</b> <sup>1</sup> <b>G1:</b> 260 <b>G2:</b> 249 <b>Age, mean yrs ± SD:</b> <b>G1:</b> 24.2 ± 4.0 <b>G2:</b> 24.9 ± 4.7 <b>Race/ethnicity:</b> NR <b>Parous, n (%):</b> <b>G1:</b> 97 (37.3) <b>G2:</b> 123 (49.4)	<b>Provider preferences:</b> NR <b>Provider specialty:</b> NR <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> NR <b>Pain management:</b> NR	<b>Pain:</b> (VAS, at onset of active labor and hourly at 1-5 hours afterward) NR <sup>2</sup> <b>Labor progress:</b> NR <b>Fetal status:</b> NR <b>Timeliness:</b> NR <b>Labor co-interventions:</b> NR <b>Adverse effects, %:</b> Maternal: Nausea: <b>G1:</b> 8.4 <b>G2:</b> 0 <b>G1/G2:</b> <i>P</i> = 0.001 Vomiting: <b>G1:</b> 2.3 <b>G2:</b> 0 G 1/G 2: <i>P</i> = .030 Dizziness: <b>G1:</b> 22.6 <b>G2:</b> 0 G 1/G 2: <i>P</i> = 0.001 Dry mouth: <b>G1:</b> 8.3 <b>G2:</b> 0 G 1/G 2: <i>P</i> = 0.001 Pins and needles/numbness: <b>G1:</b> 4.1 <b>G2:</b> 0 G 1/G 2: <i>P</i> = .001 Drowsiness: <b>G1:</b> 15.4 <b>G2:</b> 0 <b>G1/G2:</b> <i>P</i> = 0.001 Neonatal: NR Occupational: NR	<b>Satisfaction with pain management:</b> NR <b>Satisfaction with birth experience:</b> NR <b>Maternal status:</b> (SaO <sub>2</sub> levels measured at onset of active labor and hourly at 1-5 hours afterward) NR <sup>2</sup> <b>Neonatal status:</b> Apgar scores, mean ± SD: 1 <sup>st</sup> min: <b>G1:</b> 8.5 ± 0.9 <b>G2:</b> 8.5 ± 0.8 5 <sup>th</sup> min: <b>G1:</b> 9.5 ± 0.8 <b>G2:</b> 9.5 ± 0.7 <b>Adverse effects:</b> NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
			<b>Route of birth, n</b> <b>(%):</b> Vaginal: <b>G1:</b> 260 (100) <b>G2:</b> 249 (100) Assisted: <b>Total:</b> 0	

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Talebi et al., 2009 (continued)			Cesarean: <b>Total: 0</b>	

---

**Comments:**

<sup>1</sup>Authors state that four patients were lost from the study, followup N from parity reported in Table 1.

<sup>2</sup>Results only displayed graphically. For pain, G1 values were significantly lower than G2 at all time points; for SaO<sub>2</sub> levels, G2 levels were significantly higher than G1 at the first three time points.

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Waldenstrom et al., 2006 <b>Country:</b> Sweden <b>Participant source:</b> Antenatal clinics <b>Setting:</b> Other <b>Enrollment period:</b> 05/1999 to 01/2000 <b>Design:</b> Trend ***** <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>• Pregnant woman</li> <li>• Fluent in Swedish</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>• Miscarriage</li> <li>• Elective cesarean</li> <li>• Emergency cesarean not preceded by labor</li> </ul>	<b>Groups:</b> <b>G1:</b> All women <b>G1a:</b> N <sub>2</sub> O used during labor <b>N at enrollment:</b> (completed first questionnaire in early pregnancy) <b>G1:</b> 3,061 <b>N at followup:</b> <b>G1:</b> 2,482 <b>G1a:</b> 1,997 <b>Age, mean yrs, %:</b> < 25: <b>G1:</b> 15 25-35: <b>G1:</b> 75 > 35: <b>G1:</b> 10 <b>Race/ethnicity, %:</b> Native-born Swedes: <b>G1:</b> 91 <b>Parous, n (%):</b> Primipara: <b>G1:</b> 1,096 (44) <b>G1a:</b> 926 (46) Multipara: <b>G1:</b> 1,386 (55) <b>G1a:</b> 1,071 (54)	<b>Provider preferences:</b> NR <b>Provider specialty:</b> NR <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> Epidural block, pethidine, paracervical block, pudental block, bath or shower, acupuncture, psychoprophylaxis, TENS, sterile water papules <b>Pain management, %:</b> Epidural block: <b>G1:</b> 31.1 N <sub>2</sub> O: <b>G1:</b> 80.5 Pethidine: <b>G1:</b> 9.1 Paracervical block: <b>G1:</b> 3.3 Pudental block: <b>G1:</b> 4.4 No pharmacological pain management: <b>G1:</b> 14 Bath or shower: <b>G1:</b> 32.9 Acupuncture: <b>G1:</b> 21.5 Psychoprophylaxis: <b>G1:</b> 13.9 TENS: <b>G1:</b> 11.8 Sterile water papules: <b>G1:</b> 3.4 No pain management: <b>G1:</b> 9	<b>Pain, n:</b> (7 point scale ranging from 1 = no pain at all to 7 = worst imaginable pain, reported at two months post partum) 1-3: <b>G1:</b> 173 <b>G1a:</b> 88 <sup>1</sup> 4: <b>G1:</b> 243 <b>G1a:</b> 174 <sup>1</sup> 5: <b>G1:</b> 596 <b>G1a:</b> 471 <sup>1</sup> 6: <b>G1:</b> 749 <b>G1a:</b> 637 <sup>1</sup> 7: <b>G1:</b> 721 <b>G1a:</b> 627 <sup>1</sup> <b>Labor progress:</b> NR <b>Fetal status:</b> NR <b>Timeliness:</b> NR <b>Labor co-interventions:</b> Oxytocin: <b>G1:</b> NR <b>Adverse effects:</b> NR <b>Route of birth:</b> NR	<b>Satisfaction with pain management, %:</b> (scale created by author/researchers, reported two months after birth) Primiparas: Very effective: <b>G1:</b> 37.6 Some effect: <b>G1:</b> 45.6 No effect: <b>G1:</b> 16.8 Multiparas: Very effective: <b>G1:</b> 49.0 Some effect: <b>G1:</b> 42.0 No effect: <b>G1:</b> 9.0 <b>Satisfaction with birth experience:</b> Recollection of labor pain at 1 year: <b>G1a:</b> NR <sup>2</sup> <b>Maternal status:</b> NR <b>Neonatal status:</b> NR <b>Adverse effects:</b> NR

**Comments:**

<sup>1</sup> Computed from overall numbers for G1 and percentages in Table III.



<sup>2</sup> Results only displayed graphically. The authors state that high rates of nitrous oxide were associated with remembering less pain.

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
<b>Author:</b> Waldenstrom, 1999 <b>Country:</b> Sweden <b>Participant source:</b> Academic single site <b>Setting:</b> Hospital <b>Enrollment period:</b> 10/1989 to 01/1992 <b>Design:</b> Cross-sectional <ul style="list-style-type: none"> <li>Groups were randomized to either birth center or hospital birth initially, but treated as 1 group for this study</li> </ul> <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>Women giving birth between 10/1989 and 01/1992</li> <li>Low medical risk</li> <li>Recruited from greater Stockholm area in early pregnancy</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>Miscarriage, fetal or neonatal loss</li> <li>Elective cesarean</li> </ul>	<b>Groups:</b> <b>G1:</b> Entire group consisted of women randomly assigned to either standard care or in-hospital birth center birth, but treated as one group for this study <b>G1a:</b> Positive group (6 or 7 on a 7-point overall birth experience scale 1 = very negative, 7 = very positive) <b>G1b:</b> Less positive group (1-5 on a 7-point overall birth experience scale)  <b>N at enrollment:</b> (early pregnancy before randomization) <b>G1:</b> 1,230  <b>N at followup:</b> (returned followup questionnaire) <b>G1:</b> 1,148  (two months after birth, after exclusions) <b>G1:</b> 1,111 <b>G1a:</b> 790 <b>G1b:</b> 321  <b>Age, mean yrs <math>\pm</math> SD:</b> <b>G1a:</b> 30.2 $\pm$ 4.4 <b>G1b:</b> 30.5 $\pm$ 4.3  <b>Race/ethnicity:</b> NR  <b>Parous, n (%):</b> Primiparity:	<b>Provider preferences:</b> NR  <b>Provider specialty:</b> NR  <b>Cost of intervention:</b> NR  <b>Other pain management methods available:</b> Epidural, pethidine  <b>Pain management, %:</b> Nitrous: <b>G1a:</b> 25.9 <b>G1b:</b> 49.2 <b>Ga/Gb:</b> $P < 0.001$ Epidural: <b>G1a:</b> 5.6 <b>G1b:</b> 26.6 <b>Ga/Gb:</b> $P < 0.001$ Pethidine: <b>G1a:</b> 5.9 <b>G1b:</b> 14.9 <b>Ga/Gb:</b> $P < 0.001$	<b>Pain:</b> Pain intensity, mean $\pm$ SD (1 = none at all, 7 = worst imaginable): <b>G1a:</b> 4.8 $\pm$ 1.5 <b>G1b:</b> 5.6 $\pm$ 1.5  <b>Labor progress, duration of labor, mean <math>\pm</math> SD:<sup>1</sup></b> <b>G1a:</b> 12.5 $\pm$ 9.2 <b>G1b:</b> 18.0 $\pm$ 12.7  <b>Fetal status:</b> NR  <b>Timeliness:</b> NR  <b>Labor co-interventions, %:</b> Induction of labor: <b>G1a:</b> 2.0 <b>G1b:</b> 7.2  <b>Augmentation of labor, %:</b> <b>G1a:</b> 12.5 <b>G1b:</b> 37.8  <b>Adverse effects, mean <math>\pm</math> SD:</b> Maternal: Anxiety (where 1 = not at all anxious, and 7 = very anxious): <b>G1a:</b> 2.1 $\pm$ 1.5 <b>G1b:</b> 3.6 $\pm$ 1.9  Neonatal: Transfer, %: <b>G1a:</b> 7.2 <b>G1b:</b> 16.8  Occupational: NR	<b>Satisfaction with pain management:</b> NR  <b>Satisfaction with birth experience:</b> NR  <b>Maternal status:</b> NR  <b>Neonatal status, %:</b> Apgar score < 7, 5 minutes: <b>G1a:</b> 0.4 <b>G1b:</b> 2.5  <b>Adverse effects:</b> Maternal: NR  Neonatal: See neonatal transfer in labor and intermediate outcomes column.  Childhood: NR  Occupational: NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
	<b>G1a:</b> 47.1 <b>G1b:</b> 71.3 <b>G1a/G1b:</b> $P < 0.001$		<b>Route of birth, %:</b> Vaginal: <b>G1a:</b> NR G 1a: NR Vacuum extraction: <b>G1a:</b> 1.3 <b>G1b:</b> 9.7 Emergency cesarean: <b>G1a:</b> 1.4 <b>G1b:</b> 14.3	

**Comments:**

<sup>1</sup> Assumed to be hours, unit not provided.

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Waldenstrom et al., 1996 <b>Country:</b> Sweden <b>Participant source:</b> Academic multisite Community <b>Setting:</b> Hospital <b>Enrollment period:</b> 11/1994 to 12/1994 <b>Design:</b> Cross-sectional ***** <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>All women who gave birth at any of three hospitals providing maternity care in the Gothenburg region in enrollment period</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>Had a stillborn or severely ill baby</li> <li>Suffered from postpartum psychosis</li> <li>Did not have mastery of Swedish language</li> <li>Did not agree to participate or were not contacted due to very early discharge</li> <li>Underwent elective cesarean</li> </ul>	<b>Groups:</b> <sup>1</sup> <b>G1:</b> Entonox (50/50 N <sub>2</sub> O and O <sub>2</sub> mix) <b>G2:</b> Epidural <b>G3:</b> Local infiltration <b>G4:</b> Acupuncture <b>G5:</b> Bath <b>G6:</b> Breathing technique (psycho-prophylaxis) <b>Ga:</b> Less severe pain (score=1-6) <b>Gb:</b> Severe pain (score=7) <b>N at enrollment:</b> (all births from 11/21 to 12/6/1994) <b>Total:</b> 385 <b>N at followup:</b> (completed questionnaires 4 hours to 7 days after birth, mean 45 hours) <b>Total:</b> 278 <b>G1:</b> 219 <b>G2:</b> 95 <b>G3:</b> 69 <b>G4:</b> 51 <b>G5:</b> 107 G6: 85 Ga: 165 Gb: 113 <b>Age, mean yrs ± SD:</b> <b>Ga:</b> 29.5 ± 5.1 <b>Gb:</b> 28.9 ± 4.2 <b>Ga/Gb:</b> <i>P</i> = NS <b>Race/ethnicity:</b> NR <b>Parous, n (%):</b> Primiparas: <b>Total:</b> 134 (48) <b>Ga:</b> NR (45.5)	<b>Provider preferences:</b> NR <b>Provider specialty:</b> NR <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> Pethidine, morphine, paracervical block, pudendal block, shower, massage, sterile water s.c., TENS, movement, music <b>Pain management, %:</b> Entonox: <b>Total:</b> 78.8 <b>Ga:</b> 70.9 <b>Gb:</b> 85.8 Epidural block: <b>Total:</b> 34.2 <b>Ga:</b> 29.1 <b>Gb:</b> 38.9 Pethidine, morphine: <b>Total:</b> 3.4 Paracervical block: <b>Total:</b> 5.0 Pudental block: <b>Total:</b> 7.2 Local infiltration: <b>Total:</b> 24.8 <b>Ga:</b> 21.8 <b>Gb:</b> 27.4 No pharmacological analgesia: <b>Total:</b> 9.3 Nonpharmacological methods: Tub bath: <b>Total:</b> 40.5	<b>Pain, n (%):</b> (7 point scale 1-7) <sup>2</sup> Pain score, n (%): 7: <b>Total:</b> 113 (41) 1-6: <b>Total:</b> 165 (59) Pain score, mean: Primiparas: <b>Total:</b> 6.1 Multiparas: <b>Total:</b> 5.9 <b>Labor progress:</b> NR <b>Fetal status:</b> NR <b>Timeliness:</b> NR <b>Labor co-interventions, %:</b> Induction: <b>Ga:</b> 15.9 <b>Gb:</b> 19.8 Augmentation: <b>Ga:</b> 36.4 <b>Gb:</b> 53.8 <b>Adverse effects:</b> Maternal: Anxiety score, mean ± SD: <sup>3</sup> <b>Ga:</b> 3.3 ± 1.8 <b>Gb:</b> 4.4 ± 2.1 <b>Ga/Gb:</b> <i>P</i> < 0.001 Neonatal: NR Occupational: NR <b>Route of birth, n (%):</b> Vaginal: <b>Total:</b> 236 (84.9) <b>Ga:</b> NR (88.5) <b>Gb:</b> NR (79.6) Assisted: <b>Total:</b> 22 (7.5) <b>Ga:</b> NR (4.8) <b>Gb:</b> NR (12.4)	<b>Satisfaction with pain management, n (%):</b> Would use pain relief method in future labor: <b>G1:</b> 188 (69.9) <b>G2:</b> 122 (45.3) <b>G3:</b> 93 (34.6) <b>G4:</b> 55 (20.4) <b>G5:</b> 180 (66.9) <b>G6:</b> 110 (40.9) <b>Satisfaction with birth experience:</b> NR <b>Maternal status:</b> NR <b>Neonatal status:</b> NR <b>Adverse effects:</b> NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
	<b>Gb:</b> NR (52.2)	<b>Ga:</b> 33.3 <b>Gb:</b> 46.0 Shower: <b>Total:</b> 14.8 Massage:	Emergency cesarean: <b>Total:</b> 20 (6.8) <b>Ga:</b> NR (6.7) <b>Gb:</b> NR (8.0)	

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Waldenstrom et al., 1996 (continued)		<b>Total:</b> 28.4 Special breathing technique: <b>Total:</b> 32.2 <b>Ga:</b> 33.9 <b>Gb:</b> 25.7 Acupuncture: <b>Total:</b> 19.3 <b>Ga:</b> 14.5 <b>Gb:</b> 23.9 Sterile water s.c.: <b>Total:</b> 7.6 TENS: <b>Total:</b> 6.4 Movement (walking around): <b>Total:</b> 39.8 Music: <b>Total:</b> 16.3		

**Comments:**

1 Groups are not exclusive.

<sup>2</sup> 1=no pain at all; 7=worst imaginable pain

<sup>3</sup> 1=not at all anxious, 7=very anxious

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Westberg et al., 2008  <b>Country:</b> Sweden  <b>Participant source:</b> NR  <b>Setting:</b> Hospital  <b>Enrollment period:</b> 03/2003 to 05/2004  <b>Design:</b> Prospective cohort *****  <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>All subjects available during the selected shifts were included.</li> </ul> <b>Exclusion criteria:</b> NR	<b>Groups:</b> <b>G1:</b> Midwives <b>G2:</b> Assistant midwives  <b>N at enrollment:</b> <b>G1:</b> 25 <b>G2:</b> 11 <b>Total:</b> 36  <b>N at followup:</b> NR  <b>Age:</b> NR  <b>Race/ethnicity:</b> NR  <b>Parous:</b> NR	<b>Provider preferences:</b> NR  <b>Provider specialty:</b> NR  <b>Cost of intervention:</b> NR  <b>Other pain management methods available:</b> NR  <b>Pain management:</b> NR	<b>Pain:</b> NR  <b>Labor progress:</b> NR  <b>Fetal status:</b> NR  <b>Timeliness:</b> NR  <b>Labor co-interventions:</b> NR  <b>Adverse effects:</b> Maternal: NR  Neonatal: NR  Occupational: Air concentrations (mg/m <sup>3</sup> ) of 8 h time-weighted averages nitrous oxide levels in delivery suite, geometric mean $\pm$ geometric standard deviation (range): <b>G1:</b> $17 \pm 4.4$ (2.5-260) <b>G2:</b> $42 \pm 4.7$ (<3.5-220) <b>Total:</b> $22 \pm 4.7$ (2.5-260)  <b>Route of birth:</b> NR	<b>Satisfaction with pain management:</b> NR  <b>Satisfaction with birth experience:</b> NR  <b>Maternal status:</b> NR  <b>Neonatal status:</b> NR  <b>Adverse effects:</b> NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Westling et al., 1992 <b>Country:</b> Sweden <b>Participant source:</b> Academic single site <b>Setting:</b> Hospital <b>Enrollment period:</b> NR <b>Design:</b> Crossover RCT ***** <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>• Healthy</li> <li>• Normal singleton pregnancy</li> <li>• Vertex presentation</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>• See inclusion criteria</li> </ul>	<b>Groups:</b> <b>G1a:</b> Intermittent N <sub>2</sub> O/O <sub>2</sub> (40/60) <b>G1b:</b> Intermittent N <sub>2</sub> O/O <sub>2</sub> (70/30) <b>G1c:</b> Continuous N <sub>2</sub> O/O <sub>2</sub> (40/60) <b>G1d:</b> Intermittent O <sub>2</sub> Intervention delivered via face mask <b>N at enrollment:</b> (labor) <b>G1:</b> 24 <b>N at followup:</b> <b>G1:</b> 24 <b>Age, mean yrs ± SD:</b> <b>G1:</b> 26.8 ± 0.9 <b>Race/ethnicity:</b> NR <b>Parous, n (%):</b> <b>G1:</b> 12 (50)	<b>Provider preferences:</b> NR <b>Provider specialty, n (%):</b> Midwife: <b>G1:</b> 24 (100) <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> None <b>Pain management:</b> NR	<b>Pain:</b> VAS, participant report, mean: <b>G1:</b> NR <sup>1</sup> VAS, midwife report, mean: <b>G1:</b> NR <sup>1</sup> <b>Labor progress,</b> Cervical dilation, mean ± SD: Before measurements: <b>G1:</b> 5.8 ± 0.4 After measurements: <b>G1:</b> 7.9 ± 0.4 <b>Fetal status:</b> NR <b>Timeliness:</b> NR <b>Labor co-interventions:</b> NR <b>Adverse effects, n (%):</b> Maternal: Nausea <b>G1a:</b> 0 <b>G1b:</b> 0 <b>G1c:</b> 1 (4) <b>G1d:</b> 0 Vomiting: <b>G1:</b> 0 Loss of consciousness: <b>G1:</b> 0 Neonatal: NR Occupational: NR <b>Route of birth, n (%):</b> Vaginal: <b>G1:</b> 23 (96)	<b>Satisfaction with pain management:</b> NR <b>Satisfaction with birth experience:</b> NR <b>Maternal status:</b> Heart rate, mean: <b>G1:</b> NR <sup>1</sup> Stroke volume, mean: <b>G1:</b> NR <sup>1</sup> Cardiac output, mean: <b>G1:</b> NR <sup>1</sup> Systolic arterial pressure, mean: <b>G1:</b> NR <sup>1</sup> Diastolic arterial pressure, mean: <b>G1:</b> NR <sup>1</sup> Mean arterial pressure: <b>G1:</b> NR <sup>1</sup> Total peripheral vascular resistance, mean: <b>G1:</b> NR <sup>1</sup> <b>Neonatal status:</b> Weight, g, mean ± SD: <b>G1:</b> 3,652 ± 121 Apgar score, mean ± SD: 1 minute: <b>G1:</b> 9.2 ± 0.6 5 minutes: <b>G1:</b> 10.0 ± 0.2 10 minutes: <b>G1:</b> 10.0 ± 0 Umbilical cord pH, mean ± SD: <b>G1:</b> 7.29 ± 0.05 <b>Adverse effects:</b> NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

Study Description	Intervention & Population	Aspects of Care	Labor and Intermediate Outcomes	Birth and Long-Term Outcomes
			Assisted: <b>G1:</b> 0  Cesarean: <b>G1:</b> 1 (4)	

---

**Comments:**

<sup>1</sup> Data only displayed graphically.



**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Yeo et al., 2007 <b>Country:</b> United Kingdom <b>Participant source:</b> NR <b>Setting:</b> NR <b>Enrollment period:</b> NR <b>Design:</b> Crossover RCT ***** <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>Active labor</li> <li>GA &gt; 36 weeks</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>Major uterine abnormalities</li> <li>Multiple gestation</li> <li>CV or respiratory instability</li> <li>Acute/chronic OB pathology/disease</li> <li>Received any prior form of analgesia</li> </ul>	<b>Groups:</b> <b>G1:</b> ESE <sup>1</sup> (double cross-over) <b>G2:</b> SES <sup>1</sup> (double cross-over) <b>Ga:</b> Entonox (E) <b>Gb:</b> Sevoflurane (S)  <b>N at enrollment:</b> <b>G1:</b> 16 <b>G2:</b> 16  <b>N at followup:</b> <b>G1:</b> 8 <b>G2:</b> 14  <b>Age, mean yrs:</b> <b>Total:</b> 32 <b>Race/ethnicity:</b> NR <b>Parous, %:</b> Nulliparous: <b>Total:</b> 91	<b>Provider preferences:</b> NR <b>Provider specialty:</b> NR <b>Cost of intervention:</b> NR <b>Other pain management methods available:</b> Epidural <b>Pain management, n (%):</b> Epidural: <b>G1a:</b> 4 <sup>2</sup> <b>G1b:</b> 0 <b>G2a:</b> 2 <b>G2b:</b> 0	<b>Pain:</b> (100 mm VAS) VAS score, mean difference (95% CI): Pain intensity, 1 <sup>st</sup> cross-over period: <b>Gb/Ga:</b> 5 (0.2,11) <b>Gb/Ga:</b> $P = 0.0395$ Pain relief, 2 <sup>nd</sup> cross-over period: <b>Gb/Ga:</b> 2 (-2,6) <b>Gb/Ga:</b> $P = 0.0006$ Pain relief, 1 <sup>st</sup> cross-over period: <b>Gb/Ga:</b> 12 (3,21) <b>Gb/Ga:</b> $P = 0.0115$ Pain relief, 2 <sup>nd</sup> cross-over period: <b>Gb/Ga:</b> 18 (8,28) <b>Gb/Ga:</b> $P = \text{NS}$ Pain relief, VAS score, median (IQR): <b>Ga:</b> 51 (32-65) <b>Gb:</b> 67 (55-74) <b>Labor progress:</b> NR <b>Fetal status:</b> NR <b>Timeliness:</b> NR <b>Labor co-interventions:</b> NR <b>Adverse effects, n:</b>	<b>Satisfaction with pain management, % (95% CI):</b> Preferred sevoflurane to Entonox: <b>Total:</b> 97 (84,99) <b>Ga/Gb:</b> $P < 0.0001$ <b>Satisfaction with birth experience:</b> NR <b>Maternal status:</b> (100 mm VAS) VAS score, mean difference (95% CI): Mood, 1 <sup>st</sup> cross-over period: <b>Gb/Ga:</b> 3 (-3,8) <b>Gb/Ga:</b> $P = \text{NS}$ Mood, 2 <sup>nd</sup> cross-over period: <b>Gb/Ga:</b> 10 (3,19) <b>Gb/Ga:</b> $P = 0.0088$ Coping, 1 <sup>st</sup> cross-over period: <b>Gb/Ga:</b> 0.2 (-6,6) <b>Gb/Ga:</b> $P = \text{NS}$ Coping, 2 <sup>nd</sup> cross-over period: <b>Gb/Ga:</b> 3 (-4,10) <b>Gb/Ga:</b> $P = \text{NS}$ <b>Neonatal status:</b> NR <b>Adverse effects:</b> NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
			Maternal: Vomiting: <b>Ga:</b> 4 <b>Gb:</b> 0 Nausea: <b>Ga:</b> 8 <b>Gb:</b> 1 <b>Ga/Gb:</b> $P = 0.004$ Neonatal: NR Occupational: NR <b>Route of birth, n (%):</b> Vaginal spontaneous: Total: 21 (68) Assisted vaginal: <b>Total:</b> 6 (19)	

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Yeo et al., 2007 (continued)			Cesarean: <b>Total: 4 (13)</b>	

---

**Comments:**

<sup>1</sup> E: nitrous mix (Entonox by piped gas supply and demand valve); S: sevoflurane with O<sub>2</sub> via draw-over vaporizer.

<sup>2</sup> All were in the last phase.

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Zack et al., 1991  <b>Country:</b> Sweden  <b>Participant source:</b> Other (registry data)  <b>Setting:</b> Not applicable (registry data)  <b>Enrollment period:</b> 1973 to 1984  <b>Design:</b> Case control *****  <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>Born between 1973 and 1984</li> <li>Registered at birth in the Swedish Medical Birth Register</li> <li>Diagnosed with leukemia</li> <li>Enrolled in Swedish National Cancer Registry</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>See inclusion criteria</li> </ul>	<b>Groups:</b> <b>G1:</b> Has leukemia <b>G2:</b> Control matched for sex, birth year, and birth month  <b>N at enrollment:</b> <b>G1:</b> 411 <b>G2:</b> 2,055  <b>N at followup:</b> <b>G1:</b> 411 <b>G2:</b> 2,055  <b>Age:</b> NR  <b>Race/ethnicity:</b> NR  <b>Parous:</b> Not applicable	<b>Provider preferences:</b> Not applicable  <b>Provider specialty:</b> Not applicable  <b>Cost of intervention:</b> Not applicable  <b>Other pain management methods available:</b> Not applicable  <b>Pain management, nitrous oxide, n (%):</b> <b>G1:</b> 245 (60) <b>G2:</b> 1,118 (54)	<b>Pain:</b> Not applicable  <b>Labor progress:</b> Not applicable  <b>Fetal status:</b> Not applicable  <b>Timeliness:</b> Not applicable  <b>Labor co-interventions:</b> Not applicable  <b>Adverse effects:</b> Not applicable  <b>Route of birth, n:</b> Vaginal: NR  Assisted: <b>G1:</b> 22 <b>G2:</b> 116  Cesarean: <b>G1:</b> 39 <b>G2:</b> 201	<b>Satisfaction with pain management:</b> Not applicable  <b>Satisfaction with birth experience:</b> Not applicable  <b>Maternal status:</b> Not applicable  <b>Neonatal status:</b> Not applicable  <b>Adverse effects:</b> Maternal: Not applicable  Neonatal: Not applicable  Childhood leukemia, odds ratio for N <sub>2</sub> O analgesia, (95% CI): <b>G1/G2:</b> 1.3 (1.0, 1.6)  Occupational: NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
<b>Author:</b> Zelcer et al., 1989  <b>Country:</b> Australia  <b>Participant source:</b> Academic single site  <b>Setting:</b> Hospital  <b>Enrollment period:</b> NR  <b>Design:</b> Prospective cohort *****  <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>First stage of labor</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>Analgesic group changed during recording</li> <li>Distressed and did not want to continue study</li> </ul>	<b>Groups:</b> <b>G1:</b> N <sub>2</sub> O for every contraction, no pethidine <b>G2:</b> N <sub>2</sub> O during every contraction and received intramuscular pethidine within the previous 150 minutes <b>G3:</b> No analgesia (control) <b>G4:</b> Good analgesia from epidural block, no opioid in preceding 150 minutes <b>G5:</b> Intramuscular pethidine within the previous 150 minutes, no N <sub>2</sub> O  <b>N at enrollment:</b> (first stage of labor) <b>Total:</b> 75  <b>N at followup:</b> <b>G1:</b> 10 <b>G2:</b> 10 <b>G3:</b> 10 <b>G4:</b> 10 <b>G5:</b> 10  <b>Age:</b> NR  <b>Race/ethnicity:</b> NR  <b>Parous:</b> NR	<b>Provider preferences:</b> NR  <b>Provider specialty:</b> NR  <b>Cost of intervention:</b> NR  <b>Other pain management methods available:</b> NR  <b>Pain management:</b> NR	<b>Pain:</b> NR  <b>Labor progress:</b> NR  <b>Fetal status:</b> NR  <b>Timeliness:</b> NR  <b>Labor co-interventions:</b> NR  <b>Adverse effects:</b> Maternal: Inspired oxygen, F <sub>I</sub> O <sub>2</sub> , mean: <b>G1:</b> 0.69 <b>G2:</b> 0.65 <b>G3:</b> 0.21 <b>G4:</b> 0.21 <b>G5:</b> 0.21  Oxygen saturation, 5 contractions, mean %: Maximum: <b>G1:</b> 100 <b>G2:</b> 100 <b>G3:</b> 99 <b>G4:</b> 99 <b>G5:</b> 99 Minimum: <b>G1:</b> 94 <b>G2:</b> 91 <b>G3:</b> 94 <b>G4:</b> 94 <b>G5:</b> 92 <b>G2/G3:</b> $P < 0.05$ Average maximum: <b>G1:</b> 100	<b>Satisfaction with pain management:</b> NR  <b>Satisfaction with birth experience:</b> NR  <b>Maternal status:</b> NR  <b>Neonatal status:</b> NR  <b>Adverse effects:</b> NR

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
			<b>G2:</b> 99 <b>G3:</b> 99 <b>G4:</b> 99 <b>G5:</b> 98 Average Minimum: <b>G1:</b> 96 <b>G2:</b> 94 <b>G3:</b> 96 <b>G4:</b> 96 <b>G5:</b> 96 <b>G2/G3:</b> $P < 0.05$ Difference between maximum and minimum (Max- Min): <b>G1:</b> 6	

**Evidence Table 1: Nitrous Oxide for Management of Labor Pain (continued)**

<b>Study Description</b>	<b>Intervention &amp; Population</b>	<b>Aspects of Care</b>	<b>Labor and Intermediate Outcomes</b>	<b>Birth and Long-Term Outcomes</b>
Zelcer et al., 1989 (continued)			<b>G2:</b> 9 <b>G3:</b> 5 <b>G4:</b> 5 <b>G5:</b> 7 <b>G2/G3:</b> $P < 0.05$  Neonatal: NR  Occupational: NR  <b>Route of birth:</b> NR	

## **Appendix D. Applicability and Quality Tables**

Table 1. Key Question 1—Applicability

Table 2. Key Question 2—Applicability

Table 3. Key Question 3—Applicability

Table 4. Key Question 4—Applicability

Table 5. The Cochrane Risk of Bias Tool for Randomized Controlled Trials

Table 6. Quality Ratings for Randomized Controlled Trials

Table 7. Quality Ratings for Cohort studies (including case series, cross-sectional, uncontrolled, and nonrandomized trials)

Table 8. Quality Ratings for Case-control Studies



**Table 1. Key Question 1—Applicability**

Domain	Description of Applicability of Evidence Compared With Question
Population	The study populations were healthy women in labor who should be similar to the target population. The eligibility criteria and participant characteristics were not always explicitly detailed. Some participants were excluded due to choice of alternate pain management methods.
Intervention	Most studies used a 50/50 mix of nitrous and oxygen, often premixed in the form of Entonox. The 50/50 mix is available, although Entonox is not used in the U.S, and not currently approved by the FDA. In addition, mechanical equipment for delivery of N2O in labor and delivery has very limited availability in the U.S.
Comparators	The comparators include standard pain management methods, such as epidural, narcotics, and nonpharmacologic methods such as TENS. However, some comparators are not commonly used and/or available for laboring women in the U.S., such as other inhalational anesthetic gases.
Outcomes	The most frequent outcome was an assessment of pain, generally during labor. Some studies retrospectively assessed pain in the immediate postpartum period and/or weeks to months after birth. The methods of pain assessment were heterogeneous. Those assessing outcomes included participants, obstetricians, midwives, and anesthesia providers.
Setting	Only five of 21 studies were conducted in the U.S. The standards of care are not comparable because nitrous is widely available outside of the U.S. All of the studies were conducted in hospitals, thus the effectiveness of the intervention in birth centers and the home setting has not been reported.

**Table 2. Key Question 2—Applicability**

Domain	Description of Applicability of Evidence Compared With Question
Population	The study populations were healthy women in labor who should be similar to the target population. The eligibility criteria and participant characteristics were not always explicitly detailed. Some participants were excluded due to choice of alternate pain management methods.
Intervention	Most studies used a 50/50 mix of nitrous and oxygen, often premixed in the form of Entonox. The 50/50 mix is available, although Entonox is not used in the U.S, and not currently approved by the FDA. In addition, mechanical equipment for delivery of N2O in labor and delivery has very limited availability in the U.S.
Comparators	The comparators include standard pain management methods, such as epidural, narcotics, and nonpharmacologic methods such as TENS. However, some comparators are not commonly used and/or available for laboring women in the U.S., such as other inhalational anesthetic gases.
Outcomes	Satisfaction with pain management and the birth experience were the outcome measures, as reported by the women.
Setting	Only three of nine studies were conducted in the U.S. The standards of care are not comparable because nitrous is widely available outside of the U.S. All of the studies were conducted in hospitals, thus the satisfaction with the intervention in birth centers and the home setting has not been reported.

**Table 3. Key Question 3—Applicability**

Domain	Description of Applicability of Evidence Compared With Question
Population	The study populations were healthy women in labor who should be similar to the target population. The eligibility criteria and participant characteristics were not always explicitly detailed. Some participants were excluded due to choice of alternate pain management methods.
Intervention	Most studies used a 50/50 mix of nitrous and oxygen, often premixed in the form of Entonox. The 50/50 mix is available, although Entonox is not used in the U.S, and not currently approved by the FDA. In addition, mechanical equipment for delivery of N2O in labor and delivery has very limited availability in the U.S.
Comparators	The comparators include standard pain management methods, such as epidural, narcotics, and nonpharmacologic methods such as TENS. However, some comparators are not commonly used and/or available for laboring women in the U.S., such as other inhalational anesthetic gases.
Outcomes	The outcomes were vaginal birth, assisted vaginal birth, and cesarean. None of the studies had a cesarean birth rate greater than 10%, which is much lower than the most recently reported U.S. rate of 32%. <sup>1</sup>
Setting	Only one of six studies was conducted in the U.S. The standards of care are not comparable because nitrous is widely available outside of the U.S. All of the studies were conducted in hospitals, thus the route of birth in birth centers and the home setting has not been reported.

**Table 4. Key Question 4—Applicability**

Domain	Description of Applicability of Evidence Compared With Question
Population	The study populations were healthy women in labor who should be similar to the target population. The eligibility criteria and participant characteristics were not always explicitly detailed. Some participants were excluded due to choice of alternate pain management methods.
Intervention	Most studies used a 50/50 mix of nitrous and oxygen, often premixed in the form of Entonox. The 50/50 mix is available, although Entonox is not used in the U.S. and not currently approved by the FDA. The intervention varied significantly in terms of dose, frequency, and duration. In many studies participants received unspecified amounts of narcotics and/or sedating agents. Studies prior to 1980 are not applicable to current guidelines for clinical use.
Comparators	The comparators include standard pain management methods, such as epidural, narcotics, and nonpharmacologic methods such as TENS. However, some comparators are not commonly used and/or available for laboring women in the U.S., such as other inhalational anesthetic gases.
Outcomes	The most frequent outcomes were assessments of nausea, vomiting, dizziness, drowsiness, hypoxia, oxygen saturation, Apgar scores, and cord blood gases. Apoptosis was not addressed because there are no human studies.
Setting	Only six of 48 studies were conducted in the U.S. The standards of care are not comparable because nitrous is widely available outside of the U.S.

**Table 5. The Cochrane Risk of Bias Tool for Randomized Controlled Trials**

<b>RANDOM SEQUENCE GENERATION</b> <b>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence.</b>	
Criteria for a judgment of 'Low risk' of bias.	<p>The investigators describe a random component in the sequence generation process such as:</p> <ul style="list-style-type: none"> <li>• Referring to a random number table;</li> <li>• Using a computer random number generator;</li> <li>• Coin tossing;</li> <li>• Shuffling cards or envelopes;</li> <li>• Throwing dice;</li> <li>• Drawing of lots;</li> <li>• Minimization*.</li> </ul> <p>*Minimization may be implemented without a random element, and this is considered to be equivalent to being random.</p>
Criteria for the judgment of 'High risk' of bias.	<p>The investigators describe a nonrandom component in the sequence generation process. Usually, the description would involve some systematic, nonrandom approach, for example:</p> <ul style="list-style-type: none"> <li>• Sequence generated by odd or even date of birth;</li> <li>• Sequence generated by some rule based on date (or day) of admission;</li> <li>• Sequence generated by some rule based on hospital or clinic record number.</li> </ul> <p>Other nonrandom approaches happen much less frequently than the systematic approaches mentioned above and tend to be obvious. They usually involve judgement or some method of nonrandom categorization of participants, for example:</p> <ul style="list-style-type: none"> <li>• Allocation by judgement of the clinician;</li> <li>• Allocation by preference of the participant;</li> <li>• Allocation based on the results of a laboratory test or a series of tests;</li> <li>• Allocation by availability of the intervention.</li> </ul>
Criteria for the judgment of 'Unclear risk' of bias.	Insufficient information about the sequence generation process to permit judgement of 'Low risk' or 'High risk'.

**Table 5. The Cochrane Risk of Bias Tool for Randomized Controlled Trials (continued)**

<b>ALLOCATION CONCEALMENT</b>	
<b>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment.</b>	
Criteria for a judgment of 'Low risk' of bias.	<p>Participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent method, was used to conceal allocation:</p> <ul style="list-style-type: none"> <li>• Central allocation (including telephone, web-based and pharmacy-controlled randomization);</li> <li>• Sequentially numbered drug containers of identical appearance;</li> <li>• Sequentially numbered, opaque, sealed envelopes.</li> </ul>
Criteria for the judgment of 'High risk' of bias.	<p>Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation based on:</p> <ul style="list-style-type: none"> <li>• Using an open random allocation schedule (e.g. a list of random numbers);</li> <li>• Assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or nonopaque or not sequentially numbered);</li> <li>• Alternation or rotation;</li> <li>• Date of birth;</li> <li>• Case record number;</li> <li>• Any other explicitly unconcealed procedure.</li> </ul>
Criteria for the judgment of 'Unclear risk' of bias.	<p>Insufficient information to permit judgement of 'Low risk' or 'High risk'. This is usually the case if the method of concealment is not described or not described in sufficient detail to allow a definite judgement – for example if the use of assignment envelopes is described, but it remains unclear whether envelopes were sequentially numbered, opaque and sealed.</p>
<b>SELECTIVE REPORTING</b>	
<b>Reporting bias due to selective outcome reporting.</b>	
Criteria for a judgment of 'Low risk' of bias.	<p>Any of the following:</p> <ul style="list-style-type: none"> <li>• The study protocol is available and all of the study's prespecified (primary and secondary) outcomes that are of interest in the review have been reported in the prespecified way;</li> <li>• The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were prespecified (convincing text of this nature may be uncommon).</li> </ul>
Criteria for the judgment of 'High risk' of bias.	<p>Any one of the following:</p> <ul style="list-style-type: none"> <li>• Not all of the study's prespecified primary outcomes have been reported;</li> <li>• One or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not prespecified;</li> <li>• One or more reported primary outcomes were not prespecified (unless clear justification for their reporting is provided, such as an unexpected adverse effect);</li> <li>• One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis;</li> <li>• The study report fails to include results for a key outcome that would be expected to have been reported for such a study.</li> </ul>
Criteria for the judgment of 'Unclear risk' of bias.	<p>Insufficient information to permit judgement of 'Low risk' or 'High risk'. It is likely that the majority of studies will fall into this category.</p>

**Table 5. The Cochrane Risk of Bias Tool for Randomized Controlled Trials (continued)**

<b>OTHER BIAS</b> <b>Bias due to problems not covered elsewhere in the table.</b>	
Criteria for a judgment of 'Low risk' of bias.	The study appears to be free of other sources of bias.
Criteria for the judgment of 'High risk' of bias.	There is at least one important risk of bias. For example, the study: <ul style="list-style-type: none"> <li>• Had a potential source of bias related to the specific study design used; or</li> <li>• Has been claimed to have been fraudulent; or</li> <li>• Had some other problem.</li> </ul>
Criteria for the judgment of 'Unclear risk' of bias.	There may be a risk of bias, but there is either: <ul style="list-style-type: none"> <li>• Insufficient information to assess whether an important risk of bias exists; or</li> <li>• Insufficient rationale or evidence that an identified problem will introduce bias.</li> </ul>
<b>BLINDING OF PARTICIPANTS AND PERSONNEL</b> <b>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study.</b>	
Criteria for a judgment of 'Low risk' of bias.	Any one of the following: <ul style="list-style-type: none"> <li>• No blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding;</li> <li>• Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.</li> </ul>
Criteria for the judgment of 'High risk' of bias.	Any one of the following: <ul style="list-style-type: none"> <li>• No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding;</li> <li>• Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.</li> </ul>
Criteria for the judgment of 'Unclear risk' of bias.	Any one of the following: <ul style="list-style-type: none"> <li>• Insufficient information to permit judgment of 'Low risk' or 'High risk';</li> <li>• The study did not address this outcome.</li> </ul>

**Table 5. The Cochrane Risk of Bias Tool for Randomized Controlled Trials (continued)**

<b>BLINDING OF OUTCOME ASSESSMENT</b> <b>Detection bias due to knowledge of the allocated interventions by outcome assessors.</b>	
Criteria for a judgment of 'Low risk' of bias.	Any one of the following: <ul style="list-style-type: none"> <li>No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding;</li> <li>Blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.</li> </ul>
Criteria for the judgment of 'High risk' of bias.	Any one of the following: <ul style="list-style-type: none"> <li>No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding;</li> <li>Blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.</li> </ul>
Criteria for the judgment of 'Unclear risk' of bias.	Any one of the following: <ul style="list-style-type: none"> <li>Insufficient information to permit judgment of 'Low risk' or 'High risk';</li> <li>The study did not address this outcome.</li> </ul>
<b>INCOMPLETE OUTCOME DATA</b> <b>Attrition bias due to amount, nature or handling of incomplete outcome data.</b>	
Criteria for a judgment of 'Low risk' of bias.	Any one of the following: <ul style="list-style-type: none"> <li>No missing outcome data;</li> <li>Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias);</li> <li>Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups;</li> <li>For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate;</li> <li>For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size;</li> <li>Missing data have been imputed using appropriate methods.</li> </ul>
Criteria for the judgment of 'High risk' of bias.	Any one of the following: <ul style="list-style-type: none"> <li>Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups;</li> <li>For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate;</li> <li>For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size;</li> <li>'As-treated' analysis done with substantial departure of the intervention received from that assigned at randomization;</li> <li>Potentially inappropriate application of simple imputation.</li> </ul>
Criteria for the judgment of 'Unclear risk' of bias.	Any one of the following: <ul style="list-style-type: none"> <li>Insufficient reporting of attrition/exclusions to permit judgement of 'Low risk' or 'High risk' (e.g. number randomized not stated, no reasons for missing data provided);</li> <li>The study did not address this outcome.</li> </ul>



Thresholds for converting the Cochrane Risk of Bias tool to AHRQ standards (good, fair, and poor):

**Good quality:** All criteria met (i.e. low for each domain)

Using the Cochrane ROB tool, it is possible for a criterion to be met even when the element was technically not part of the method. For instance, a judgment that knowledge of the allocated interventions was adequately prevented can be made even if the study was not blinded, if EPC team members judge that the outcome and the outcome measurement are not likely to be influenced by lack of blinding.

**Fair quality:** One criterion not met (i.e. high risk of bias for one domain) or two criteria unclear, and the assessment that this was **unlikely** to have biased the outcome, and there is no known important limitation that could invalidate the results

**Poor quality:** One criterion not met (i.e. high risk of bias for one domain) or two criteria unclear, and the assessment that this was **likely** to have biased the outcome, and there are important limitations that could invalidate the results

**Poor quality:** Two or more criteria listed as high or unclear risk of bias

**Table 6. Quality ratings for randomized control trials**

<b>Citation</b>	<b>Quality Rating</b>	<b>Random Sequence Generation</b>	<b>Allocation Concealment</b>	<b>Selective Reporting</b>	<b>Other Sources of Bias</b>	<b>Blinding (Participants and Personnel)</b>	<b>Blinding (Outcome Assessment)</b>	<b>Incomplete Outcome Data</b>
Abboud et al., <sup>2</sup> 1995	Poor	L	L	L	L	H	H	L
Abboud et al., <sup>3</sup> 1989	Poor	U	U	L	L	H	H	L
Abboud et al., <sup>4</sup> 1981	Poor	U	U	L	U	H	H	L
Arora et al., <sup>5</sup> 1992	Fair	L	L	L	U	L	L	L
Bergsjö and Lindbaek, <sup>6</sup> 1971	Poor	L	L	L	U	U	U	L
Carstoniu et al., <sup>7</sup> 1994	Poor	L	H	L	L	H	H	L
Chia et al., <sup>8</sup> 1990	Poor	H	H	L	H	H	H	L
Constantine et al., <sup>9</sup> 1989	Poor	U	H	L	U	H	H	L
Einarsson et al., <sup>10</sup> 1996	Poor	U	U	L	U	U	U	L
Jones et al., <sup>11</sup> 1969	Poor	U	U	L	U	L	U	L
Jones et al., <sup>12</sup> 1969	Poor	U	U	L	U	U	U	L
McGuinness and Rosen, <sup>13</sup> 1984	Poor	U	U	L	U	U	L	L
McLeod et al., <sup>14</sup> 1985	Poor	U	U	L	U	L	U	L
NA, <sup>15</sup> 1970	Fair	U	L	L	L	L	L	L

**Table 6. Quality ratings for randomized control trials (continued)**

<b>Citation</b>	<b>Quality Rating</b>	<b>Random Sequence Generation</b>	<b>Allocation Concealment</b>	<b>Selective Reporting</b>	<b>Other Sources of Bias</b>	<b>Blinding (Participants and Personnel)</b>	<b>Blinding (Outcome Assessment)</b>	<b>Incomplete Outcome Data</b>
Phillips and Macdonald, <sup>16</sup> 1971	Poor	U	U	L	H	U	U	H
Rosen et al., <sup>17</sup> 1972	Poor	H	U	L	L	H	U	L
Talebi et al., <sup>18</sup> 2009	Poor	L	U	L	U	U	U	U
Westling et al., <sup>19</sup> 1992	Poor	H	H	L	U	H	H	L
Yeo et al., <sup>20</sup> 2007	Poor	U	H	H	U	H	H	L

H = high; L = low; U = unclear

## Newcastle-Ottawa Quality Assessment Form for Cohort Studies

Note: A study can be given a maximum of one star for each numbered item within the Selection and Outcome categories. A maximum of two stars can be given for Comparability.

### Selection

- 1) Representativeness of the exposed cohort
  - a) Truly representative (*one star*)
  - b) Somewhat representative (*one star*)
  - c) Selected group
  - d) No description of the derivation of the cohort
- 2) Selection of the nonexposed cohort
  - a) Drawn from the same community as the exposed cohort (*one star*)
  - b) Drawn from a different source
  - c) No description of the derivation of the non exposed cohort
- 3) Ascertainment of exposure
  - a) Secure record (e.g., surgical record) (*one star*)
  - b) Structured interview (*one star*)
  - c) Written self report
  - d) No description
  - e) Other
- 4) Demonstration that outcome of interest was not present at start of study
  - a) Yes (*one star*)
  - b) No

### Comparability

- 1) Comparability of cohorts on the basis of the design or analysis controlled for confounders
  - ☐ The study controls for age, sex and marital status (*one star*)
  - ☐ Study controls for other factors (list) \_\_\_\_\_ (*one star*)
  - ☐ Cohorts are not comparable on the basis of the design or analysis controlled for confounders
  - ☐ No comparison group\*
  - ☐ N/A\*

### Outcome

- 1) Assessment of outcome
  - a) Independent blind assessment (*one star*)
  - b) Record linkage (*one star*)
  - c) Self report
  - d) No description
  - e) Other
- 2) Was followup long enough for outcomes to occur
  - ☐ Yes (*one star*)
  - ☐ No

Indicate the median duration of followup and a brief rationale for the assessment above:\_\_\_\_\_

3) Adequacy of followup of cohorts

- a) Complete follow up- all subject accounted for (*one star*)
- b) Subjects lost to follow up unlikely to introduce bias- number lost less than or equal to 20% or description of those lost suggested no different from those followed. (*one star*)
- c) Follow up rate greater than 80% and no description of those lost
- d) No statement

*\*Added by Vanderbilt EPC*

## Newcastle-Ottawa Quality Assessment Form for Case-control Studies

Note: A study can be given a maximum of one star for each numbered item within the Selection and Exposure categories. A maximum of two stars can be given for Comparability.

### Selection

- 1) Is the case definition adequate?
  - a) Yes, with independent validation (*one star*)
  - b) Yes, e.g., record linkage or based on self report
  - c) No description
- 2) Representativeness of the cases
  - a) Consecutive or obviously representative series of cases (*one star*)
  - b) Potential for selection biases or not stated
- 3) Selection of controls
  - a) Community controls (*one star*)
  - b) Hospital controls
  - c) No description
- 4) Definition of controls
  - a) No history of disease (endpoint) (*one star*)
  - b) No description of source

### Comparability

- 1) Comparability of cases and controls on the basis of the design or analysis controlled for confounders
  - ☐ The study controls for age, sex and marital status (*one star*)
  - ☐ Study controls for other factors (list) \_\_\_\_\_ (*one star*)
  - ☐ Cohorts are not comparable on the basis of the design or analysis controlled for confounders
  - ☐ No comparison group\*
  - ☐ N/A\*

### Exposure

- 1) Ascertainment of exposure
  - a) Secure record (e.g., surgical record) (*one star*)
  - b) Structured interview where blind to case/control status (*one star*)
  - c) Interview not blinded to case/control status
  - d) Written self report or medical record only
  - e) No description
- 2) Same method of ascertainment for cases and controls
  - ☐ Yes (*one star*)
  - ☐ No
- 3) Nonresponse rate
  - a) Same rate for both groups (*one star*)
  - b) Nonrespondents described
  - c) Rate different between cases and controls with no description

*\*Added by Vanderbilt EPC*

Thresholds for converting the Newcastle-Ottawa scales to AHRQ standards (good, fair, and poor):

**Good quality:** 3 or 4 stars in selection domain AND 1 or 2 stars in comparability domain AND 2 or 3 stars in outcome/exposure domain

**Fair quality:** 2 stars in selection domain AND 1 or 2 stars in comparability domain AND 2 or 3 stars in outcome/exposure domain

**Poor quality:** 0 or 1 star in selection domain OR 0 stars in comparability domain OR 0 or 1 stars in outcome/exposure domain

The Vanderbilt EPC included two additional options in the comparability domain not generally included in the Newcastle-Ottawa scales: “no comparison group” and “not applicable”. This was necessary because the review included single-arm studies for both the effectiveness and harms assessments.

Studies of the effectiveness of nitrous oxide for the management of labor pain that included only one study arm were marked as “no comparison group”, which equates to receiving no stars and an automatic rating of poor quality.

Cross sectional studies used to identify potential harms and measures of environmental exposure could appropriately have no comparison group, and were marked for comparability as “not applicable.” The quality scores for these studies were downgraded to account for their noncomparative study designs. For example, a study with three or four stars in the selection domain and two or three stars in the outcome/exposure domain, which would normally equate to a “good” quality rating, would be deemed “fair” quality if the comparability domain response was “not applicable”.



**Table 7. Quality ratings for cohort studies (including case series, cross-sectional, uncontrolled and nonrandomized trials)**

Citation	Quality Rating	Selection (0-4 Stars)				Comparability (n/a, 0-2 Stars)	Outcome (0-3 Stars)		
		Representativeness of Exposed Cohort	Selection of Nonexposed	Ascertainment of Exposure	Outcome Not Present at Start of Study	Comparability of Cohorts	Assessment	Long Enough Followup	Adequacy of Followup
Ahlborg et al., <sup>21</sup> 1996	Fair	c)selected group	a)drawn from same community	c)written self report	a) yes	N/A	c)self report	a) yes	b)unlikely to introduce bias
Arfeen et al., <sup>22</sup> 1994	Poor	a)truly representative	a)drawn from same community	a)secure record	a) yes	no	b)record linkage	a) yes	b)unlikely to introduce bias
Arthurs et al., <sup>23</sup> 1979	Poor	d)no description	a)drawn from same community cohort	a)secure record	a) yes	no	c) self report	a) yes	a)complete follow up for
Axelsson et al., <sup>24</sup> 1996	Poor	c)selected group	a)drawn from same community	c)written self report	a) yes	N/A	c)self report	a) yes	b)unlikely to introduce bias
Beppu <sup>25</sup> 1968	Poor	d) no description	c) no description	a)secure record	a) yes	NC	b) record linkage	a) yes	a)complete follow up
Bodin et al., <sup>26</sup> 1999	Poor	c)selected group	a)drawn from same community	c)written self report	a) yes	no	b)record linkage	a) yes	b)unlikely to introduce bias lost
Clark et al., <sup>27</sup> 1967	Fair	d) no description	c) no description	a)secure record	a) yes	no	b) record linkage	a) yes	a)complete follow up
Deckardt et al., <sup>28</sup> 1987	Poor	d)no description	a)drawn from same community	a)secure record	a) yes	no	b) record linkage	a) yes	a)complete follow up

**Table 7. Quality ratings for cohort studies (including case series, cross-sectional, uncontrolled and nonrandomized trials) (continued)**

Citation	Quality Rating	Selection (0-4 Stars)				Comparability (n/a, 0-2 Stars)	Outcome (0-3 Stars)		
		Representativeness of Exposed Cohort	Selection of Nonexposed	Ascertainment of Exposure	Outcome Not Present at Start of Study	Comparability of Cohorts	Assessment	Long Enough Followup	Adequacy of Followup
Harrison et al., <sup>29</sup> 1987	Poor	b)somewhat representative	a)drawn from same community	a)secure record	a) yes	no	c) self report	a) yes	a)complete follow up
Harrison and Cullen <sup>30</sup> 1986	Poor	b)somewhat representative	a) drawn from same community	a) secure record	a) yes	no	a)independent assessment	a) yes	a)complete follow up
Henderson et al., <sup>31</sup> 2003	Fair	a)truly representative	a)drawn from same community	a)secure record	b) no	N/A	a)independent assessment	a) yes	a)complete follow up
Henry and Nand, <sup>32</sup> 2004	Poor	b)somewhat representative	a)drawn from same community	a)secure record	a) yes	no	c) self report	a) yes	b)unlikely to introduce bias
Holdcroft and Morgan, <sup>33</sup> 1974	Poor	b)somewhat representative	a) drawn from same community	c)written self report	a) yes	no	c) self report	a) yes	b)unlikely to introduce bias
Landon et al., <sup>34</sup> 1992	Poor	a)truly representative	a)drawn from same community	a)secure record	a) yes	no	b) record linkage	a) yes	a)complete follow up
Leong et al., <sup>35</sup> 2000	Good	b)somewhat representative	a)drawn from same community	a)secure record	a) yes	both	c) self report	a) yes	b)unlikely to introduce bias

**Table 7. Quality ratings for cohort studies (including case series, cross-sectional, uncontrolled and nonrandomized trials) (continued)**

Citation	Quality Rating	Selection (0-4 Stars)				Comparability (n/a, 0-2 Stars)	Outcome (0-3 Stars)		
		Representativeness of Exposed Cohort	Selection of Nonexposed	Ascertainment of Exposure	Outcome Not Present at Start of Study	Comparability of Cohorts	Assessment	Long Enough Followup	Adequacy of Followup
Marx et al., <sup>36</sup> 1970	Poor	c)selected group	a) drawn from same community	a)secure record	a) yes	NC	b) record linkage	a) yes	d) no statement
McAneny and Doughty, <sup>37</sup> 1963	Poor	d) no description	a) drawn from same community	a)secure record	a) yes	no	a)independent blind assessment	a) yes	b)unlikely to introduce bias
Mills et al., <sup>38</sup> 1996	Fair	c)selected group	a) drawn from same community	a)secure record	a) yes	N/A	b) record linkage	a) yes	a)complete follow up
Morgan et al., <sup>39</sup> 1982	Poor	a)truly representative	a)drawn from same community	a)secure record	a) yes	no	c) self report	a) yes	a)complete follow up
Murphy et al., <sup>40</sup> 1984	Poor	a) truly representative	a) drawn from same community	a)secure record	a) yes	no	b) record linkage	a) yes	a)complete follow up
Newton et al., <sup>41</sup> 1999	Fair	c)selected group	a) drawn from same community	a)secure record	a) yes	N/A	b) record linkage	a) yes	b)unlikely to introduce bias
Peach, <sup>42</sup> 1999	Fair	a)truly representative	a)drawn from same community	a)secure record	a) yes	N/A	c) self report	a) yes	b)unlikely to introduce bias lost

**Table 7. Quality ratings for cohort studies (including case series, cross-sectional, uncontrolled and nonrandomized trials) (continued)**

Citation	Quality Rating	Selection (0-4 Stars)				Comparability (n/a, 0-2 Stars)	Outcome (0-3 Stars)		
		Representativeness of Exposed Cohort	Selection of Nonexposed	Ascertainment of Exposure	Outcome Not Present at Start of Study	Comparability of Cohorts	Assessment	Long Enough Followup	Adequacy of Followup
Ranta et al., <sup>43</sup> 1995	Fair	a) truly representative	a) drawn from same community	a)secure record	a) yes	N/A	c) self report	a) yes	b)unlikely to introduce bias
Ranta et al., <sup>44</sup> 1994	Poor	b)somewhat representative	a) drawn from same community	a)secure record	a) yes	no	c) self report	a) yes	b)unlikely to introduce bias
Reed et al., <sup>45</sup> 1988	Poor	b)somewhat representative	a)drawn from same community	a)secure record	a) yes	no	b) record linkage	a) yes	a)complete follow up
Rosen et al., <sup>46</sup> 1969	Poor	a)truly representative	a) drawn from same community	a)secure record	a) yes	no	c) self report	a) yes	b)unlikely to introduce bias -
Ross et al., <sup>47</sup> 1999	Poor	c)selected group	c)no description	a)secure record	a) yes	NC	b) record linkage	a) yes	b)unlikely to introduce bias
Smith et al., <sup>48</sup> 1968	Poor	a) truly representative	a) drawn from same community	a)secure record	a) yes	no	a)independent assessment	a) yes	b)unlikely to introduce bias
Soyannwo, <sup>49</sup> 1985	Poor	d)no description	a)drawn from same community	a)secure record	a) yes	no	c) self report	a) yes	a)complete follow up

**Table 7. Quality ratings for cohort studies (including case series, cross-sectional, uncontrolled and nonrandomized trials) (continued)**

Citation	Quality Rating	Selection (0-4 Stars)				Comparability (n/a, 0-2 Stars)	Outcome (0-3 Stars)		
		Representativeness of Exposed Cohort	Selection of Nonexposed	Ascertainment of Exposure	Outcome Not Present at Start of Study	Comparability of Cohorts	Assessment	Long Enough Followup	Adequacy of Followup
Stirk et al., <sup>50</sup> 2002	Poor	b)somewhat representative	a) drawn from same community	a)secure record	a) yes	no	b) record linkage	a) yes	a) complete follow up
Waldenstrom and Irestedt, <sup>51</sup> 2006	Fair	a)truly representative	a)drawn from same community	c) written self report	a) yes	N/A	c) self report	a) yes	b)unlikely to introduce bias -
Waldenstrom, <sup>52</sup> 1999	Fair	b)somewhat representative	a)drawn from same community	a) secure record	a) yes	N/A	c) self report	a) yes	b)unlikely to introduce bias -
Waldenstrom et al., <sup>54</sup> 1996	Fair	a) truly representative	a) drawn from same community	a)secure record	a) yes	N/A	c) self report	a) yes	b)unlikely to introduce bias
Westberg et al., <sup>53</sup> 2008	Fair	c)selected group	a) drawn from same community	a)secure record	a) yes	N/A	b) record linkage	a) yes	a)complete follow up
Zelcer et al., <sup>55</sup> 1989	Poor	d)no description	c)no description	a)secure record	a) yes	no	b) record linkage	a) yes	b)unlikely to introduce bias

**Table 8. Quality ratings for case-control studies**

Citation	Quality Rating	Selection (0-4 Stars)				Comparability (n/a, 0-2 Stars)	Outcome (0-3 Stars)		
		Adequate Case Definition	Representativeness of Cases	Selection of Controls	Definition of Controls	Comparability of Cases and controls	Ascertainment of Exposure	Same Method of Ascertainment	Nonresponse rate
Jacobson et al., <sup>56</sup> 1990	Poor	b) yes, e.g., record linkage or based on self report	b) potential for selection biases or not stated	a)community	a) no history of disease (endpoint)	no	a) secure record	a) yes	a) same
Jacobson et al., <sup>57</sup> 1988	Poor	b) yes, e.g., record linkage or based on self report	b) potential for selection biases or not stated	a)community	a) no history of disease (endpoint)	no	a) secure record (	a) yes	a) same
Nyberg et al., <sup>58</sup> 1992	Poor	b) yes, e.g., record linkage or based on self report	a) consecutive or obviously representative series of cases	a)community	a) no history of disease (endpoint)	no	a) secure record	a) yes	a) same
Zack et al., <sup>59</sup> 1991	Good	b) yes, e.g., record linkage or based on self report	a) consecutive or obviously representative series of cases	a)community	a) no history of disease (endpoint)	other	a) secure record	a) yes	a) same

1. Martin JA, Hamilton BE, Sutton PD, et al. Births: Final Data for 2008. National Vital Statistics Reports. Released December 8, 2010;59(1):1-72.
2. Abboud TK, Swart F, Zhu J, et al. Desflurane analgesia for vaginal delivery. *Acta Anaesthesiol Scand*. 1995 Feb;39(2):259-61.
3. Abboud TK, Gangolly J, Mosaad P, et al. Isoflurane in obstetrics. *Anesth Analg*. 1989 Mar;68(3):388-91.
4. Abboud TK, Shnider SM, Wright RG, et al. Enflurane analgesia in obstetrics. *Anesth Analg*. 1981 Mar;60(3):133-7.
5. Arora S, Tunstall M and Ross J. Self-administered mixture of Entonox and isoflurane in labour. *Int J Obstet Anesth*. 1992 Sep;1(4):199-202.
6. Bergsjö P and Lindbaek E. Comparison between nitrous oxide and methoxyflurane for obstetrical analgesia. *Acta Obstet Gynecol Scand*. 1971;50(3):285-90.
7. Carstoniu J, Levytam S, Norman P, et al. Nitrous oxide in early labor. Safety and analgesic efficacy assessed by a double-blind, placebo-controlled study. *Anesthesiology*. 1994 Jan;80(1):30-5.
8. Chia YT, Arulkumaran S, Chua S, et al. Effectiveness of transcutaneous electric nerve stimulator for pain relief in labour. *Asia Oceania J Obstet Gynaecol*. 1990 Jun;16(2):145-51.
9. Constantine G, Luesley DM, O'Connor A, et al. The use of Entonox in conjunction with a rebreathing humidifier. *J Obstet Gynaecol*. 1989;10(1):23-25.
10. Einarsson S, Stenqvist O, Bengtsson A, et al. Gas kinetics during nitrous oxide analgesia for labour. *Anaesthesia*. 1996 May;51(5):449-52.
11. Jones PL, Rosen M, Mushin WW, et al. Methoxyflurane and nitrous oxide as obstetric analgesics. I. A comparison by continuous administration. *Br Med J*. 1969 Aug 2;3(5665):255-9.
12. Jones PL, Rosen M, Mushin WW, et al. Methoxyflurane and nitrous oxide as obstetric analgesics. II. A comparison by self-administered intermittent inhalation. *Br Med J*. 1969 Aug 2;3(5665):259-62.
13. McGuinness C and Rosen M. Enflurane as an analgesic in labour. *Anaesthesia*. 1984 Jan;39(1):24-6.
14. McLeod DD, Ramayya GP and Tunstall ME. Self-administered isoflurane in labour. A comparative study with Entonox. *Anaesthesia*. 1985 May;40(5):424-6.
15. Clinical trials of different concentrations of oxygen and nitrous oxide for obstetric analgesia. Report to the Medical Research Council of the Committee on Nitrous Oxide and Oxygen Analgesia in Midwifery. *Br Med J*. 1970 Mar 21;1(5698):709-13.
16. Phillips TJ and Macdonald RR. Comparative effect of pethidine, trichloroethylene, and Entonox on fetal and neonatal acid-base and PO<sub>2</sub>. *Br Med J*. 1971 Sep 4;3(5774):558-60.

17. Rosen M, Latto P and Asscher AW. Kidney function after methoxyflurane analgesia during labour. *Br Med J*. 1972 Jan 8;1(5792):81-3.
18. Talebi H, Nourozi A, Jamilian M, et al. Entonox for labor pain: a randomized placebo controlled trial. *Pak J Biol Sci*. 2009 Sep 1;12(17):1217-21.
19. Westling F, Milsom I, Zetterstrom H, et al. Effects of nitrous oxide/oxygen inhalation on the maternal circulation during vaginal delivery. *Acta Anaesthesiol Scand*. 1992 Feb;36(2):175-81.
20. Yeo ST, Holdcroft A, Yentis SM, et al. Analgesia with sevoflurane during labour: ii. Sevoflurane compared with Entonox for labour analgesia. *Br J Anaesth*. 2007 Jan;98(1):110-5.
21. Ahlborg G, Jr., Axelsson G and Bodin L. Shift work, nitrous oxide exposure and subfertility among Swedish midwives. *Int J Epidemiol*. 1996 Aug;25(4):783-90.
22. Arfeen Z, Armstrong PJ and Whitfield A. The effects of Entonox and epidural analgesia on arterial oxygen saturation of women in labour. *Anaesthesia*. 1994 Jan;49(1):32-4.
23. Arthurs GJ and Rosen M. Self-administered intermittent nitrous oxide analgesia for labour. Enhancement of effect with continuous nasal inhalation of 50 per cent nitrous oxide (Entonox). *Anaesthesia*. 1979 Apr;34(4):301-9.
24. Axelsson G, Ahlborg G, Jr. and Bodin L. Shift work, nitrous oxide exposure, and spontaneous abortion among Swedish midwives. *Occup Environ Med*. 1996 Jun;53(6):374-8.
25. Beppu K. Transmission of the anesthetic agents through the placenta in painless delivery and their effects on newborn infants. *Keio J Med*. 1968 Jun;17(2):81-107.
26. Bodin L, Axelsson G and Ahlborg G, Jr. The association of shift work and nitrous oxide exposure in pregnancy with birth weight and gestational age. *Epidemiology*. 1999 Jul;10(4):429-36.
27. Clark RB, Cooper JO, Brown WE, et al. An evaluation of methoxyflurane analgesia and anesthesia for obstetrics. *South Med J*. 1968 Jul;61(7):687-91.
28. Deckardt R, Fembacher PM, Schneider KT, et al. Maternal arterial oxygen saturation during labor and delivery: pain-dependent alterations and effects on the newborn. *Obstet Gynecol*. 1987 Jul;70(1):21-5.
29. Harrison RF, Shore M, Woods T, et al. A comparative study of transcutaneous electrical nerve stimulation (TENS), entonox, pethidine + promazine and lumbar epidural for pain relief in labor. *Acta Obstet Gynecol Scand*. 1987;66(1):9-14.
30. Harrison RF and Cullen R. A comparative study of the behaviour of the neonate following various forms of maternal intrapartum analgesia and anaesthesia. *Ir J Med Sci*. 1986;155(1):12-18.



31. Henderson KA, Matthews IP, Adishes A, et al. Occupational exposure of midwives to nitrous oxide on delivery suites. *Occup Environ Med.* 2003 Dec;60(12):958-61.
32. Henry A and Nand SL. Intrapartum pain management at the Royal Hospital for Women. *Aust N Z J Obstet Gynaecol.* 2004 Aug;44(4):307-13.
33. Holdcroft A and Morgan M. An assessment of the analgesic effect in labour of pethidine and 50 per cent nitrous oxide in oxygen (Entonox). *J Obstet Gynaecol Br Commonw.* 1974 Aug;81(8):603-7.
34. Landon MJ, Creagh-Barry P, McArthur S, et al. Influence of vitamin B12 status on the inactivation of methionine synthase by nitrous oxide. *Br J Anaesth.* 1992 Jul;69(1):81-6.
35. Leong EW, Sivanesaratnam V, Oh LL, et al. Epidural analgesia in primigravidae in spontaneous labour at term: a prospective study. *J Obstet Gynaecol Res.* 2000 Aug;26(4):271-5.
36. Marx GF, Joshi CW and Orkin LR. Placental transmission of nitrous oxide. *Anesthesiology.* 1970 May;32(5):429-32.
37. McAneny T and Doughty A. Self-administered nitrous-oxide/oxygen analgesia in obstetrics. *Anaesthesia.* 1963 1963;18(4):488-497.
38. Mills GH, Singh D, Longan M, et al. Nitrous oxide exposure on the labour ward. *Int J Obstet Anesth.* 1996 Jul;5(3):160-4.
39. Morgan B, Bulpitt CJ, Clifton P, et al. Effectiveness of pain relief in labour: survey of 1000 mothers. *Br Med J (Clin Res Ed).* 1982 Sep 11;285(6343):689-90.
40. Murphy JF, Dauncey M and Rees GAD. Obstetric analgesia, anaesthesia and the Apgar score. *Anaesthesia.* 1984;39(8):760-763.
41. Newton C, Fitz-Henry J and Bogod D. The occupational exposure of midwives to nitrous oxide - a comparison between two labour suites. *Int J Obstet Anesth.* 1999 Jan;8(1):7-10.
42. Paech MJ. The King Edward Memorial Hospital 1,000 mother survey of methods of pain relief in labour. *Anaesth Intensive Care.* 1991 Aug;19(3):393-9.
43. Ranta P, Spalding M, Kangas-Saarela T, et al. Maternal expectations and experiences of labour pain - options of 1091 Finnish parturients. *Acta Anaesthesiol Scand.* 1995;39(1):60-66.
44. Ranta P, Jouppila P, Spalding M, et al. Parturients' assessment of water blocks, pethidine, nitrous oxide, paracervical and epidural blocks in labour. *Int J Obstet Anesth.* 1994;3(4):193-198.
45. Reed PN, Colquhoun AD and Hanning CD. Maternal oxygenation during normal labour. *Br J Anaesth.* 1989 Mar;62(3):316-8.
46. Rosen M, Mushin WW, Jones PL, et al. Field trial of methoxyflurane, nitrous oxide, and trichloroethylene as obstetric analgesics. *Br Med J.* 1969 Aug 2;3(5665):263-7.

47. Ross JA, Tunstall ME, Campbell DM, et al. The use of 0.25% isoflurane premixed in 50% nitrous oxide and oxygen for pain relief in labour. *Anaesthesia*. 1999 Dec;54(12):1166-72.
48. Smith BE and Moya F. Inhalational analgesia with methoxyflurane for vaginal delivery. *South Med J*. 1968 Apr;61(4):386-90.
49. Soyannwo OA. Self-administered Entonox (50% nitrous oxide in oxygen) in labour: report of the experience in Ibadan. *Afr J Med Med Sci*. 1985 Mar-Jun;14(1-2):95-8.
50. Stirk P, Staines J and Brown DW. Maternal diamorphine administration during labour: the effect on neonate admissions to NNU. *J Neonatal Nurs*. 2002;8(2):56-7.
51. Waldenstrom U and Irestedt L. Obstetric pain relief and its association with remembrance of labor pain at two months and one year after birth. *J Psychosom Obstet Gynaecol*. 2006 Sep;27(3):147-56.
52. Waldenstrom U. Experience of labor and birth in 1111 women. *J Psychosom Res*. 1999 Nov;47(5):471-82.
53. Westberg H, Egelrud L, Ohlson CG, et al. Exposure to nitrous oxide in delivery suites at six Swedish hospitals. *Int Arch Occup Environ Health*. 2008;81(7):829-836.
54. Waldenstrom U, Bergman V and Vasell G. The complexity of labor pain: Experiences of 278 women. *J Psychosom Obstet Gynaecol*. 1996;17(4):215-228.
55. Zelcer J, Owers H and Paull JD. A controlled oximetric evaluation of inhalational, opioid and epidural analgesia in labour. *Anaesth Intensive Care*. 1989 Nov;17(4):418-21.
56. Jacobson B, Nyberg K, Gronbladh L, et al. Opiate addiction in adult offspring through possible imprinting after obstetric treatment. *BMJ*. 1990 Nov 10;301(6760):1067-70.
57. Jacobson B, Nyberg K, Eklund G, et al. Obstetric pain medication and eventual adult amphetamine addiction in offspring. *Acta Obstet Gynecol Scand*. 1988;67(8):677-82.
58. Nyberg K, Allebeck P, Eklund G, et al. Socio-economic versus obstetric risk factors for drug addiction in offspring. *Br J Addict*. 1992 Dec;87(12):1669-76.
59. Zack M, Adami HO and Ericson A. Maternal and perinatal risk factors for childhood leukemia. *Cancer Res*. 1991 Jul 15;51(14):3696-701.

## Appendix E. Excluded Studies

### Exclusion codes:

**X-1: Not original research (reviews, editorials, commentaries, letters to editor, etc)**

**X-2: Ineligible study size**

**X-3: Not related to the use of nitrous oxide for the management of labor pain**

**X-4: Not published in English**

**X-5: Did not address study questions**

1. Penthrane for obstetrical anesthesia. *Med Lett Drugs Ther* 1967 Mar 24;9(6):23-4. X-3.
2. End of an era. *Br Med J* 1969 Dec 13;4(5684):636-7. X-1, X-2, X-3, X-5.
3. Editorial: Nitrous-oxide analgesia. *Lancet* 1973 Oct 20;2(7834):891. X-1, X-2, X-3, X-5.
4. Letter: Complication of laparoscopy during early pregnancy. *Br Med J* 1974 Mar 30;1(5908):637-8. X-1, X-2, X-3, X-5.
5. Occupational disease among operating room personnel: a national study. Report of an Ad Hoc Committee on the Effect of Trace Anesthetics on the Health of Operating Room Personnel, American Society of Anesthesiologists. *Anesthesiology* 1974 Oct;41(4):321-40. X-3d, X-5.
6. Editorial: Pregnancy and anaesthesia. *Lancet* 1975 Jul 26;2(7926):169. X-1, X-2, X-3, X-5.
7. Editorial: Awareness during anaesthesia. *Br Med J* 1976 Apr 24;1(6016):977. X-1, X-2, X-3, X-5.
8. Intrauterine foetal death associated with dental anaesthesia. *SAAD Dig* 1980 Jul;4(7):166-7. X-1, X-2, X-3, X-5.
9. Environmental hazards. *Canadian Anaesthetists Society Journal* 1985;32(2):143-144. X-1, X-2, X-5.
10. Review of recommendations for labor and birth care. *Am Fam Physician* 1992;45(2). X-1, X-2, X-3, X-5.
11. Controlling reproductive hazards: how to minimize harmful exposures. *Hosp Employee Health* 1994;13(8):97-104. X-1, X-2, X-3, X-5.
12. Pain relief in labour: your guide to a comfortable birth. *Modern Midwife* 1995;5(2):S1-4. X-1, X-2, X-5.
13. Plenty of scope for individualised pain control during labour and delivery. *Drugs and Therapy Perspectives* 1996;7(4):7-10. X-1, X-2, X-5.
14. Practice advisory for intraoperative awareness and brain function monitoring: A report by the American Society of Anesthesiologists Task Force on Intraoperative Awareness. *Anesthesiology* 2006;104(4):847-864. X-1, X-2, X-3d, X-5.
15. Midwifery and childbirth news. *Midwifery Today* 2007;81:60-1. X-1, X-2, X-5.
16. From the American College of Nurse-Midwives. Nitrous oxide for labor analgesia. *J Midwifery Womens Health* 2010 May-Jun;55(3):292-6. X-1, X-2, Background.
17. The most important goal in managing labour pain is patient satisfaction. *Drugs & Therapy Perspectives* 2010;26(3):15-7. X-1, X-2, X-3, X-5.
18. Aalto Setälä M and Heinonen J. Oxygen delivery during endobronchial anaesthesia: A comparison of halothane-oxygen and nitrous oxide-oxygen. *Acta Anaesthesiol Scand* 1982;26(6):550-553. X-2, X-3.
19. Abboud TK, D'Onofrio L, Reyes A, et al. Isoflurane or halothane for cesarean section: comparative maternal and neonatal effects. *Acta*

- Anaesthesiol Scand 1989 Oct;33(7):578-81. X-2, X-3d, X-5.
20. Abboud TK, Kim SH, Henriksen EH, et al. Comparative maternal and neonatal effects of halothane and enflurane for cesarean section. *Acta Anaesthesiol Scand* 1985 Oct;29(7):663-8. X-2, X-3.
  21. Abboud TK, Nagappala S, Murakawa K, et al. Comparison of the effects of general and regional anesthesia for cesarean section on neonatal neurologic and adaptive capacity scores. *Anesth Analg* 1985 Oct;64(10):996-1000. X-2, X-3.
  22. Abboud TK, Noueihed R, Khoo S, et al. Effects of induction of general and regional anesthesia for cesarean section on maternal plasma beta-endorphin levels. *Am J Obstet Gynecol* 1983 Aug 15;146(8):927-30. X-2, X-3.
  23. Abboud TK, Zhu J, Richardson M, et al. Desflurane: a new volatile anesthetic for cesarean section. Maternal and neonatal effects. *Acta Anaesthesiol Scand* 1995 Aug;39(6):723-6. X-2, X-3.
  24. Abboud TK, Zhu J, Richardson M, et al. Intravenous propofol vs thiamylal-isoflurane for caesarean section, comparative maternal and neonatal effects. *Acta Anaesthesiol Scand* 1995 Feb;39(2):205-9. X-2, X-3.
  25. Abdulatif M and Taylouni E. Surgeon-controlled mivacurium administration during elective caesarean section. *Can J Anaesth* 1995 Feb;42(2):96-102. X-2, X-3.
  26. Abdul-Khalik H, Uhlig R, Bottcher W, et al. Factors influencing the change in cerebral hemodynamics in pediatric patients during and after corrective cardiac surgery of congenital heart diseases by means of full-flow cardiopulmonary bypass. *Perfusion* 2002;17(3):179-185. X-2, X-3.
  27. Abouleish E, Abboud T, Lechevalier T, et al. Rocuronium (Org 9426) for caesarean section. *Br J Anaesth* 1994 Sep;73(3):336-41. X-2, X-3.
  28. Abouleish E and Taylor FH. Effect of morphine-diazepam on signs of anesthesia, awareness, and dreams of patients under N<sub>2</sub>O for cesarean section. *Anesth Analg* 1976 Sep-Oct;55(5):702-5. X-2, X-3.
  29. Ackerman IWE. Anesthesia considerations for complicated hydatidiform molar pregnancies. *Anesthesiology Review* 1984;11(7):20-24. X-1, X-2, X-3a, X-5.
  30. Ademuyiwa O, Odusoga OL, Adebawo OO, et al. Endogenous antioxidant defences in plasma and erythrocytes of pregnant women during different trimesters of pregnancy. *Acta Obstet Gynecol Scand* 1175;86(10):1175-1180. X-2, X-3.
  31. Adriani J. Analgesia and anesthesia in cesarean hysterectomy. *Clin Obstet Gynecol* 1969 Sep;12(3):590-617. X-1, X-2, X-3a, X-3d, X-5.
  32. Aghdashi MM, Abbasiavash R, Hassani E, et al. Fatal respiratory thermal injury following accidental administration of carbon dioxide using the circle system for a cesarean delivery. *Int J Obstet Anesth* 2009;18(4):400-402. X-2, X-3.
  33. Aitkenhead AR. Complications following large-bowel surgery. *Regional Anesthesia* 1982;7(Suppl. 4):S99-S104. X-1, X-2, X-3d.
  34. Ajuzieogu OV, Ezike HA, Amucheazi AO, et al. A retrospective study of the outcome of cesarean section for women with severe pre-eclampsia in a third world setting. *Saudi J Anaesthesia* 2011;5(1):15-18. X-3d.
  35. Akimova E, Savli M, Haeusler D, et al. Increase of 5-HTT occupancy during escitalopram or citalopram treatment correlates with antidepressant efficacy in major depressive disorder. *J Cancer Educ Conference: Joint Annual Meeting for AACE, CPEN, and EACE*. 2009;24(pp S424-S425). X-2, X-3.
  36. Al Zahrani T, Ibraheim O, Turkistani A, et al. Bispectral index profile during general anaesthesia using nitrous oxide for lower segment caesarean delivery. *Internet J Anesthesiology* 2006;10(1). X-2, X-3, X-5.

37. Al-Areibi A, Coveney L, Singh S, et al. Case report: Anesthetic management for sequential Cesarean delivery and laminectomy. *Can J Anaesth* 2007;54(6):471-474. X-2, X-3d.
38. Aldridge LM and Tunstall ME. Nitrous oxide and the fetus. A review and the results of a retrospective study of 175 cases of anaesthesia for insertion of Shirodkar suture. *Br J Anaesth* 1986 Dec;58(12):1348-56. X-2, X-3, X-5.
39. Allahyary E, Zand F and Tabatabaee HR. Evaluation of the adequacy of general anesthesia in cesarean section by auditory evoked potential index: an observational study. *Acta Anaesthesiol Taiwan* 2008 Mar;46(1):16-24. X-2, X-3.
40. Allen TK, George RB, Olufolabi AJ, et al. The management of Cesarean delivery in a parturient with paroxysmal nocturnal hemoglobinuria complicated by severe preeclampsia. *Can J Anaesth* 2007;54(8):646-651. X-2, X-3d.
41. Alon E and Himmelseher S. Ondansetron in the treatment of postoperative vomiting: a randomized, double-blind comparison with droperidol and metoclopramide. *Anesth Analg* 1992 Oct;75(4):561-5. X-2, X-3b, X-3d.
42. Andersen LW, Qvist T, Hertz J, et al. Concentrations of thiopentone in mature breast milk and colostrum following an induction dose. *Acta Anaesthesiol Scand* 1987;31(1):30-32. X-2, X-3, X-5.
43. Anderson BJ, Dyson A and Henderson AM. Inspired oxygen and nitrous oxide concentrations in volunteers during nitrous oxide sedation with a Hudson mask. *Anaesth Intensive Care* 1988;16(4):423-426. X-2, X-3, X-5.
44. Anil M, Helvacı M, Ozkalay N, et al. Salmonella typhimurium outbreak in a neonatal unit in Turkey. *Indian J Pediatr* 2009;76(6):629-633. X-2, X-3d.
45. Antal M and Benko M. Introduction of anaesthesia in caesarean section by using ketamine and fentanyl. *Acta Chirurgica Hungarica* 1986;27(1):19-25. X-2, X-3d, X-5.
46. Anwari JS, Ehsan FM and Al-Dar MM. Intravenous patient-controlled analgesia for labor pain. *Saudi Med J* 2003;24(6):691-693. X-1, X-2, X-3, X-5.
47. Aoyama K, Yasunaga E, Takenaka I, et al. Positive pressure ventilation during fiberoptic intubation: Comparison of the laryngeal mask airway, intubating laryngeal mask and endoscopy mask techniques. *Br J Anaesth* 2002;88(2):246-254. X-2, X-3.
48. Arai M, Nishijima M and Tatsumi H. Analgesia and anesthesia during labor in Japan and developed countries. *Asia Oceania J Obstet Gynaecol* 1989 Sep;15(3):213-21. X-2, X-3d.
49. Arellano RJ, Pole ML, Rafuse SE, et al. Omission of nitrous oxide from a propofol-based anesthetic does not affect the recovery of women undergoing outpatient gynecologic surgery. *Anesthesiology* 2000 Aug;93(2):332-9. X-2, X-3b, X-3d.
50. Aroenius S, Dahlgren BE, Lindwall L, et al. A comparison of the analgesic effects of methoxyflurane-nitrous oxide and nitrous oxide alone during labour related to the Eysenck personality inventory test. *Acta Obstet Gynecol Scand* 1980;59(3):203-7. X-5.
51. Arthurs GJ and Rosen M. Acceptability of continuous nasal nitrous oxide during labour--a field trial in six maternity hospitals. *Anaesthesia* 1981 Apr;36(4):384-8. X-5.
52. Axelsson G and Rylander R. Exposure to anaesthetic gases and spontaneous abortion: response bias in a postal questionnaire study. *Int J Epidemiol* 1982 Sep;11(3):250-6. X-3, X-5.
53. Aydın GB, Coskun F, Sahin A, et al. Influence of sevoflurane and desflurane on neurological and adaptive capacity scores in newborns. *Saudi Med J* 2008 Jun;29(6):841-6. X-2, X-3, X-5.
54. Baccetti B, Piomboni P, Bruni E, et al. Effect of follicle-stimulating

- hormone on sperm quality and pregnancy rate. *Asian J Androl* 2004;6(2):133-137. X-2, X-3d.
55. Baden JM. Chronic toxicity of inhalation anaesthetics. *Clin Anaesthesiol* 1983;1(2):441-454. X-1, X-2, X-3, X-5.
56. Bagshaw RJ, Smith DS, Young MS, et al. Anesthetic management of surgery in the vertebral canal. *Anesthesiol Rev* 1985;12(2):13-32. X-1, X-2, X-3d.
57. Baird DD. Characteristics of fertile menstrual cycles. *Scand J Work Environ Health* 1999;25(SUPPL. 1):20-22. X-2, X-3d, X-5.
58. Baird PA. Occupational exposure to nitrous oxide--not a laughing matter. *N Engl J Med* 1992 Oct 1;327(14):1026-7. X-1, X-2, X-3, X-5.
59. Baird WLM and Savage DS. Vecuronium - The first years. *Clin Anaesthesiol* 1985;3(2):347-360. X-1, X-2, X-3a, X-3d.
60. Bajekal RR, Turner R and Yentis SM. Anti-infective measures and Entonox equipment: a survey. *Anaesthesia* 2000 Feb;55(2):153-4. X-2, X-5.
61. Bajorek J and Walaszek M. Assessment of the condition of newborns delivered by caesarean section performed for intrauterine foetal distress in relation to the type of anaesthesia. *Anaesth Resusc Intensive Ther* 1974 Apr-Jun;2(2):145-8. X-2, X-3, X-5.
62. Bajoria R, Ward S and Sooranna SR. Atrial natriuretic peptide mediated polyuria: Pathogenesis of polyhydramnios in the recipient twin of twin-twin transfusion syndrome. *Placenta* 2001;22(8-9):716-724. X-2, X-3c.
63. Bamber J. Anaesthetist provided labour analgesia. *Curr Anaesthesia Crit Care*. 2006;17(3-4):131-141. X-1, X-2.
64. Bancroft GH and Lauria JJ. Ketamine induction for cesarean section in a patient with acute intermittent porphyria and achondroplastic dwarfism. *Anesthesiol* 1983;59(2):143-144. X-1, X-2, X-3a, X-3d, X-5.
65. Bannister CF, Brosius KK, Sigl JC, et al. The effect of bispectral index monitoring on anesthetic use and recovery in children anesthetized with sevoflurane in nitrous oxide. *Anesth Analg* 2001;92(4):877-881. X-2, X-3.
66. Baraka A. Correlation between maternal and foetal PO2 and PCO2 during Caesarean section. *Br J Anaesth* 1970 May;42(5):434-8. X-2, X-3, X-5.
67. Baraka A, Louis F, Noueihid R, et al. Awareness following different techniques of general anaesthesia for caesarean section. *Br J Anaesth* 1989 Jun;62(6):645-8. X-2, X-3d, X-5.
68. Baraka A, O'Brien M, Aslanian E, et al. Propanidid versus thiopentone for induction of general anaesthesia in elective Caesarean section. *Br J Anaesth* 1971 Jun;43(6):609-12. X-2, X-3a, X-3d, X-5.
69. Baraka A, Siddik S and Assaf B. Supplementation of general anaesthesia with tramadol or fentanyl in parturients undergoing elective caesarean section. *Can J Anaesth* 1998 Jul;45(7):631-4. X-1, X-2, X-3a, X-3d, X-5.
70. Baraka A, Wakid N and Noueihid R. Pseudocholinesterase activity and atracurium v. Suxamethonium block. *Br J Anaesth* 1986;58(SUPPL. 1). X-3a.
71. Barker TA and Cotter L. Pregnancy following heart transplantation: A case report. *Br J Cardiol* 2003;10(1):56-57. X-1, X-2, X-3, X-5.
72. Barrier G and Sureau C. Effects of anaesthetic and analgesic drugs on labour, fetus and neonate. *Clin Obstet Gynaecol* 1982;9(2):351-367. X-1, X-2.
73. Bassell GM. Anesthesia for cesarean section. *Clin Obstet Gynecol* 1985;28(4):722-734. X-3.
74. Baston H. Midwifery basics: care during labour: pharmacological methods of pain relief. *Practising Midwife* 2003;6(11):31-6. X-1, X-2, X-5.
75. Basu A, Nishanth P and Ifaturoti O. Pregnancy in women with myotonia

- congenita. *Int J Gynecol Obstet* 2009;106(1):62-63. X-1, X-2, X-3, X-5.
76. Batt B. Is halothane safe for surgical removal of retained products of conception? *Anesth Analg* 1969 May-Jun;48(3):338-40. X-2, X-3a, X-3d, X-5.
  77. Baum JA. New and alternative delivery concepts and techniques. *Best Pract Res Clin Anaesthesiol* 2005;19(3 SPEC. ISS):415-428. X-1, X-2.
  78. Beeby D and Hughes JOM. Oxytocic drugs and anaesthesia. A controlled clinical trial of ergometrine, syntocinon and normal saline during evacuation of the uterus after spontaneous abortion. *Anaesthesia* 1984;39(8):764-767. X-2, X-3a, X-3b.
  79. Beilin Y, Bodian CA, Mukherjee T, et al. The use of propofol, nitrous oxide, or isoflurane does not affect the reproductive success rate following gamete intrafallopian transfer (GIFT): a multicenter pilot trial/survey. *Anesthesiology* 1999 Jan;90(1):36-41. X-2, X-3, X-5.
  80. Beke A, Takacs G, Sziller I, et al. Obstetric anaesthesia in Hungary. *Int J Obstet Anesth* 1997;6(4):235-238. X-3, X-5.
  81. Bell GT and Taylor JC. Subdural block - Further points. *Anaesthesia* 1994;49(9):794-795. X-1, X-2, X-3, X-5.
  82. Bellomo R, Goldsmith D, Uchino S, et al. A prospective before-and-after trial of a medical emergency team. *Med J Aust* 2003;179(6):283-287. X-2, X-3d.
  83. Bennett EJ, Ramamurthy S, Dalal FY, et al. Pancuronium and the neonate. *Br J Anaesth* 1975 Jan;47(1):75-8. X-2, X-3.
  84. Bennett JA, Lingaraju N, Horrow JC, et al. Elderly patients recover more rapidly from desflurane than from isoflurane anesthesia. *J Clin Anesth* 1992 Sep-Oct;4(5):378-81. X-2, X-3.
  85. Bennis J, Dottori O, Gundersen K, et al. Nitrous oxide-oxygen analgesia after denitrogenation with pure oxygen in Caesarean section. *Acta Anaesthesiol Scand Suppl* 1969;37:212-9. X-2, X-3a, X-3d, X-5,
  86. Benson KT, Dozier NJ and Goto H. Anesthesia for cesarean section in patient with spondylometepiphyseal dysplasia. *Anesthesiology* 1985;63(5):548-550. X-2, X-3.
  87. Berg TG and Rayburn WF. Effects of analgesia on labor. *Clin Obstet Gynecol* 1992;35(3):457-463. X-1, X-2, X-3.
  88. Berge JA, Gramstad L and Grimnes S. A simplified concept for controlling oxygen mixtures in the anaesthetic machine - Better, cheaper and more user-friendly? *Acta Anaesthesiol Scand* 1995;39(4):563-567. X-1, X-2, X-3.
  89. Berger N, Vaillancourt C and Boksa P. Interactive effects of anoxia and general anesthesia during birth on the degree of CNS and systemic hypoxia produced in neonatal rats. *Exp Brain Res* 2000 Apr;131(4):524-31. X-2, X-3d.
  90. Berggren L and Eriksson I. Midazolam for induction of anaesthesia in outpatients: a comparison with thiopentone. *Acta Anaesthesiol Scand* 1981 Dec;25(6):492-6. X-2, X-3.
  91. Berghorn KA, Albrecht ED and Pepe GJ. Responsivity of the baboon fetal pituitary to corticotropin-releasing hormone in utero at midgestation. *Endocrinology* 1991 Sep;129(3):1424-8. X-2, X-3.
  92. Bergmans G, Vanacker B, Van Aken H, et al. Investigation of the pharmacokinetics and analgesic effects of an intramuscular injection of sustained-release sufentanil for postoperative pain: An open study. *J Clin Anesth* 1994;6(6):462-468. X-2, X-3.
  93. Bergstrom H and Bernstein K. Psychic reactions after analgesia with nitrous oxide for caesarean section. *Lancet* 1968 Sep 7;2(7567):541-2. X-2, X-3d, X-5.
  94. Beringer RM and Patteril M. Puerperal uterine inversion and shock. *Br J Anaesth* 2004;92(3):439-441. X-1, X-2, X-3.

95. Bernow J, Bjordal J and Wiklund KE. Pollution of delivery ward air by nitrous oxide. Effects of various modes of room ventilation, excess and close scavenging. *Acta Anaesthesiol Scand* 1984 Feb;28(1):119-23. X-2, X-5.
96. Bernstein K, Gisselsson L, Jacobsson L, et al. Influence of two different anaesthetic agents on the newborn and the correlation between foetal oxygenation and induction-delivery time in elective caesarean section. *Acta Anaesthesiol Scand* 1985 Feb;29(2):157-60. X-2, X-3a, X-5.
97. Bertucci F, Tarpin C, Charafe-Jauffret E, et al. Multivariate analysis of survival in inflammatory breast cancer: Impact of intensity of chemotherapy in multimodality treatment. *Bone Marrow Transplant* 2004;33(9):913-920. X-2, X-3.
98. Bhadresha S and Enever G. A potted history of obstetric anaesthesia. *CPD Anaesthesia* 2004;6(1):36-40. X-1, X-2, X-3.
99. Bhargava AK. First public demonstration of surgical anaesthesia. *Med J Armed Forces India* 2003;59(4). X-1, X-2, X-3, X-5.
100. Bhattacharya S, Wang T and Knox F. Analgesia for labour pain - Analysis of the trends and associations in the Grampian region of Scotland between 1986 and 2001. *BMC Pregnancy Childbirth* 2006;6(14). X-5.
101. Bhavani Shankar K, Moseley HSL, Mushlin PS, et al. Anaesthesia in Barbados. *Can J Anaesth* 1997;44(5 I):559-568. X-1, X-2, X-3.
102. Billard V, Servin F, Guignard B, et al. Desflurane-remifentanyl-nitrous oxide anaesthesia for abdominal surgery: Optimal concentrations and recovery features. *Acta Anaesthesiol Scand* 2004;48(3):355-364. X-2, X-3.
103. Bishop JT. Administration of nitrous oxide in labor: expanding the options for women. *J Midwifery Womens Health* 2007 May-Jun;52(3):308-9. X-1, X-2, X-5.
104. Biswas RG, Bandyopadhyay BK, Sarkar M, et al. Perioperative management of pregnant patients with heart disease for caesarian section under anaesthesia. *J Indian Med Assoc* 2003;101(11). X-2, X-3.
105. Biswas TK and Hatch PD. A comparison of alfentanil, halothane and enflurane as supplements for outpatient urological surgery. *Anaesth Intensive Care* 1989 Aug;17(3):275-9. X-2, X-3.
106. Blair JM, Dobson GT, Hill DA, et al. Patient controlled analgesia for labour: A comparison of remifentanyl with pethidine. *Anaesthesia* 2005;60(1):22-27. X-3.
107. Blair JM, Hill DA and Fee JPH. Patient-controlled analgesia for labour using remifentanyl: A feasibility study. *Br J Anaesth* 2001;87(3):415-420. X-2, X-3.
108. Bland BA, Lawes EG, Duncan PW, et al. Comparison of midazolam and thiopental for rapid sequence anesthetic induction for elective cesarean section. *Anesth Analg* 1987 Nov;66(11):1165-8. X-2, X-3.
109. Blechner JN, Stenger VG, Eitzman DV, et al. Oxygenation of the human fetus and newborn infant during maternal metabolic acidosis. *Am J Obstet Gynecol* 1970 Sep 1;108(1):47-55. X-3.
110. Blechner JN, Stenger VG and Prystowsky H. Uterine blood flow in women at term. *Am J Obstet Gynecol* 1974 Nov 1;120(5):633-40. X-2, X-3d, X-5.
111. Blechner JN, Stenger VG and Prystowsky H. Blood flow to the human uterus during maternal metabolic acidosis. *Am J Obstet Gynecol* 1975 Mar 15;121(6):789-94. X-2, X-3.
112. Blincoe AJ. TENS machines and their use in managing labour pain. *Br J Midwifery* 2007;15(8):518-9. X-1, X-2, X-3.
113. Blitt CD, Petty WC, Alberternst EE, et al. Correlation of plasma cholinesterase activity and duration of action of succinylcholine during pregnancy. *Anesth Analg* 1977 Jan-Feb;56(1):78-83. X-2, X-3a.



114. Blumgart CH, Hughes DG and Redfern N. Obstetric anaesthesia in dystrophia myotonica. *Anaesthesia* 1990;45(1):26-29. X-1, X-2, X-3.
115. Bobak M. Outdoor air pollution, low birth weight, and prematurity. *Environ Health Perspect* 2000 Feb;108(2):173-6. X-2, X-3d.
116. Bodner M and White PF. Antiemetic efficacy of ondansetron after outpatient laparoscopy. *Anesth Analg* 1991;73(3):250-254. X-2, X-3a.
117. Boekstegers P, Weidenhofer S, Pilz G, et al. Peripheral oxygen availability within skeletal muscle in sepsis and septic shock: Comparison to limited infection and cardiogenic shock. *Infection* 1991;19(5):317-323. X-2, X-3.
118. Bogod DG, Rosen M and Rees GA. Maximum FIO<sub>2</sub> during caesarean section. *Br J Anaesth* 1988 Sep;61(3):255-62. X-2, X-3a, X-3d.
119. Bohra U, Donnelly J, O'Connell MP, et al. Active management of labour revisited: The first 1000 primiparous labours in 2000. *J Obstet Gynaecol* 2003;23(2):118-120. X-3, X-5.
120. Boker A and Ong BY. Anesthesia for Cesarean section and posterior fossa craniotomy in a patient with von Hippel-Lindau disease. *Can J Anaesth* 2001;48(4):387-390. X-1, X-2, X-3.
121. Bonsu AK and Stead AL. Accidental cross-connection of oxygen and nitrous oxide in an anaesthetic machine. *Anaesthesia* 1983;38(8):767-769. X-1, X-2, X-3.
122. Borup L, Wurlitzer W, Hedegaard M, et al. Acupuncture as pain relief during delivery: a randomized controlled trial. *Birth* 2009 Mar;36(1):5-12. X-3, X-5.
123. Botta G, D'Angelo A, D'Ari G, et al. Epidural anesthesia in an in vitro fertilization and embryo transfer program. *J Assist Reprod Genet* 1995 Mar;12(3):187-90. X-2, X-3a, X-5.
124. Bovill JG, Coppel DL, Dundee JW, et al. Current status of ketamine anaesthesia. *Lancet* 1971 Jun 19;1(7712):1285-8. X-1, X-2, X-3a, X-5.
125. Bowen SE and Hannigan JH. Developmental toxicity of prenatal exposure to Toluene. *AAPS Journal* 2006;8(2):E419-E424. X-1, X-2, X-3d.
126. Boyle RK. Intra- and postoperative anaesthetic management of an opioid addict undergoing caesarean section. *Anaesth Intensive Care* 1991;19(2):276-279. X-3.
127. Bradbury CL, Christensen BK, Lau MA, et al. The Efficacy of Cognitive Behavior Therapy in the Treatment of Emotional Distress After Acquired Brain Injury. *Arch Phy Med Rehabil* 2008;89(12 SUPPL):S61-S68. X-2, X-3.
128. Brady JP and Rigatto H. Pulmonary capillary flow in the newborn infant: a new method using the plethysmograph and nitrous oxide. *Pediatrics* 1971 Aug;48(2):207-15. X-2, X-3d, X-5.
129. Breslin DS, Mirakhur RK, Reid JE, et al. Manual versus target-controlled infusions of propofol. *Anaesthesia* 1059;59(11):1059-1063. X-2, X-3a, X-3d.
130. Brinsmead M. Fetal and neonatal effects of drugs administered in labour. *Med J Aust* 1987 May 4;146(9):481-6. X-1, X-2, X-3, X-5.
131. Brito MB, Ferriani RA, Quintana SM, et al. Safety of the etonogestrel-releasing implant during the immediate postpartum period: a pilot study. *Contraception* 2009;80(6):519-526. X-2, X-3d.
132. Brock-Utne JG, Love AJ, Mankowitz E, et al. Indoprofen - a new non-opioid analgesic. A comparison with pethidine. *S Afr Med J* 1985;68(11):803-804. X-2, X-3a.
133. Brodsky JB. Anesthesia and surgery during early pregnancy and fetal outcome. *Clin Obstet Gynecol* 1983;26(2):449-457. X-1, X-2, X-3, X-5.
134. Brodsky JB. Exposure to anesthetic gases: a controversy. *AORN J* 1983 Jul;38(1):132-7, 140-1, 144. X-1, X-2, X-5.
135. Brodsky JB and Cohen EN. Adverse effects of nitrous oxide. *Med*

- Toxicol 1986 Sep-Oct;1(5):362-74. X-1, X-2, X-3, X-5.
136. Brown DR, Fishburne JI, Roberson VO, et al. Ventilatory and blood gas changes during laparoscopy with local anesthesia. *Am J Obstet Gynecol* 1976 Apr 1;124(7):741-5. X-2, X-3.
  137. Brown SC, Hart G, Chastain DP, et al. Reducing distress for children during invasive procedures: Randomized clinical trial of effectiveness of the PediSedate. *Paediatr Anaesth* 2009;19(8):725-731. X-2, X-3, X-5.
  138. Browning AJ, Butt WR, Lynch SS, et al. Maternal and cord plasma concentrations of beta-lipotrophin, beta-endorphin and gamma-lipotrophin at delivery; effect of analgesia. *Br J Obstet Gynaecol* 1983 Dec;90(12):1152-6. X-3d.
  139. Brownridge P. A three-year survey of an obstetric epidural service with top-up doses administered by midwives. *Anaesth Intensive Care* 1982;10(4):298-308. X-3, X-5.
  140. Brownridge P. Shivering related to epidural blockade with bupivacaine in labour, and the influence of epidural pethidine. *Anaesth Intensive Care* 1986 Nov;14(4):412-7. X-3, X-5.
  141. Brownridge P. Treatment options for the relief of pain during childbirth. *Drugs* 1991 Jan;41(1):69-80. X-1, X-2, X-3, X-5.
  142. Brownridge P and Frewin DB. A comparative study of techniques of postoperative analgesia following Caesarean section and lower abdominal surgery. *Anaesth Intensive Care* 1985;13(2):123-130. X-2, X-3a, X-3d.
  143. Bryant HE and Love EJ. Effect of employment and its correlates on spontaneous abortion risk. *Soc Sci Med* 1991;33(7):795-800. X-2, X-3.
  144. Bui TH, Grunewald C, Frenckner B, et al. Successful EXIT (Ex Utero Intrapartum Treatment) procedure in a fetus diagnosed prenatally with congenital high-airway obstruction syndrome due to laryngeal atresia. *Eur J Pediatr Surg* 2000;10(5):328-333. X-1, X-2, X-3.
  145. Bunatian A, Trekova N, Flerov E, et al. Oxygen delivery and consumption during open heart surgery: A comparison of combined inhalational and total intravenous anaesthesia. *J Cardiothorac Vasc Anesth* 1994;8(3 SUPPL. 2). X-2, X-3a, X-5.
  146. Bundsen P, Ericson K, Peterson LE, et al. Pain relief in labor by transcutaneous electrical nerve stimulation. Testing of a modified stimulation technique and evaluation of the neurological and biochemical condition of the newborn infant. *Acta Obstet Gynecol Scand* 1982;61(2):129-36. X-5.
  147. Bundsen P, Peterson LE and Selstam U. Pain relief in labor by transcutaneous electrical nerve stimulation. A prospective matched study. *Acta Obstet Gynecol Scand* 1981;60(5):459-68. X-3, X-5.
  148. Bundsen P, Peterson LE and Selstam U. Pain relief during delivery. An evaluation of conventional methods. *Acta Obstet Gynecol Scand* 1982;61(4):289-97. X-5.
  149. Burkhart JE and Stobbe TJ. Real-time measurement and control of waste anesthetic gases during veterinary surgeries. *Am Ind Hyg Assoc J* 1990;51(12):640-645. X-2, X-3, X-5.
  150. Burns AM, Dorje P, Lawes EG, et al. Anaesthetic management of caesarean section for a mother with pre-eclampsia, the Klippel-Feil syndrome and congenital hydrocephalus. *Br J Anaesth* 1988;61(3):350-354. X-1, X-2, X-3.
  151. Burns SM and Barclay PM. Regional anaesthesia for Caesarean section. *Curr Anaesth Crit Care* 2000;11(2):73-79. X-1, X-2, X-3.
  152. Cade L and Ross AW. Is fentanyl effective for postoperative analgesia in day-surgery? *Anaesth Intensive Care* 1992 Feb;20(1):38-40. X-2, X-3a, X-3b.
  153. Calleja MA. Extradural analgesia and previous spinal surgery. A radiological appraisal. *Anaesthesia* 1991;46(11):946-947. X-1, X-2, X-3, X-5.

154. Camous J, N'Da A, Etienne-Julan M, et al. Anesthetic management of pregnant women with sickle cell disease - Effect on postnatal sickling complications. *Can J Anaesth* 2008;55(5):276-283. X-2, X-3d.
155. Candido R, Toffoli B, Bernardi S, et al. Systemic osteoprotegerin delivery induces pancreatic islet structural and functional alterations in non-diabetic mice. *Diabetologia*. Conference: 45th EASD Annual Meeting of the European Association for the Study of Diabetes Vienna Austria. Conference Start 2009;52(S1). X-2, X-3.
156. Capogna G, Alahuhtat S, Celleno D, et al. Maternal expectations and experiences of labour pain and analgesia: a multicentre study of nulliparous women. *Int J Obstet Anesth* 1996 Oct;5(4):229-35. X-5.
157. Carli F, Creagh-Barry P, Gordon H, et al. Does epidural analgesia influence the mode of delivery in primiparae managed actively? A preliminary study of 1250 women. *Int J Obstet Anesth* 1993;2(1):15-20. X-3, X-5.
158. Carlsson C, Nybell-Lindahl G and Ingemarsson I. Extradural block in patients who have previously undergone caesarean section. *Br J Anaesth* 1980 Aug;52(8):827-30. X-3d, X-5.
159. Carnie JC and Perks D. The pattern of postoperative analgesic administration in non-English speaking Asian women following Caesarean section. *Ann R Coll Surg Engl* 1984;66(5):365-366. X-2, X-3a, X-3d.
160. Carnie JC, Street MK and Kumar B. Emergency intubation of the trachea facilitated by suxamethonium. Observations in obstetric and general surgical patients. *Br J Anaesth* 1986;58(5):498-501. X-2, X-3a.
161. Carr D. Epidural analgesia in labor--why not? The patient's point of view. *Proc R Soc Med* 1972 Sep;65(9):758. X-1, X-2, X-3, X-5.
162. Carson RJ. Clinical The administration of analgesics. *Modern Midwife* 1996;6(11):12-6. X-1, X-2, X-5.
163. Carter JA, Dye AM and Cooper GM. Recovery from day-case anaesthesia. The effect of different inhalational anaesthetic agents. *Anaesthesia* 1985 Jun;40(6):545-8. X-2, X-3a.
164. Carvalho B, Mirikitani EJ, Lyell D, et al. Neonatal chest wall rigidity following the use of remifentanyl for cesarean delivery in a patient with autoimmune hepatitis and thrombocytopenia. *Int J Obstet Anesth* 2004;13(1):53-56. X-1, X-2, X-3.
165. Caton D, Corry MP, Frigoletto FD, et al. The nature and management of labor pain: Executive summary. *Am J Obstet Gynecol* 2002;186(5 SUPPL):S1-S15. X-1, X-2, X-3.
166. Celeski D, Micho J and Walters L. Anesthetic implications of a partial molar pregnancy and associated complications. *J Am Assoc Nurse Anesth* 2001;69(1):49-53. X-2, X-3b, X-3d.
167. Celik-Ozenci C, Tekcan M, Sati L, et al. Abamectin pesticide exposure and male infertility: Human exposure studies supported by animal studies point out a considerable relationship. *Fertility and Sterility*. Conference: 65th Annual Meeting of the American Society for Reproductive Medicine, ASRM 2009;92(3 SUPPL. 1). X-2, X-3.
168. Cesur M, Alici HA, Erdem AF, et al. Decreased incidence of headache after unintentional dural puncture in patients with cesarean delivery administered with postoperative epidural analgesia. *J Anesth* 2009;23(1):31-35. X-2, X-3d.
169. Chambers JA and Guly HR. The need for better pre-hospital analgesia. *Arch Emerg Med* 1993;10(3):187-192. X-2, X-3, X-5.
170. Chan CS, Lo JR and Wong KC. Vomiting after anaesthesia for termination of pregnancy in Chinese. *Singapore Med J* 1984;25(3):173-175. X-2, X-3a, X-3b, X-5.

171. Chan SC, Lo JR and Wong KC. Vomiting after anaesthesia for termination of pregnancy in Chinese. *Singapore Med J* 1983;24(6):360-362. X-2, X-3a, X-3b, X-5.
172. Chan SY and Chiu JW. Intrathecal labor analgesia using levobupivacaine 2.5 mg with fentanyl 25 mug - Would half the dose suffice? *Med Sci Monit* 2004;10(10):II10-PII14. X-3a, X-3d.
173. Chance DKE and Alderson JD. Adult spina bifida. Care of the Critically Ill 1999;15(5):176-179. X-1, X-2, X-3d.
174. Chandler M. Pressure changes in tracheal tube cuffs. *Anaesthesia* 1986;41(3):287-293. X-1, X-2, X-3d.
175. Chang L, Looi-Lyons L, Bartosik L, et al. Anesthesia for cesarean section in two patients with brain tumours. *Can J Anaesth* 1999;46(1):61-65. X-2, X-3d.
176. Chapman AB, Zamudio S, Woodmansee W, et al. Systemic and renal hemodynamic changes in the luteal phase of the menstrual cycle mimic early pregnancy. *Am J Physiol Renal Physiol* 1997;273(5 42-5):F777-F782. X-2, X-3.
177. Chatterjee DJ, Bukunola B, Samuels TL, et al. Resuscitation in massive obstetric haemorrhage using an intraosseous needle. *Anaesthesia* 2011;66(4):306-310. X-1, X-2, X-3d.
178. Chauhan G, Verma Y, Sood A, et al. Full term secondary abdominal pregnancy and its anaesthetic management. *J Anaesthesiol Clin Pharmacol* 2003;19(1):73-75. X-2, X-3d.
179. Chessor E, Verhoeven M, Hon CY, et al. Evaluation of a modified scavenging system to reduce occupational exposure to nitrous oxide in labor and delivery rooms. *J Occup Environ Hyg* 2005 Jun;2(6):314-22. X-5.
180. Chestnut DH. Effect of anesthesia for repeat cesarean section on postoperative infectious morbidity. *Obstet Gynecol* 1985;66(2):199-202. X-2, X-3, X-5.
181. Chestnut DH and Noe AL. Effect of anesthesia for primary cesarean section on postoperative infectious morbidity. *Obstet Gynecol* 1986;68(5):667-670. X-2, X-3d, X-5.
182. Chi C, Lee CA, England A, et al. Obstetric analgesia and anaesthesia in women with inherited bleeding disorders. *Thromb Haemost* 2009 Jun;101(6):1104-11. X-3, X-5.
183. Chilvers RJ and Weisz M. Entonox equipment as a potential source of cross-infection. *Anaesthesia* 2000 Feb;55(2):176-9. X-2, X-3, X-5.
184. Chin KJ and Yeo SW. A BIS-guided study of sevoflurane requirements for adequate depth of anaesthesia in Caesarean section. *Anaesthesia* 1064;59(11):1064-1068. X-2, X-3d.
185. Chin KJ and Yeo SW. Bispectral index values at sevoflurane concentrations of 1% and 1.5% in lower segment cesarean delivery. *Anesth Analg* 2004 Apr;98(4):1140-4, table of contents. X-2, X-3, X-5.
186. Chiodo GT and Rosenstein DI. Pregnancy and risks in the dental office. *Dent Assist* 1986 Mar-Apr;55(2):9-12. X-1, X-2, X-3d, X-5.
187. Chortkoff BS, Gonsowski CT, Bennett HL, et al. Subanesthetic concentrations of desflurane and propofol suppress recall of emotionally charged information. *Anesth Analg* 1995;81(4):728-736. X-2, X-3d.
188. Cieslak GD, Watcha MF, Phillips MB, et al. The dose-response relation and cost-effectiveness of granisetron for the prophylaxis of pediatric postoperative emesis. *Anesthesiol* 1076;85(5):1076-1085. X-2, X-3d.
189. Clark AJ and Hurtig JB. Premedication with meperidine and atropine does not prolong recovery to street fitness after out-patient surgery. *Can Anaesth Soc J* 1981 Jul;28(4):390-3. X-2, X-3b, X-3d.
190. Clark RB, Cooper JO, Stephens SR, et al. Neonatal acid-base studies. II. Effect of a heavy medication-

- narcotic antagonists regimen for labor and delivery. *Obstet Gynecol* 1969 Jan;33(1):30-4. X-3, X-5.
191. Clark V. Women should be told ALL risks before regional anaesthesia is performed. *Int J Obstet Anesth* 2006;15(4):303-305. X-1, X-2, X-3, X-5.
  192. Clarke RB, Cooper JO, Brown WE, et al. The effect of methoxyflurane on the foetus. *Br J Anaesth* 1970 Apr;42(4):286-94. X-3, X-5.
  193. Cluett E. Analgesia in labour: a review of the TENS method. *Prof Care Mother Child* 1994 Mar;4(2):50-2. X-1, X-2, X-3d.
  194. Coad NR, Mills PJ, Verma R, et al. Evaluation of blood loss during suction termination of pregnancy: Ketamine compared with methohexitone. *Acta Anaesthesiol Scand* 1986;30(3):253-255. X-2, X-3b.
  195. Coen VLMA, Marijnissen JPA, Ligthart JMR, et al. Inaccuracy in manual multisegmental irradiation in coronary arteries. *Radiother Oncol* 2002;63(1):89-95. X-2, X-3.
  196. Coffey PS and Kilbourne-Brook M. Wear and care of the SILCS diaphragm: Experience from three countries. *Sex Health* 2010;7(2):159-164. X-2, X-3.
  197. Cohen E, Eisenkraft JB, Thys DM, et al. Oxygenation and hemodynamic changes during one-lung ventilation: Effects of CPAP10, PEEP10, and CPAP10/PEEP10. *J Cardiothorac Anesth* 1988;2(1):34-40. X-2, X-3.
  198. Cohen EN, Bellville JW and Brown BW, Jr. Anesthesia, pregnancy, and miscarriage: a study of operating room nurses and anesthesiologists. *Anesthesiology* 1971 Oct;35(4):343-7. X-3a, X-5.
  199. Cohen EN, Gift HC, Brown BW, et al. Occupational disease in dentistry and chronic exposure to trace anesthetic gases. *J Am Dent Assoc* 1980 Jul;101(1):21-31. X-2, X-3, X-5.
  200. Cohen LB. Fospropofol disodium: New perspectives on endoscopic procedures. *Rev Gastroenterol Disord* 2008;8(3):213-216. X-1, X-2, X-3, X-5.
  201. Coker A, Govindan DSOT, Richardson RE, et al. Antenatal care and delivery of a patient with a ventriculo-peritoneal shunt. *J Obstet Gynaecol* 1997;17(5):489-490. X-1, X-2, X-3, X-5.
  202. Cole PV. The problem of pollution in the dental surgery. *SAAD Dig* 1981 Jan;4(9):210-6. X-1, X-2, X-3d, X-5.
  203. Cole PV, Crawford JS, Doughty AG, et al. Specifications and recommendations for nitrous oxide-oxygen apparatus to be used in obstetric analgesia. *Anaesthesia* 1970 Jul;25(3):317-27. X-1, X-2, X-5.
  204. Coleman AJ and Downing JW. Ethrane anaesthesia for caesarean section. *S Afr Med J* 1975 Nov 1;49(46):1927-9. X-2, X-3d.
  205. Coleman P. McArdle's disease. Problems of anaesthetic management for Caesarean section. *Anaesthesia* 1984;39(8):784-787. X-2, X-3d.
  206. Colle I, Van Steenkiste C, Geerts A, et al. Hepatopulmonary Syndrome and Portopulmonary Hypertension: What's new? *Acta Gastroenterol Belg* 2007;70(2):203-209. X-1, X-2, X-3d.
  207. Collins KM and Plantevin OM. Use of alfentanil in short anaesthetic procedures. *J R Soc Med* 1985;78(6):456-458. X-1, X-2, X-3d.
  208. Collins KM, Plantevin OM, Whitburn RH, et al. Outpatient termination of pregnancy: Halothane or alfentanil-supplemented anaesthesia. *Br J Anaesth* 1992;57(12):1226-1231. X-2, X-3b.
  209. Collis R. Combined spinal epidural (CSE) analgesia is the preferred technique for labour pain relief. *Acta Anaesthesiol Belg* 2002;53(4):283-287. X-1, X-2, X-3a, X-5.
  210. Colohan DP. Nitrous oxide: A nonnarcotic analgesic for emergency use. *Med Instrum* 1982;16(6):293-294. X-2, X-3d.
  211. Compagnoni G, Lista G, Giuffre B, et al. Coenzyme Q10 levels in

- maternal plasma and cord blood: correlations with mode of delivery. *Biol Neonate* 2004;86(2):104-7. X-3a, X-3d, X-5.
212. Condie RG and Tunstall ME. Chlormethiazole as a sedative in normal labour. *Acta Anaesthesiol Scand Suppl* 1969;37:192-7. X-3a, X-3d, X-5.
  213. Conkin KA, Herr G and Fung D. Anaesthesia for Caesarean section and cerebral aneurysm clipping. *Canadian Anaesthetists Society Journal* 1984;31(4):451-454. X-2, X-3d.
  214. Connell H, Dalglish JG and Downing JW. General anaesthesia in mothers with severe pre-eclampsia/eclampsia. *Br J Anaesth* 1975;59(11):1375-1380. X-2, X-3d.
  215. Constantine G, Luesley DM, Redman CW, et al. Racial variations in the choice of analgesia in labour. *J Obstet Gynaecol* 1989;9(3):189-192. X-5.
  216. Cook DJ, Oliver Jr WC, Orszulak TA, et al. Cardiopulmonary bypass temperature, hematocrit, and cerebral oxygen delivery in humans. *Ann Thorac Surg* 1971;60(6):1671-1677. X-2, X-3.
  217. Cook IHE. Cesarean section in a patient with brain tumor: A clinical report. *Military Medicine* 1989;154(6):330-331. X-2, X-3a, X-3d.
  218. Cook WP, Shultetus RR and Caton D. A comparison of d-tubocurarine pretreatment and no pretreatment of obstetric patients. *Anesth Analg* 1987;66(8):756-760. X-2, X-3a, X-3d.
  219. Cooper GM, MacArthur C, Wilson MJA, et al. Satisfaction, control and pain relief: short- and long-term assessments in a randomised controlled trial of low-dose and traditional epidurals and a non-epidural comparison group. *Int J Obstet Anesth* 2010;19(1):31-37. X-5.
  220. Corbett TH. Anesthetics as a cause of abortion. *Fertil Steril* 1972 Nov;23(11):866-9. X-1, X-2, X-3, X-5.
  221. Corbett TH, Cornell RG, Endres JL, et al. Birth defects among children of nurse-anesthetists. *Anesthesiology* 1974 Oct;41(4):341-4. X-3d, X-5.
  222. Corbett WL, Reiter CM, Schultz JR, et al. Anaesthetic management of a parturient with the postural orthostatic tachycardia syndrome: A case report. *Br J Anaesth* 2006;97(2):196-199. X-2, X-3a, X-3d.
  223. Corriveau S, Berthiaume M, Rousseau E, et al. Is it possible to improve the tocolytic effect of indomethacin by inhibition of eicosanoids metabolic pathways in pregnant women uterus? *Am J Obstet Gynecol Conference* 2010;201(6 SUPPL. 1). X-2, X-3d.
  224. Corssen G. Ketamine in obstetric anesthesia. *Clin Obstet Gynecol* 1974 Jun;17(2):249-58. X-1, X-2, X-3, X-5.
  225. Corssen G. Neuroleptanalgesia and anesthesia in obstetrics. *Clin Obstet Gynecol*. 1974 Jun;17(2):241-8. X-1, X-2, X-3, X-5.
  226. Cosmi EV and Marx GF. Acid-base status of the fetus and clinical condition of the newborn following cesarean section. *Am J Obstet Gynecol* 1968 Oct 1;102(3):378-82. X-3.
  227. Cousins MJ, Plummer JL and De la Hall MP. Toxicity of volatile anaesthetic agents. *Clin Anaesthesiol* 1984;2(3):551-575. X-1, X-2, X-3d.
  228. Craig J, Cooper GM and Sear JW. Recovery from day-case anaesthesia. Comparison between methohexitone, Althesin and etomidate. *Br J Anaesth* 1982 Apr;54(4):447-51. X-2, X-3d.
  229. Cravello L, D'Ercole C, Roger V, et al. Laparoscopic surgery in gynecology: Randomized prospective study comparing pneumoperitoneum and abdominal wall suspension. *Eur J Obstet Gynecol Reprod Biol* 1999;83(1):9-14. X-2, X-3a, X-3d.
  230. Crawford JS. Analgesia and anaesthesia in labour. *Practitioner*

- 1974 May;212(1271):677-88. X-1, X-2, X-5.
231. Crawford JS. Premedication for elective caesarean section. *Anaesthesia* 1979;34(9):892-897. X-2, X-3d.
232. Crawford JS. General analgesia and anaesthesia in obstetrics. *Clinics in Anaesthesiology* 1986;4(1):157-169. X-1, X-2, X-3, X-5.
233. Crawford JS, Burton M and Davies P. Anaesthesia for section: further refinements of a technique. *Br J Anaesth*. 1973 Jul;45(7):726-32. X-2, X-3a, X-3d, X-5.
234. Crawford JS, Ellis DB, Hill DW, et al. Effects of cooling on the safety of premixed gases. *Br Med J*. 1967 Apr 15;2(5545):138-42. X-2, X-3, X-5.
235. Crawford JS and Lewis M. Nitrous oxide in early human pregnancy. *Anaesthesia*. 1986 Sep;41(9):900-5. X-2, X-3d.
236. Crawford JS, Lewis M and Davies P. Maternal and neonatal responses related to the volatile agent used to maintain anaesthesia at Caesarean section. *Br J Anaesth* 1985;57(5):482-487. X-2, X-3a, X-3d.
237. Crawford JS and Tunstall ME. Notes on respiratory performance during labour. *Br J Anaesth* 1968 Aug;40(8):612-4. X-3d, X-5.
238. Crawford ME, Carl P, Andersen RS, et al. Comparison between midazolam and thiopentone-based balanced anaesthesia for day-case surgery. *Br J Anaesth* 1984 Feb;56(2):165-9. X-2, X-3b, X-3d.
239. Crawford ME, Carl P, Bach V, et al. A randomized comparison between midazolam and thiopental for elective cesarean section anesthesia. I. Mothers. *Anesth Analg* 1989 Mar;68(3):229-33. X-2, X-3a, X-3d.
240. Crimi E, Baggish A, Leffert L, et al. Acute reversible stress-induced cardiomyopathy associated with cesarean delivery under spinal anesthesia. *Circulation* 3052;117(23):3052-3053. X-1, X-2, X-3, X-5.
241. Critchlow BM, Ibrahim Z and Pollard BJ. General anaesthesia for gamete intra-fallopian transfer. *Eur J Anaesthesiol* 1991 Sep;8(5):381-4. X-2, X-3a, X-3d.
242. Crowhurst JA and Rosen M. General anaesthesia for caesarean section in severe pre-eclampsia. Comparison of the renal and hepatic effects of enflurane and halothane. *Br J Anaesth* 1984 Jun;56(6):587-97. X-2, X-3, X-5.
243. Cui T, Liu Y, Men X, et al. Bile acid transport correlative protein mRNA expression profile in human placenta with intrahepatic cholestasis of pregnancy. *Saudi Med J* 1406;30(11):1406-1410. X-2, X-3d.
244. Cullen BF, Margolis AJ and Eger EI, 2nd. The effects of anesthesia and pulmonary ventilation on blood loss during elective therapeutic abortion. *Anesthesiology* 1970 Feb;32(2):108-13. X-2, X-3b, X-5.
245. Cundy JM and Arunasalam K. Use of an emulsion formulation of propofol ('Diprivan') in intravenous anaesthesia for termination of pregnancy. A comparison with methohexitone. *Postgrad Med J* 1985;61(SUPPL. 3):129-131. X-2, X-3b, X-3d.
246. Cundy JM and Read PJ. The acceptability of day stay for termination of pregnancy. *Br J Clin Pract* 1981 Jun;35(6):215-8. X-1, X-2, X-3b, X-5.
247. Cunningham AJ, Crowley KJ and Tierney E. Elderly parturient with rheumatic heart disease presenting for caesarean section: Haemodynamic monitoring and anaesthesia management. *Irish Medical Journal* 1985;78(11):333-337. X-1, X-2, X-3d.
248. Curatolo M, Derighetti M, Petersen-Felix S, et al. Fuzzy logic control of inspired isoflurane and oxygen concentrations using minimal flow anaesthesia. *Br J Anaesth* 1996;76(2):245-250. X-2, X-3d.
249. Curran MJ, Donati F and Bevan DR. Onset and recovery of atracurium and suxamethonium-induced neuromuscular blockade with simultaneous train-of-four and single twitch stimulation. *Br J Anaesth* 1987;59(8):989-994. X-2, X-3d.

250. Dabo F, Nyberg F, Qin Z, et al. Plasma levels of beta-endorphin during pregnancy and use of labor analgesia. *Reprod Sci* 2010 Aug;17(8):742-7. X-3d, X-5.
251. Dahl V, Fjellanger F and Raeder JC. No effect of preoperative paracetamol and codeine suppositories for pain after termination of pregnancies in general anaesthesia. *Eur J Pain* 2000;4(2):211-215. X-2, X-3b, X-3d.
252. Dahlgren BE. Influence of methoxyflurane-nitrous oxide analgesia during childbirth on renal and hepatic function. *Br J Anaesth* 1977 Dec;49(12):1271-7. X-5.
253. Dahlgren BE. Urinary fluoride concentration in mothers and neonates after methoxyflurane-nitrous oxide analgesia during labour. *Acta Pharm Suec* 1978;15(3):211-7. X-3, X-5.
254. Dahlgren BE. Fluoride concentrations in urine of delivery ward personnel following exposure to low concentrations of methoxyflurane. *J Occup Med* 1979 Sep;21(9):624-6. X-5.
255. Dahlgren BE, Olander L and Ovrum P. Pollution of delivery ward air by nitrous oxide--methoxyflurane. *Am Ind Hyg Assoc J* 1979 Aug;40(8):666-72. X-3, X-5.
256. Dahlgren G, Tornberg DC, Pregner K, et al. Four cases of the ex utero intrapartum treatment (EXIT) procedure: Anesthetic implications. *Int J Obstet Anesth* 2004;13(3):178-182. X-1, X-2, X-3d.
257. Dailey PA, Fisher DM and Shnider SM. Pharmacokinetics, placental transfer, and neonatal effects of vecuronium and pancuronium administered during cesarean section. *Anesthesiology* 1984;60(6):569-574. X-2, X-3d.
258. Dailland P, Cockshott ID, Lirzin JD, et al. Intravenous propofol during cesarean section: placental transfer, concentrations in breast milk, and neonatal effects. A preliminary study. *Anesthesiology* 1989 Dec;71(6):827-34. X-2, X-3d.
259. Dale O and Husum B. Nitrous oxide: at threat to personnel and global environment? *Acta Anaesthesiol Scand* 1994 Nov;38(8):777-9. X-1, X-2, X-5.
260. Daniel-Spiegel E, Weiner Z, Ben-Shlomo I, et al. For how long should oxytocin be continued during induction of labour? *BJOG* 2004;111(4):331-334. X-2, X-3d.
261. Dannecker C, Lienemann A, Fischer T, et al. Influence of spontaneous and instrumental vaginal delivery on objective measures of pelvic organ support: Assessment with the pelvic organ prolapse quantification (POPQ) technique and functional cine magnetic resonance imaging. *Eur J Obstet Gynecol Reprod Biol* 2004;115(1):32-38. X-2, X-3d, X-5.
262. Daponte A, Nzewenga G, Dimopoulos KD, et al. The use of vaginal misoprostol for second-trimester pregnancy termination in women with previous single cesarean section. *Contraception* 2006;74(4):324-327. X-2, X-3b.
263. Das S and Mitra S. A comparative apgar score study on neonates born by caesarean section under general anaesthesia and epidural analgesia. *J Indian Med Assoc* 1988;86(6):149-151. X-2, X-3, X-5.
264. Datta S and Brown WU, Jr. Acid-base status in diabetic mothers and their infants following general or spinal anesthesia for cesarean section. *Anesthesiology* 1977 Sep;47(3):272-6. X-2, X-3d.
265. David AL, Kotecha M and Girling JC. Factors influencing postnatal liver function tests. *BJOG* 2000 Nov;107(11):1421-6. X-2, X-3a, X-3d, X-5.
266. Davies CK. Anaesthesia for an obstetric flying squad. *Br J Anaesth* 1969 Jun;41(6):545-50. X-1, X-2, X-3, X-5.
267. Davies JM, Hogg M and Rosen M. Maternal arterial oxygen tension during intermittent inhalation analgesia. *Br J Anaesth* 1975 Mar;47(3):370-8. X-2.
268. Davies JM, Hogg M, Rosen M, et al. Upper limits of resistance of apparatus used for inhalation



- analgesia during labour: response of mothers. *Br J Anaesth* 1973 Jan;45(1):116. X-3, X-5.
269. Davies JM, Hogg MI and Rosen M. The resistance of Entonox valves. *Br J Anaesth* 1974 Feb;46(2):145-8. X-2, X-3, X-5.
  270. Davies JM, Hogg MI and Rosen M. Upper limits of resistance of apparatus for inhalation analgesia during labour. Response of mothers to increasing apparatus resistance. *Br J Anaesth* 1974 Feb;46(2):136-44. X-3d, X-5.
  271. Davies JM, Willis BA and Rosen M. Entonox analgesia in labour. A pilot study to reduce the delay between demand and supply. *Anaesthesia* 1978 Jun;33(6):545-7. X-2.
  272. Davis AG and Moir DD. Anaesthesia during pregnancy. *Clin Anaesthesiol* 1986;4(2):233-245. X-1, X-2, X-3, X-5.
  273. De Assuncao Braga ADF, Sampaio Rousselet M, Zambelli H, et al. Anesthesia for intrauterine myelomeningocele correction. Case report. [Portuguese, English]. *Rev Bras Anesthesiol* 2005;55(3):329-335. X-1, X-2, X-3.
  274. De Cooman S, De Mey N, Dewulf BBC, et al. Desflurane consumption during automated closed-circuit delivery is higher than when a conventional anesthesia machine is used with a simple vaporizer-O<sub>2</sub>-N<sub>2</sub>O fresh gas flow sequence. *BMC Anesthesiology* 2008;8(4). X-2, X-3.
  275. De Cooman S, De Mey N, Dewulf BBC, et al. Desflurane consumption during automated closed-circuit delivery is higher than when a conventional anesthesia machine is used with a simple vaporizer-O<sub>2</sub>-N<sub>2</sub>O fresh gas flow sequence. *BMC Anesthesiology* 2008;8(4). X-2, X-3.
  276. de Costa CM. Snow - At Christmas. *Med J Aust* 2007;187(11-12):690-692. X-1, X-2, X-3, X-5.
  277. De Jongh RF, Bosmans EP, Puylaert MJ, et al. The influence of anaesthetic techniques and type of delivery on peripartum serum interleukin-6 concentrations. *Acta Anaesthesiol Scand* 1997;41(7):853-860. X-3d, X-5.
  278. De Oliveira Rodrigues Filho G, Gesser N, Ghellar MR, et al. Minimum analgesic concentration of bupivacaine after continuous epidural infusion following spinal anesthesia in the postoperative period of leg, ankle and foot surgery. [Portuguese, English]. *Rev Bras Anesthesiol* 2001;51(5):385-393. X-2, X-3.
  279. Delaney AG. Anesthesia in the pregnant woman. *Clin Obstet Gynecol* 1983;26(4):795-800. X-1, X-2, X-3.
  280. Delis KT, Knaggs AL, Mason P, et al. Effects of epidural-and-general anesthesia combined versus general anesthesia alone on the venous hemodynamics of the lower limb. A randomized study. *Thromb Haemost* 1003;92(5):1003-1011. X-2, X-3.
  281. Denison FC, Kelly RW, Calder AA, et al. Secretory leukocyte protease inhibitor concentration increases in amniotic fluid with the onset of labour in women: Characterization of sites of release within the uterus. *J Endocrinol* 1999;161(2):299-306. X-2, X-3.
  282. Dermitzaki E, Staikou C, Petropoulos G, et al. A randomized study of maternal serum cytokine levels following cesarean section under general or neuraxial anesthesia. *Int J Obstet Anesth*. 2009 Jan;18(1):33-7. X-2, X-3.
  283. Derom R, Thiery M and Rolly G. Effects of general anesthesia on the acid-base balance of the human fetus during elective caesarean section. *Acta Anaesthesiol Belg* 1974;25(1):33-5. X-2, X-3a, X-3d, X-5.
  284. Desai S, Leong SB, Yvonne L, et al. Chronobiology of parturients receiving neuraxial labour analgesia with ropivacaine and fentanyl: a prospective cohort study. *Int J Obstet Anesth* 2009;18(1):43-47. X-3.
  285. Desai SK, Nariani CM, Allahbadia GN, et al. Fallopian tube sperm perfusion versus intrauterine insemination: A preliminary report

- from a University teaching hospital. Middle East Fertil Soc J 1998;3(3):267-271. X-2, X-3.
286. Deschler PE. Anesthetic assessment and management of the pregnant renal transplant recipient. J Am Assoc Nurse Anesth 1983;51(5):511-520. X-1, X-2, X-3d, X-5,
  287. Dewan DM, Floyd HM and Thistlewood JM. Sodium citrate pretreatment in elective cesarean section patients. Anesth Analg 1985;64(1):34-37. X-2, X-3.
  288. Dewan DM, Wheeler AS, James FM, 3rd, et al. Antacid anticholinergic regimens in patients undergoing elective caesarean section. Can Anaesth Soc J 1982 Jan;29(1):27-30. X-2, X-3.
  289. Dewan DM, Writer WD, Wheeler AS, et al. Sodium citrate premedication in elective caesarean section patients. Can Anaesth Soc J 1982 Jul;29(4):355-8. X-2, X-3.
  290. Dich-Nielsen J and Holasek J. Ketamine as induction agent for caesarean section. Acta Anaesthesiol Scand 1982 Apr;26(2):139-42. X-2, X-3a, X-3d, X-5.
  291. Dick W, Traub E, Kraus H, et al. General anaesthesia versus epidural anaesthesia for primary caesarean section--a comparative study. Eur J Anaesthesiol 1992 Jan;9(1):15-21. X-2, X-3.
  292. Dickinson JE, Godfrey M, Evans SF, et al. Factors influencing the selection of analgesia in spontaneously labouring nulliparous women at term. Aust N Z J Obstet Gynaecol 1997 Aug;37(3):289-93. X-3a, X-5.
  293. Dickinson JE, Paech MJ, McDonald SJ, et al. The impact of intrapartum analgesia on labour and delivery outcomes in nulliparous women. Aust NZ J Obstet Gynaecol 2002;42(1):59-66. X-5.
  294. Dickinson JE, Paech MJ, McDonald SJ, et al. Maternal satisfaction with childbirth and intrapartum analgesia in nulliparous labour. Aust N Z J Obstet Gynaecol 2003 Dec;43(6):463-8. X-3a, X-5.
  295. Ding Y, Fredman B and White PF. Use of ketorolac and fentanyl during outpatient gynecologic surgery. Anesth Analg 1993;77(2):205-210. X-2, X-3.
  296. Dingley J and Hughes LG. Xenon: A replacement for nitrous oxide. Curr Opin Anaesthesiol 2000;13(4):443-447. X-1, X-2, X-3, X-5.
  297. Dinwiddie R and Russell G. The measurement of effective pulmonary capillary blood flow in the newborn, using low concentrations of nitrous oxide. Biol Neonate 1972;21(1):83-9. X-2, X-3, X-5.
  298. Dixon JB, Dixon ME and O'Brien PE. Pregnancy after Lap-Band surgery: Management of the band to achieve healthy weight outcomes. Obes Surg 2001;11(1):59-65. X-2, X-3.
  299. Dob DP and Yentis SM. UK registry of high-risk obstetric anaesthesia: Report on cardiorespiratory disease. Int J Obstet Anesth 2001;10(4):267-272. X-1, X-2, X-3, X-5.
  300. Dogan R, Birdane A, Bilir A, et al. Frequency of electrocardiographic changes indicating myocardial ischemia during elective cesarean delivery with regional and general anesthesia: detection based on continuous Holter monitoring and serum markers of ischemia. J Clin Anesth 2008;20(5):347-351. X-2, X-3.
  301. Dolan PF and Rosen M. Inhalational analgesia in labour: facemask or mouthpiece. Lancet 1975 Nov 22;2(7943):1030-1. X-3d, X-5.
  302. Dolan WM, Eger EI, 2nd and Margolis AJ. Forane increases bleeding in therapeutic suction abortion. Anesthesiology 1972 Jan;36(1):96-7. X-1, X-3b, X-5.
  303. Dolk A, Cannerfelt R, Anderson RE, et al. Inhalation anaesthesia is cost-effective for ambulatory surgery: A clinical comparison with propofol during elective knee arthroscopy. Eur J Anaesthesiol 2002;19(2):88-92. X-2, X-3d.
  304. Donvig M, Secher O and Ovlisen B. The influence of enibomalum on infants delivered by Caesarean

- section. *Acta Anaesthesiol Scand Suppl* 1966;23:133-7. X-2, X-3a, X-5.
305. Douglas MJ, Gunka VB and Von Dadelszen P. Anesthesia for the parturient with pseudoxanthoma elasticum. *Int J Obstet Anesth* 2003;12(1):45-47. X-2, X-3.
  306. Downing JW, Coleman AJ, Mahomedy MC, et al. General anaesthesia for caesarean section. I. A review of the special problems confronting the obstetric anaesthetist. *S Afr Med J* 1974 Jul 20;48(35):1497-9. X-1, X-2, X-3a, X-5.
  307. Downing JW, Fairbrother PE, Buley RJ, et al. Hypothesis: volatile anaesthetic agents enhance transplacental exchange between mother and fetus. A preliminary study of fetal scalp blood gas changes associated with enflurane anaesthesia. *S Afr Med J* 1979 Jan 6;55(1):17-20. X-3a, X-5.
  308. Downing JW, Mahomedy MC, Jeal DE, et al. Anaesthesia for Caesarean section with ketamine. *Anaesthesia* 1976 Sep;31(7):883-92. X-2, X-3.
  309. Driessen JJ, Gielen MJM and Nijhuis GMM. Epidural anesthesia with plain bupivacaine 0.75% for elective caesarean section. *Acta Anaesthesiol Belg* 1984;35(2):145-154. X-2, X-3, X-5.
  310. Drongowski RA, Smith Jr RK, Goran AG, et al. Contribution of demographic and environmental factors to the etiology of gastroschisis: A hypothesis. *Fetal Diagn Ther* 1991;6(1-2):14-27. X-2, X-3.
  311. Drover DR, Lemmens HJ, Pierce ET, et al. Patient State Index. *Anesthesiology*. 2002;97(1):82-89. X-2, X-3.
  312. Drury WL, LaVallee DA and Vacanti CJ. Effects of laparoscopic tubal ligation on arterial blood gases. *Anesth Analg* 1971 May-Jun;50(3):349-51. X-2, X-3a, X-5.
  313. Du Plessis L, Langley N, Slabbert C, et al. Enhancement of the in vitro antimalarial efficacy of atemisinin and quinolines by Pheroid vesicles. *Tropical Medicine and International Health. Conference: 6th European Congress on Tropical Medicine and International Health and 1st Mediterranean Conference on Migration and Travel Health Verona Italy. Conference Start 2009*;14(pp 128). X-2, X-3.
  314. Dubey PK, Tulika, Singh AK, et al. Anaesthesia for adrenalectomy in a patient of Von Hippel-Lindau disease with pregnancy. *J Anaesthesiol Clin Pharmacol* 2005;21(3):329-332. X-2, X-3.
  315. Dubois L, Girard M and Tatone-Tokuda F. Determinants of high birth weight by geographic region in Canada. *Chronic Dis Can* 2007;28(1-2):63-70. X-2, X-3.
  316. Dubus JC, Guillot C and Badier M. Electrostatic charge on spacer devices and salbutamol response in young children. *Int J Pharm* 2003;261(1-2):159-164. X-2, X-3.
  317. Duffy BL and Lee JS. Intravenous access: a comparison of two methods. *Anaesth Intensive Care* 1983 May;11(2):135-7. X-3.
  318. Duffy BL, Woodhouse PC, Schramm MD, et al. Ranitidine prophylaxis before anaesthesia in early pregnancy. *Anaesth Intensive Care* 1985;13(1):29-32. X-2, X-3.
  319. Dugas G, Fuller J, Singh S, et al. Pheochromocytoma and pregnancy: A case report and review of anesthetic management. *Can J Anaesth* 2004;51(2):134-138. X-2, X-3.
  320. Duggan AB and Katz SG. Combined spinal and epidural anaesthesia for caesarean section in a parturient with severe primary pulmonary hypertension. *Anaesth Intensive Care* 2003;31(5):565-569. X-2, X-3.
  321. Dullenkopf A, Lohmeyer U, Salgo B, et al. Non-invasive monitoring of haemoglobin concentration in paediatric surgical patients using near-infrared spectroscopy. *Anaesthesia* 2004;59(5):453-458. X-2, X-3.
  322. Duncan T and McEwan A. An evidence-based approach to the management of abnormal labour. *Curr Obstet Gynaecol* 2004;14(4):277-284. X-1, X-2, X-3.

323. Duncanson E, Richards V, Luce KM, et al. Medical homicide and extreme negligence. *Am J Forensic Med Pathol* 2009;30(1):18-22. X-1, X-2, X-3, X-5.
324. Dunn A, Davies A and Eckert G. Intraoperative death during Caesarian section in a patient with sickle-cell trait. *Can J Anaesth* 1987;34(1):67-70. X-2, X-3.
325. Dunn GL, Houlton PJ, Morison DH, et al. A comparative assessment of alfathesin for use in outpatient anaesthesia. *Can Anaesth Soc J* 1978 Mar;25(2):125-9. X-2, X-3.
326. Dunn SR, Walker JS, Aston DL, et al. Effect of anaesthetic technique on blood loss in termination of pregnancy. *Br J Anaesth* 1973 Jun;45(6):633-7. X-2, X-3b, X-5.
327. Dunson DB and Neelon B. Bayesian inference on order-constrained parameters in generalized linear models. *Biometrics* 2003 Jun;59(2):286-95. X-2, X-3.
328. Dwyer R, Fee JP and Moore J. Uptake of halothane and isoflurane by mother and baby during caesarean section. *Br J Anaesth* 1995 Apr;74(4):379-83. X-2, X-3a, X-3d, X-5.
329. Dyer RA, Els I, Farbas J, et al. Prospective, randomized trial comparing general with spinal anesthesia for cesarean delivery in preeclamptic patients with a nonreassuring fetal heart trace. *Anesthesiology* 2003 Sep;99(3):561-9; discussion 5A-6A. X-2, X-3.
330. Eason JR, Swaine CN and Jones PIE. Unstable cervical fracture. Anaesthetic management for an urgent Caesarean section. *Anaesthesia* 1987;42(7):745-749. X-1, X-2, X-3a, X-5.
331. Edelist G. A comparison of propofol and thiopentone as induction agents in outpatient surgery. *Can J Anaesth* 1987 Mar;34(2):110-6. X-2, X-3.
332. Edwards R. Anaesthesia for caesarean section in haemoglobin SC disease complicated by eclampsia: a case report. *Br J Anaesth* 1973 Jul;45(7):757-8. X-1, X-2, X-3a, X-3d, X-5.
333. Edwards RD, Hansel NK, Pruessner HT, et al. Intrathecal morphine sulfate for labor pain. *Tex Med* 1985;81(11):46-48. X-3.
334. Edwards RD, Hansel NK, Pruessner HT, et al. Intrathecal morphine as analgesia for labor pain. *J Am Board Fam Pract* 1988 Oct-Dec;1(4):245-50. X-3d, X-5.
335. Eger EI, 2nd. Fetal injury and abortion associated with occupational exposure to inhaled anesthetics. *AANA J* 1991 Aug;59(4):309-12. X-1, X-5.
336. Eger EI, 2nd and Gaskey NJ. A review of the present status of nitrous oxide. *AANA J* 1986 Feb;54(1):29-36. X-1, X-2, X-5.
337. Eger EI, White PF and Bogetz MS. Clinical and economic factors important to anaesthetic choice for day- case surgery. *Pharmacoeconomics* 2000;17(3):245-262. X-1, X-2.
338. Eger IEI. Current and future perspectives on inhaled anesthetics. *Pharmacotherapy* 1998;18(5):895-910. X-1.
339. Eid L, Ginosar Y, Elchalal U, et al. Caesarean section following the Fontan procedure: Two different deliveries and different anaesthetic choices in the same patient. *Anaesthesia* 1137;60(11):1137-1140. X-2, X-3.
340. Eide BI, Nilsen AB and Rasmussen S. Births in two different delivery units in the same clinic--a prospective study of healthy primiparous women. *BMC Pregnancy Childbirth* 2009;9:25. X-5.
341. Einarsson S, Stenqvist O, Bengtsson A, et al. Nitrous oxide elimination and diffusion hypoxia during normo- and hypoventilation. *Br J Anaesth* 1993 Aug;71(2):189-93. X-2, X-3d.
342. Elden H, Ostgaard HC, Fagevik-Olsen M, et al. Treatments of pelvic girdle pain in pregnant women: Adverse effects of standard treatment, acupuncture and stabilising exercises on the pregnancy, mother, delivery and the fetus/neonate. *BMC Complement Altern Med* 2008;8(34). X-3.

343. Elhakim M, el-Sebiae S, Kaschef N, et al. Intravenous fluid and postoperative nausea and vomiting after day-case termination of pregnancy. *Acta Anaesthesiol Scand* 1998 Feb;42(2):216-9. X-3.
344. Elhakim M, Kamel M and Moursi GE. Effects of thiopentone and propofol on uterine activity during day case abortion surgery. *Acta Anaesthesiol Ital* 1992;43(SUPPL. 2):155-160. X-2, X-3, X-5.
345. Elias S, Simpson JL and Martin AO. Chorionic villus sampling for first-trimester prenatal diagnosis: Northwestern University Program. *Am J Obstet Gynecol* 1985;152(2):204-213. X-2, X-3d.
346. Ellingson A, Haram K and Sagen N. Ketamine and diazepam as anaesthesia for forceps delivery. A comparative study. *Acta Anaesthesiol Scand* 1977;21(1):37-40. X-3, X-5.
347. Elmfors B and Stormby N. A study of cryosurgery for dysplasia and carcinoma in situ of the uterine cervix. *Br J Obstet Gynaecol* 1979 Dec;86(12):917-21. X-2, X-3d.
348. El-Tahan MR, Warda OM, Diab DG, et al. A randomized study of the effects of perioperative i.v. lidocaine on hemodynamic and hormonal responses for cesarean section. *J Anesth* 2009;23(2):215-21. X-2, X-3a, X-3d, X-5.
349. El-Tahan MR, Warda OM, Yasseen AM, et al. A randomized study of the effects of preoperative ketorolac on general anaesthesia for caesarean section. *Int J Obstet Anesth* 2007 Jul;16(3):214-20. X-2, X-3a, X-3d.
350. El-Wahab N and Robinson N. Analgesia and anaesthesia in labour. *Obstet Gynaecol Reprod Med* 2011;21(5):137-141. X-1, X-2, X-5.
351. Emenius G, Svartengren M, Korsgaard J, et al. Indoor exposures and recurrent wheezing in infants: a study in the BAMSE cohort. *Acta Paediatr* 2004 Jul;93(7):899-905. X-2, X-3d, X-5.
352. Enlund M, Kobosko P and Rhodin A. A cost-benefit evaluation of using propofol and alfentanil for a short gynecological procedure. *Acta Anaesthesiol Scand* 1996 Apr;40(4):416-20. X-2, X-3.
353. Enright AB and Parker JB. Double blind comparison of alfentanil N2O and fentanyl N2O for outpatient surgical procedures. *Can J Anaesth* 1988 Sep;35(5):462-7. X-2, X-3.
354. Enting RH, Oldenmenger WH, van der Rijt CCD, et al. Nitrous oxide is not beneficial for breakthrough cancer pain. *Palliat Med* 2002;16(3):257-259. X-1, X-2, X-3a, X-5.
355. Eom M, Lee JH, Chung JH, et al. An autopsy case of postpartum acute myocardial infarction associated with postpartum ergot alkaloids administration in old-aged pregnant women. *Yonsei Med J* 2005;46(6):866-869. X-2, X-3.
356. Erden V, Erkalp K, Yangin Z, et al. The effect of labor on sevoflurane requirements during cesarean delivery. *Int J Obstet Anesth* 2011;20(1):17-21. X-3d, X-5.
357. Ericson A and Kallen B. Survey of infants born in 1973 or 1975 to Swedish women working in operating rooms during their pregnancies. *Anesth Analg* 1979 Jul-Aug;58(4):302-5. X-3a, X-5.
358. Ericson HA and Kallen AJ. Hospitalization for miscarriage and delivery outcome among Swedish nurses working in operating rooms 1973-1978. *Anesth Analg* 1985 Oct;64(10):981-8. X-3a, X-5.
359. Eriksson H, Haasio J and Korttila K. Comparison of etanalone and thiopental in anaesthesia for termination of pregnancy. *Acta Anaesthesiol Scand* 1995 May;39(4):479-84. X-2, X-3.
360. Euliano TY and Yeager A. Cesarean section combined with splenectomy in a parturient with immune thrombocytopenic purpura. *J Clin Anesth* 2001;13(4):313-318. X-1, X-2, X-3d.
361. Evans JM. Anesthesia for in vitro fertilization oocyte retrieval. *Infertility* 1983;6(1-4):97-106. X-1, X-2, X-3d, X-5.
362. Evans NR, Skowno JJ, Bennett PJ, et al. A prospective observational study of the use of the

- Proseal<sup>TM</sup> laryngeal mask airway for postpartum tubal ligation. *Int J Obstet Anesth* 2005;14(2):90-95. X-2, X-3.
363. Everitt I, Younge P and Barnett P. Paediatric sedation in emergency departments: What is our practice? *Emergency Medicine* 2002;14(1):62-66. X-2, X-3.
  364. Evron S, Samueloff A and Sado vsky E. The effect of phenoxybenzamine on postoperative urinary complications during extradural morphine analgesia. *Eur J Anaesthesiol* 1984;1(1):45-54. X-2, X-3a, X-5.
  365. Eyres R. Update on TIVA. *Paediatric Anaesthesia*. 2004;14(5):374-379. X-1, X-2, X-3, X-5.
  366. Fadl ET and Utting JE. A study of maternal acid-base state during labour. *Br J Anaesth*. 1969 Apr;41(4):327-37. X-5, No accurate data.
  367. Famewo CE. Awareness and dreams during general anaesthesia for Caesarian section a study of incidence. *Can Anaesth Soc J*. 1976 Nov;23(6):636-9. X-2, X-3.
  368. Fanning J. Safety and the gas supply: Focus on anesthesia systems. *Biomed Instrum Technol* 2005;39(2):141-142. X-1, X-2, X-3, X-5.
  369. Fassoulaki A, Gatzou V, Petropoulos G, et al. Spread of subarachnoid block, intraoperative local anaesthetic requirements and postoperative analgesic requirements in Caesarean section and total abdominal hysterectomy. *Br J Anaesth* 2004;93(5):678-682. X-2, X-3.
  370. Fava M, Loyola S, Papapavlou P, et al. Cryoplasty for femoropopliteal arterial disease: Late angiographic results of initial human experience. *J Vasc Interv Radiol* 1239;15(11):1239-1243. X-2, X-3.
  371. Feigal RJ. Nitrous oxide: potential hazards to health professionals. *Northwest Dent* 1977 Sep-Oct;56(5):232-5. X-1, X-2, X-5.
  372. Feldman JM. Cardiac arrest after succinylcholine administration in a pregnant patient recovered from Guillain-Barre syndrome. *Anesthesiology* 1990;72(5):942-944. X-2, X-3.
  373. Ferguson A, Whittaker M, Britten JJ, et al. Suxamethonium apnoea associated with pregnancy and liver dysfunction in a treated cretin. *Anaesthesia* 1983;38(6):567-571. X-1, X-2, X-3a, X-5.
  374. Filos KS, Goudas LC, Patroni O, et al. Intrathecal clonidine as a sole analgesic for pain relief after cesarean section. *Anesthesiology* 1992;77(2):267-274. X-2, X-3.
  375. Filos KS, Goudas LC, Patroni O, et al. Hemodynamic and analgesic profile after intrathecal clonidine in humans. A dose-response study. *Anesthesiology* 1994 Sep;81(3):591-601; discussion 27A-28A. X-2, X-3.
  376. Findlay JY, Jankowski CJ, Vasdev GM, et al. Fast track anesthesia for liver transplantation reduces postoperative ventilation time but not intensive care unit stay. *Liver Transplantation* 2002;8(8):670-675. X-2, X-3.
  377. Findley I and Chamberlain G. ABC of labour care: Relief of pain. *BMJ* 1999;318(7188):927-930. X-1, X-2, X-5.
  378. Fineberg HV, Gabel RA and Sosman MB. Acquisition and application of new medical knowledge by anesthesiologists: three recent examples. *Anesthesiology* 1978 Jun;48(6):430-6. X-1, X-2, X-3a, X-3d, X-5.
  379. Finkelstein SE, Carey T, Fricke I, et al. Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma. *J Immunother* 2010;33(8):817-827. X-2, X-3.
  380. Finster M, Mark LC, Morishima HO, et al. Plasma thiopental concentrations in the newborn following delivery under thiopental-nitrous oxide anesthesia. *Am J Obstet Gynecol* 1966 Jul 1;95(5):621-9. X-5.
  381. Finster M, Morishima HO, Mark LC, et al. Thiopental and the fetal liver. *Anesthesiology* 1972

- Nov;37(5):571-2. X-1, X-2, X-3, X-5.
382. Finucane BT, Symbas PN and Braswell R. Ligation of patent ductus arteriosus in premature neonates: anesthetic management. *South Med J* 1981 Jan;74(1):21-3. X-2, X-3.
  383. Fischerstrom A, Ohqvist G and Settergren G. Comparison of fentanyl and halothane as supplement to nitrous-oxide-oxygen anaesthesia for coronary artery surgery. *Acta Anaesthesiol Scand* 1985;29(1):16-21. X-2, X-3.
  384. Fisher JT, Mortola JP, Smith B, et al. Neonatal pattern of breathing following cesarean section: epidural versus general anaesthesia. *Anesthesiology* 1983 Nov;59(5):385-9. X-2, X-3.
  385. Fletcher G. On ethics in human experimentation. *Anesthesiology* 1970 May;32(5):471-2. X-1, X-2, X-3d, X-5.
  386. Fletcher GC, Beck SA and Goudie TA. Labour analgesia - Can prospective mothers predict their needs? *Int J Obstet Anesth* 1994;3(3):176-177. X-3, X-5.
  387. Floyd RL, Belodoff B, Sidhu J, et al. A survey of obstetrician-gynecologists on their patients' use of tobacco and other drugs during pregnancy. *Prenat Neonatal Med* 2001;6(4):201-207. X-2, X-3.
  388. Fox GS and Houle GL. Acid-base studies in elective caesarean sections during epidural and general anaesthesia. *Can Anaesth Soc J* 1971 Jan;18(1):60-71. X-3.
  389. Frank M, Evans M, Flynn P, et al. Comparison of the prophylactic use of magnesium trisilicate mixtures B.P.C., sodium citrate mixture or cimetidine in obstetrics. *Br J Anaesth* 1984;56(4):355-362. X-2, X-3.
  390. Fretzin S, Beeson WH and Hanke CW. Ignition potential of the 585-nm pulsed-dye laser: Review of the literature and safety recommendations. *Dermatol Surg* 1996;22(8):699-702. X-2, X-3.
  391. Fryer ME and Boulton TB. Apparatus for emergency anaesthesia outside main hospitals. *Anaesthesia* 1977 Feb;32(2):189-96. X-1, X-2, X-3.
  392. Fujii Y, Tanaka H and Somekawa Y. A randomized, double-blind, placebo-controlled trial of ramosetron for preventing nausea and vomiting during termination of pregnancy. *Int J Obstet Anesth* 2004;13(1):15-18. X-2, X-3.
  393. Furst SR and Reisner LS. Risk of high spinal anaesthesia following failed epidural block for cesarean delivery. *J Clin Anesth* 1995;7(1):71-74. X-2, X-3.
  394. Furuya A, Matsukawa T, Ozaki M, et al. Propofol anaesthesia for cesarean section successfully managed in a patient with moyamoya disease. *J Clin Anesth* 1998;10(3):242-245. X-1, X-2, X-3a.
  395. Fyneface-Ogan S and Uzoigwe SA. Caesarean section outcome in eclamptic patients: A comparison of infiltration and general anaesthesia. *West Afr J Med* 2008;27(4):250-254. X-2, X-3.
  396. Gaiser RR, Cheek TG and Kurth CD. Anesthetic management of cesarean delivery complicated by ex utero intrapartum treatment of the fetus. *Anesth Analg* 1150;84(5):1150-1153. X-3.
  397. Galbert MW and Gardner AE. Use of halothane in a balanced technic for cesarean section. *Anesth Analg* 1972 Sep-Oct;51(5):701-4. X-3.
  398. Gale T, Leslie K and Kluger M. Propofol anaesthesia via target controlled infusion or manually controlled infusion: Effects on the bispectral index as a measure of anaesthetic depth. *Anaesth Intensive Care* 2001;29(6):579-584. X-2, X-3.
  399. Galletly DC, Yee P and Maling TJB. Anaesthetic management of combined caesarean section and pheochromocytoma removal. *Anaesth Intensive Care* 1983;11(3):249-253. X-2, X-3.
  400. Gambling DR, Sharma SK, White PF, et al. Use of sevoflurane during elective cesarean birth: a comparison with isoflurane and spinal

- anesthesia. *Anesth Analg* 1995 Jul;81(1):90-5. X-2, X-3.
401. Gan TJ, El-Molem H, Ray J, et al. Patient-controlled antiemesis: A randomized, double-blind comparison of two doses of propofol versus placebo. *Anesthesiology* 156;90(6):1564-1570. X-2, X-3.
  402. Gant NF and Wallace DH. Pregnancy-induced hypertension and the anaesthetic management of the patient. *Clin Anaesthesiol* 1986;4(2):321-350. X-1, X-2, X-3, X-5.
  403. Gardosi J. Fetal monitoring during labour. *Curr Anaesth Crit Care* 1991;2(3):187-193. X-1, X-2, X-3, X-5.
  404. Garrioch MA, McClure JH and Wildsmith JAW. Haemodynamic effects of diaspirin crosslinked haemoglobin (DCLHb) given before abdominal aortic aneurysm surgery. *Br J Anaesth* 1999;83(5):702-707. X-2, X-3.
  405. Gaspar LS. Hamman's syndrome: Pneumomediastinum and subcutaneous emphysema occurring in labour. *Int J Obstet Anesth* 1997;6(1):55-58. X-1, X-2, X-3, X-5.
  406. Gasparoni A, Chirico G, De Amici D, et al. Neutrophil chemotaxis in infants delivered by caesarean section. *Eur J Pediatr* 1991 May;150(7):481-2. X-2, X-3d, X-5.
  407. Gauert WB and Hustead RF. Differences in metered and measured oxygen concentrations during nitrous oxide analgesia. *Anesth Analg* 1968 Jul-Aug;47(4):441-5. X-2, X-3, X-5.
  408. Geary M, Fanagan M and Boylan P. Maternal satisfaction with management in labour and preference for mode of delivery. *J Perinat Med* 1997;25(5):433-9. X-3a, X-5.
  409. Gejervall AL, Lundin K, Stener-Victorin E, et al. Effect of alfentanil dosage during oocyte retrieval on fertilization and embryo quality. *Eur J Obstet Gynecol Reprod Biol* 2010;150(1):66-71. X-2, X-3.
  410. Gepts E, Heytens L and Camu F. Pharmacokinetics and placental transfer of intravenous and epidural alfentanil in parturient women. *Anesth Analg* 1155;65(11):1155-1160. X-2, X-3.
  411. Gerges FJ, Dalal AR, Robelen GT, et al. Anesthesia for cesarean section in a patient with placenta previa and methylenetetrahydrofolate reductase deficiency. *J Clin Anesth* 2006;18(6):455-459. X-2, X-3.
  412. Gerhardt RT, King KM and Wiegert RS. Inhaled nitrous oxide versus placebo as an analgesic and anxiolytic adjunct to peripheral intravenous cannulation. *Am J Emerg Med* 2001 Oct;19(6):492-4. X-2, X-3.
  413. Ghaly RG, Flynn RJ and Moore J. Isoflurane as an alternative to halothane for caesarean section. *Anaesthesia* 1988 Jan;43(1):5-7. X-2, X-3.
  414. Ghazi M, Seibel RE and Courey NG. Pelvic pneumography. Diagnostic aid in gynecology. *Obstet Gynecol* 1970 Dec;36(6):827-34. X-1, X-2, X-3, X-5.
  415. Ghods AA, Soleimani M and Narimani M. Effect of postoperative supplemental oxygen on nausea and vomiting after cesarean birth. *J Perianesth Nurs* 2005 Jun;20(3):200-5. X-2, X-3.
  416. Ghosh S and Marton S. Anesthetic management for cesarean delivery in a patient with severe aortic stenosis and severe obesity. *Obes Surg* 2011;21(2):264-266. X-1, X-2, X-3.
  417. Gibbs CP, Munson ES and Tham MK. Anesthetic solubility coefficients for maternal and fetal blood. *Anesthesiology* 1975 Jul;43(1):100-3. X-5.
  418. Gillett GB, Watson JD and Langford RM. Ranitidine and single-dose antacid therapy as prophylaxis against acid aspiration syndrome in obstetric practice. *Anaesthesia* 1984;39(7):638-644. X-2, X-3.
  419. Gilmer T. An analysis of the effects of organization and financing on the utilization and costs of public mental health services in San Diego County. *J Ment Health Policy Econ* 2007;10(3):123-132. X-2, X-3.



420. Gilstrap LC, 3rd, Hauth JC, Hankins GD, et al. Effect of type of anesthesia on blood loss at cesarean section. *Obstet Gynecol* 1987 Mar;69(3 Pt 1):328-32. X-2, X-3.
421. Gin T, Derrick JL, Chan MT, et al. Postpartum patients have slightly prolonged neuromuscular block after mivacurium. *Anesth Analg* 1998 Jan;86(1):82-5. X-2, X-3.
422. Gin T, Kan AF, Lam KK, et al. Analgesia after caesarean section with intramuscular ketorolac or pethidine. *Anaesth Intensive Care* 1993 Aug;21(4):420-3. X-2, X-3.
423. Gin T, Ngan-Kee WD, Siu YK, et al. Alfentanil given immediately before the induction of anesthesia for elective cesarean delivery. *Anesth Analg* 2000 May;90(5):1167-72. X-2, X-3.
424. Gin T, O'Meara ME, Kan AF, et al. Plasma catecholamines and neonatal condition after induction of anaesthesia with propofol or thiopentone at caesarean section. *Br J Anaesth* 1993 Mar;70(3):311-6. X-2, X-3.
425. Gin T, Yau G, Chan K, et al. Disposition of propofol infusions for caesarean section. *Can J Anaesth* 1991 Jan;38(1):31-6. X-2, X-3.
426. Giorgino FL, Mega M, Agnello A, et al. Beta-endorphin levels and general anaesthesia for cesarean section. Preliminary report. *Clin Exp Obstet Gynecol* 1984;11(4):165-167. X-2, X-3.
427. Glen JB and Jewell WH. Halothane vapour warnings. *Vet Rec* 1973 May 19;92(20):544. X-1, X-2, X-3, X-5.
428. Glen JB and Servin F. Evaluation of the predictive performance of four pharmacokinetic models for propofol. *Br J Anaesth* 2009;102(5):626-632. X-2, X-3.
429. Goetz LM. ACOG practice bulletin: No 36, July 2002, obstetrics analgesia and anesthesia. *Int J Gynaecol Obstet* 2002;78(3):321-335. X-2, X-3.
430. Goff LC, Pratt RR and Madrigal JL. Music listening and S-IgA levels in patients undergoing a dental procedure. *International Journal of Arts Medicine* 1997;5(2):22-6. X-2, X-3d, X-5.
431. Goldstein BD, Paz J, Giuffrida JG, et al. Atmospheric derivatives of anaesthetic gases as a possible hazard to operating-room personnel. *Lancet* 1976 Jul 31;2(7979):235-7. X-2, X-3, X-5.
432. Gonen O, Shulman A, Ghetler Y, et al. The impact of different types of anesthesia on in vitro fertilization-embryo transfer treatment outcome. *J Assist Reprod Genet* 1995 Nov;12(10):678-82. X-2, X-3.
433. Gong TK and Kim SS. Combined epidural anesthesia and ultrasound guided peripheral nerve block for wound revision in a patient with peripartum cardiomyopathy -A case report. *Korean J Anesthesiol* 2010;59(5):353-358. X-1, X-2, X-3.
434. Gonzalez RM, Bjerke RJ, Drobycki T, et al. Prevention of endotracheal tube-induced coughing during emergence from general anesthesia. *Anesth Analg* 1994;79(4):792-795. X-3.
435. Goodyear-Smith F, Knowles A and Masters J. First trimester medical termination of pregnancy: An alternative for New Zealand women. *Aust N Z J Obstet Gynaecol* 2006;46(3):193-198. X-2, X-3.
436. Gorelick M, Nagler J, Losek JD, et al. Pediatric Sedation Pearls. *Clin Pediatr Emerg Med* 2007;8(4):268-278. X-1, X-2, X-3.
437. Goto T, Saito H, Nakata Y, et al. Emergence times from xenon anaesthesia are independent of the duration of anaesthesia. *Br J Anaesth* 1997 Nov;79(5):595-9. X-2, X-3.
438. Goto T, Saito H, Shinkai M, et al. Xenon provides faster emergence from anesthesia than does nitrous oxide-sevoflurane or nitrous oxide-isoflurane. *Anesthesiology* 1997 Jun;86(6):1273-8. X-2, X-3.
439. Gotsch F, Romero R, Kusanovic JP, et al. The anti-inflammatory limb of the immune response in preterm labor, intra-amniotic infection/inflammation, and spontaneous parturition at term: A role for interleukin-10. *J Matern*

- Fetal Neonatal Med 2008;21(8):529-547. X-2, X-3.
440. Gozdemir M, Sert H, Yilmaz N, et al. Remifentanyl-propofol in vertebral disk operations: hemodynamics and recovery versus desflurane-n(2)o inhalation anesthesia. *Adv Ther* 2007 May-Jun;24(3):622-31. X-2, X-3.
  441. Grant D and Haas C. Nitrous nightmares? Hygienists compare notes on N2O, pregnancy. *Rdh*. 2009;29(12):40-4. X-1, X-2, X-3d, X-5.
  442. Grant IS. Anaesthesia for termination of pregnancy. *Br J Anaesth* 1980 Aug;52(8):711-3. X-1, X-2, X-3b, X-5.
  443. Graulau MF and Phelps M, Jr. Bilateral pneumothorax and cardiovascular collapse on induction of anesthesia. *Anesth Analg* 1972 Sep-Oct;51(5):671-5. X-3.
  444. Gray RH. Nitrous oxide and fertility. *N Engl J Med* 1993 Jan 28;328(4):284. X-3d, X-5.
  445. Gray WM. Occupational exposure to nitrous oxide in four hospitals. *Anaesthesia* 1989 Jun;44(6):511-4. X-5.
  446. Gregoretti S, Gelman S, Dimick A, et al. Total body oxygen supply-demand balance in burned patients under enflurane anesthesia. *J Trauma* 1987;27(2):158-160. X-2, X-3.
  447. Gregory MA, Gin T, Yau G, et al. Propofol infusion anaesthesia for caesarean section. *Can J Anaesth* 1990 Jul;37(5):514-20. X-2, X-3.
  448. Gregory TL, Hughes S, Coleman MA, et al. Acute fatty liver of pregnancy; three cases and discussion of analgesia and anaesthesia. *Int J Obstet Anesth* 2007;16(2):175-179. X-2, X-3.
  449. Griffin RP and Reynolds F. Maternal hypoxaemia during labour and delivery: The influence of analgesia and effect on neonatal outcome. *Int J Obstet Anesth* 1994;3(3):171-172. X-1.
  450. Griffin RP and Reynolds F. Maternal hypoxaemia during labour and delivery: the influence of analgesia and effect on neonatal outcome. *Anaesthesia* 1995 Feb;50(2):151-6. X-2.
  451. Gruss M, Bushell TJ, Bright DP, et al. Two-Pore-Domain K<sup>+</sup> Channels Are a Novel Target for the Anesthetic Gases Xenon, Nitrous Oxide, and Cyclopropane. *Mol Pharmacol* 2004;65(2):443-452. X-2, X-3.
  452. Guirguis SS, Pelmeur PL, Roy ML, et al. Health effects associated with exposure to anaesthetic gases in Ontario hospital personnel. *Br J Ind Med* 1990 Jul;47(7):490-7. X-3a, X-5.
  453. Gunaydin B, Candan N, Onan A, et al. Anesthesia for cesarean delivery in the term pregnant following acute onset severe intracranial superior sagittal sinus thrombosis. *Acta Anaesthesiol Belg* 2009;60(3):189-190. X-1, X-2, X-3.
  454. Guo X, Jiang Y and Lu Y. Applying of N2O inhalation for analgesia and nursing care of patients undergoing artificial abortion [Chinese]. *Chin Nurs Res* 2004;18(3B):509-10. X-2, X-3b, X-4.
  455. Gupta A, Kullander M, Ekberg K, et al. Anaesthesia for day-care arthroscopy. A comparison between desflurane and isoflurane. *Anaesthesia* 1996 Jan;51(1):56-62. X-2, X-3a.
  456. Gupta B, Prakash S and Gujral K. Anaesthetic management of the parturient with protein S deficiency and lumboperitoneal shunt. *Anaesth Intensive Care* 2003;31(5):573-575. X-1, X-2, X-3.
  457. Habib AS, Helsley SE, Millar S, et al. Anesthesia for cesarean section in a patient with spinal muscular atrophy. *J Clin Anesth* 2004;16(3):217-219. X-1, X-2, X-3.
  458. Hagnevik K, Lagercrantz H and Sjoqvist BA. Establishment of functional residual capacity in infants delivered vaginally and by elective cesarean section. *Early Human Development* 1991;27(1-2):103-110. X-2, X-3d.
  459. Hahn CEW, Palayiwa E, Sugg BR, et al. A microprocessor-controlled anaesthetic vaporizer. *Br J Anaesth*

- 1161;58(10):1161-1166. X-1, X-2, X-3d.
460. Hall JE, Ng WS and Smith S. Blood loss during first trimester termination of pregnancy: Comparison of two anaesthetic techniques. *Br J Anaesth* 1997;78(2):172-174. X-2, X-3b.
461. Halpern S. Low concentration epidural infusion increases the risk of instrumental vaginal delivery, but not cesarean delivery - Meta-analysis. *Evid Based Obstet Gynecol* 2005;7(2):66-67. X-1, X-2, X-3, X-5.
462. Hamilton A, Sirrs S, Schmidt N, et al. Anaesthesia for pheochromocytoma in pregnancy. *Can J Anaesth* 1997;44(6):654-657. X-1, X-2, X-3d.
463. Hammadeh ME, Wilhelm W, Huppert A, et al. Effects of general anaesthesia vs. sedation on fertilization, cleavage and pregnancy rates in an IVF program. *Arch Gynecol Obstet* 1999 Nov;263(1-2):56-9. X-2, X-3a, X-3d.
464. Han TH, Brimacombe J, Lee EJ, et al. The laryngeal mask airway is effective (and probably safe) in selected healthy parturients for elective Cesarean section: A prospective study of 1067 cases. *Can J Anaesth* 1117;48(11):1117-1121. X-2, X-3d.
465. Hanisch EC, Sankawa H, Gauert WB, et al. Clinical and mechanical evaluation of an A.E. gas machine for obstetric analgesia and anesthesia. *Anesth Analg* 1971 Mar-Apr;50(2):190-4. X-2, X-3, X-5.
466. Hara K, Saito Y, Morimoto N, et al. Anaesthetic management of Cesarean section in a patient with myelodysplastic syndrome. *Can J Anaesth* 1998;45(2):157-163. X-1, X-2, X-3d.
467. Haram K and Bakke OM. Diazepam as an induction agent for caesarean section: a clinical and pharmacokinetic study of fetal drug exposure. *Br J Obstet Gynaecol* 1980 Jun;87(6):506-12. X-2, X-3d.
468. Haram K, Bakke OM, Sandvei R, et al. Foetal drug exposure following intravenous injection of diazepam immediately before breech delivery. *Ann Chir Gynaecol* 1979;68(3):104-8. X-2, X-3d.
469. Haram K, Lund T, Sagen N, et al. Comparison of thiopentone and diazepam as induction agents of anaesthesia for Caesarean section. *Acta Anaesthesiol Scand* 1981 Dec;25(6):470-6. X-2, X-3d.
470. Harrad J and Howell P. General anaesthesia for Caesarean section. *Curr Anaesth Crit Care* 2000;11(2):66-72. X-1, X-2, X-3d.
471. Harrison JM, Girling KJ and Mahajan RP. Effects of propofol and nitrous oxide on middle cerebral artery flow velocity and cerebral autoregulation. *Anaesthesia* 2002;57(1):27-32. X-2, X-3a, X-3d.
472. Hartsilver EL, Vanner RG, Bewley J, et al. Gastric pressure during emergency Caesarean section under general anaesthesia. *Br J Anaesth* 1999;82(5):752-754. X-2, X-3.
473. Hasan SS, Khan FH and Ahmed M. Comparison of Ketorolac with Morphine for Intra-operative Analgesia in Patients undergoing total Abdominal Hysterectomy. *Journal of the Pakistan Medical Association* 2003;53(10):467-471. X-2, X-3a, X-3d.
474. Hawkins JL. Epidural analgesia for labor and delivery. *N Engl J Med* 2010;362(16):1503-1510. X-1, X-2.
475. Hay DM. Nitrous oxide transfer across the placenta and condition of the newborn at delivery. *Br J Obstet Gynaecol* 1978 Apr;85(4):299-302. X-2, X-3a, X-3d.
476. Hayes NE, Aslani A and McCaul CL. Anaesthetic management of a patient with Liddle's syndrome for emergency caesarean hysterectomy. *Int J Obstet Anesth* 2011;20(2):178-180. X-1, X-2, X-3.
477. Hazama A, Kinouchi K, Kitamura S, et al. Brachial plexus birth injuries: anaesthesia for surgical nerve reconstruction and preoperative myelography and computed tomographic myelography. *Paediatr Anaesth* 1999;9(5):403-7. X-2, X-3a, X-3d.
478. Hearn M. Black rubber or clear plastic delivery tubing for nitrous

- oxide: Patient preference. *Int J Obstet Anesth* 1993;2(1):39-40. X-3d, X-5.
479. Heath BJ, Done M, Balog O, et al. The effect of scavenging on nitrous oxide pollution in the delivery suite. *Aust N Z J Obstet Gynaecol* 1994 Aug;34(4):484-6. X-5.
480. Heather DJ and Martin-Sheridan D. Discharge time in patients who receive fentanyl or alfentanil for general anesthesia. *Nurse Anesth*. 1993 Dec;4(4):160-5. X-2, X-3b.
481. Heese Hde V, Davey DA, Rorke M, et al. Effect of maternal anaesthesia on oxygenation and acid-base status of the newborn infant. *S Afr Med J* 1973 Oct 27;47(42):1991-9. X-2, X-3, X-5.
482. Hegarty KL and Taft AJ. Overcoming the barriers to disclosure and inquiry of partner abuse for women attending general practice. *Aust N Z J Public Health* 2001;25(5):433-437. X-2, X-3.
483. Heidam LZ. Spontaneous abortions among dental assistants, factory workers, painters, and gardening workers: a follow up study. *J Epidemiol Community Health* 1984 Jun;38(2):149-55. X-3d, X-5.
484. Hein A, Jakobsson J and Ryberg G. Paracetamol 1 g given rectally at the end of minor gynaecological surgery is not efficacious in reducing postoperative pain. *Acta Anaesthesiol Scand* 1999 Mar;43(3):248-51. X-2, X-3b.
485. Hein A, Norlander C, Blom L, et al. Is pain prophylaxis in minor gynaecological surgery of clinical value? A double-blind placebo controlled study of paracetamol 1 g versus lornoxicam 8 mg given orally. *Ambulatory Surgery* 2001;9(2):91-4. X-2, X-3b.
486. Heinrichs WL. Reproductive hazards of the workplace and the home. *Clin Obstet Gynecol* 1983;26(2):429-436. X-1, X-2, X-3, X-5.
487. Heller ML. Nitrous oxide--relaxant anesthesia in cesarean section. *Trans N Engl Obstet Gynecol Soc* 1965;19:43-7. X-1, X-2, X-3, X-5.
488. Hemminki K, Kyyronen P and Lindbohm ML. Spontaneous abortions and malformations in the offspring of nurses exposed to anaesthetic gases, cytostatic drugs, and other potential hazards in hospitals, based on registered information of outcome. *J Epidemiol Community Health* 1985;39(2):141-147. X-2, X-3a, X-5.
489. Henderson JJ, Dickinson JE, Evans SF, et al. Impact of intrapartum epidural analgesia on breast-feeding duration. *Aust N Z J Obstet Gynaecol* 2003;43(5):372-377. X-5.
490. Henderson KA and Matthews IP. Staff exposure to anaesthetic gases in theatre and non theatre areas. *Eur J Anaesthesiol* 2000;17(3):149-151. X-3d, X-5.
491. Hendrickx JFA, Cardinael S, Carette R, et al. The ideal oxygen/nitrous oxide fresh gas flow sequence with the Anesthesia Delivery Unit machine. *J Clin Anesth* 2007;19(4):274-279. X-2, X-3a.
492. Hendrickx JFA, Coddens J, Callebaut F, et al. Effect of N<sub>2</sub>O on sevoflurane vaporizer settings during minimal- and low-flow anesthesia. *Anesthesiology* 2002;97(2):400-404. X-2, X-3a.
493. Hendrickx JFA, Dewulf BBC, De Mey N, et al. Development and performance of a two-step desflurane-O<sub>2</sub>/N<sub>2</sub>O fresh gas flow sequence. *J Clin Anesth* 2008;20(7):501-507. X-2, X-3.
494. Hendrickx JFA, Dewulf BBC, De Mey N, et al. Development and performance of a two-step desflurane-O<sub>2</sub>/N<sub>2</sub>O fresh gas flow sequence. *J Clin Anesth* 2008;20(7):501-507. X-2, X-3a.
495. Henry A and Nand SL. Women's antenatal knowledge and plans regarding intrapartum pain management at the Royal Hospital for Women. *Aust N Z J Obstet Gynaecol* 2004;44(4):314-317. X-2, X-3, X-5.
496. Henry RJ. Assessing environmental health concerns associated with

- nitrous oxide. *J Am Dent Assoc* 1992 Dec;123(12):41-7. X-1, X-2.
497. Herff H, Paal P, Von Goedecke A, et al. Fatal errors in nitrous oxide delivery. *Anaesthesia* 1202;62(12):1202-1206. X-1, X-2, X-3a, X-5.
  498. Herrmann W, Hubner U, Koch I, et al. Alteration of homocysteine catabolism in pre-eclampsia, HELLP syndrome and placental insufficiency. *Clin Chem Lab Med* 1109;42(10):1109-1116. X-1, X-2, X-3.
  499. Hervey WH and Hustead RF. Ketamine for dilatation and curettage procedures: patient acceptance. *Anesth Analg* 1972 Jul-Aug;51(4):647-55. X-3.
  500. Herzog S, Cunze T, Martin M, et al. Pulsatile vs. continuous parenteral tocolysis: comparison of side effects. *Eur J Obstet Gynecol Reprod Biol* 1999;85(2):199-204. X-2, X-3.
  501. Heytens L and Camu F. Pulmonary edema during cesarean section related to the use of oxytocic drugs. *Acta Anaesthesiol Belg* 1984;35(2):155-164. X-1, X-2, X-3a, X-5.
  502. Higuma T, Oikawa K, Kato T, et al. Comparison of the effects of long-acting nifedipine CR and diltiazem R in patients with vasospastic angina: Aomori coronary spastic angina study. *Journal of Cardiology* 2010;56(3):354-360. X-2, X-3.
  503. Hildingsson I, Karlstrom A and Nystedt A. Women's experiences of induction of labour - Findings from a Swedish regional study. *Aust N Z J Obstet Gynaecol* 2011;51(2):151-157. X-2, X-3.
  504. Hildingsson IM, Lindgren HE, Haglund B, et al. Characteristics of women giving birth at home in Sweden: A national register study. *Am J Obstet Gynecol* 1366;195(5):1366-1372. X-2, X-3, X-5.
  505. Hill RP, Lubarsky DA, Phillips-Bute B, et al. Cost-effectiveness of prophylactic antiemetic therapy with ondansetron, droperidol, or placebo. *Anesthesiology* 2000 Apr;92(4):958-67. X-2, X-3d.
  506. Hiltunen P, Raudaskoski T, Ebeling H, et al. Does pain relief during delivery decrease the risk of postnatal depression? *Acta Obstet Gynecol Scand* 2004 Mar;83(3):257-61. X-2, X-5.
  507. Hines RS, Hines SH and Isaacs JD, Jr. Anesthetic effects on reproductive outcome. *Assisted Reproduction Reviews* 1998;8(1):47-50. X-1, X-2, X-3a.
  508. Hla Yee Y, Shirley DG, Singer DRJ, et al. Is renal lithium clearance altered in essential hypertension? *Journal of Hypertension* 1989;7(12):955-960. X-2, X-3.
  509. Ho AMH, Ngan Kee WD and Chung DC. Should laboring parturients with Harrington rods receive lumbar epidural analgesia? *Int J Gynaecol Obstet* 1999;67(1):41-43. X-1, X-2, X-3, X-5.
  510. Hodgkinson R, Bhatt M, Kim SS, et al. Neonatal neurobehavioral tests following cesarean section under general and spinal anesthesia. *Am J Obstet Gynecol* 1978 Nov 15;132(6):670-4. X-2, X-3d.
  511. Hodgkinson R, Bhatt M and Wang CN. Double-blind comparison of the neurobehaviour of neonates following the administration of different doses of meperidine to the mother. *Can Anaesth Soc J* 1978 Sep;25(5):405-11. X-2, X-3, X-5.
  512. Hodgkinson R, Husain FJ and Hayashi RH. Systemic and pulmonary blood pressure during caesarean section in parturients with gestational hypertension. *Can Anaesth Soc J* 1980 Jul;27(4):389-94. X-2, X-3d.
  513. Hodgkinson R, Marx GF, Kim SS, et al. Neonatal neurobehavioral tests following vaginal delivery under ketamine, thiopental, and extradural anesthesia. *Anesth Analg* 1977 Jul-Aug;56(4):548A. X-3a, X-5.
  514. Hogg MI, Davies JM, Mapleson WW, et al. Proposed upper limit of respiratory resistance for inhalation apparatus used in labour. *Br J*

- Anaesth 1974 Feb;46(2):149-52. X-1, X-2, X-3, X-5.
515. Holdcroft A. UK drug analysis prints and anaesthetic adverse drug reactions. *Pharmacoepidemiol Drug Saf* 2007;16(3):316-328. X-2, X-3d, X-5.
  516. Holdcroft A, Gibberd FB, Hargrove RL, et al. Neurological complications associated with pregnancy. *Br J Anaesth* 1995;75(5):522-526. X-2, X-3, X-5.
  517. Holdcroft A, Robinson MJ, Gordon H, et al. Comparison of effect of two induction doses of methohexitone on infants delivered by elective caesarean section. *Br Med J* 1974 Jun 1;2(5917):472-5. X-2, X-3a, X-5.
  518. Holland R. The Inventors. *Anaesthesia and Intensive Care* 2006;34(SUPPL. 1):33-38. X-1, X-2.
  519. Hollenbeck AR, Smith RF, Edens ES, et al. Early trimester anesthetic exposure: Incidence rates in an urban hospital population. *Child Psychiatry Hum Dev* 1985;16(2):126-134. X-3a, X-3d, X-5.
  520. Hollmen A. Neurobehavioural effects of drugs and anaesthetics on the neonate. *Eur J Obstet Gynecol Reprod Biol* 1983;15(4-6):362-364. X-1, X-2, X-5.
  521. Hollmen A and Jagerhorn M. Does increased maternal Pa CO<sub>2</sub> during general anaesthesia for caesarean section improve foetal acid-base parameters? Comparison of patients with normal and suspected pathological uteroplacental circulation. *Acta Anaesthesiol Scand* 1972;16(4):221-9. X-3.
  522. Hollmen AI, Eskelinen P and Tolonen U. Effects of anaesthesia for Caesarean section on the computerized EEG of the neonate. *Eur J Anaesthesiol* 1985;2(1):39-51. X-2, X-3, X-5.
  523. Hollmen AI, Jouppila R, Koivisto M, et al. Neurologic activity of infants following anesthesia for cesarean section. *Anesthesiology* 1978 May;48(5):350-6. X-2, X-3a, X-3d, X-5.
  524. Holmdahl MH. Demand-flow apparatus with control of preset N<sub>2</sub>O-O<sub>2</sub> mixture for use in labour. *Acta Anaesthesiol Scand Suppl* 1969;37:188-91. X-1, X-2, X-3, X-5.
  525. Holmes GL, Harden C, Liporace J, et al. Postnatal concerns in children born to women with epilepsy. *Epilepsy Behav* 2007;11(3):270-276. X-1, X-2, X-3d.
  526. Holmes JL, Hooper MJ, Barraclough BH, et al. Anaesthesia for thyroid surgery. *Anaesth Intensive Care*. 1973 Feb;1(3):218-25. X-3.
  527. Holzman RS, Riley LE, Aron E, et al. Perioperative care of a patient with acute fatty liver of pregnancy. *Anesth Analg* 1268;92(5):1268-1270. X-3.
  528. Hong JY, Jung WP and Jong IO. Comparison of preoperative gastric contents and serum gastrin concentrations in pregnant and nonpregnant women. *J Clin Anesth* 2005;17(6):451-455. X-1, X-2, X-3a, X-3d.
  529. Hood DD, Dewan DM and James IFM. The use of nitroglycerin in preventing the hypertensive response to tracheal intubation in severe preeclampsia. *Anesthesiology* 1985;63(3):329-332. X-2, X-3d, X-5.
  530. Hood DD and Holubec DM. Elective repeat cesarean section. Effect of anesthesia type on blood loss. *J Reprod Med* 1990 Apr;35(4):368-72. X-2, X-3, X-5.
  531. Horrigan BJ. Institute for alternative futures seeks input. *Explore (NY)* 2006;2(5):388-393. X-3d, X-5.
  532. Hosoda R, Hattori M and Shimada Y. Favorable effects of epidural analgesia on hemodynamics, oxygenation and metabolic variables in the immediate post-anesthetic period. *Acta Anaesthesiol Scand* 1993;37(5):469-474. X-2, X-3.
  533. Houghton IT. The Marrett apparatus: Is hospital anaesthetic equipment compatible with field use? *Anaesthe Intensive Care* 2005;33(SUPPL. 1):7-13. X-1, X-2, X-3.

534. Hovorka J, Korttila K and Erkola O. Nitrous oxide does not increase nausea and vomiting following gynaecological laparoscopy. *Can J Anaesth* 1989 Mar;36(2):145-8. X-2, X-3a, X-3d, X-5.
535. Howell CJ and Chalmers I. A review of prospectively controlled comparisons of epidural with non-epidural forms of pain relief during labour. *Int J Obstet Anesth* 1992 Jan;1(2):93-110. X-1, X-2.
536. Howell CJ, Kidd C, Roberts W, et al. A randomised controlled trial of epidural compared with non-epidural analgesia in labour. *BJOG* 2001;108(1):27-33. X-5.
537. Howorth FH. Air flow patterns in the operating theatre. *Eng Med* 1980 Apr;9(2):87-92. X-1, X-2, X-3, X-5.
538. Hsu SH and Shalansky SJ. Pharmacoeconomics of propofol versus thiopental for induction of anaesthesia in short procedures. *Can J Hosp Pharm* 1995 Aug;48(4):208-13. X-2, X-3.
539. Hu Y, Zhou J, Hao S, et al. Changes in the ratio of Tc1/Tc2 and Th1/Th2 cells but not in subtypes of NK-cells in preeclampsia. *Int J Mol Sci* 2007;8(6):492-504. X-2, X-3.
540. Hudome SM, Ergenekon EN, Darrow KA, et al. Precise control of nitric oxide concentration in the inspired gas of continuous flow respiratory devices. *Pediatr Pulmonol* 1996;22(3):182-187. X-2, X-3.
541. Hudson RJ and Stanski DR. Barbiturates - Pharmacokinetics and pharmacodynamics. *Clin Anaesthesiol* 1984;2(1):27-41. X-1, X-2, X-3.
542. Huebner CE, Milgrom P, Conrad D, et al. Providing dental care to pregnant patients: a survey of Oregon general dentists. *J Am Dent Assoc* 2009 Feb;140(2):211-22. X-2, X-3.
543. Hughes R. Atracurium - The first years. *Clinics in Anaesthesiology*. 1985;3(2):331-345. X-2, X-3.
544. Hughes SC. Analgesia methods during labour and delivery. *Can J Anaesth* 1992 May;39(5 Pt 2):R18-28. X-1, X-2, X-3, X-5.
545. Hull CJ and Jacobson L. A clinical trial of alfentanil as an adjuvant for short anaesthetic procedures. *Br J Anaesth* 1983;55 Suppl 2:173S-178S. X-2, X-3.
546. Humphrey M, Chang A, Gilbert M, et al. The effect of intravenous ritodrine on the acid-base status of the fetus during the second stage of labour. *Br J Obstet Gynaecol* 1975 Mar;82(3):234-45. X-3.
547. Hunter JG, Swanstrom L and Thornburg K. Carbon dioxide pneumoperitoneum induces fetal acidosis in a pregnant ewe model. *Surg Endosc* 1995 Mar;9(3):272-7; discussion 277-9. X-2, X-3.
548. Hunter T and Kleiman S. Anaesthesia for Caesarean hysterectomy in a patient with a preoperative diagnosis of placenta percreta with invasion of the urinary bladder. *Can J Anaesth* 1996;43(3):246-251. X-1, X-2, X-3.
549. Hunton J and Oswal VH. Metal tube anaesthesia for ear, nose and throat carbon dioxide laser surgery. *Anaesthesia* 1210;40(12):1210-1212. X-1, X-2, X-3a, X-3d, X-5.
550. Husemeyer RP, Cummings AJ, Rosankiewicz JR, et al. A study of pethidine kinetics and analgesia in women in labour following intravenous intramuscular and epidural administration. *Br J Clin Pharmacol* 1982;13(2):171-176. X-3, X-5.
551. Hutchison AA, Forbes AM and Russell G. Effective pulmonary blood flow in preterm and light-for-date infants. *Pediatrics* 1976 Feb;57(2):187-90. X-2, X-3.
552. Hutchison AA, Ogletree ML and Palme CJH. Plasma 6-keto prostaglandin F<sub>1α</sub> and thromboxane B<sub>2</sub> in sick preterm neonates. *Prostaglandins Leukot Med* 1985;18(2):163-181. X-2, X-3.
553. Huttel FA, Mitchell I, Fischer WM, et al. A quantitative evaluation of psycho-prophylaxis in childbirth. *J Psychosom Res* 1972 Apr;16(2):81-92. X-3, X-5.
554. Ickx BE, Rigolet M and Van Der Linden PJ. Cardiovascular and

- metabolic response to acute normovolemic anemia: Effects of anesthesia. *Anesthesiology*. 1011;93(4):1011-1016. X-2, X-3.
555. Idris AH, McDermott MF, Raucci JC, et al. Emergency department treatment of severe asthma: Metered-dose inhaler plus holding chamber is equivalent in effectiveness to nebulizer. *Chest* 1993;103(3):665-672. X-2, X-3.
  556. Imberti R, Preseglio I, Imbriani M, et al. Low flow anaesthesia reduces occupational exposure to inhalation anaesthetics. Environmental and biological measurements in operating room personnel. *Acta Anaesthesiol Scand* 1995 Jul;39(5):586-91. X-2, X-5.
  557. Imbriani M and Chittari SP, G. Nitrous oxide in urine as biological index of exposure in operating room personnel. *Appl IndHygiene* 1988 1988;3:223-7. X-3d, X-5.
  558. Imbriani M, Ghittori S and Pezzagno G. The biological monitoring of inhalation anaesthetics. *G Ital Med Lav Ergon* 1998 Jan-Mar;20(1):44-9. X-4.
  559. Imtiaz A, Mustafa S, Masroorudin, et al. Effect of spinal and general anaesthesia over APGAR score in neonates born after elective cesarean section. *J Liaquat Univ Med Health Sci* 2010;9(3):151-154. X-2, X-3.
  560. Ingram J, Domagala C and Yates S. The effects of shiatsu on post-term pregnancy. *Complement Ther Med* 2005;13(1):11-15. X-2, X-3.
  561. Inomata S, Nishikawa T, Saito S, et al. 'Best' PEEP during one-lung ventilation. *Br J Anaesth* 1997;78(6):754-756. X-2, X-3.
  562. Ioscovich A, Gislason R, Fadeev A, et al. Peripartum anesthetic management of patients with Takayasu's arteritis: case series and review. *Int J Obstet Anesth* 2008;17(4):358-364. X-1, X-2, X-3.
  563. Ioscovich A, Shen O, Sichel JY, et al. Remifentanyl-nitroglycerin combination as an anesthetic support for ex utero intrapartum treatment (EXIT) procedure. *J Clin Anesth* 2011;23(2):142-144. X-1, X-2, X-3.
  564. Irestedt L. Current status of nitrous oxide for obstetric pain relief. *Acta Anaesthesiol Scand* 1994 Nov;38(8):771-2. X-1, X-2, X-5.
  565. Isobe K, Kusaka T, Fujikawa Y, et al. Measurement of cerebral oxygenation in neonates after vaginal delivery and cesarean section using full-spectrum near infrared spectroscopy. *Comp Biochem Physiol A Mol Integr Physiol* 2002;132(1):133-138. X-2, X-3.
  566. Ittichaikulthol W, Sriswasdi S, Prachanpanich N, et al. Bispectral index in assessment of 3% and 4.5% desflurane in 50% N2O for caesarean section. *J Med Assoc Thai* 2007 Aug;90(8):1546-50. X-2, X-3.
  567. Ivankovic AD, Elam JO and Huffman J. Methoxyflurane anesthesia for cesarian section. *J Reprod Med* 1971 Mar;6(3):105-9. X-3.
  568. Jacobs DE and Middendorf PJ. Control of nitrous oxide exposures in dental operatories using local exhaust ventilation: A pilot study. *Anesth Prog* 1986;33(5):235-242. X-2, X-3d, X-5.
  569. Jacobson B, Eklund G, Hamberger L, et al. Perinatal origin of adult self-destructive behavior. *Acta Psychiatr Scand* 1987 Oct;76(4):364-71. X-2, X-3.
  570. Jakobsson J, Davidson S, Andreen M, et al. Opioid supplementation to propofol anaesthesia for outpatient abortion: a comparison between alfentanil, fentanyl and placebo. *Acta Anaesthesiol Scand* 1991 Nov;35(8):767-70. X-2, X-3.
  571. Jakobsson J, Oddby E and Rane K. Patient evaluation of four different combinations of intravenous anaesthetics for short outpatient procedures. *Anaesthesia*. 1993 Nov;48(11):1005-7. X-2, X-3.
  572. Jalkanen A, Alanen A and Airas L. Pregnancy outcome in women with multiple sclerosis: Results from a prospective nationwide study in Finland. *Multiple Sclerosis* 2010;16(8):950-955. X-2, X-3.
  573. James CF, Banner T and Caton D. Cardiac output in women



- undergoing cesarean section with epidural or general anesthesia. *Am J Obstet Gynecol* 1178;160(5 I):1178-1184. X-2, X-3.
574. James MFM, Huddle KRL, Owen AD, et al. Use of magnesium sulphate in the anaesthetic management of phaeochromocytoma in pregnancy. *Can J Anaesth* 1988;35(2):178-182. X-1, X-2, X-3.
  575. James MFM and White JF. Anesthetic considerations at moderate altitude. *Anesth Analg* 1097;63(12):1097-1105. X-1, X-2, X-3.
  576. Jan GS, Tong WN, Chan AM, et al. Recovery from mivacurium block with or without anticholinesterase following continuous infusion in obstetric patients. *Anaesth Intensive Care* 1996 Oct;24(5):585-9. X-2, X-3, X-5.
  577. Janeczko GF, el-Etr AA and Younes S. Low-dose ketamine anesthesia for obstetrical delivery. *Anesth Analg* 1974 Nov-Dec;53(6):828-31. X-3d, X-5.
  578. Jansen GFA, Van Praagh BH, Kedaria MB, et al. Jugular bulb oxygen saturation during propofol and isoflurane/nitrous oxide anesthesia in patients undergoing brain tumor surgery. *Anesth Analg* 1999;89(2):358-363. X-2, X-3.
  579. Jarvi K, Osborn N and Wall N. An obstetric patient with neurocardiogenic syncope. *Int J Obstet Anesth* 2009;18(4):396-399. X-1, X-2, X-3.
  580. Jeffs SA, Hall JE and Morris S. Comparison of morphine alone with morphine plus clonidine for postoperative patient-controlled analgesia. *Br J Anaesth* 2002;89(3):424-427. X-2, X-3.
  581. Jenssen H. The shape of the amniotic pressure curve before and after paracervical block during labour. *Acta Obstet Gynecol Scand Suppl* 1975(42):1-29. X-3.
  582. Jenstrup M, Fruergaard KO and Mortensen CR. Pollution with nitrous oxide using laryngeal mask or face mask. *Acta Anaesthesiol Scand* 1999;43(6):663-666. X-2, X-3, X-5.
  583. Jha S, Chiu JW and Yeo ISW. Intravenous nitroglycerine versus general anaesthesia for placental extraction - A sequential comparison. *Med Sci Monit* 2003;9(7). X-1, X-2, X-3c.
  584. Jirasiritham S, Tanti vitayatan K and Sirivararom P. Over half MAC sevoflurane in cesarean section. *J Med Assoc Thai* 2005 Jul;88(7):914-20. X-2, X-3d.
  585. Joffe M. Time to pregnancy: A measure of reproductive function in either sex. *Occup Environ Med* 1997;54(5):289-295. X-1, X-2, X-3.
  586. John AH. The effect of maternal hypoxia on the heart rate of the foetus in utero. *Br J Anaesth* 1965 Jul;37(7):515-9. X-5.
  587. Johnson JA, Buchan RM and Reif JS. Effect of waste anesthetic gas and vapor exposure on reproductive outcome in veterinary personnel. *Am Ind Hyg Assoc J* 1987;48(1):62-66. X-2, X-3, X-5.
  588. Johnson MD and Flusche G. The anaesthetic management of selected respiratory problems in the obstetric patient. *Clin Anaesthesiol* 1986;4(2):261-273. X-1, X-2, X-3d, X-5.
  589. Johnstone MJ. The effect of lorazepam on neonatal feeding behaviour at term. *Pharmatherapeutica*. 1982;3(4):259-262. X-2, X-3d.
  590. Jones BP, Milliken BC and Penning DH. Anesthesia for Cesarean section in a patient with paraplegia resulting from tumour metastases to spinal cord. *Can J Anaesth* 1122;47(11):1122-1128. X-1, X-2, X-3d.
  591. Jones CR, McCullough J and Butters L. Plasma catecholamines and modes of delivery: The relation between catecholamine levels and in-vitro platelet aggregation and adrenoreceptor radioligand binding characteristics *BJOG* 1985;92(6):593-599. X-2, X-3d.
  592. Jones D. The problem patient. Anaesthesia during pregnancy and delivery. *Curr Ther (Seaforth)* 1985;26(6):97-109. X-1, X-2, X-3, X-5.

593. Jones HE, Svikis DS and Tran G. Patient compliance and maternal/infant outcomes in pregnant drug-using women. *Subst Use Misuse* 1411;37(11):1411-1422. X-2, X-3.
594. Jones I and Craddock N. Familiality of the puerperal trigger in bipolar disorder: Results of a family study. *Am J Psychiatry* 2001;158(6):913-917. X-2, X-3.
595. Jordan S, Emery S, Bradshaw C, et al. The impact of intrapartum analgesia on infant feeding. *Obstet Gynecol Surv* 2005;60(12):790-791. X-1, X-2, X-3, X-5.
596. Jouppila R, Puolakka J, Kauppila A, et al. Maternal and umbilical cord plasma noradrenaline concentrations during labour with and without segmental extradural analgesia, and during caesarean section. *Br J Anaesth* 1984;56(3):251-255. X-3d, X-5.
597. Juvin P, Servin F, Giraud O, et al. Emergence of elderly patients from prolonged desflurane, isoflurane, or propofol anesthesia. *Anesth Analg* 1997 Sep;85(3):647-51. X-2, X-3a, X-3d.
598. Kainuma M, Kimura N, Nonami T, et al. The effect of dobutamine on hepatic blood flow and oxygen supply-uptake ratio during enflurane nitrous oxide anesthesia in humans undergoing liver resection. *Anesthesiology* 1992;77(3):432-438. X-2, X-3a, X-3d.
599. Kaita TM, Nikkola EM, Rantala MI, et al. Fetal oxygen saturation during epidural and paracervical analgesia. *Acta Obstet Gynecol Scand* 2000;79(5):336-340. X-3, X-5.
600. Kalappa R, Ueland K, Hansen JM, et al. Maternal acid-base status during cesarean section under thiopental, N2O1 and succinylcholine anesthesia. *Am J Obstet Gynecol* 1971 Feb 1;109(3):411-7. X-2, X-3d, X-5.
601. Kallela H, Haasio J and Korttila K. Comparison of eltanolone and propofol in anesthesia for termination of pregnancy. *Anesth Analg* 1994;79(3):512-516. X-2, X-3b.
602. Kamal NM, Omar SH, Radwan KG, et al. Bispectral index monitoring tailors clinical anesthetic delivery and reduces anesthetic drug consumption. *J Med Sci* 2009;9(1):10-16. X-2, X-3a, X-3d.
603. Kampe S, Kiencke P, Delis A, et al. The continuous epidural infusion of ropivacaine 0.1% with 0.5 mugmL-1 sufentanil provides effective postoperative analgesia after total hip replacement: A pilot study. *Can J Anaesth* 2003;50(6):580-585. X-2, X-3a, X-3d.
604. Kan AS, Caves N, Wong SY, et al. A double-blind, randomized controlled trial on the use of a 50:50 mixture of nitrous oxide/oxygen in pain relief during suction evacuation for the first trimester pregnancy termination. *Hum Reprod* 2006 Oct;21(10):2606-11. X-2, X-3b.
605. Kanazawa M, Kinefuchi Y, Suzuki T, et al. The use of sevoflurane anesthesia during early pregnancy. *Tokai Journal of Experimental and Clinical Medicine*. 1999;24(2):53-55. X-1, X-2, X-3d.
606. Kangas L, Erkkola R, Kanto J, et al. Halothane anaesthesia in caesarean section. *Acta Anaesthesiol Scand* 1976;20(3):189-94. X-2, X-3a, X-3d.
607. Kanto J, Erkkola R, Mansikka M, et al. Segmental epidural analgesia. A modern method for safe and effective management of labor pains. *Biol Res Pregnancy Perinatol* 1983;4(4):172-176. X-3, X-5.
608. Kanto J and Pihlajamaki K. Oropharyngeal absorption of atropine. *Int J Clin Pharmacol Ther Toxicol* 1986;24(11):627-629. X-3.
609. Karadia S, Walford C, McSwiney M, et al. Hepatic rupture complicating eclampsia in pregnancy. *Br J Anaesth* 1996;77(6):792-794. X-1, X-2, X-3, X-5.
610. Karakaya H, Sahin N, Arslan A, et al. Complete sternal cleft in adolescence. *Internet J Anesthesiol* 2003;6(2). X-1, X-2, X-3.
611. Karasawa F, Takita A, Fukuda I, et al. Nitrous oxide concentrations in maternal and fetal blood during

- caesarean section. *Eur J Anaesthesiol* 2003 Jul;20(7):555-9. X-2, X-3a, X-3d, X-5.
612. Kardong-Edgren S. Is it time to change the paradigm? *JOGNN: Journal of Obstetric, Gynecologic & Neonatal Nursing* 1999;28(5):477-9. X-1, X-2.
  613. Kaul HL, Mehta M, Bhanumati G, et al. Vecuronium is not suitable for rapid sequence intubation for caesarean section. *J Anaesthesiol Clin Pharmacol* 1998;14(3):241-244. X-3.
  614. Keating IHJ and Kundrat M. Patient-controlled analgesia with nitrous oxide in cancer pain. *J Pain Symptom Manage* 1996;11(2):126-130. X-2, X-3, X-5.
  615. Keats AS. The effect of drugs on respiration in man. *Annu Rev Pharmacol Toxicol* 1985;25(pp 41-65). X-1, X-2, X-3.
  616. Kelly D and Brull SJ. The cost of modern technology. *J Clin Anesth* 1995;7(1):80-81. X-1, X-3.
  617. Kennedy GL, Jr., Smith SH, Keplinger ML, et al. Reproductive and teratologic studies with halothane. *Toxicol Appl Pharmacol* 1976 Mar;35(3):467-74. X-2, X-3d, X-5.
  618. Kennedy RL. General analgesia and anesthesia in obstetrics. *Clin Obstet Gynecol* 1974 Jun;17(2):227-39. X-1, X-2, X-5.
  619. Kenny GNC and Sutcliffe NP. Target-controlled infusions: Stress free anesthesia? *J Clin Anesth* 1996;8(3 SUPPL). X-1, X-2, X-3, X-5.
  620. Kersten JR, Kane K and Coon R. Bronchospasm during pneumoperitoneum. *Anesth Analg* 1999;81(5):1099-1101. X-2, X-3a, X-5.
  621. Kestin IG and Dorje P. Anaesthesia for evacuation of retained products of conception. Comparison between alfentanil plus etomidate and fentanyl plus thiopentone. *Br J Anaesth* 1987 Mar;59(3):364-8. X-3.
  622. Khaw KS, Ngan Kee WD, Chu CY, et al. Effects of different inspired oxygen fractions on lipid peroxidation during general anaesthesia for elective Caesarean section. *Br J Anaesth* 2010 Sep;105(3):355-60. X-3.
  623. Khaw KS, Ngan Kee WD, Chu CY, et al. Effects of different inspired oxygen fractions on lipid peroxidation during general anaesthesia for elective Caesarean section+. *Br J Anaesth* 2010;105(3):355-360. X-3.
  624. Kilickan L, Solak M and Bayindir O. Thoracic epidural anesthesia preserves myocardial function during intraoperative and postoperative period in coronary artery bypass grafting operation *J Cardiovasc Surg (Torino)* 2005;46(6):559-567. X-2, X-3.
  625. Kim TY and Ryu DH. The effect of fundal pressure at Caesarean section on maternal haemodynamics. *Anaesthesia* 2006;61(5):434-438. X-2, X-3.
  626. King H, Ashley S, Brathwaite D, et al. Adequacy of general anesthesia for cesarean section. *Anesth Analg* 1993 Jul;77(1):84-8. X-3.
  627. King MJ, Bowden MI and Cooper GM. Epidural fentanyl and 0.5% bupivacaine for elective caesarean section. *Anaesthesia* 1990 Apr;45(4):285-8. X-3.
  628. Kinoshita O, Aoki A, Yamamura T, et al. Plasma glucagon levels during spinal anesthesia and surgery in a glucagon-deficient patient. *Anesth Analg* 1983;62(9):846-847. X-1, X-2, X-3.
  629. Kitajima T, Miyamoto H, Takiguchi T, et al. General anesthesia for Cesarean section in a parturient with quintuplet pregnancy. *J Anesth* 1993;7(2):240-244. X-2, X-3a, X-5.
  630. Kivalo I, Timonen S and Castren O. The influence of anaesthesia and the induction-delivery interval on the newborn delivered by Caesarean section. *Ann Chir Gynaecol Fenn* 1971;60(2):71-5. X-2, X-3a, X-5.
  631. Kizilarslan S, Kuvaki B, Onat U, et al. Epidural fentanyl-bupivacaine compared with clonidine-bupivacaine for analgesia in labour. *Eur J Anaesthesiol* 2000;17(11):692-697. X-3a, X-3d, X-5.

632. Kizilarlan S, Kuvaki B, Onat U, et al. Epidural fentanyl-bupivacaine compared with clonidine-bupivacaine for analgesia in labour. *Eur J Anaesthesiol* 2000;17(11):692-697. X-3.
633. Kjellmer I, Magno R and Karlsson K. Anesthesia for Cesarean section. I. Effects on the respiratory adaptation of the newborn in elective Cesarean section. *Acta Anaesthesiol Scand* 1974;18(1):48-57. X-2, X-3, X-5.
634. Klebanoff MA, Shiono PH and Rhoads GG. Spontaneous and induced abortion among resident physicians. *JAMA* 1991 Jun 5;265(21):2821-5. X-2, X-3.
635. Kline JK. Maternal occupation: effects on spontaneous abortions and malformations. *Occup Med* 1986 Jul-Sep;1(3):381-403. X-1.
636. Knill-Jones RP, Rodrigues LV, Moir DD, et al. Anaesthetic practice and pregnancy. Controlled survey of women anaesthetists in the United Kingdom. *Lancet* 1972 Jun 17;1(7764):1326-8. X-3, X-5.
637. Kobielski J, Wysocki M and Orlicz P. Clinical evaluation of calypsol used for induction of anaesthesia for cesarean section. *Ther Hung* 1985;33(3):140-147. X-2, X-3, X-5.
638. Konieczko KM, Chapple JC and Nunn JF. Fetotoxic potential of general anaesthesia in relation to pregnancy. *Br J Anaesth* 1987;59(4):449-454. X-2, X-3, X-5.
639. Krantz ML, Campbell WT and Edwards WL. The effect of spontaneous ventilation on blood gases in obstetric patients under general anesthesia. *Anesth Analg* 1973 Nov-Dec;52(6):965-8. X-3, X-5.
640. Kressig P, Beinder E, Schweer H, et al. Post-delivery oxidative stress in women with preeclampsia or IUGR. *J Perinat Med* 2008;36(4):310-315. X-3.
641. Krestow M. The effect of post-anaesthetic dreaming on patient acceptance of ketamine anaesthesia: a comparison with thiopentone-nitrous oxide anaesthesia. *Can Anaesth Soc J* 1974 Jul;21(4):385-9. X-2, X-3, X-5.
642. Krintel JJ and Wegmann F. Aminophylline reduces the depth and duration of sedation with barbiturates. *Acta Anaesthesiol Scand* 1987 May;31(4):352-4. X-3.
643. Krishnan L, Gunasekaran N and Bhaskaranand N. Anesthesia for caesarean section and immediate neonatal outcome. *Indian Journal of Pediatrics* 1995;62(2):219-223. X-3.
644. Krishnan L, Gunasekaran N and Bhaskaranand N. Neonatal effects of anesthesia for caesarean section. *Indian J Pediatr* 1995;62(1):109-113. X-3.
645. Kugel G, Letelier C and Attallah H. Chronic low level nitrous oxide exposure and infertility. *J Dent Res* 1989;68:313. X-3d, X-5.
646. Kugel G, Letelier C, Zive MA, et al. Nitrous oxide and infertility. *Anesth Prog* 1990 Jul;37(4):176-80. X-2, X-3.
647. Kumar IH and Borkar JD. Twin surgeries in a case of pheochromocytoma. *Journal of Anaesthesiology Clinical Pharmacology* 2008;24(2):217-218. X-1, X-2, X-3, X-5.
648. Kvorning Ternov N, Nilsson M, Lofberg L, et al. Acupuncture for pain relief during childbirth. *Acupunct Electrother Res* 1998;23(1):19-26. X-3a.
649. Ladakhi GM, Mubarik M, Nabi B, et al. Neonatal risk factors and outcome of birth asphyxia. *JK Practitioner* 2000;7(4):267-270. X-2, X-3d, X-5.
650. Lahoud GY and Averley PA. Comparison of sevoflurane and nitrous oxide mixture with nitrous oxide alone for inhalation conscious sedation in children having dental treatment: A randomised controlled trial. *Anaesthesia* 2002;57(5):446-450. X-2, X-3.
651. Laine K, Heikkinen T, Ekblad U, et al. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin

- concentrations. *Arch Gen Psychiatry* 2003;60(7):720-726. X-2, X-3.
652. Laishley RS and Morgan BM. A single dose epidural technique for caesarean section. A comparison between 0.5% bupivacaine plain and 0.5% bupivacaine with adrenaline. *Anaesthesia* 1988 Feb;43(2):100-3. X-3.
  653. Lally JE, Murtagh MJ, Macphail S, et al. More in hope than expectation: A systematic review of women's expectations and experience of pain relief in labour. *BMC Medicine* 2008;6(7). X-1, X-2, X-3.
  654. Lam SP, Yat FSY and Wing YK. Status cataplecticus leading to the obstetric complication of prolonged labor. *J Clin Sleep Med* 2007;3(1):56-57. X-2, X-3.
  655. LaMarca B, Speed J, Fournier L, et al. Hypertension in response to chronic reductions in uterine perfusion in pregnant rats effect of tumor necrosis factor-alpha blockade. *Hypertension* 1161;52(6):1161-1167. X-2, X-3.
  656. Landon MJ and Toothill VJ. Effect of nitrous oxide on placental methionine synthase activity. *Br J Anaesth.* 1986 May;58(5):524-7. X-2, X-3d, X-5.
  657. Lange AP, Secher NJ, Westergaard JG, et al. Neonatal jaundice after labour induced or stimulated by prostaglandin E2 or oxytocin. *Lancet* 8279;1(8279):991-994. X-2, X-3.
  658. Lao TT, Halpern SH, MacDonald D, et al. Spinal subdural haematoma in a parturient after attempted epidural anaesthesia. *Can J Anaesth* 1993;40(4):340-345. X-2, X-3c.
  659. Latto IP, Molloy MJ and Rosen M. Arterial concentrations of nitrous oxide during intermittent patient-controlled inhalation of 50 percent nitrous oxide in oxygen (Entonox) during the first stage of labour. *Br J Anaesth* 1973 Oct;45(10):1029-34. X-2, X-5.
  660. Latto IP, Rosen M and Molloy MJ. Absence of accumulation of methoxyflurane during intermittent self-administration for pain relief in labour. *Br J Anaesth* 1972 Apr;44(4):391-400. X-3a, X-5.
  661. Latto IP and Wainwright AC. Anaesthesia for Caesarean section. Analysis of blood concentrations of methoxyflurane using 0.1 per cent methoxyflurane and 40 per cent oxygen. *Br J Anaesth* 1972 Oct;44(10):1050-6. X-2, X-3a, X-3d, X-5.
  662. Latto IP and Waldron BA. Anaesthesia for Caesarean section. Analysis of blood concentrations of halothane using 0.2% or 0.65% halothane with 50% nitrous oxide in oxygen. *Br J Anaesth* 1977 Apr;49(4):371-8. X-2, X-3.
  663. Lauretti GR and Lima ICPR. The effects of intrathecal neostigmine on somatic and visceral pain: Improvement by association with a peripheral anticholinergic. *Anesth Analg* 1996;82(3):617-620. X-2, X-3d.
  664. Lavand'homme P and Roelants F. Patient-controlled intravenous analgesia as an alternative to epidural analgesia during labor: questioning the use of the short-acting opioid remifentanyl. Survey in the French part of Belgium (Wallonia and Brussels). *Acta Anaesthesiol Belg* 2009;60(2):75-82. X-2, X-3.
  665. Law NL, Ng KFJ, Irwin MG, et al. Comparison of coagulation and blood loss during anaesthesia with inhaled isoflurane or intravenous propofol. *Br J Anaesth* 2001;86(1):94-98. X-2, X-3.
  666. Lawes EG, Newman B, Campbell MJ, et al. Maternal inspired oxygen concentration and neonatal status for caesarean section under general anaesthesia. Comparison of effects of 33% or 50% oxygen in nitrous oxide. *Br J Anaesth* 1988 Sep;61(3):250-4. X-2, X-3d, X-5.
  667. Lawler K. Entonox: too useful to be limited to childbirth? *Prof Care Mother Child* 1995;5(1):19-21. X-1, X-2, X-3.
  668. Laws PJ, Lim C, Tracy S, et al. Characteristics and practices of birth centres in Australia. *Aust N Z J*

- Obstet Gynaecol. 2009 Jun;49(3):290-5. X-2, X-3.
669. Layzer RB. Myeloneuropathy after prolonged exposure to nitrous oxide. *Lancet* 1978 Dec 9;2(8102):1227-30. X-3.
  670. Leaming HL. Awareness during anaesthesia. *Br Med J* 1969 Oct 4;4(5674):51. X-1, X-2, X-3d, X-5.
  671. Ledin Eriksson S, Gentile C and Olofsson CH. PCEA compared to continuous epidural infusion in an ultra-low-dose regimen for labor pain relief: a randomized study. *Acta Anaesthesiol Scand* 2003 Oct;47(9):1085-90. X-3a, X-3d, X-5.
  672. Lee A. Drug use in pregnancy. (6) Drugs in labour and the puerperium: Part 2. *Pharm J* 6857;255(6857):322-325. X-1, X-2, X-3, X-5.
  673. Lee CN, Chang SW, Cho NH, et al. Nitrous oxide synthase expression in placenta of preeclampsia. *J Korean Med Sci* 1997 Dec;12(6):532-8. X-2, X-3d.
  674. Lee H, Ryu JW, Kim DY, et al. Anesthetic management of the ex utero intrapartum treatment (EXIT) procedure. *Korean J Anesthesiol* 2010;59(SUPPL):S154-S157. X-2, X-3.
  675. Lee K and Ho KM. Obstetric regional analgesia services in New Zealand: A national survey. *N Z Med J* 1206;117(1206). X-5.
  676. Lee PF. Methohexital anaesthesia in caesarean section. *Acta Obstet Gynecol Scand* 1965;44(3):458-66. X-3.
  677. Lee PF. Anaesthesia for Caesarean section with methohexital. *Acta Anaesthesiol Scand Suppl.* 1966;23:138-43. X-3a, X-3d, X-5.
  678. Lee RSY, Milgrom P, Huebner CE, et al. Dentists' perceptions of barriers to providing dental care to pregnant women. *Womens Health Issues* 2010;20(5):359-365. X-2, X-3d.
  679. Lee SE, Han BD, Park IS, et al. Evidence supporting proteolytic cleavage of insulin-like growth factor binding protein-1 (IGFBP-1) protein in amniotic fluid. *J Perinat Med* 2008;36(4):316-323. X-2, X-3.
  680. Lee SY and Hagen DF. Laparoscopic sterilization in a free-standing clinic: a report of 1,092 cases. *Contraception* 1984 Dec;30(6):545-53. X-2, x-3a.
  681. Lee YS, Kim WY, Choi JH, et al. The effect of ketamine on the incidence of emergence agitation in children undergoing tonsillectomy and adenoidectomy under sevoflurane general anesthesia. *Korean J Anesthesiol* 2010;58(5):440-445. X-2, X-3a.
  682. Leeman L, Fontaine P, King V, et al. The nature and management of labor pain: part II. Pharmacologic pain relief. *Am Fam Physician.* 2003 Sep 15;68(6):1115-20. X-1, X-2, X-3.
  683. Leeson PD, Davis AM and Steele J. Drug-like properties: Guiding principles for design - Or chemical prejudice? *Drug Discov Today Technol* 2004;1(3):189-195. X-1, X-2, X-3d.
  684. Leighton BL, Cheek TG and Gross JB. Succinylcholine pharmacodynamics in peripartum patients. *Anesthesiology* 1986;64(2):202-205. X-2, X-3d.
  685. Lemmens HJM, Saidman LJ, Eger EI, et al. Obesity modestly affects inhaled anesthetic kinetics in humans. *Anesth Analg* 1864;107(6):1864-1870. X-2, X-3a.
  686. Leo S, Ocampo CE, Lim Y, et al. A randomized comparison of automated intermittent mandatory boluses with a basal infusion in combination with patient-controlled epidural analgesia for labor and delivery. *Int J Obstet Anesth* 2010;19(4):357-364. X-3a, X-3d, X-5.
  687. Leo S, Sng BL, Lim Y, et al. A randomized comparison of low doses of hyperbaric bupivacaine in combined spinal-epidural anesthesia for cesarean delivery. *Anesth Analg* 1600;109(5):1600-1605. X-2, X-3d.
  688. Lepage L, Frangie MC, Detaint D, et al. Nitrous oxide inhalation for transoesophageal echocardiography: An alternative to benzodiazepine

- sedation? *Eur J Echocardiogr* 2008;9(5):621-624. X-2, X-3a.
689. Leslie K, Sessler DI, Smith WD, et al. Prediction of movement during propofol/nitrous oxide anesthesia. Performance of concentration, electroencephalographic, pupillary, and hemodynamic indicators. *Anesthesiology* 1996 Jan;84(1):52-63. X-2, X-3a.
  690. Levack ID and Tunstall ME. Systems modification in obstetric analgesia. *Anaesthesia* 1984 Feb;39(2):183-5. X-1, X-2, X-5.
  691. Lew TW, Tay DH and Thomas E. Venous air embolism during cesarean section: more common than previously thought. *Anesth Analg* 1993 Sep;77(3):448-52. X-2, X-3d.
  692. Li J, Schulze-Neick I, Lincoln C, et al. Oxygen consumption after cardiopulmonary bypass surgery in children: Determinants and implications. *J Thorac Cardiovasc Surg* 2000;119(3):525-533. X-2, X-3a.
  693. Lichtenstein M, Mellander M, Milsom I, et al. The influence of epidural blockade and pethidine administered during delivery on neonatal myocardial performance. *Acta Obstet Gynecol Scand* 1991;70(4-5):315-9. X-2.
  694. Lieberman BA, Bostock JF and Anderson MC. Evaluation of laparoscopic sterilization using a spring-loaded clip. *J Obstet Gynaecol Br Commonw* 1974 Dec;81(12):921-32. X-2, X-3d, X-3a, X-5.
  695. Lin CM, Li CY and Mao IF. Increased risks of term low-birth-weight infants in a petrochemical industrial city with high air pollution levels. *Arch Environ Health* 2004 Dec;59(12):663-8. X-2, X-3d.
  696. Lindow SW, Dhillon AR, Husaini SW, et al. A randomised double-blind comparison of epidural fentanyl versus fentanyl and bupivacaine for pain relief in the second stage of labour. *BJOG* 1075;111(10):1075-1080. X-3d.
  697. Lippmann M, Appel PL, Mok MS, et al. Sequential cardiorespiratory patterns of anesthetic induction with ketamine in critically ill patients. *Crit Care Med* 1983;11(9):730-734. X-2, X-3d.
  698. Littler WA, Redman CW, Bonnar J, et al. Reduced pulmonary arterial compliance in hypertensive pregnancy. *Lancet* 1973 Jun 9;1(7815):1274-8. X-2, X-3d, X-5.
  699. Liu PL, Warren TM and Ostheimer GW. Foetal monitoring in parturients undergoing surgery unrelated to pregnancy. *Can Anaesth Soc J* 1985;32(5):525-532. X-2, X-3a.
  700. Liu W, Loo CC, Chiu JW, et al. Analgesic efficacy of pre-operative etoricoxib for termination of pregnancy in an ambulatory centre. *Singapore Med J* 2005;46(8):397-400. X-2, X-3b, X-3d.
  701. Loan PB, Mirakhur RK, Paxton LD, et al. Comparison of desflurane and isoflurane in anaesthesia for dental surgery. *Br J Anaesth* 1995 Sep;75(3):289-92. X-2, X-3a.
  702. Loft S, Jensen V and Rorsgaard S. Influence of moderate alcohol intake on wakening plasma thiopental concentration. *Acta Anaesthesiol Scand* 1983 Jun;27(3):266-9. X-2, X-3b.
  703. Loft S, Jensen V, Rorsgaard S, et al. Influence of moderate alcohol intake on thiopental anesthesia. *Acta Anaesthesiol Scand* 1982 Feb;26(1):22-6. X-1, X-2, X-3b.
  704. Loizzi P, Carriero C, Di Gesu A, et al. Rational use of cryosurgery and cold knife conization for treatment of cervical intraepithelial neoplasia. *Eur J Gynaecol Oncol* 1992;13(6):507-13. X-2, X-3d.
  705. Long J and Yue Y. Patient controlled intravenous analgesia with tramadol for labor pain relief. *Chin Med J* 1752;116(11):1752-1755. X-3a, X-5.
  706. Loop T and Priebe HJ. Recovery after anesthesia with remifentanyl combined with propofol, desflurane, or sevoflurane for otorhinolaryngeal surgery. *Anesth Analg* 2000 Jul;91(1):123-9. X-2, X-3a, X-3d.
  707. Loughnan BA, Carli F, Romney M, et al. Randomized controlled comparison of epidural bupivacaine

- versus pethidine for analgesia in labour. *Br J Anaesth* 2000 Jun;84(6):715-9. X-2, X-5.
708. Loughran PG, Moore J and Dundee JW. Maternal stress response associated with caesarean delivery under general and epidural anaesthesia. *BJOG* 1986;93(9):943-949. X-2, X-3d, X-5.
  709. Lowe NK. Context and process of informed consent for pharmacologic strategies in labor pain care. *J Midwifery Womens Health* 2004;49(3):250-9. X-1, X-2.
  710. Lowe SW, House W and Garrett T. Comparison of outcome of low-risk labour in an isolated general practice maternity unit and a specialist maternity hospital. *J R Coll Gen Pract* 1987 Nov;37(304):484-7. X-3, X-5.
  711. Lucas DN, Siemaszko O and Yentis SM. Maternal hypoxaemia associated with the use of Entonox in labour. *Int J Obstet Anesth* 2000;9(4):270-272. X-1, X-2, X-5.
  712. Luhmann JD, Kennedy RM, Jaffe DM, et al. Continuous-flow delivery of nitrous oxide and oxygen: A safe and cost-effective technique for inhalation analgesia and sedation of pediatric patients. *Pediatr Emerg Care* 1999;15(6):388-392. X-2, X-3a, X-3d.
  713. Lum Hee WC and Metias VF. Intramuscular ketamine in a parturient in whom pre-operative intravenous access was not possible. *Br J Anaesth* 2001;86(6):891-893. X-2, X-3d.
  714. Lutz E, Lind B, Herin P, et al. Concentrations of mercury, cadmium and lead in brain and kidney of second trimester fetuses and infants. *J Trace Elem Med Biol* 1996;10(2):61-67. X-2, X-3d.
  715. Luzardo GE, Karlinski RA, Williams B, et al. Anesthetic management of a parturient with hyperhomocysteinemia. *Anesth Analg* 1983;106(6):1833-1836. X-1, X-2, X-3, X-5.
  716. M.T.B TJ, Yao FS and Van Poznak A. Depressant effects of anesthetics on isolated human gravid and non-gravid uterine muscle. *Chin Med J* 1986;99(3):235-242. X-3d.
  717. Macario A, Scibetta WC, Navarro J, et al. Analgesia for labor pain: a cost model. *Anesthesiology* 2000 Mar;92(3):841-50. X-1, X-2, X-3a, X-5.
  718. Magno R, Karlsson K, Selstam U, et al. Anesthesia for cesarean section V: effects of enflurane anesthesia on the respiratory adaptation of the newborn in elective cesarean section. *Acta Anaesthesiol Scand* 1976;20(2):147-55. X-2, X-3, X-5.
  719. Magno R, Kjellmer I and Karlsson K. Anesthesia for cesarean section III: effects of epidural analgesia on the respiratory adaptation of the newborn in elective cesarean section. *Acta Anaesthesiol Scand* 1976;20(1):73-82. X-2, X-3d, X-5.
  720. Mahmoud NA, Rose DJA and Laurence AS. Desflurane or sevoflurane for gynaecological day-case anaesthesia with spontaneous respiration? *Anaesthesia* 2001;56(2):171-174. X-2, X-3a, X-3d.
  721. Mahomedy MC, Downing JW, Jeal DE, et al. Ketamine for anaesthetic induction at Caesarean section. *S Afr Med J*. 1976 May 22;50(22):846-8. X-2, X-3d, X-5.
  722. Mahomedy MC, Downing JW, Jeal DE, et al. Propanidid for anaesthetic induction at Caesarean section. *S Afr Med J* 1975 Aug 2;49(33):1358-60. X-2, X-3a, X-3d.
  723. Mahomedy MC, Downing JW, Jeal DE, et al. Anaesthetic induction for Caesarean section with propanidid. *Anaesthesia* 1976 Mar;31(2):205-11. X-2, X-3d, X-5.
  724. Mahomedy MC, Downing JW and Mahomedy YH. Alfathesin for anaesthetic induction at caesarean section. *S Afr Med J* 1975 Jun 28;49(27):1095-6. X-2, X-3a, X-3d.
  725. Mahomedy YH, Downing JW, Coleman AJ, et al. Ketamine and the obstetric patient. *S Afr Med J* 1974 Apr 13;48(17):734-6. X-2, X-3d, X-5.
  726. Mahony R, Enright F, O'Herlihy C, et al. Cerebral palsy following neonatal hypoxic seizures in



- singleton term infants; the influence of parity. *Ir Med J* 2009;102(8). X-2, X-3d.
727. Maiz N, Valencia C, Emmanuel EE, et al. Screening for adverse pregnancy outcome by Ductus venosus Doppler at 11-13+6 weeks of gestation. *Obstet Gynecol* 2008;112(3):598-605. X-3.
  728. Major V, Rosen M and Mushin WW. Concentration of methoxyflurane for obstetric analgesia by self-administered intermittent inhalation. *Br Med J* 1967 Dec 30;4(5582):767-70. X-3a, X-5.
  729. Malhotra N, Bhardwaj R, Vani, et al. MTP in a patient with Factor VII deficiency. *J Anaesthesiol Clin Pharmacol* 2002;18(2):213-214. X-1, X-2, X-3b, X-5.
  730. Mallick MS, Jado AM and Al-Bassam AR. Surgical procedures performed in the neonatal intensive care unit on critically ill neonates: feasibility and safety. *Ann Saudi Med* 2008 Mar-Apr;28(2):105-8. X-2, X-3.
  731. Maltau JM, Andersen HT and Skrede S. Obstetrical analgesia assessed by free fatty acid mobilisation. *Acta Anaesthesiol Scand* 1975;19(4):245-9. X-2, X-3.
  732. Maltau JM, Eielsen OV and Stokke KT. Effect of stress during labor on the concentration of cortisol and estriol in maternal plasma. *Am J Obstet Gynecol* 1979 Jul 15;134(6):681-4. X-2.
  733. Maltby JR, Hamilton RC and Phillips R. Comparison of flunitrazepam and thiopentone for induction of general anaesthesia. *Can Anaesth Soc J* 1980 Jul;27(4):331-7. X-2, X-3.
  734. Manber R, Schnyer RN, Allen JJB, et al. Acupuncture: A promising treatment for depression during pregnancy. *J Affect Disord* 2004;83(1):89-95. X-2, X-3d.
  735. Mankowitz E, Brock-Utne JG and Downing JW. Nitrous oxide elimination by the newborn. *Anaesthesia* 1981 Nov;36(11):1014-6. X-2, X-3.
  736. Mankowitz E, Downing JW, Brock-Utne JG, et al. Total intravenous anaesthesia using low-dose ketamine infusion for caesarean section. A comparison with a standard inhalation anaesthetic technique. *S Afr Med J* 1984 Feb 18;65(7):246-50. X-2, X-3.
  737. Maplestone PA. Pain relief in labour. *Med J Aust* 1977 Oct 29;2(18):610-2. X-1, X-2, X-5.
  738. Marc I, Rainville P, Verreault R, et al. The use of hypnosis to improve pain management during voluntary interruption of pregnancy: an open randomized preliminary study. *Contraception* 2007 Jan;75(1):52-8. X-2, X-3.
  739. Marmor TR and Krol DM. Labor pain management in the United States: understanding patterns and the issue of choice. *Am J Obstet Gynecol* 2002 May;186(5 Suppl Nature):S173-80. X-1, X-2.
  740. Marshall CA, Jones RM, Bajorek PK, et al. Recovery characteristics using isoflurane or propofol for maintenance of anaesthesia: a double-blind controlled trial. *Anaesthesia* 1992 Jun;47(6):461-6. X-2, X-3.
  741. Martensson L, Nyberg K and Wallin G. Subcutaneous versus intracutaneous injections of sterile water for labour analgesia: A comparison of perceived pain during administration. *BJOG* 1248;107(10):1248-1251. X-2, X-3.
  742. Martin TC, Bell P and Ogunbiyi O. Comparison of general anaesthesia and spinal anaesthesia for Caesarean section in Antigua and Barbuda. *West Indian Med J* 2007;56(4):330-333. X-2, X-3.
  743. Marx GF. Newer aspects of general anesthesia for cesarean section. *N Y State J Med* 1971 May 15;71(10):1084-6. X-1, X-2, X-3a, X-3d, X-5.
  744. Massaro M, Di Carlo C, Gargano V, et al. Effects of the contraceptive patch and the vaginal ring on bone metabolism and bone mineral density: a prospective, controlled, randomized study. *Contraception* 2010;81(3):209-214. X-2, X-3.

745. Massouda D and Muram D. Laparoscopic tubal ligation under local anesthesia. *J Tenn Med Assoc* 1986 Feb;79(2):75-6. X-3a.
746. Matorras R, Tacuri C, Nieto A, et al. Fetal cardiotocography and acid-base status during cesarean section. *European Journal of Obstetrics Gynecology and Reproductive Biology* 1998;80(2):161-167. X-3.
747. Matt DW, Steingold KA, Dastvan CM, et al. Effects of sera from patients given various anesthetics on preimplantation mouse embryo development in vitro. *J In Vitro Fert Embryo Transf* 1991 Aug;8(4):191-7. X-2, X-3.
748. Mattia MA. Hazards in the hospital environment. Anesthesia gases and methylmethacrylate. *Am J Nurs* 1983 Jan;83(1):73-7. X-1, X-2, X-5.
749. Mattila M and Larma I. A simple method for the administration of doxapram. *Br J Clin Pharmacol* 1987;23(3):371-372. X-3.
750. Mauritz W, Hackl W, Winkler M, et al. Anesthesia in malignant hyperthermia susceptible patients. *Acta Anaesthesiol Belg* 1990;41(2):87-94. X-2, X-3.
751. May AE, Fombon FN and Francis S. UK registry of high-risk obstetric anaesthesia: report on neurological disease. *Int J Obstet Anesth* 2008;17(1):31-36. X-3d, X-5.
752. Mazze RI and Kallen B. Reproductive outcome after anesthesia and operation during pregnancy: A registry study of 5405 cases. *Am J Obstet Gynecol* 1178;161(5):1178-1185. X-3.
753. McCool WF, Packman J and Zwerling A. Obstetric anesthesia: Changes and choices. *Journal of Midwifery and Women's Health* 2004;49(6):505-513. X-1, X-2, X-5.
754. McCormack JG. Total intravenous anaesthesia in children. *Current Anaesthesia and Critical Care* 2008;19(5-6):309-314. X-2, X-3.
755. McCracken FM, Madeley RJ and McCracken JS. A comparative study between the use of analgesia/anaesthesia and of episiotomy in women delivered under consultant supervision or general practitioner care. *Public Health* 1989 Jul;103(4):245-50. X-3d, X-5.
756. McDonald AD, McDonald JC, Armstrong B, et al. Fetal death and work in pregnancy. *Br J Ind Med* 1988 Mar;45(3):148-57. X-3d, X-5.
757. McDonald JS, Mateo CV and Reed EC. Modified nitrous oxide or ketamine hydrochloride for cesarean section. *Anesth Analg* 1972 Nov-Dec;51(6):975-85. X-2, X-3a, X-3d, X-5.
758. McGonnell M, Corkum P, McKinnon M, et al. Doing it right: An interdisciplinary model for the diagnosis of ADHD. *J Can Acad Child Adolesc Psychiatry* 2009;18(4):283-286. X-2, X-3d.
759. McGranahan TT. Methoxyflurane, nitrous oxide, oxygen analgesia for delivery. *Rocky Mt Med J* 1967 Jul;64(7):55-9. X-5.
760. McInnes RJ, Hillan E, Clark D, et al. Diamorphine for pain relief in labour : a randomised controlled trial comparing intramuscular injection and patient-controlled analgesia. *BJOG* 2004 Oct;111(10):1081-9. X-3d, X-5.
761. McKenzie R, Wadhwa RK and Lim Uy NT. Antiemetic effectiveness of intramuscular hydroxyzine compared with intramuscular droperidol. *Anesth Analg* 1981;60(11):783-788. X-3.
762. McKie BD. Postoperative vomiting: the effects of premedication, anaesthetic and oxytocic drugs. *Med J Aust* 1969 Jun 14;1(24):1236-8. X-2, X-3, X-5.
763. McLean BY, Rottman RL and Kotelko DM. Failure of multiple test doses and techniques to detect intravascular migration of an epidural catheter. *Anesth Analg* 1992;74(3):454-456. X-1, X-2, X-3, X-5.
764. McLeod B and Boheimer N. Propofol ('Diprivan') infusion as main agent for day case surgery. *Postgrad Med J* 1985;61 Suppl 3:105-7. X-2, X-3.
765. McMurray TJ, Robinson FP and Dundee JW. A method for producing constant plasma

- concentrations of drugs. Application to methohexitone. *Br J Anaesth* 1985;58(10):1085-1090. X-3.
766. McNeill JA, Alderdice FA and McMurray F. A retrospective cohort study exploring the relationship between antenatal reflexology and intranatal outcomes. *Complement Ther Clin Pract* 2006 May;12(2):119-25. X-3a, X-3d, X-5.
  767. McNeill MJ and Bennet A. Use of regional anaesthesia in a patient with acute porphyria. *Br J Anaesth* 1990;64(3):371-373. X-2, X-3.
  768. McSweeney ME, Atmadja ML, Ganesh M, et al. Outcomes of percutaneous endoscopic gastrostomy (PEG) tube placement in small infants. *Gastrointestinal Endoscopy. Conference: Digestive Disease Week, DDW 2011;73(4 SUPPL. 1)*. X-2, X-3d.
  769. Mehta S, Burton P and Simms JS. Monitoring of occupational exposure to nitrous oxide. *Can Anaesth Soc J* 1978 Sep;25(5):419-23. X-2, X-3, X-5.
  770. Meinardi JR, Van Der Schaaf W, Bom FH, et al. A new screening test for the Protein C anticoagulant Pathway: The PCP test. *Fibrinolysis Proteolysis* 1999;13(SUPPL. 1):16-20. X-2, X-3.
  771. Meiser A and Laubenthal H. Inhalational anaesthetics in the ICU: Theory and practice of inhalational sedation in the ICU, economics, risk-benefit. *Best Pract Res Clin Anaesthesiol* 2005;19(3 SPEC. ISS):523-538. X-2, X-3.
  772. Meneses F, Ney JG, Torres AG, et al. Erythrocyte membrane and plasma non-esterified n-3 and n-6 polyunsaturated fatty acids of pregnant and non-pregnant Brazilian adolescents. *Prostaglandins Leukot Essent Fatty Acids* 2009;80(2-3):137-142. X-2, X-3d.
  773. Messahel FM and Al-Qahtani AS. Awareness during surgery. *Saudi Medical Journal* 2003;24(9):967-970. X-2, X-3.
  774. Metcalfe NH. Military influence upon the development of anaesthesia from the American Civil War (1861-1865) to the outbreak of the First World War. *Anaesthesia* 1960;15(12):1213-1217. X-1, X-2, X-3.
  775. Mettam I and Wee M. Update on pain relief in labour. *Curr Anaesth Crit Care* 1995;6(4):206-211. X-1, X-2, X-3, X-5.
  776. Mhyre JM. Anesthetic management for the morbidly obese pregnant woman. *Int Anesthesiol Clin* 2007;45(1):51-70. X-1, X-2, X-3, X-5.
  777. Michel TC, Rosenberg AL and Polley LS. EXIT to ECMO. *Anesthesiology* 2002;97(1):267-268. X-1, X-2, X-3d, X-5.
  778. Middendorf PJ, Jacobs DE, Smith KA, et al. Occupational exposure to nitrous oxide in dental operatories. *Anesthesia Progress* 1986;33(2):91-97. X-2, X-3d, X-5.
  779. Milesi C, Pidoux O, Sabatier E, et al. Nitrous oxide analgesia for intubating preterm neonates: a pilot study. *Acta Paediatr* 2006 Sep;95(9):1104-8. X-2, X-3d, X-5.
  780. Miller CL. Nitric oxide therapy for persistent pulmonary hypertension of the newborn. *Neonatal Network* 1995;14(8):9-15. X-2, X-3.
  781. Miller FL and Mann DL. Anesthetic management of a pregnant patient with the hyperimmunoglobulin E (Job's) syndrome. *Anesth Analg* 1990;70(4):454-456. X-1, X-2, X-3, X-5.
  782. Miller MC. The pregnant dental patient. *J Calif Dent Assoc* 1995 Aug;23(8):63-70. X-1, X-2, X-3, X-5.
  783. Milsom I, Forssman L and Biber B. Maternal haemodynamic changes during caesarean section: A comparison of epidural and general anaesthesia. *Acta Anaesthesiol Scand* 1985;29(2):161-167. X-2, X-3.
  784. Mimpriss TJ. Nitrous oxide versus ether anaesthesia for caesarian section. *East Afr Med J* 1973 May;50(5):244-7. X-2, X-3a, X-3d, X-5.
  785. Mischel E and Brighthouse D. Does the primiparous woman have a realistic expectation of childbirth?

- Int J Obstet Anesth 1995;4(1):64-65. X-3, X-5.
786. Mitchell SZ, Freilich JD, Brant D, et al. Anesthetic management of pheochromocytoma resection during pregnancy. *Anesth Analg* 1987;66(5):478-480. X-1, X-2, X-3a, X-5.
  787. Mittal P, Romero R, Kusanovic JP, et al. CXCL6 (granulocyte chemotactic protein-2): A novel chemokine involved in the innate immune response of the amniotic cavity. *Am J Reprod Immunol* 2008;60(3):246-257. X-2, X-3.
  788. Mittal P, Romero R, Mazaki-To vi S, et al. Fetal membranes as an interface between inflammation and metabolism: Increased Aquaporin 9 expression in the presence of spontaneous labor at term and chorioamnionitis. *J Matern Fetal Neonatal Med* 1167;22(12):1167-1175. X-3d.
  789. Mittal P, Romero R, Tarca AL, et al. The molecular signature of an arrest of descent in human parturition. *Am J Obstet Gynecol Conference* 2010;201(6 SUPPL. 1). X-2, X-3d.
  790. Miyasaka K, Fujiwara H, Takata M, et al. A safe clinical system for nitric oxide inhalation therapy for pediatric patients. *Pediatr Pulmonol* 1996;22(3):174-181. X-2, X-3.
  791. Miyazu M, Sobue K, Ito H, et al. Anesthetic and airway management of general anesthesia in a patient with Meckel-Gruber syndrome. *J Anesth* 2005;19(4):309-310. X-1, X-2, X-3a.
  792. Moghbeli N, Srinivas SK, Bastek J, et al. N-terminal pro-brain natriuretic peptide as a biomarker for hypertensive disorders of pregnancy. *Am J Perinatol* 2010;27(4):313-319. X-2, X-3.
  793. Mohapatra SN, Costeloe KL and Hill DW. Blood resistivity and its implications for the calculation of cardiac output by the thoracic electrical impedance technique. *Intensive Care Med* 1977 Aug;3(2):63-7. X-2, X-3.
  794. Moir DD. Anaesthesia for Caesarean section. An evaluation of a method using low concentrations of halothane and 50 per cent of oxygen. *Br J Anaesth.* 1970 Feb;42(2):136-42. X-2, X-3d, X-5.
  795. Monte S and Lyons G. Peripartum management of a patient with Glanzmann's thrombasthenia using thrombelastograph. *Br J Anaesth* 2002;88(5):734-738. X-2, X-3.
  796. Moore TR, Key TC, Reisner LS, et al. Evaluation of the use of continuous lumbar epidural anesthesia for hypertensive pregnant women in labor. *Am J Obstet Gynecol* 1985;152(4):404-412. X-2, X-3.
  797. Moos DD, Prasch M, Cantral DE, et al. Are patients with obstructive sleep apnea syndrome appropriate candidates for the ambulatory surgical center? *AANA Journal* 2005;73(3):197-205. X-2, X-3.
  798. Morgan BM, Aulakh JM and Barker JP. Anaesthesia for caesarean section. A medical audit of junior anaesthetic staff practice. *Br J Anaesth* 1983;55(9):885-889. X-2, X-3.
  799. Morishima HO, Hyman AI, Adamsons K, et al. Anesthetic management for fetal operation in the subhuman primate. *Am J Obstet Gynecol* 1971 Aug 1;110(7):926-33. X-3.
  800. Morley-Forster PK, Reid DW and Vandeberghe H. A comparison of patient-controlled analgesia fentanyl and alfentanil for labour analgesia. *Can J Anaesth* 2000 Feb;47(2):113-9. X-2, X-3a.
  801. Morley-Forster PK and Toll M. Effect of labour room ventilation design and scavenging on ambient nitrous oxide levels. *Can J Respir Ther* 1999;35(3):37-43. X-2, X-5.
  802. Morrison PJ, Robinson PN and MacLeod KGA. Emergency anaesthesia in a patient with plasma cholinesterase deficiency. *Anaesthesia* 1986;41(3):323-324. X-1, X-2, X-3a, X-5.
  803. Moseley HSL, Shankar KB and Krishnan A. Flow requirements for the Bain breathing circuit during anaesthesia for Caesarean section. *Can Anaesth Soc J* 1986;33(5):583-587. X-2, X-3.

804. Moslemi F and Rasooli S. Comparison of spinal versus general anesthesia for cesarean delivery in patients with severe preeclampsia. *J Med Sci.* 1044;7(6):1044-1048. X-2, X-3.
805. Mosler KH. The dynamics of uterine muscle. *Bibl Gynaecol* 1968;48:1-82. X-1, X-2, X-3, X-5.
806. Mueksch JN and Stevens WA. Undiagnosed myasthenia gravis masquerading as eclampsia. *Int J Obstet Anesth* 2007;16(4):379-382. X-2, X-3.
807. Muller H, Gips H and Brahler A. Haemodynamic effects of fenoterol for labour inhibition during spinal or epidural anaesthesia. *Gynecol Obstet Invest* 1985;19(2):64-72. X-2, X-3, X-5.
808. Muller M, Sticher J, Schindler E, et al. Effects of dexmedetomidine and volume loading on hemodynamics and oxygenation parameters in patients undergoing pulmonary resection. *Acta Anaesthesiol Scand* 2000;44(7):858-863. X-2, X-3.
809. Munley AJ, Railton R, Gray WM, et al. Exposure of midwives to nitrous oxide in four hospitals. *Br Med J (Clin Res Ed)* 1986 Oct 25;293(6554):1063-4. X-5.
810. Murayama K, Mamiya K, Nozaki K, et al. Cesarean section in a patient with syringomyelia. *Can J Anaesth* 2001;48(5):474-477. X-2, X-3d.
811. Murphy DF, MacGrath P and Stritch M. Postoperative analgesia in hip surgery. A controlled comparison of epidural buprenorphine with intramuscular morphine. *Anaesthesia* 1984 Feb;39(2):181-3. X-2, X-3.
812. Murphy EJ. Intra-arterial injection of metoclopramide, midazolam, propofol and pethidine. *Anaesth Intensive Care.* 2002;30(3):367-369. X-2, X-3.
813. Mushin WW, Campbell H and Ng WS. The pattern of anaesthesia in a general hospital. *Br J Anaesth* 1967 Apr;39(4):323-34. X-1, X-2, X-3a, X-5.
814. Mutoh S, Kobayashi M, Hirata J, et al. Studies on blood coagulation-fibrinolysis system regarding kallikrein-kinin system in the utero-placental circulation during normal pregnancy, labor and puerperium. *Agents and Actions* 1992;38(SUPPL. II):320-329. X-2, X-3.
815. Nafiu OO and Urquhart JC. Pneumocephalus with headache complicating labour epidural analgesia: should we still be using air? *Int J Obstet Anesth* 2006;15(3):237-239. X-2, X-3a.
816. Nair V and Henry R. Bilateral paravertebral block: A satisfactory alternative for labour analgesia. *Can J Anaesth* 2001;48(2):179-184. X-2, X-3.
817. Nakamura H, Tanaka O, Kaetsu H, et al. Cesarean section in a pregnant woman with primary pulmonary hypertension. *Hiroshima J Anesth* 1987;23(4):315-318. X-1, X-2, X-3d, X-5.
818. Nancekieve DG. An apparatus for the delivery of 50% premixed nitrous oxide and oxygen on demand or by controlled ventilation. *Anaesthesia* 1983;38(7):674-677. X-1, X-2, X-3a, X-5.
819. Nathan N, Peyclit A, Lahrimi A, et al. Comparison of sevoflurane and propofol for ambulatory anaesthesia in gynaecological surgery. *Can J Anaesth* 1998 Dec;45(12):1148-50. X-2, X-3.
820. Nayebzadeh A. Exposure to exhaled nitrous oxide in hospitals post-anaesthesia care units. *Ind Health* 2007;45(2):334-337. X-2, X-3b, X-5.
821. Neff SPW, Stapelberg F and Warmington A. Excruciating perineal pain after intravenous dexamethasone. *Anaesth Intensive Care* 2002;30(3):370-371. X-2, X-3.
822. Negovsky VA, Manevich LE and Kassil VL. Anaesthesia and intensive care in eclampsia. *Resuscitation* 1974;3(3):157-63. X-3d, X-5.
823. Nel MR, Watts JD and Lockwood GG. An alternative method of nitrous oxide delivery into a minimal-flow circle breathing system. *Anaesthesia* 1997;52(1):57-61. X-2, X-3a, X-5.

824. Neppert J, Witzleben-Schurholz EV, Zupanska B, et al. High incidence of maternal HLA A, B and C antibodies associated with a mild course of haemolytic disease of the newborn. *Eur J Haematol* 1999;63(2):120-125. X-2, X-3.
825. Nesheim BI and Kinge R. Performance of acupuncture as labor analgesia in the clinical setting. *Acta Obstet Gynecol Scand* 2006;85(4):441-3. X-5.
826. Nesheim BI, Kinge R, Berg B, et al. Acupuncture during labor can reduce the use of meperidine: A controlled clinical study. *Clin J Pain* 2003;19(3):187-191. X-5.
827. Newman B and Lam AM. Induced hypotension for clipping of a cerebral aneurysm during pregnancy: A case report and brief review. *Anesth Analg* 1986;65(6):675-678. X-1, X-2, X-3a, X-5.
828. Ng A, Parker J, Toogood L, et al. Does the opioid-sparing effect of rectal diclofenac following total abdominal hysterectomy benefit the patient? *Br J Anaesth* 2002;88(5):714-716. X-2, X-3a, X-3d.
829. Ng KH and Gurubatham AI. Awareness during caesarean section under general anaesthesia. *Med J Aust* 1974 Nov 23;2(21):774-6. X-3.
830. Ngan Kee WD, Khaw KS, Ma KC, et al. Randomized, double-blind comparison of different inspired oxygen fractions during general anaesthesia for Caesarean section. *Br J Anaesth* 2002;89(4):556-561. X-2, X-3a.
831. Ngan Kee WD, Khaw KS, Ma KC, et al. Maternal and neonatal effects of remifentanyl at induction of general anesthesia for cesarean delivery: A randomized, double-blind, controlled trial. *Anesthesiology* 2006;104(1):14-20. X-2, X-3.
832. Ngan Kee WD, Khaw KS, Ma ML, et al. Postoperative analgesic requirement after cesarean section: a comparison of anesthetic induction with ketamine or thiopental. *Anesth Analg* 1997 Dec;85(6):1294-8. X-2, X-3.
833. Nhan-Chang CL, Romero R, Kusanovic JP, et al. A role for CXCL13 (BCA-1) in pregnancy and intra-amniotic infection/inflammation. *J Matern Fetal Neonatal Med* 2008;21(11):763-775. X-3.
834. Niinimäki M, Pouta A, Bloigu A, et al. Immediate complications after medical compared with surgical termination of pregnancy. *Obstet Gynecol* 2009;114(4):795-804. X-2, X-3b.
835. Nijland R, Nierlich S, Jongsma HW, et al. Validation of reflectance pulse oximetry: an evaluation of a new sensor in piglets. *J Clin Monit* 1997 Jan;13(1):43-9. X-2, X-3.
836. Nishiyama T. Saving sevoflurane and hastening emergence from anaesthesia using an anaesthetic-conserving device. *Eur J Anaesthesiol* 2009;26(1):35-38. X-2, X-3a.
837. Nishiyama T and Hanaoka K. Case reports of anesthesia for cerebral hemorrhage during pregnancy - Cerebral aneurysm and arteriovenous malformation. *Anesthesia Resuscitation* 1999;35(1):55-57. X-1, X-2, X-3a, X-5.
838. Noble J and Ogg TW. The effect of propofol ('Diprivan') and methohexitone on memory after day case anaesthesia. *Postgrad Med J* 1985;61(SUPPL. 3):103-104. X-3.
839. Norris MC. Labour analgesia: What are the (new) options? *Can J Anaesth* 1998;45(5 II SUPPL):R138-R148. X-1, X-2, X-5.
840. Northwood D, Sapsford DJ, Jones JG, et al. Nitrous oxide sedation causes post-hyperventilation apnoea. *Br J Anaesth* 1991 Jul;67(1):7-12. X-2, X-3d, X-5.
841. Nour El Din BM. Clinical evaluation of oxygen transport in patients undergoing off-pump compared to conventional coronary artery bypass grafting. *Egyptian J Anaesthesia* 2004;20(4):351-355. X-2, X-3.
842. Nunn H, Lalli A, Fortune F, et al. Oral cancer screening in the

- Bangladeshi community of Tower Hamlets: A social model. *Br J Cancer* 2009;101(SUPPL. 2):S68-S72. X-2, X-3d.
843. Nunn JF. Faulty cell replication: abortion, congenital abnormalities. *Int Anesthesiol Clin* 1981 Winter;19(4):77-97. X-1, X-2, X-5.
844. Nunn JF and Chanarin I. Nitrous oxide and vitamin B12. *Br J Anaesth* 1978 Nov;50(11):1089-90. X-1, X-2, X-3, X-5.
845. Obara H, Sugiyama D, Maekawa N, et al. Plasma cortisol levels in paediatric anaesthesia. *Can Anaesth Soc J* 1984 Jan;31(1):24-7. X-2.
846. Ochiai N, Tashiro C, Okutani R, et al. Improved oxygen delivery to the fetus during cesarean section under sevoflurane anesthesia with 100% oxygen. *J Anesth* 1999;13(2):65-70. X-2, X-3d, X-5.
847. Odin I and Feiss P. Low flow and economics of inhalational anaesthesia. *Best Pract Res Clin Anaesthesiol* 2005;19(3 SPEC. ISS):399-413. X-1, X-2, X-3.
848. Oduntan SA and Gool RY. Clinical trial of ketamine (CI-581): a preliminary report. *Can Anaesth Soc J* 1970 Jul;17(4):411-6. X-3.
849. Ogasawara H, Hashimoto Y, Ishihara H, et al. Anesthetic experience of emergency Cesarean section for a patient with myotonic dystrophy. *Japanese Journal of Anesthesiology* 1993;42(5):738-741. X-1, X-2, X-3.
850. Ogbonna B and Daw E. Epidural analgesia and the length of labour for vaginal twin delivery. *J Obstet Gynaecol* 1986;6(3):166-168. X-5.
851. Ogg TW, Jennings RA and Morrison CG. Day-case anaesthesia for termination of pregnancy. Evaluation of a total intravenous anaesthetic technique. *Anaesthesia*. 1983 Nov;38(11):1042-6. X-3b.
852. O'Hara DA, Derbyshire GJ, Overdyk FJ, et al. Closed-loop infusion of atracurium with four different anesthetic techniques. *Anesthesiology* 1991;74(2):258-263. X-2, X-3.
853. Okafor UV and Aniebue U. Anaesthesia for uterine rupture in a Nigerian teaching hospital: Maternal and fetal outcome. *Int J Obstet Anesth* 2006;15(2):124-128. X-3d.
854. Okojie P and Cook P. Immediate and delayed complications of epidural analgesia in labour and delivery. *J Obstet Gynaecol* 1999;19(4):370-372. X-3, X-5.
855. Olenmark M, Biber B, Dottori O, et al. Fatal iron intoxication in late pregnancy. *J Toxicol Clin Toxicol* 1987;25(4):347-359. X-1, X-2, X-3.
856. Olkkola KT and Schwilden H. Quantitation of the interaction between atracurium and succinylcholine using closed-loop feedback control of infusion of atracurium. *Anesthesiology* 1990;73(4):614-618. X-2, X-3.
857. Olney JW, Farber NB, Wozniak DF, et al. Environmental agents that have the potential to trigger massive apoptotic neurodegeneration in the developing brain. *Environ Health Perspect* 2000;108(SUPPL. 3):383-388. X-1, X-2.
858. Olsson GL, Hallen B and Hambræus-Jonzon K. Aspiration during anaesthesia: A computer-aided study of 185,358 anaesthetics. *Acta Anaesthesiol Scand* 1986;30(1):84-92. X-2, X-3.
859. Olufolabi AJ, Charlton GA, Allen SA, et al. Use of implantable cardioverter defibrillator and anti-arrhythmic agents in a parturient. *Br J Anaesth* 2002;89(4):652-655. X-1, X-2, X-3.
860. Olufolabi AJ and Wee MYK. Caesarean section in a patient with torsion dystonia. *Br J Anaesth* 2006;96(5):611-613. X-1, X-2, X-3.
861. Ooi R, Joshi P and Soni N. Nitrous oxide-oxygen analgesia: The performance of the MC mask delivery system. *J R Soc Med* 1992;85(9):534-536. X-2, X-3, X-5.
862. Orlikowski CEP, Dickinson JE, Paech MJ, et al. Intrapartum analgesia and its association with post-partum back pain and headache in nulliparous women. *Aust N Z J Obstet Gynaecol* 2006;46(5):395-401. X-3d, X-5.
863. Orme RMLE, Grange CS, Ainsworth QP, et al. General

- anaesthesia using remifentanyl for caesarean section in parturients with critical aortic stenosis: A series of four cases. *Int J Obstet Anesth* 2004;13(3):183-187. X-1, X-2, X-3, X-5.
864. Ormezzano X, Francois TP, Viaud JY, et al. Aspiration pneumonitis prophylaxis in obstetric anaesthesia: Comparison of effervescent cimetidine-sodium citrate mixture and sodium citrate. *Br J Anaesth* 1990;64(4):503-506. X-2, X-3d.
865. Ostreicher DS. Vitamin B12 supplements as protection against nitrous oxide inhalation. *N Y State Dent J* 1994 Mar;60(3):47-9. X-1, X-2, X-3, X-5.
866. O'Sullivan G. Analgesia and anaesthesia in labour. *Curr Obstet Gynaecol* 2002;12(1):8-14. X-1, X-2.
867. O'Sullivan G. Non-neuraxial analgesia in labour. *South Afr J Anaesth Analg* 2008;14(1):98-100. X-1, X-2.
868. Ounsted M, Scott A and Moar V. Pain relief during childbirth and development at 4 years. *J R Soc Med* 1981;74(8):629-630. X-1, X-2, X-3, X-5.
869. Owe KM, Nystad W and Bo K. Association between regular exercise and excessive newborn birth weight. *Obstet Gynecol* 2009;114(4):770-776. X-2, X-3d.
870. Oyston J. Obstetrical anaesthesia in Ontario. *Can J Anaesth* 1995 Dec;42(12):1117-25. X-2.
871. Ozkose Z, Ercan B, Unal Y, et al. Inhalation versus total intravenous anaesthesia for lumbar disc herniation: Comparison of Hemodynamic Effects, Recovery Characteristics, and Cost. *J Neurosurg Anesthesiol* 2001;13(4):296-302. X-2, X-3d.
872. Padhye SM. Rupture uterus in primigravida: Morbidity and mortality. *Kathmandu Univ Med J* 2007;5(20):497-500. X-3d.
873. Padmini E, Sowmya S and Phil M. Atherosclerosis: A major event in the pathophysiology of preeclampsia. *Biomedicine* 2005;25(3-4):6-12. X-2, X-3d.
874. Paech M. Newer techniques of labor analgesia. *Anesthesiol Clin North America* 2003 Mar;21(1):1-17. X-1, X-2.
875. Paech MJ, Scott KL, Clavisi O, et al. A prospective study of awareness and recall associated with general anaesthesia for caesarean section. *Int J Obstet Anesth* 2008;17(4):298-303. X-2, X-3.
876. Palahniuk RJ and Cumming M. Serum cholinesterase activity following the use of methoxyflurane in obstetrics. *Anesthesiology* 1977 Dec;47(6):520-2. X-1, X-2, X-3d, X-5.
877. Palahniuk RJ, Scatliff J, Biehl D, et al. Maternal and neonatal effects of methoxyflurane, nitrous oxide and lumbar epidural anaesthesia for Caesarean section. *Can Anaesth Soc J* 1977 Sep;24(5):586-96. X-2, X-3d.
878. Palmer RB, Mautz DS, Cox K, et al. Endotracheal lidocaine administration via an esophageal combitube. *J Emerg Med* 2000;18(2):153-157. X-2, X-3a, X-3d.
879. Palomo T, Archer T, Beninger RJ, et al. Neurodevelopment liabilities of substance abuse. *Neurotox Res* 2002;4(4):267-279. X-1, X-2, X-3.
880. Pan PH and Moore C. Comparison of cisatracurium-induced neuromuscular blockade between immediate postpartum and nonpregnant patients *J Clin Anesth*. 2001 Mar;13(2):112-7. X-2, X-3a.
881. Pang D and O'Sullivan G. Analgesia and anaesthesia in labour. *Obstet Gynaecol Reprod Med* 2008;18(4):87-92. X-1, X-2.
882. Pang WW, Wu HS, Lin CH, et al. Metoclopramide decreases emesis but increases sedation in tramadol patient-controlled analgesia. *Can J Anaesth* 1029;49(10):1029-1033. X-2, X-3a.
883. Parkhouse J. Inhalation anaesthesia and analgesia. *Int Anesthesiol Clin* 1967 Spring;5(1):1-20. X-1, X-2, X-3, X-5.
884. Parkins GE and Boamah MO. Congenital maxillomandibular syngnathia: Case report. *J*



- Craniomaxillofac Surg 2009;37(5):276-278. X-2, X-3d.
885. Parpaglion R, Capogna G, Celleno D, et al. Intraoperative fetal oxygen saturation during Caesarean section: general anaesthesia using sevoflurane with either 100% oxygen or 50% nitrous oxide in oxygen. Eur J Anaesthesiol 2002 Feb;19(2):115-8. X-2, X-3a, X-3d, X-5.
  886. Pathy GV and Rosen M. Prolonged block with recovery after extradural analgesia for labour. Br J Anaesth 1975 Apr;47(4):520-2. X-2, X-3a.
  887. Patterson KW and O'Toole DP. HELLP-syndrome: A case report with guidelines for diagnosis and management. Br J Anaesth 1991;66(4):513-515. X-2, X-3d.
  888. Paull J. International overview of obstetric anaesthesia. Clin Anaesthesiol 1986;4(2):429-439. X-1, X-2, X-3, X-5.
  889. Paull J and Ziccone S. Halothane, enflurane, methoxyflurane, and isolated human uterine muscle. Anaesthesia and Intensive Care 1980;8(4):397-401. X-2, X-3, X-5.
  890. Peat S. Providing pain relief for the surgical patient. Care of the Critically Ill 1995;11(1):16-17. X-1, X-2, X-3d.
  891. Pedersen H and Finster M. Anesthetic risk in the pregnant surgical patient. Anesthesiology 1979 Nov;51(5):439-51. X-1, X-2, X-3d, X-5.
  892. Pedersen JE, Fernandes A and Christensen M. Halothane 2% for caesarean section. Eur J Anaesthesiol 1992 Jul;9(4):319-24. X-2, X-3d, X-5.
  893. Peng AT, Blancato LS and Motoyama EK. Effect of maternal hypocapnia v. eucapnia on the foetus during Caesarean section. Br J Anaesth 1972 Nov;44(11):1173-8. X-2, X-3a, X-3d, X-5.
  894. Perry LB. Current concepts of obstetric anesthesia and analgesia. Primary Care Clin Office Pract 1983;10(2):269-283. X-1, X-2, X-3, X-5.
  895. Pershad J and Kost S. Emergency Department Based Sedation Services. Clin Pediatr Emerg Med 2007;8(4):253-261. X-1, X-2, X-3d.
  896. Petrek JA. Breast cancer during pregnancy. Cancer. 1994;74(1 SUPPL):518-527. X-1, X-2, X-3d.
  897. Phairas D. Wrongful birth and birth injury claims: new risks for oral surgeons. J Mass Dent Soc 1992 Spring;41(2):82-3. X-1, X-2, X-3d, X-5.
  898. Pharoah PO, Alberman E, Doyle P, et al. Outcome of pregnancy among women in anaesthetic practice. Lancet 1977 Jan 1;1(8001):34-6. X-3, X-5.
  899. Phillips AS, Mirakhur RK, Glen JB, et al. Total intravenous anaesthesia with propofol or inhalational anaesthesia with isoflurane for major abdominal surgery. Recovery characteristics and postoperative oxygenation--an international multicentre study. Anaesthesia 1996 Nov;51(11):1055-9. X-2, X-3.
  900. Pierce JT. Continuing education - "The Action Level". J Occup Environ Hyg 2005;2(6):D51-D52. X-1, X-2, X-3, X-5.
  901. Piggott SE, Bogod DG, Rosen M, et al. Isoflurane with either 100% oxygen or 50% nitrous oxide in oxygen for caesarean section. Br J Anaesth 1990 Sep;65(3):325-9. X-2, X-3a, X-3d, X-5.
  902. Pihlajamaki KK, Kanto JH and Oksman-Caldentey KM. Pharmacokinetics and clinical effects of scopolamine in caesarean section patients. Acta Pharmacol Toxicol 1986;59(4):259-262. X-2, X-3, X-5.
  903. Pillai P and Spears FD. Intra-operative diagnosis of hypopituitarism in a patient undergoing radical nephrectomy. Anaesthesia 2005;60(9):924-927. X-1, X-2, X-3d.
  904. Pilon RN. Anesthesia for uncomplicated obstetric delivery. Am Fam Physician 1974 Jan;9(1):113-20. X-1, X-2, X-5.
  905. Pitter C and Preston R. Modern pharmacologic methods in labor analgesia. Int J Childbirth Educ 2001;16(2):15-9. X-1, X-2, X-5.

906. Polonen P, Hippelainen M, Takala R, et al. Relationship between intra- and postoperative oxygen transport and prolonged intensive care after cardiac surgery: A prospective study. *Acta Anaesthesiol Scand* 1997;41(7):810-817. X-2, X-3d.
907. Polvi HJ, Pirhonen JP and Erkkola RU. Nitrous oxide inhalation: effects on maternal and fetal circulations at term. *Obstet Gynecol* 1996 Jun;87(6):1045-8. X-2, X-3d, X-5.
908. Pope WD, Halsey MJ, Hammond G, et al. Occupational Hazards of anaesthesia. A panel discussion. *Can Anaesth Soc J* 1985 Mar;32(2):142-8. X-1, X-2, X-5.
909. Prendergast B, Scott DHT and Mankad PS. Beneficial effects of inhaled nitric oxide in hypoxaemic patients after coronary artery bypass surgery. *Eur J Cardiothorac Surg* 1998;14(5):488-493. X-2, X-3d.
910. Prendergast J and Austin MP. Early childhood nurse-delivered cognitive behavioural counselling for post-natal depression. *Australasian Psychiatry* 2001;9(3):255-259. X-2, X-3d.
911. Prichep LS, Gugino LD, John ER, et al. The Patient State Index as an indicator of the level of hypnosis under general anaesthesia. *Br J Anaesth* 2004;92(3):393-399. X-2, X-3d.
912. Pritchard JA, Cunningham FG and Pritchard SA. The Parkland Memorial Hospital protocol for treatment of eclampsia: Evaluation of 245 cases. *Am J Obstet Gynecol* 1984;148(7):951-963. X-3d, X-5.
913. Puhlinger FK, Sparr HJ, Mitterschiffthaler G, et al. Extended duration of action of rocuronium in postpartum patients. *Anesth Analg* 1997 Feb;84(2):352-4. X-2, X-3.
914. Puri GD, George MA, Singh H, et al. Awareness under anaesthesia due to a defective gas-loaded regulator. *Anaesthesia* 1987;42(5):539-540. X-1, X-2, X-3.
915. Puri GD, Jayant A, Dorje M, et al. Propofol-fentanyl anaesthesia at high altitude: Anaesthetic requirements and haemodynamic variations when compared with anaesthesia at low altitude. *Acta Anaesthesiol Scand* 2008;52(3):427-431. X-2, X-3d.
916. Qiu J, Zhang A and Tuo D. Clinical observation on N<sub>2</sub>O inhalation used in the course of artificial abortion [Chinese]. *Chin Nurs Res* 2004;18(2B):326-7. X-2, X-3b.
917. Qublan HS, Merhej A, Dabbas MA, et al. Spinal versus general anesthesia for elective cesarean delivery: A prospective comparative study. *Clin Exp Obstet Gynecol* 2001;28(4):246-248. X-2, X-3d.
918. Qvist N and Storm K. Cimethidine pre-anesthetic. A prophylactic method against Mendelson's syndrome in cesarean section. *Acta Obstet Gynecol Scand* 1983;62(2):157-159. X-2, X-3.
919. Rachootin P and Olsen J. The risk of infertility and delayed conception associated with exposures in the Danish workplace. *J Occup Med* 1983 May;25(5):394-402. X-3a, X-5.
920. Radomsky NA. Family practice obstetrics in a community hospital. *Canadian Family Physician* 1995;41(APR):617-624. X-2, X-3d.
921. Raeder JC. Propofol anaesthesia versus paracervical blockade with alfentanil and midazolam sedation for outpatient abortion. *Acta Anaesthesiol Scand* 1992 Jan;36(1):31-7. X-2, X-3b, X-3d.
922. Raeder JC, van der Linden J and Breivik H. Premedication for day-case surgery: double-blind comparison of ketobemidone + dimethylaminodiphenylbuten (A-29) and morphine + scopolamine. *Acta Anaesthesiol Scand* 1986 Oct;30(7):502-6. X-2, X-3b, X-3d.
923. Rahimi M and Makarem J. Effects of diclofenac epolamine patch on postoperative sore throat in parturients after cesarean delivery under endotracheal general anaesthesia. *Acta Anaesthesiol Taiwan* 2009;47(1):17-21. X-2, X-3d.
924. Rainaldi MP, Busi T, Melloni C, et al. Pharmacokinetics and placental transmission of fazadinium in elective caesarean sections. *Acta*

- Anaesthesiol Scand 1984;28(2):222-225. X-2, X-3.
925. Rajah A, Powell H and Morgan M. Etanalone for induction of anaesthesia and to supplement nitrous oxide for minor gynaecological surgery. *Anaesthesia* 1993 Nov;48(11):951-4. X-2, X-3d.
  926. Rajan L. Perceptions of pain and pain relief in labour: the gulf between experience and observation. *Midwifery* 1993 Sep;9(3):136-45. X-5.
  927. Rajan L. The impact of obstetric procedures and analgesia/anaesthesia during labour and delivery on breast feeding. *Midwifery* 1994 Jun;10(2):87-103. X-2, X-5.
  928. Rajhans GS, Brown DA, Whaley D, et al. Hygiene aspects of occupational exposure to waste anaesthetic gases in Ontario hospitals. *Ann Occup Hyg* 1989;33(1):27-45. X-2, X-3, X-5.
  929. Ramanathan J, Coleman P and Sibai B. Anesthetic modification of hemodynamic and neuroendocrine stress responses to cesarean delivery in women with severe preeclampsia. *Anesth Analg* 1991;73(6):772-779. X-2, X-3d.
  930. Ramanathan S, Sheth R and Turndorf H. Anesthesia for cesarean section in patients with genital herpes infections: A retrospective study. *Anesthesiology* 1986;64(6):807-809. X-3.
  931. Rampton AJ, Mallaiah S and Garrett CPO. Increased ventilation requirements during obstetric general anaesthesia. *Br J Anaesth* 1988;61(6):730-737. X-2, X-3a, X-5.
  932. Ranbhushan, Gupta S and Kohli GB. Drug error due to similarity between the ampoules. *J Anaesthesiol Clin Pharmacol* 2003;19(3):319-321. X-1, X-2, X-3, X-5.
  933. Rawal N, Schollin J and Weststrom G. Epidural versus combined spinal epidural block for cesarean section. *Acta Anaesthesiol Scand* 1988 Jan;32(1):61-6. X-2, X-3d.
  934. Raymond JA. Respiratory performance and the Mid-O-Gas. *N Z Med J* 1971 Feb;73(465):80-2. X-2, X-3, X-5.
  935. Reber A, Bobbia SA, Hammer J, et al. Effect of airway opening manoeuvres on thoraco-abdominal asynchrony in anaesthetized children. *Eur Respir J* 1239;17(6):1239-1243. X-2, X-3d.
  936. Redfern N, Stafford MA, Brooker J, et al. Incremental propofol for minor gynaecological procedures. *Postgrad Med J* 1985;61(SUPPL. 3):127-128. X-3.
  937. Reed PN and Jago RH. Comparison of the frequency of muscle pain associated with suxamethonium in pre- and post-ovulatory women and in those taking a combined oral contraceptive pill. *Br J Anaesth* 1983 May;55(5):377-80. X-2, X-3d.
  938. Reeve BK, Cook DJ, Babineau D, et al. Prophylactic Diclectin reduces the incidence of postoperative vomiting. *Can J Anaesth* 2005;52(1):55-61. X-2, X-3d.
  939. Regaert P and Noorduyn H. General anesthesia with etomidate, alfentanil and droperidol for caesarean section. *Acta Anaesthesiol Belg* 1984 Sep;35(3):193-200. X-2, X-3d.
  940. Reid DH. Diffusion anoxia at birth. *Lancet* 1968 Oct 5;2(7571):757-8. X-2.
  941. Reinhart K, Foehring U, Kersting T, et al. Effects of thoracic epidural anesthesia on systemic hemodynamic function and systemic oxygen supply-demand relationship. *Anesth Analg* 1989;69(3):360-369. X-2, X-3d.
  942. Reisner LS. Anesthesia for cesarean section. *Clin Obstet Gynecol* 1980 Jun;23(2):517-23. X-1, X-2, X-3, X-5.
  943. Reynolds AC, Abram SE and Worthington D. Anesthetic management of a patient with spinal muscular atrophy. Case report and review of the literature. *Anesthesiology Review* 1982;9(11-12):24-26. X-1, X-2, X-3, X-5.
  944. Reynolds F. Pain relief in labour. *Br J Obstet Gynaecol* 1993 Nov;100(11):979-83. X-1, X-2, X-5.

945. Reynolds F. Analgesia for labour. *Prescribers' Journal* 1998;38(1):26-31. X-1, X-2, X-5.
946. Reynolds F and Crowhurst JA. Opioids in labour - No analgesic effect. *Lancet* 9044;349(9044):4-5. X-1, X-2, X-3, X-5.
947. Reynolds F, Sharma SK and Seed PT. Analgesia in labour and fetal acid-base balance: A meta-analysis comparing epidural with systemic opioid analgesia. *BJOG* 1344;109(12):1344-1353. X-1, X-2, X-3d.
948. Reza FM, Zahra F, Esmael F, et al. Preemptive analgesic effect of ketamine in patients undergoing elective cesarean section. *Clin J Pain* 2010 Mar-Apr;26(3):223-6. X-2, X-3.
949. Rezaeipour A, Idenloo F, Khakbazan Z, et al. The effects of Entonox on implication of painless labor and delivery satisfaction rate among pregnant women [Farsi]. *Hayat* 2007;13(4):92. X-4.
950. Rice SA. Behavioural toxicity of inhalation anaesthetic agents. *Clin Anaesthesiol* 1983;1(2):507-519. X-1, X-2, X-3, X-5.
951. Richards KA and Stasko T. Dermatologic surgery and the pregnant patient. *Dermatol Surg* 2002;28(3):248-256. X-1, X-2, X-3d.
952. Rising S, Dodgson MS and Steen PA. Isoflurane v fentanyl for outpatient laparoscopy. *Acta Anaesthesiol Scand* 1985 Apr;29(3):251-5. X-2, X-3d.
953. Riss PA and Bieglmayer C. Obstetric analgesia and immunoreactive endorphin peptides in maternal plasma during labor. *Gynecol Obstet Invest* 1984;17(3):127-130. X-3.
954. Ritchie RG, Ernst EA, Pate BL, et al. Automatic control of anesthetic delivery and ventilation during surgery. *Med Prog Technol* 1990;16(1-2):61-67. X-2, X-3, X-5.
955. Robert-Gnansia E and Saillenfait AM. Physical and chemical factors in the home and workplace before and during pregnancy. *Community Genet* 2002;5(1):78-85. X-1, X-2, X-3.
956. Roberts SW, Leveno KJ, Sidawi JE, et al. Fetal acidemia associated with regional anesthesia for elective cesarean delivery. *Obstet Gynecol* 1995;85(1):79-83. X-2, X-3a, X-3d.
957. Robertson A. Nitrous oxide -- no laughing matter. *MIDIRS Midwifery Digest* 2006;16(1):123-8. X-1, X-2.
958. Robertson CH, Lund RR, Soroosh F, et al. Percutaneous fetal ventriculography. A new technic and case report. *Obstet Gynecol* 1969 Dec;34(6):841-6. X-1, X-2, X-3d, X-5.
959. Robinson J. Consumer comments Drugged babies: drugged adults? *Br J Midwifery* 1998;6(1). X-1, X-2, X-5.
960. Robinson JO, Rosen M and Evans JM. Maternal opinion about analgesia for labour. A controlled trial between epidural block and intramuscular pethidine combined with inhalation. *Anaesthesia* 1980;35(12):1173-1181. X-5.
961. Rocke DA, Rout CC, Russell HD, et al. The labour ward analgesic service at King Edward VIII Hospital, Durban. *S Afr Med J* 1993 Jan;83(1):32-3. X-3, X-5.
962. Rodgers L, Dangel-Palmer MC and Berner N. Acute circulatory and respiratory collapse in obstetrical patients: a case report and review of the literature. *AANA Journal* 2000;68(5):444-50. X-1, X-2, X-3d.
963. Rodier PM. Differential structural effects of three behavioral teratogens. *Dev Toxicol Environ Sci* 1983;11:53-60. X-1, X-2, X-3, X-5.
964. Roeleveld N. Pregnant operating room personnel: risks and prevention. *Acta Anaesthesiol Belg* 2002;53(4):327-9. X-2, X-3, X-5.
965. Rooks JP. Nitrous oxide for pain in labor--why not in the United States? *Birth* 2007 Mar;34(1):3-5. X-1, X-5.
966. Rooks JP. Use of nitrous oxide in midwifery practice -- complementary, synergistic, and needed in the United States. *J Midwifery Womens Health* 2007;52(3):186-9. X-1, X-2.

967. Rooth G. Maternal hypoxaemia during labor. *Pediatr Padol* 1982;17(2):231-6. X-1, X-2, X-3.
968. Rosen MA. Management of anesthesia for the pregnant surgical patient. *Anesthesiology* 1159;91(4):1159-1163. X-1, X-2, X-5.
969. Rosen MA. Papillary thyroid cancer in pregnancy: Therapeutic consideration of thyroid surgery under local anaesthesia. *Asian J Surg* 2001;24(3):314-315. X-1, X-2, X-3a, X-5.
970. Rosen MA. Nitrous oxide for relief of labor pain: A systematic review. *Am J Obstet Gynecol* 2002;186(5 SUPPL):S110-S126. X-1, X-2.
971. Rosen MA, Roizen MF, Eger EI, 2nd, et al. The effect of nitrous oxide on in vitro fertilization success rate. *Anesthesiology* 1987 Jul;67(1):42-4. X-2, X-3d.
972. Rosenthal J, Bolotin E, Shakhnovits M, et al. High-dose therapy with hematopoietic stem cell rescue in patients with poor prognosis Ewing family tumors. *Bone Marrow Transplant* 2008;42(5):311-318. X-2, X-3d.
973. Ross A. Maternal satisfaction with labour analgesia. *Baillieres Clin Obstet Gynaecol* 1998 Sep;12(3):499-512. X-1, X-2, X-5.
974. Ross JA and Tunstall ME. Simulated use of premixed 0.25% isoflurane in 50% nitrous oxide and 50% oxygen. *Br J Anaesth* 2002 Dec;89(6):820-4. X-2, X-3.
975. Rowland AS, Baird DD, Shore DL, et al. Ethylene oxide exposure may increase the risk of spontaneous abortion, preterm birth, and postterm birth. *Epidemiology* 1996 Jul;7(4):363-8. X-2, X-3a, X-3d, X-5.
976. Rowland AS, Baird DD, Shore DL, et al. Nitrous oxide and spontaneous abortion in female dental assistants. *Am J Epidemiol* 1995 Mar 15;141(6):531-8. X-2, X-3, X-5.
977. Rowland AS, Baird DD, Weinberg CR, et al. Reduced fertility among women employed as dental assistants exposed to high levels of nitrous oxide. *N Engl J Med* 1992 Oct 1;327(14):993-7. X-2, X-3d, X-5.
978. Rubin RR, Peyrot M, Chen X, et al. Patient-reported outcomes from a 16-week open-label, multicenter study of insulin pump therapy in patients with type 2 diabetes mellitus. *Diabetes Technol Ther* 2010;12(11):901-906. X-2, X-3d.
979. Rungreungvanich M, Thienthong S, Charuluxananan S, et al. Predictors of intra-operative recall of awareness: Thai anesthesia incidents study (THAI Study): A case-control study. *J Med Assoc Thai* 1551;90(8):1551-1557. X-2, X-3a, X-3d.
980. Russell IF. Effect of posture during the induction of subarachnoid analgesia for Caesarean section. Right v. left lateral. *Br J Anaesth* 1987;59(3):342-346. X-2, X-3d.
981. Russell JT. Awareness under anesthesia. *Anaesthesia* 1969 Jul;24(3):494-5. X-1, X-2, X-3d, X-5.
982. Russell R, Groves P, Taub N, et al. Assessing long term backache after childbirth. *BMJ* 6888;306(6888):1299-1303. X-2, X-3, X-5.
983. Ryhanen P, Jouppila R and Lanning M. Natural killer cell activity after elective Cesarean section under general and epidural anesthesia in healthy parturients and their newborns. *Gynecol Obstet Invest* 1985;19(3):139-142. X-2, X-3d.
984. Sahajananda H and Meneges J. Anaesthesia for a child with Walker-Warburg syndrome. *Paediatric Anaesthesia* 2003;13(7):624-628. X-1, X-2, X-3.
985. Sakai T, Vallejo MC and Shannon KT. A parturient with neurofibromatosis type 2: Anesthetic and obstetric considerations for delivery. *Int J Obstet Anesth* 2005;14(4):332-335. X-1, X-2, X-3d.
986. Saleh AM, Abotalib ZM, Al-Ibrahim AA, et al. Comparison of maternal and fetal outcomes, in epileptic and non-epileptic women. *Saudi Med J* 2008;29(2):261-266. X-3d.

987. Samieh-Tucker A and Rupasinghe M. Anaesthesia for caesarean section in a patient with acute generalised pustular psoriasis. *Int J Obstet Anesth* 2007;16(4):375-378. X-2, X-3d.
988. Sampson IH, Plosker H, Cohen M, et al. Comparison of propofol and thiamylal for induction and maintenance of anaesthesia for outpatient surgery. *Br J Anaesth* 1988 Dec;61(6):707-11. X-2, X-3b.
989. Sanci M, Dikis C, Inan S, et al. Distributions of estrogen and progesterone receptors and Ki-67 on human leiomyomas, cellular leiomyomas and leiomyosarcomas. IUBMB Life. Conference: 3rd International Congress of Molecular Medicine of the Turkish Society of Molecular Medicine Istanbul Turkey. Conference Start 2009;61(3). X-2, X-3d.
990. Sanders J, Campbell R and Peters TJ. Effectiveness of pain relief during perineal suturing. *BJOG* 2002 Sep;109(9):1066-8. X-2, X-3a, X-3d.
991. Sanders RD, Weimann J and Maze M. Biologic effects of nitrous oxide: a mechanistic and toxicologic review. *Anesthesiology*. 2008 Oct;109(4):707-22. X-1, X-2.
992. Sanders RS, Sinclair ME and Sear JW. Alfentanil in short procedures. A comparison with halothane using etomidate or methohexitone for induction of anaesthesia. *Anaesthesia* 1984 Dec;39(12):1202-6. X-2, X-3b.
993. Sanderson JH and Blades JF. Multicentre study of propofol in day case surgery. *Anaesthesia* 1988 Mar;43 Suppl:70-3. X-2, X-3d.
994. Sandhya and Yaddanapudi LN. Evaluation of two antiemetic agents during outpatient gynaecological surgery. *Singapore Med J* 1994 Jun;35(3):271-3. X-2, X-3b.
995. Sands TD and Pynn BR. Management considerations for the pregnant or nursing emergency patient. *Ont Dent*. 1998 Jul-Aug;75(6):17-9. X-1, X-2, X-3d.
996. Saravanakumar K, Rao SG and Cooper GM. Obesity and obstetric anaesthesia. *Anaesthesia* 2006;61(1):36-48. X-1, X-2.
997. Sass-Kortsak AM, Purdham JT, Bozek PR, et al. Exposure of hospital operating room personnel to potentially harmful environmental agents. *American Industrial Hygiene Association Journal* 1992;53(3):203-209. X-3, X-5.
998. Sato N, Shirotani T, Miyawaki I, et al. Retrospective assessment of anesthesia, cesarean section and toxemia of pregnancy. *Hiroshima J Anesth* 1992;28(4):339-343. X-2, X-3, X-5.
999. Sato T, Hashiguchi A and Mitsuse T. Anesthesia for cesarean delivery in a pregnant woman with acute hepatic failure. *Anesth Analg* 1441;91(6):1441-1442. X-1, X-2, X-3a, X-5.
1000. Saunders JF. Nitrous oxide. *RDH* 1988 Oct;8(8):22, 26-7. X-1, X-2, X-3, X-5.
1001. Scavee C, Jais P, Hsu LF, et al. Prospective randomised comparison of irrigated-tip and large-tip catheter ablation of cavotricuspid isthmus-dependent atrial flutter. *European Heart Journal* 2004;25(11):963-969. X-2, X-3.
1002. Schapera A. An anesthesia mask gas-scavenging system. *J Occup Med* 1138;35(11):1138-1141. X-2, X-3d, X-5.
1003. Schindler AW, Scheeren TWL, Picker O, et al. Accuracy of feedback-controlled oxygen delivery into a closed anaesthesia circuit for measurement of oxygen consumption. *Br J Anaesth* 2003;90(3):281-290. X-2, X-3d.
1004. Schrading W, Kaplan R and Stewart R. Effect of scavenging on ambient levels of nitrous oxide in ambulances. *Ann Emerg Med* 1990;19(8):910-913. X-2, X-3, X-5.
1005. Schug SA, MacIntyre P, Power I, et al. The scientific evidence in acute pain management. *Acute Pain* 2005;7(4):161-165. X-1, X-2, X-3, X-5.
1006. Schulpis KH, Margeli A, Akalestos A, et al. Effects of mode of delivery on maternal-neonatal plasma antioxidant status and on protein

- S100B serum concentrations. *Scand J Clin Lab Invest* 2006;66(8):733-742. X-3.
- 1007.Schultetus RR, Hill CR and Dharamraj CM. Wakefulness during cesarean section after anesthetic induction with ketamine, thiopental, or ketamine and thiopental combined. *Anesth Analg* 1986;65(7):723-728. X-2, X-3.
- 1008.Schultetus RR, Paulus DA and Spohr GL. Haemodynamic effects of ketamine and thiopentone during anaesthetic induction for Caesarean section. *Can Anaesth Soc J* 1985;32(6):592-596. X-3.
- 1009.Schumann D. Nitrous oxide anaesthesia: risks to health personnel. *Int Nurs Rev* 1990;37(1):214-7. X-1, X-2.
- 1010.Schwartz DA, Moriarty KP, Tashjian DB, et al. Anesthetic management of the exit (Ex Utero intrapartum treatment) procedure. *J Clin Anesth* 2001;13(5):387-391. X-2, X-3d.
- 1011.Schwender D, Madler C, Klasing S, et al. Mid-latency auditory evoked potentials and wakefulness during caesarean section. *Eur J Anaesthesiol* 1995 Mar;12(2):171-9. X-2, X-3.
- 1012.Schwilden H and Stoeckel H. Closed-loop feedback controlled administration of alfentanil during alfentanil-nitrous oxide anaesthesia. *Br J Anaesth* 1993;70(4):389-393. X-2, X-3a, X-5.
- 1013.Scotland GS, McNamee P, Cheyne H, et al. Women's Preferences for Aspects of Labor Management: Results from a Discrete Choice Experiment. *Birth* 2011;38(1):36-46. X-2, X-5.
- 1014.Scott WA, Whitwam JG and Wilkinson RT. Choice reaction time. A method of measuring postoperative psychomotor performance decrements. *Anaesthesia* 1983 Dec;38(12):1162-8. X-2, X-3.
- 1015.Sear JW, Cooper GM and Kumar V. The effect of age on recovery. A comparison of the kinetics of thiopentone and Althesin. *Anaesthesia* 1983 Dec;38(12):1158-61. X-2, X-3.
- 1016.Sear JW, Walters FJ, Wilkins DG, et al. Etomidate by infusion for neuroanaesthesia. Kinetic and dynamic interactions with nitrous oxide. *Anaesthesia* 1984 Jan;39(1):12-8. X-2, X-3.
- 1017.Secher NJ, Arnsbo P, Andersen LH, et al. Measurements of cardiac stroke volume in various body positions in pregnancy and during Caesarean section: a comparison between thermodilution and impedance cardiography. *Scand J Clin Lab Invest* 1979 Oct;39(6):569-76. X-2, X-3.
- 1018.Sechzer PH. Dreams with low-dose ketamine in obstetrical patients. *Curr Ther Res Clin Exp* 1984;35(3):396-404. X-3a, X-5.
- 1019.Sedaghat N, Ellwood D, Shadbolt B, et al. The effect of mode of delivery and anaesthesia on neonatal blood pressure. *Aust N Z J Obstet Gynaecol* 2008;48(2):172-178. X-5, No way to pull out N20 data.
- 1020.Segatto A, Vincenti E, Valenti S, et al. TIVA with propofol vs thiopental-nitrous oxide anaesthesia for uterine cerclage (A prospective randomized clinical study on 200 pregnant patients). *Acta Anaesthesiol Ital* 1993;44(SUPPL. 1):59-65. X-2, X-3, X-5.
- 1021.Sen A, Rudra A, Sarkar SK, et al. Intrathecal midazolam for postoperative pain relief in caesarean section delivery. *J Indian Med Assoc* 2001;99(12):683-686. X-2, X-3a.
- 1022.Sener EB, Guldogus F, Karakaya D, et al. Comparison of neonatal effects of epidural and general anaesthesia for cesarean section. *Gynecol Obstet Invest* 2003;55(1):41-5. X-2, X-3.
- 1023.Sener EB, Kocamanoglu S, Ustun E, et al. Anesthetic management for cesarean delivery in a woman with Gilles de la Tourette's syndrome. *Int J Obstet Anesth* 2006;15(2):163-165. X-2, X-3.
- 1024.Sengupta P and Nielsen M. The effect of labour and epidural analgesia on pain threshold. *Anaesthesia* 1984;39(10):982-986. X-3d, X-5.
- 1025.Settergren G, Ohqvist G and Ekstrom S. Sequential myocardial

- depressant and non-depressant anaesthesia for coronary artery surgery. *Acta Anaesthesiol Scand* 1985;29(1):26-31. X-2, X-3.
1026. Sevarino FB, Paige D, Sinatra RS, et al. Postoperative analgesia with parenteral opioids: Does continuous delivery utilizing a transdermal opioid preparation affect analgesic efficacy or patient safety? *J Clin Anesth* 1997;9(3):173-178. X-2, X-3.
1027. Seward EH. Obstetric analgesia; a new machine for the self-administration of nitrous oxide oxygen. *Proc R Soc Med* 1949 Sep;42(9):745. X-1, X-2, X-5.
1028. Shankar KA, Puri R and Dutta PK. Anaesthetic management of a case of early pregnancy with systemic sclerosis. *Med J Armed Forces India* 2005;61(3):287-288. X-1, X-2, X-3d, X-5.
1029. Shankar KB, Posner M, Moore Jr FD, et al. Laryngeal nerve monitoring during thyroid surgery in pregnancy. *J Clin Anesth* 2005;17(5):369-371. X-2, X-3.
1030. Shapira SC, Chrubasik S, Hoffmann A, et al. Use of alfentanil for in vitro fertilization oocyte retrieval. *J Clin Anesth* 1996 Jun;8(4):282-5. X-2, X-3.
1031. Shapira SC and Weiss YS. Analgesia for labour. *Curr Opin Anaesthesiol* 1996;9(3):207-210. X-1, X-2.
1032. Sharifi N, Sadeghian MH, Ayatollahi H, et al. Validity of P57kip2 immunohistochemical marker in differential diagnosis of molar pregnancy. *J Turkish German Gynecol Assoc Artemis* 2009;10(1):39-42. X-2, X-3.
1033. Sharley CB. The value of physiotherapy in obstetrics. *Med J Aust* 1970 Jun 6;1(23):1159-62. X-3.
1034. Sharma RM and Vardhan S. Flash pulmonary oedema following prostodin in pregnancy. *Med J Armed Forces India* 2008;64(4):375-376. X-1, X-2, X-3, X-5.
1035. Sharma SK, Vera RL, Stegall WC, et al. Management of a postpartum coagulopathy using thrombelastography. *J Clin Anesth* 1997;9(3):243-247. X-2, X-3.
1036. Sharp LM and Levy DM. Rapid sequence induction in obstetrics revisited. *Curr Opin Anesthesiol* 2009;22(3):357-61. X-1, X-2, X-3.
1037. Shaw DB and Wheeler AS. Anesthesia for obstetric emergencies. *Clin Obstet Gynecol* 1984 Mar;27(1):112-24. X-1, X-2, X-3, X-5.
1038. Shek KL and Dietz HP. Intrapartum risk factors for levator trauma. *BJOG* 1485;117(12):1485-1492. X-2, X-3.
1039. Sher AM, Braude BM and Cleaton-Jones PE. Nitrous oxide sedation in dentistry. A comparison between Rotameter settings, pharyngeal concentrations and blood levels of nitrous oxide. *Anaesthesia* 1984;39(3):236-239. X-2, X-3.
1040. Sherke RR and Rao MS. Anaesthetic management of splenectomy in Evan's syndrome during pregnancy with pregnancy induced hypertension. *J Postgrad Med* 2001;47(3):196-198. X-2, X-3.
1041. Shetty A, Danielian P and Templeton A. A comparison of oral and vaginal misoprostol tablets in induction of labour at term. *BJOG* 2001;108(3):238-243. X-3d.
1042. Shira RB, Greenfield W and Karpinski JF. Citanest Forte--its use in oral surgery. *Oral Surg Oral Med Oral Pathol* 1975 Feb;39(2):177-83. X-2, X-3.
1043. Shokry M, Elsedfy GO, Bassiouny MM, et al. Effects of antenatal magnesium sulfate therapy on cerebral and systemic hemodynamics in preterm newborns. *Acta Obstet Gynecol Scand* 2010;89(6):801-806. X-2, X-3.
1044. Short SM, Rutherford CF and Sebel PS. A comparison between isoflurane and alfentanil supplemented anaesthesia for short procedures. *Anaesthesia* 1985 Dec;40(12):1160-4. X-2, X-3.
1045. Shortridge-McCauley LA. Reproductive hazards: an overview of exposures to health care workers. *AAOHN Journal* 1995;43(12):614-21. X-1, X-2, X-5.



- 1046.Shrestha SM, Costello MF, Sjoblom P, et al. Power doppler ultrasound assessment of follicular vascularity in the early follicular phase and its relationship with outcome of in vitro fertilization. *J Assist Reprod Genet* 2006;23(4):161-169. X-2, X-3d.
- 1047.Shuhaiber S and Koren G. Occupational exposure to inhaled anesthetic. Is it a concern for pregnant women? *Can Fam Physician* 2000 Dec;46:2391-2. X-1, X-2, X-3.
- 1048.Sia AT, Lim Y and Ocampo CE. Computer-integrated patient-controlled epidural analgesia: A preliminary study on a novel approach of providing pain relief in labour. *Singapore Med J* 2006;47(11):951-956. X-3, X-5.
- 1049.Siafarikas A, Piazena H, Feister U, et al. Randomised controlled trial analysing supplementation with 250 versus 500 units of vitamin D3, sun exposure and surrounding factors in breastfed infants. *Arch Dis Child* 2011;96(1):91-95. X-2, X-3.
- 1050.Sibai BM, Spinnato JA and Watson DL. Eclampsia IV. Neurological findings and future outcome. *Am J Obstet Gynecol* 1985;152(2):184-192. X-2, X-3d.
- 1051.Sidhu MS and Cullen BF. Low-dose enflurane does not increase blood loss during therapeutic abortion. *Anesthesiology* 1982 Aug;57(2):127-9. X-1, X-2, X-3a, X-3b, X-5.
- 1052.Simmons PD. Genital warts. *International Journal of Dermatology* 1983;22(7):410-414. X-1, X-2, X-3.
- 1053.Simpson PJ, Radford SG, Lockyer JA, et al. Some factors predisposing to althesin hypersensitivity. *Br J Anaesth* 1131;54(10). X-2, X-3, X-5.
- 1054.Simpson PJ, Radford SG, Lockyer JA, et al. Some predisposing factors to hypersensitivity reactions following first exposure to Althesin. *Anaesthesia* 1985;40(5):420-423. X-2, X-3.
- 1055.Sinatra RS, Philip BK, Naulty JS, et al. Prolonged neuromuscular blockade with vecuronium in a patient treated with magnesium sulfate. *Anesth Analg* 1220;64(12):1220-1222. X-1, X-2, X-3d, X-5.
- 1056.Sindram-Trujillo AP, Scherjon SA, Miert PPVHV, et al. Comparison of decidual leukocytes following spontaneous vaginal delivery and elective cesarean section in uncomplicated human term pregnancy. *J Reprod Immunol* 2004;62(1-2):125-137. X-2, X-3.
- 1057.Singh SI, Brooks C and Dobkowski W. General anesthesia using remifentanyl for Cesarean delivery in a parturient with Marfan's syndrome. *Can J Anaesth* 2008;55(8):526-531. X-2, X-3.
- 1058.Sivan E and Ben-Baruch G. Cryotherapy - Preliminary treatment of genital condylomata. *Isr J Med Sci* 1992;28(6):365-367. X-3.
- 1059.Sivevski A. Effects of varying doses of plain bupivacaine with fentanyl in patients undergoing cesarean section: Haemodynamics and neonatal outcome. *Anaesthes Intensive Care* 2009;39(5):30-35. X-2, X-3.
- 1060.Skilnand E, Fossen D and Heiberg E. Acupuncture in the management of pain in labor. *Acta Obstet Gynecol Scand* 2002;81(10):943-948. X-3a.
- 1061.Slater RM, Bowles BJM and Pumphrey RSH. Anaphylactoid reaction to oxytocin in pregnancy. *Anaesthesia* 1985;40(7):655-656. X-1, X-2, X-3d, X-5.
- 1062.Sloan PA and Rasul M. Prolongation of rapacuronium neuromuscular blockade by clindamycin and magnesium. *Anesth Analg* 2002;94(1):123-124. X-1, X-2, X-3d, X-5.
- 1063.Smetkin AA, Kirov MY, Kuzkov VV, et al. Single transpulmonary thermodilution and continuous monitoring of central venous oxygen saturation during off-pump coronary surgery. *Acta Anaesthesiol Scand* 2009;53(4):505-514. X-2, X-3.
- 1064.Smith BE. Teratology in anesthesia. *Clin Obstet Gynecol.* 1974 Jun;17(2):145-63. X-1, X-2, X-3, X-5.

- 1065.Smith BE. Anesthetic emergencies. Clin Obstet Gynecol 1985;28(2):391-404. X-1, X-2, X-3d, X-5.
- 1066.Smith MA, Ruffin IMT and Green LA. The rational management of labor. Am Fam Physician 1471;47(6):1471-1481. X-1, X-2.
- 1067.Sng BL, Lim Y and Sia AT. An observational prospective cohort study of incidence and characteristics of failed spinal anaesthesia for caesarean section. Int J Obstet Anesth. 2009 Jul;18(3):237-41. X-2, X-3a, X-3d.
- 1068.Solca M, Salvo I, Russo R, et al. Anaesthesia with desflurane-nitrous oxide in elderly patients. Comparison with isoflurane-nitrous oxide. Minerva Anesthesiol 2000 Sep;66(9):621-6. X-2, X-3a.
- 1069.Sonander H, Stenqvist O and Nilsson K. Urinary N<sub>2</sub>O as a measure of biologic exposure to nitrous oxide anaesthetic contamination. Ann Occup Hyg 1983;27(1):73-9. X-2, X-3, X-5.
- 1070.Soyannwo OA, Elegbe EO and Odugbesan CO. Effect of flunitrazepam (Rohypnol) on awareness during anaesthesia for caesarean section. Afr J Med Med Sci 1988 Mar;17(1):23-6. X-2, X-3.
- 1071.Soydemir F, Kuruvilla S, Brown M, et al. Adapting in vitro dual perfusion of the human placenta to soluble oxygen tensions associated with normal and pre-eclamptic pregnancy. Lab Invest 2011;91(2):181-189. X-2, X-3.
- 1072.Spence AA, Cohen EN, Brown BW, Jr., et al. Occupational hazards for operating room-based physicians. Analysis of data from the United States and the United Kingdom. JAMA 1977 Aug 29;238(9):955-9. X-1, X-3.
- 1073.Spence AA and Knill-Jones RP. Is there a health hazard in anaesthetic practice? Br J Anaesth 1978 Jul;50(7):713-9. X-3d, X-5.
- 1074.Spielman FJ. Anesthesia for in vitro fertilization. Anesthesiol Clin North America 1989;7(3):723-739. X-1, X-2, X-3.
- 1075.Spielman FJ and Corke BC. Advantages and disadvantages of regional anesthesia for cesarean section. A review. J Reprod Med 1985;30(11):832-840. X-1, X-2, X-3.
- 1076.Spierdijk J and Regjer V. Dangers of chronic exposure to inhalation anaesthetics. Preventive measures. Acta Anaesthesiol Belg 1973 May;24(2):115-27. X-1, X-2, X-3, X-5.
- 1077.Spodick DH. Directly applied cardiac therapy. Cardiol Rev 1999;16(7):53-54. X-1, X-2, X-3, X-5.
- 1078.Sprung J, Flick RP, Wilder RT, et al. Anesthesia for cesarean delivery and learning disabilities in a population-based birth cohort. Anesthesiology 2009;111(2):302-310. X-2, X-3, X-5.
- 1079.Stallabrass P. Halothane and blood loss at delivery. Acta Anaesthesiol Scand Suppl 1966;25:376. X-1, X-2, X-3, X-5.
- 1080.Stange K and Halldin M. Hypothermia in pregnancy. Anesthesiology 1983;58(5):460-461. X-1, X-2, X-3, X-5.
- 1081.Stanway G. Potential hazards of trace inhalation of anaesthetic gases: a risk assessment. SAAD Dig 2002 Apr;19(2):14-9. X-1, X-2, X-3, X-5.
- 1082.Stefani SJ, Hughes SC, Schnider SM, et al. Neonatal neurobehavioral effects of inhalation analgesia for vaginal delivery. Anesthesiology 1982 May;56(5):351-5. X-2.
- 1083.Stenger VG, Blechner JN, Andersen TW, et al. Observations on pentothal, nitrous oxide, and succinylcholine anesthesia at cesarean section. Am J Obstet Gynecol 1967 Nov 1;99(5):690-701. X-2, X-3, X-5.
- 1084.Stenger VG, Blechner JN and Prystowsky H. A study of prolongation of obstetric anesthesia. Am J Obstet Gynecol 1969 Apr 1;103(7):901-7. X-2, X-3, X-5.
- 1085.Stevens WD, Dolan WM, Gibbons RT, et al. Minimum alveolar concentrations (MAC) of isoflurane with and without nitrous oxide in patients of various ages.

- Anesthesiology 1975 Feb;42(2):197-200. X-3d, X-5.
- 1086.Steverlynck N. Birth in Sweden. Midwifery Today 2007;81:56-7. X-1, X-2, X-3, X-5.
- 1087.Stewart A, Sodhi V, Harper N, et al. Assessment of the effect upon maternal knowledge of an information leaflet about pain relief in labour. Anaesthesia 1015;58(10):1015-1019. X-2, X-3, X-5.
- 1088.Stewart RD. Nitrous oxide sedation/analgesia in emergency medicine. Ann Emerg Med 1985 Feb;14(2):139-48. X-1, X-2, X-3.
- 1089.Stojanovic N, Lewandowski K, Salata I, et al. Serum levels of matrix metalloproteinases MMP-2 and MMP-9 and their inhibitors in women with glucose intolerance in pregnancy and normal controls. Gynecol Endocrinol 2010;26(3):201-207. X-2, X-3.
- 1090.Stovner J and Vangen O. Diazepam compared to thiopentone as induction agent for caesarean sections. Acta Anaesthesiol Scand 1974;18(4):264-9. X-2, X-3a, X-3d, X-5.
- 1091.Stow PJ and White JB. Anaesthesia for paediatric tonsillectomy. Comparison of spontaneous ventilation and intermittent positive pressure ventilation. Br J Anaesth 1987;59(4):419-423. X-2, X-3d.
- 1092.Street D. A practical guide to giving Entonox. Nurs Times 2000 Aug 24-30;96(34):47-8. X-1, X-2, X-5.
- 1093.Srintzi Paschalaki N, Karathanos A and Demopoulos H. Neurobehavioral responses of newborn infants after maternal epidural vs. general anesthesia. Rev Med Chir Soc Med Nat Iasi 1982;86(4):619-621. X-2, X-3, X-5.
- 1094.Stubblefield MD, Manfield L and Riedel ER. A preliminary report on the efficacy of a dynamic jaw opening device (dynamaplast trismus system) as part of the multimodal treatment of trismus in patients with head and neck cancer. Arch Phys Med Rehabil 1278;91(8):1278-1282. X-2, X-3a, X-3d.
- 1095.Su HT, Chen KB, Liu YC, et al. Cerebral arteriovenous malformation diagnosed during labor induction with headache and convulsions as presentations - A case report. Acta Anaesthesiol Taiwan 2005;43(4):247-251. X-2, X-3d.
- 1096.Sudunagunta S, Eckersall SJ and Gowrie-Mohan S. Continuous caudal analgesia in labour for a patient with Harrington rods. Int J Obstet Anesth 1998;7(2):128-130. X-1, X-2, X-3, X-5.
- 1097.Sungurtekin H, Cook DJ, Orszulak TA, et al. Cerebral response to hemodilution during hypothermic cardiopulmonary bypass in adults. Anesth Analg 1078;89(5):1078-1083. X-2, X-3.
- 1098.Suver J, Arikian SR, Doyle JJ, et al. Use of anesthesia selection in controlling surgery costs in an HMO hospital. Clin Ther 1995;17(3):561-571. X-1, X-2, X-3d.
- 1099.Svanstrom MC, Biber B, Hanes M, et al. Signs of myocardial ischaemia after injection of oxytocin: A randomized double-blind comparison of oxytocin and methylergometrine during Caesarean section. Br J Anaesth 2008;100(5):683-689. X-2, X-3a, X-3d.
- 1100.Sylvester IE and Paul A. Effects of socio demographic factors on plasma ascorbic acid and alpha tocopherol anti oxidants during pregnancy. Pak J Med Sci 2009;25(5):755-759. X-2, X-3d.
- 1101.Tahseen S and McLean G. Spontaneous delivery through perineum, bypassing the vaginal introitus. J Obstet Gynaecol 2003;23(6):671-672. X-1, X-2, X-3, X-5.
- 1102.Tailor TD, Hanna G, Yarmolenko PS, et al. Targeting the tumor microenvironment via inhibition of VEGF and PDGF to improve liposomal drug delivery in human non-small cell lung cancer xenografts. Molecular Cancer Therapeutics. Conference: AACR NCI EORTC International Conference: Molecular Targets and Cancer Therapeutics Boston, MA

- United States. Conference Start 2009;8(12 SUPPL. 1). X-2, X-3d.
1103. Takauchi Y, Inamori N, Ohashi Y, et al. Anesthetic management for cesarean section in two parturients with quintuplet gestation. *Masui* 1993;42(12):1844-1848. X-4.
  1104. Tay SM, Ong BC and Tan SA. Cesarean section in a mother with uncorrected congenital coronary to pulmonary artery fistula. *Can J Anaesth* 1999;46(4):368-371. X-1, X-2, X-3.
  1105. Taylor DJ, Nelson J and Howie PW. Neurodevelopmental disability--a sibling-control study. *Dev Med Child Neurol* 1993 Nov;35(11):957-64. X-2, X-3d.
  1106. Tazeh-Kand NF, Eslami B and Mohammadian K. Inhaled fluticasone propionate reduces postoperative sore throat, cough, and hoarseness. *Anesth Analg* 2010;111(4):895-898. X-2, X-3a, X-4.
  1107. Tekavec CD. The pregnant auxiliary: reducing risks in the office setting. *Dent Assist (Waco Tx)*. 1984 Jan-Feb;3(3):20-3. X-1, X-2, X-3, X-5.
  1108. Ternov K, Nilsson M, Lofberg L, et al. Acupuncture for pain relief during childbirth. *Acupunct Electrother Res* 1998;23(1):19-26. X-3a, X-5.
  1109. Ternov NK, Buchhave P, Svensson G, et al. Acupuncture during childbirth reduces use of conventional analgesia without major adverse effects: A retrospective study. *Am J Acupunct* 1998;26(4):233-239. X-3, X-5.
  1110. Teschke K, Abanto Z, Arbour L, et al. Exposure to anesthetic gases and congenital anomalies in offspring of female registered nurses. *Am J Ind Med* 2011 Feb;54(2):118-27. X-5.
  1111. Thalme B, Belfrage P and Raabe N. Lumbar epidural analgesia in labour. I. Acid-base balance and clinical condition of mother, fetus and newborn child. *Acta Obstet Gynecol Scand* 1974;53(1):27-35. X-3.
  1112. Thalme B, Raabe N and Belfrage P. Lumbar epidural analgesia in labour. II. Effects on glucose, lactate, sodium, chloride, total protein, haematocrit and haemoglobin in maternal, fetal and neonatal blood. *Acta Obstet Gynecol Scand* 1974;53(2):113-9. X-3.
  1113. Thind GS and Bryson THL. Single dose suxamethonium and muscle pain in pregnancy. *Br J Anaesth* 1983;55(8):743-745. X-2, X-3a, X-3d.
  1114. Thistlewood JM. Obstetric analgesia. *Can Fam Physician* 2013;34(SEP). X-1, X-2, X-5.
  1115. Thomas I, Thomas M and Scrutton M. Spinal anaesthesia in a patient with hereditary spastic paraplegia: case report and literature review. *Int J Obstet Anesth* 2006;15(3):254-256. X-1, X-2, X-3.
  1116. Thomas TA, Fletcher JE and Hill RG. Influence of medication, pain and progress in labour on plasma beta-endorphin-like immunoreactivity. *Br J Anaesth* 1982 Apr;54(4):401-8. X-2.
  1117. Thorburn J and Reid JA. Alternative methods of pain relief in pregnancy. *Curr Obstet Gynaecol* 1996;6(2):61-66. X-1, X-2, X-5.
  1118. Thorniley A, Moyes DG, Pike RF, et al. Comparison of nalbuphine and pethidine for the relief of pain after caesarean section. *S Afr Med J* 1986;69(11):682-683. X-2, X-3a, X-3d.
  1119. Thurlow JA, Laxton CH, Dick A, et al. Remifentanyl by patient-controlled analgesia compared with intramuscular meperidine for pain relief in labour. *Br J Anaesth* 2002;88(3):374-378. X-2, X-3d.
  1120. Todorova K, Palaveev O, Petkova VB, et al. A pharmacoeconomical model for choice of a treatment for pregnant women with gestational diabetes. *Acta Diabetologica* 2007;44(3):144-148. X-2, X-3d.
  1121. Tooley G. Normal birth: a new beginning. *RCM Midwives* 2005;8(8):338-9. X-1, X-2, X-3, X-5.
  1122. Torricelli M, Sabatini L, Florio P, et al. Levels of antibodies against protein C and protein S in pregnancy and in preeclampsia. *J Matern Fetal Neonatal Med* 2009;22(11):993-999. x-2, X-3d.

1123. Tortosa JC, Parry NS, Mercier FJ, et al. Efficacy of augmentation of epidural analgesia for Caesarean section. *Br J Anaesth* 2003;91(4):532-535. X-2, X-3a, X-3d.
1124. Tournaire M. Alternative approaches to pain relief during labor and delivery. *Adv Exp Med Biol* 2004;546(pp 193-206). X-1, X-2, X-5.
1125. Trevisan A and Gori GP. Biological monitoring of nitrous oxide exposure in surgical areas. *Am J Ind Med*. 1990;17(3):357-62. X-3d, X-5.
1126. Tsai FF, Wu GJ, Lin CJ, et al. Optimizing epidural fentanyl loading dose for early labor pain. *Acta Anaesthesiol Taiwan* 2009;47(4):167-172. X-3a, X-3d.
1127. Tsai PS, Huang CJ, Hung YC, et al. Effects on the bispectral index during elective caesarean section: a comparison of propofol and isoflurane. *Acta Anaesthesiol Sin*. 2001 Mar;39(1):17-22. X-2, X-3a, X-3d, X-5.
1128. Tsen LC. Anesthesia for assisted reproductive technologies. *Int Anesthesiol Clin* 2007;45(1):99-113. X-1, X-2, X-3, X-5.
1129. Tuckey JP, Prout RE and Wee MYK. Prescribing intramuscular opioids for labour analgesia in consultant-led maternity units: a survey of UK practice. *Int J Obstet Anesth* 2008;17(1):3-8. X-2, X-3.
1130. Tunell R. Method for determination of pulmonary gas exchange in connection with birth. *Acta Paediatr Scand* 1975 Jan;64(1):49-56. X-2, X-3d.
1131. Tunstall ME. Obstetric analgesia. The use of a fixed nitrous oxide and oxygen mixture from one cylinder. *Lancet* 1961 Oct 28;2(7209):964. X-1, X-2, X-3, X-4, X-5.
1132. Tunstall ME. The reduction of amnesic wakefulness during caesarean section. *Anaesthesia* 1979 Apr;34(4):316-9. X-2, X-3d, X-5.
1133. Tunstall ME and Hawksworth GM. Halothane uptake and nitrous oxide concentration. Arterial halothane levels during Caesarean section. *Anaesthesia* 1981 Feb;36(2):177-82. X-2, X-3a, X-3d, X-5.
1134. Tunstall ME and Sheikh A. Comparison of 1.5% enflurane with 1.25% isoflurane in oxygen for caesarean section: avoidance of awareness without nitrous oxide. *Br J Anaesth* 1989 Feb;62(2):138-43. X-2, X-3d.
1135. Tveit TO, Halvorsen A and Rosland JH. Analgesia for labour: a survey of Norwegian practice - with a focus on parenteral opioids. *Acta Anaesthesiol Scand* 2009 Jul;53(6):794-9. X-2, X-3d, X-5.
1136. Tylleskar J, Finnstrom O and Leijon I. Spontaneous labor and elective induction - a prospective randomized study. I. Effects on mother and fetus. *Acta Obstet Gynecol Scand* 1979;58(6):513-518. X-3, X-5.
1137. Ueland K, Hansen J, Eng M, et al. Maternal cardiovascular dynamics. V. Cesarean section under thiopental, nitrous oxide, and succinylcholine anesthesia. *Am J Obstet Gynecol* 1970 Oct 15;108(4):615-22. X-2, X-3d, X-5.
1138. Uppington J, Kay NH and Sear JW. Propofol ('Diprivan') as a supplement to nitrous oxide-oxygen for the maintenance of anaesthesia. *Postgrad Med J* 1985;61 Suppl 3:80-3. X-2, X-3a, X-3d, X-5.
1139. Uys PC, Morrell DF, Bradlow HS, et al. Self-tuning, microprocessor-based closed-loop control of atracurium-induced neuromuscular blockade. *Br J Anaesth* 1988;61(6):685-692. X-2, X-3d.
1140. Vaillancourt C, Berger N and Boksa P. Effects of vaginal birth versus caesarean section birth with general anesthesia on blood gases and brain energy metabolism in neonatal rats. *Exp Neurol* 1999 Nov;160(1):142-50. X-2, X-3d.
1141. Vakkuri O, Arnason SS, Pouta A, et al. Radioimmunoassay of plasma ouabain in healthy and pregnant individuals. *J Endocrinol* 2000;165(3):669-677. X-2, X-3d.
1142. Vallejo MC, Phelps AL, Shepherd CJ, et al. Nitrous oxide anxiolysis for elective cesarean section. *J Clin*

- Anesth 2005 Nov;17(7):543-8. X-2, X-3d.
1143. Van Buul BJA, Nijhuis JG, Slappendel R, et al. General anesthesia for surgical repair of intracranial aneurysm in pregnancy: Effects on fetal heart rate. *Am J Perinatol* 1993;10(2):183-186. X-2, X-3d.
  1144. Van Damme C and Berre J. Influence of enflurane on blood loss from the pregnant uterus. *Acta Anaesthesiol Belg* 1976;27 suppl:259-61. X-2, X-3b, X-5.
  1145. Van de Velde M. CONTROVERSY cont. to follow after "Remifentanyl patient-controlled analgesia should be routinely available for use in labour" on same page. *Int J Obstet Anesth* 2008;17(4):339-342. X-1, X-3d, X-5.
  1146. Van Der Linden P, Wathieu M, Gilbert E, et al. Cardiovascular effects of moderate normovolaemic haemodilution during enflurane-nitrous oxide anaesthesia in man. *Acta Anaesthesiol Scand* 1994;38(5):490-498. X-2, X-3d.
  1147. Van Nimwegen D and Dyer DC. The action of vasopressors on isolated uterine arteries. *Am J Obstet Gynecol* 1974 Apr 15;118(8):1099-103. X-3.
  1148. Van Wijngaarden WJ, Strachan BK, Sahota DS, et al. Improving intrapartum surveillance: An individualised T/QRS ratio? *Eur J Obstet Gynecol Reprod Biol* 2000;88(1):43-48. X-3d, X-5.
  1149. Vande water SL. Anaesthesia for the primiparous patient. *Acta Anaesthesiol Scand Suppl* 1966;23:167-71. X-3a, X-5.
  1150. Vangen S, Stoltenberg C and Schei B. Ethnicity and use of obstetrical analgesia: do Pakistani women receive inadequate pain relief in labour? *Ethn Health* 1996 May;1(2):161-7. X-3, X-5.
  1151. Vanhorebeek I, Vos RD, Mesotten D, et al. Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose control with insulin in critically ill patients. *Lancet* 9453;365(9453):53-59. X-2, X-3d.
  1152. Vardanyan A, Mastis B, Serriello J, et al. Development of behavioral measures of osteoarthritis-induced pain in rabbits. *Osteoarthritis Cartilage. Conference* 2010;18(pp S222). X-2, X-3d.
  1153. Vassiliadis J, Hitos K and Hill CT. Factors influencing prehospital and emergency department analgesia administration to patients with femoral neck fractures. *Emerg Med* 2002;14(3):261-266. X-2, X-3d.
  1154. Vedam S, Goff M and Marnin VN. Closing the Theory-Practice Gap: Intrapartum Midwifery Management of Planned Homebirths. *Journal of Midwifery and Women's Health*. 2007;52(3):291-300. X-1, X-2.
  1155. Vella L, Francis D, Houlton P, et al. Comparison of the antiemetics metoclopramide and promethazine in labour. *Br Med J (Clin Res Ed)* 1985 Apr 20;290(6476):1173-5. X-1, X-3d, X-5.
  1156. Velzing-Aarts FV, Van Der Klis FRM, Van Der Dijs FPL, et al. Effect of three low-dose fish oil supplements, administered during pregnancy, on neonatal long-chain polyunsaturated fatty acid status at birth. *Prostaglandins Leukot Essent Fatty Acids* 2001;65(1):51-57. X-2, X-3d.
  1157. Verma R, Ramasubramanian R and Sachar RM. Anesthesia for termination of pregnancy: midazolam compared with methohexital. *Anesth Analg* 1985 Aug;64(8):792-4. X-2, X-3b, X-3d.
  1158. Versichelen L, Serreyn R, Rolly G, et al. Physiopathologic changes during anesthesia administration for gynecologic laparoscopy. *J Reprod Med* 1984;29(10):697-700. X-2, X-3d.
  1159. Vessey MP and Nunn JF. Occupational hazards of anesthesia. *Br Med J* 1980 Sep 13;281(6242):696-8. X-1, X-2, X-3a, X-5.
  1160. Victory RA, Gajraj NM, Van Elstraete A, et al. Effect of preincision versus postincision infiltration with bupivacaine on postoperative pain. *J Clin Anesth* 1995;7(3):192-196. X-2, X-3d.

1161. Vieira E, Cleaton-Jones P and Moyes D. Effects of intermittent 0.5% nitrous oxide/air (v/v) on the fertility of male rats and the post-natal growth of their offspring. *Anaesthesia* 1983;38(4):319-23. X-2, X-3d, X-5.
1162. Villeneuve V, Kaufman I, Weeks S, et al. Anesthetic management of a labouring parturient with urticaria pigmentosa. *Can J Anaesth* 2006;53(4):380-384. X-2, X-3d.
1163. Vincent RD, Jr., Syrop CH, Van Voorhis BJ, et al. An evaluation of the effect of anesthetic technique on reproductive success after laparoscopic pronuclear stage transfer. Propofol/nitrous oxide versus isoflurane/nitrous oxide. *Anesthesiology* 1995 Feb;82(2):352-8. X-2, X-3d.
1164. Vincenti E, Giorgino F, Agnello A, et al. Is the current general anaesthesia for caesarean section really protective for the mother and the foetus? A study on beta-endorphin levels with different techniques of general anaesthesia. *Agressologie* 1988;29(3):193-197. X-2, X-3d.
1165. Vogel TM, Ratner EF, Thomas Jr RC, et al. Pregnancy complicated by severe osteogenesis imperfecta: A report of two cases. *Anesth Analg* 1994;79(5):1315-1317. X-2, X-3d.
1166. Volmanen P, Akural E, Raudaskoski T, et al. Comparison of remifentanyl and nitrous oxide in labour analgesia. *Acta Anaesthesiol Scand* 2005 Apr;49(4):453-8. X-2.
1167. Volmanen P, Akural EI, Raudaskoski T, et al. Remifentanyl in obstetric analgesia: A dose-finding study. *Anesth Analg* 2002;94(4):913-917. X-3a, X-3d.
1168. Volmanen P, Palomäki O and Ahonen J. Alternatives to neuraxial analgesia for labor. *Curr Opin Anesthesiol* 2011;24(3):235-41. X-1, X-2.
1169. Volmanen PVE, Akural EI, Raudaskoski T, et al. Timing of intravenous patient-controlled remifentanyl bolus during early labour. *Acta Anaesthesiol Scand* 2011;55(4):486-494. X-3a, X-3d.
1170. Voss L and Shimoda T. Protect against free NO<sub>2</sub> in the operating room for health's sake. *Dent Stud* 1977 May;55(8):62-6. X-1, X-2, X-5.
1171. Vural P, Akgul C, Yildirim A, et al. Antioxidant defence in recurrent abortion. *Clinica Chimica Acta* 2000;295(1-2):169-177. X-2, X-3b.
1172. Wagner RL and White PF. Etomidate inhibits adrenocortical function in surgical patients. *Anesthesiology* 1984 Dec;61(6):647-51. X-2, X-3d.
1173. Wakeling HG, McFall MR, Jenkins CS, et al. Intraoperative oesophageal Doppler guided fluid management shortens postoperative hospital stay after major bowel surgery. *Br J Anaesth* 2005;95(5):634-642. X-2, X-3d.
1174. Waldenstrom U. Midwives' attitudes to pain relief during labour and delivery. *Midwifery* 1988 Jun;4(2):48-57. X-5.
1175. Waldenstrom U. Variations between midwives regarding administration of obstetrical analgesia. *Scand J Caring Sci* 1989;3(2):83-9. X-2, X-3d, X-5.
1176. Waldmann CS, Verghese C and Short SM. The evaluation of domperidone and metoclopramide as antiemetics in day care abortion patients. *Br J Clin Pharmacol* 1985;19(3):307-310. X-2, X-3b, X-3d.
1177. Waldron Ble G. Awareness under general anaesthesia. *Br J Anaesth* 1971 Jun;43(6):591. X-1, X-2, X-3, X-5.
1178. Warde DJ. Anaesthesia and the practice of medicine: Historical perspectives. *Ir Med J* 2008;101(7). X-1, X-2, X-3, X-5.
1179. Warren TM, Datta S, Ostheimer GW, et al. Comparison of the maternal and neonatal effects of halothane, enflurane, and isoflurane for cesarean delivery. *Anesth Analg* 1983 May;62(5):516-20. X-2, X-3a, X-3d.
1180. Watanabe KI, Hatakenaka S, Ikemune K, et al. A case of suspected liver dysfunction induced by sevoflurane anesthesia. *Masui* 1993;42(6):902-905. X-2, X-3a.
1181. Watcha MF, White PF, Tychsen L, et al. Comparative effects of laryngeal

- mask airway and endotracheal tube insertion on intraocular pressure in children. *Anesth Analg* 1992;75(3):355-360. X-2, X-3a.
1182. Wathen KA, Stenman UH, Leinonen E, et al. Concentrations of vascular endothelial growth factor C and D in amniotic fluid and maternal plasma. *Acta Obstet Gynecol Scand* 2009;88(6):629-634. X-2, X-3.
1183. Watson ED, Henderson-Smart DJ, Storey GNB, et al. Perinatal factors and the development of chronic lung disease in preterm infants: A case control study. *Aust Paediatr J* 1987;23(3):181-184. X-2, X-3d.
1184. Waud BE and Waud DR. Calculated kinetics of distribution of nitrous oxide and methoxyflurane during intermittent administration in obstetrics. *Anesthesiology* 1970 Apr;32(4):306-16. X-1, X-2, X-5.
1185. Wee MY, Hasan MA and Thomas TA. Isoflurane in labour. *Anaesthesia* 1993 May;48(5):369-72. X-2.
1186. Weinberg CR, Baird DD and Rowland AS. Pitfalls inherent in retrospective time-to-event studies: the example of time to pregnancy. *Stat Med* 1993 May 15;12(9):867-79. X-1, X-2, X-3.
1187. Weingarten AE, Korsh JJ, Neuman GG, et al. Postpartum uterine atony after intravenous dantrolene. *Anesth Analg* 1987;66(3):269-270. X-1, X-2, X-3, X-5.
1188. Weiniger CF, Ivri S, Ioscovich A, et al. Obstetric anesthesia units in Israel: a national questionnaire-based survey. *Int J Obstet Anesth* 2010 Oct;19(4):410-6. X-5.
1189. Weis OF, Muller FO and Lyell H. Materno-fetal cholinesterase inhibitor poisoning. *Anesth Analg* 1983;62(2):233-235. X-1, X-2, X-3, X-5.
1190. Weiss JE, Uribe AG, Malleson PN, et al. Anesthesia for intra-articular corticosteroid injections in juvenile idiopathic arthritis: A survey of pediatric rheumatologists. *Pediatr Rheumatol* 2010;8(3). X-2, X-3.
1191. Weissman DB and Ehrenwerth J. Prolonged neuromuscular blockade in a parturient associated with succinylcholine. *Anesth Analg* 1983;62(4):444-446. X-1, X-2, X-3, X-5.
1192. Wessen A, Elowsson P, Axemo P, et al. The use of intravenous nitroglycerin for emergency cervico-uterine relaxation. *Acta Anaesthesiol Scand* 1995;39(6):847-849. X-1, X-2, X-3a.
1193. West SL, Moore CA, Gillard M, et al. Anaesthesia for suction termination of pregnancy. *Anaesthesia* 1985 Jul;40(7):669-72. X-2, X-3b.
1194. Westenskow DR, Jordan WS and Hayes JK. Uptake of enflurane: A study of the variability between patients. *Br J Anaesth* 1983;55(7):595-601. X-2, X-3.
1195. Westgren M, Lindahl SG and Norden NE. Maternal and fetal endocrine stress response at vaginal delivery with and without an epidural block. *J Perinat Med* 1986;14(4):235-41. X-2.
1196. White PF, Coe V, Shafer A, et al. Comparison of alfentanil with fentanyl for outpatient anesthesia. *Anesthesiology* 1986;64(1):99-106. X-1, X-2, X-3.
1197. Whittaker M and Selwyn Crawford J. Postoperative ileus, pregnancy-related cholinesterase deficiency and suxamethonium after-pains. A case report. *Br J Anaesth* 1983;55(6):581-584. X-2, X-3.
1198. Wikstrom AK, Larsson A, Eriksson UJ, et al. Early postpartum changes in circulating pro- and anti-angiogenic factors in early-onset and late-onset pre-eclampsia. *Acta Obstet Gynecol Scand* 2008;87(2):146-153. X-2, X-3.
1199. Wildsmith JA. Serum cholinesterase, pregnancy and suxamethonium. *Anaesthesia* 1972 Jan;27(1):90-1. X-1, X-2, X-3a, X-3d, X-5.
1200. Wilhelm W, Hammadeh ME, White PF, et al. General anesthesia versus monitored anesthesia care with remifentanyl for assisted reproductive technologies: effect on pregnancy rate. *J Clin Anesth* 2002 Feb;14(1):1-5. X-2, X-3.
1201. Wilkins CJ, Reed PN and Aitkenhead AR. Hypoxaemia after inhalation of 50% nitrous oxide and oxygen. *Br J*



- Anaesth 1989 Sep;63(3):346-7. X-2, X-3, X-5.
1202. Willdeck Lund G. General anaesthesia versus epidural block for caesarean section in patient with pre-eclampsia. *Acta Obstet Gynecol Scand* 1983;62(SUPPL. 118):117-119. X-2, X-3.
  1203. Williams CE, Povey RC and White DG. Predicting women's intentions to use pain relief medication during childbirth using the Theory of Planned Behaviour and Self-Efficacy Theory. *J Reprod Infant Psychol* 2008;26(3):168-79. X-2.
  1204. Williamson LM, Buston K and Sweeting H. Young women and limits to the normalisation of condom use: A qualitative study. *AIDS Care* 2009;21(5):561-566. X-2, X-3.
  1205. Willis BA and Rosen M. Entonox analgesia--a method of reducing the delay between demand and supply. *Anaesthesia* 1977 Jun;32(6):573-6. X-2, X-3d, X-5.
  1206. Wilson IH, Nair KR, Chibwe K, et al. Awareness during anaesthesia for caesarean section in Zambia. *Trop Doct.* 1990 Oct;20(4):160-2. X-2, X-3, X-5.
  1207. Wilson J. Methoxyflurane in Caesarean section. *Br J Anaesth* 1973 Feb;45(2):233-4. X-1, X-2, X-3, X-5.
  1208. Wilson J and Turner DJ. Awareness during caesarean section under general anaesthesia. *Br Med J* 1969 Feb 1;1(5639):280-3. X-2, X-3a, X-3d, X-5.
  1209. Wilson MJA, MacArthur C, Cooper GM, et al. Epidural analgesia and breastfeeding: A randomised controlled trial of epidural techniques with and without fentanyl and a non-epidural comparison group. *Anaesthesia* 2010;65(2):145-153. X-2, X-3d.
  1210. Wilson RD, Priano LL, Allen CR, et al. Demand analgesia and anesthesia in obstetrics: an evaluation of apparatus and technic. *South Med J* 1972 May;65(5):556-62. X-3, X-5.
  1211. Wolff J, Carl P, Clausen TG, et al. Ro 15-1788 for postoperative recovery: A randomised clinical trial in patients undergoing minor surgical procedures under midazolam anaesthesia. *Anaesthesia* 2001;41(10):1001-1006. X-2, X-3b.
  1212. Wong AYC, Chan RSN and Irwin MG. Anesthetic management of Cesarean delivery in a patient with hypoplastic anemia and severe pre-eclampsia. *Can J Anaesth* 2004;51(9):923-927. X-1, X-2, X-3.
  1213. Yabe M, Enzan K, Takahashi H, et al. Anesthetic management of a patient with HELLP syndrome with bronchial asthma. *Masui* 1993;42(8):1230-1232. X-1, X-2, X-3.
  1214. Yacoub O, Doell D, Kryger MH, et al. Depression of hypoxic ventilatory response by nitrous oxide. *Anesthesiology* 1976 Oct;45(4):385-9. X-2.
  1215. Yamada K, Takahashi R and Hamatani K. Hemorrhagic shock due to ruptured left common iliac artery aneurysm during pregnancy. *J Anesth* 2002;16(4):342-344. X-1, X-2, X-3.
  1216. Yamani-Zamzami TY. Delivery outcomes at term after one previous cesarean section. *Saudi Med J* 1845;28(12):1845-1849. X-3d, X-5.
  1217. Yang J, Leng J and Lang J. Clinical Analysis of 5 Cases of Laparoscopy in Pregnant Patients. *Chin Med Sci J* 2003;18(4). X-2, X-3, X-5.
  1218. Yao FSF and Savarese JJ. Pseudocholinesterase hyperactivity with succinylcholine resistance: An unusual cause of difficult intubation. *J Clin Anesth* 1997;9(4):328-330. X-1, X-2, X-3.
  1219. Yau G, Gin T, Ewart MC, et al. Propofol for induction and maintenance of anaesthesia at caesarean section. A comparison with thiopentone/enflurane. *Anaesthesia* 1991 Jan;46(1):20-3. X-2, X-3d.
  1220. Yavascaoglu B and Girgin NK. General anesthesia for urgent Caesarean section in a patient with untreated Takayasu's arteritis. *Am J Case Rep* 2008;9(pp 273-276). X-2, X-3.
  1221. Yentur EA, Topcu I, Ekici Z, et al. The effect of epidural and general

- anesthesia on newborn rectal temperature at elective cesarean section. *Braz J Med Biol Res* 2009;42(9):863-867. X-2, X-3d.
1222. Yeo SN and Lo WK. Bispectral index in assessment of adequacy of general anaesthesia for lower segment caesarean section. *Anaesth Intensive Care* 2002 Feb;30(1):36-40. X-2, X-3d.
1223. Yerby M. Managing pain in labour Part 3: pharmacological methods of pain relief. *Mod Midwife* 1996;6(5):22-5. X-1, X-2, X-5.
1224. Yoo KY, Jeong CW, Kang MW, et al. Bispectral index values during sevoflurane-nitrous oxide general anesthesia in women undergoing cesarean delivery: a comparison between women with and without prior labor. *Anesth Analg* 2008 Jun;106(6):1827-32. X-2, X-3d, X-5.
1225. Yoon HJ, Hong JY and Kim SM. The effect of anesthetic method for prophylactic cervical cerclage on plasma oxytocin: a randomized trial. *Int J Obstet Anesth* 2008;17(1):26-30. X-2, X-3a.
1226. Yoshizumi J, Vaughan RS and Jasani B. Pregnancy associated with Gorlin's syndrome. *Anaesthesia* 1046;45(12):1046-1048. X-1, X-2, X-3.
1227. Young KD. What's New in Topical Anesthesia. *Clin Pediatr Emerg Med* 2007;8(4):232-239. X-1, X-2, X-3.
1228. Youngs PJ, Sice P and Harvey P. Labour analgesia and pseudoxanthoma elasticum (PXE). *Int J Obstet Anesth* 2003;12(1):48-50. X-2, X-3d.
1229. Younker D and Harrison B. Scleroderma and pregnancy. Anaesthetic considerations. *Br J Anaesth* 1136;57(11):1136-1139. X-2, X-3.
1230. Youssef AR, Topozada MK, El-Damarawi HA, et al. Effects of analgesics during labor. *Middle East J Anaesthesiol* 1978 Jun;5(1):46-56. X-2.
1231. Youssef HAE, El Shafi S and Alfay A. Low-dose ketamine infusion as an analgesic for vaginal delivery. *Med Princ Pract* 1990;2(3-4):190-198. X-3d.
1232. Zagorzycki MT and Brinkman CR, 3rd. The effect of general and epidural anesthesia upon neonatal Apgar scores in repeat cesarean section. *Surg Gynecol Obstet* 1982 Nov;155(5):641-5. X-2, X-3a, X-3d.
1233. Zanzardo V, Caroni G and Burlina A. Higher homocysteine concentrations in women undergoing caesarean section under general anesthesia. *Thromb Res* 2003;112(1-2):33-6. X-2, X-3a, X-3d, X-5.
1234. Zavos PM, Correa JR, Kaskar K, et al. Precoital sexual stimulation and its effects on seminal characteristics. *Middle East Fertil Soc J* 2003;8(1):69-73. X-2, X-3d.

## **Appendix F. Regulatory Considerations of Nitrous Oxide**

Nitrous oxide is used in the U.S. for both medical and nonmedical purposes. The following section will focus on the regulation of nitrous oxide used as analgesia for labor pain. Nitrous oxide as a labor analgesia is governed by a limited patchwork of laws, regulations, and standards.

### **Regulation by federal entities**

Like all medical gases, nitrous oxide is regulated by the U.S. Food and Drug Administration (FDA) as a prescription drug.<sup>1</sup> Title 21 of the Code of Federal Regulations describes the required manufacturing (Good Manufacturing Practices) and distribution practices for prescription drugs, performance standards for medical gas delivery devices, and safety requirements for medical gas containers. There are only a few FDA regulations that specifically or solely apply to nitrous oxide. These regulations describe labeling requirements, manufacturing requirements, and performance standards for delivery systems.<sup>2</sup>

Nitrous oxide also falls under the purview of the United States Pharmacopeia (USP). The USP is a scientific nonprofit organization that sets standards for the quality, purity, identity, and strength of medicines and food ingredients distributed and consumed worldwide. USP standards are enforced by the FDA.

Two federal agencies have weighed in on the use of nitrous oxide in the workplace. The National Institute for Occupational Health and Safety (NIOSH), the federal agency responsible for conducting research and making recommendations to prevent injury and illness in the workplace, has established a recommended exposure limit (REL) for nitrous oxide of 25 parts per million as a eight hour time weighted average. In 1994, NIOSH published an alert (DHHS (NIOSH) Publication No. 94-100) that provided guidance on how to control workplace exposures to nitrous oxide during anesthetic administration.<sup>3</sup>

The Occupational Safety and Health Administration (OSHA) is the federal agency that sets and enforces workplace health and safety standards. OSHA has not set a threshold standard for nitrous oxide exposures in the workplace,<sup>3</sup> but is developing requirements for monitoring workplace exposures to nitrous oxide.<sup>4</sup> OSHA has addressed public safety by requiring all piped systems that transfer and distribute nitrous oxide to comply with safety standards set by the Compressed Gas Association.<sup>5</sup>

Companies that sell nitrous oxide and facilities that store nitrous oxide are subject to certain environmental regulations. The U.S. Environmental Protection Agency (EPA) maintains and publishes every two years a list of chemicals sold in the U.S. This list, the Toxic Substances Control Act (TSCA) inventory, includes nitrous oxide. Facilities that use and store nitrous oxide must submit material safety data sheets and report nitrous oxide inventories to the local emergency planning commission, the organization responsible for local emergency preparedness and response.

### **Regulation by state legislatures and agencies**

In addition to the federal regulations that govern the manufacture, distribution, and storage of nitrous oxide, there are state laws that are meant to promote the safe use, storage, and delivery of nitrous oxide. An increasing number of states have enacted legislation that attempt to limit youth

access to nitrous oxide in order to reduce the prevalence of nitrous oxide abuse by young people. Some state legislatures and licensing boards have enacted legislation or rules that define who may administer or assist in administering nitrous oxide in a medical setting. Some states have enacted community and worker right to know laws. These laws mandate reporting of environmental exposures (accidental releases and on-site storage exposures) to a local agency and mandate notice of exposures to employees and community residents. Finally, it is not uncommon for state and local governments to regulate and enforce building codes that address the installation, testing, and maintenance of pipelines used to deliver nitrous oxide to medical facilities.

## **Regulation by national organizations**

Professional organizations are an integral part of the regulator environment for nitrous oxide. The American Conference of Governmental Industrial Hygienists (ACGIH) is a professional association of industrial hygiene personnel within government agencies. ACGIH establishes the Threshold Limit Values (TLVs) for chemical substances and physical agents and Biological Exposure Indices (BEIs) as guidelines for use in the industrial hygiene field. This group has set a threshold limit value (TLV) for nitrous oxide of 50 ppm of air as an eight hour time weighted average.<sup>6</sup>

The Compressed Gas Association (CGA) writes regulations and standards for compressed gases. Title 41 of the Code of Federal Regulations applies to federal contracts and requires that “the pipe systems for the in-plant transfer and distribution of nitrous oxide shall be designed, installed, maintained and operated in accordance with Compressed Gas Association Pamphlet G8.11964.”<sup>7</sup> OSHA has also adopted the CGA code for piped systems that deliver and transfer nitrous oxide.<sup>5</sup>

The National Fire Protection Association (NFPA) develops and writes consensus standards for medical gas delivery systems (pipelines) in healthcare facilities. NFPA 99 sets standards for monitoring and testing of nitrous oxide delivery systems. The Joint Commission for the Accreditation of Healthcare Organizations (JCAHO) requires healthcare facilities to comply with NFPA 99 (Annex C). The American Welding Society, the Manufacturers’ Standardization Society of the Valve and Fittings Industry, the American Society of Mechanical Engineers, and the American National Standard Institute (ANSI) all have set standards for the installation, design and testing of medical gas pipelines.

1. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for hospitals, nursing homes and other health care facilities. March 2001.
2. Code of Federal Regulations Title 21: Food and Drugs. Department of Health and Human Services, Food and Drug Administration. 2011.
3. NIOSH alert: request for assistance in controlling exposures to nitrous oxide during anesthetic administration. MMWR Morb Mortal Wkly Rep 1994 Jul 22;43(28):522.
4. Occupational Safety and Health Guideline for Nitrous Oxide. Occupational Safety and Health Administration, Department of Labor. 2011.
5. Code of Federal Regulations Title 29: Labor. Department of Labor, Occupational Safety and Health Administration. 2010.
6. Available at: Conference of Governmental Industrial Hygienists. [cited August 30, 2011]; [www.acgih.org/About/American](http://www.acgih.org/About/American).
7. Code of Federal Regulations Title 41: Public Contracts and Property Management. Department of Labor, Public Contracts. 2005